

WO2005117909

Publication Title:

KINASE MODULATORS AND METHODS OF USE

Abstract:

Abs 1160 tract of WO2005117909

The present invention relates to compounds of the Formula I and II wherein R, R₂₁, R₂₅-R₃₃, m, n, X₂₁-X₂₃, and Q₁ are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 December 2005 (15.12.2005)

PCT

(10) International Publication Number
WO 2005/117909 A2

(51) International Patent Classification⁷: **A61K 31/7076**

(21) International Application Number:
PCT/US2005/013860

(22) International Filing Date: 22 April 2005 (22.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/564,908 23 April 2004 (23.04.2004) US

(71) Applicant (*for all designated States except US*): **EX-ELIXIS, INC.** [US/US]; P. O. Box 511, 170 Harbor Way, South San Francisco, CA 94083-0511 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ANAND, Neel, K.** [GB/US]; 977 El Camino Real, Unit #303, Burlingame, CA 94010 (US). **BLAZEY, Charles, M.** [US/US]; 201 Cornwall Street, #3, San Francisco, CA 94118 (US). **BOWLES, Owen, Joseph** [US/US]; 468 Manor Drive, #C1, Pacifica, CA 94044 (US). **BUSSENIUS, Joerg** [DE/US]; 1042 Helm Lane, Foster City, CA 94404 (US). **CANNE BANNEN, Lynne** [US/US]; 1086 Rio Vista Drive, Pacifica, CA 94044 (US). **CHAN, Diva Sze-Ming** [US/US]; 1775 46th Ave, San Francisco, CA 94122 (US). **CHEN, Baili** [US/US]; 1054 Colorado Avenue, Palo Alto, CA 94303 (US). **CO, Erick Wang** [US/US]; 864 Boardwalk Place, Redwood City, CA 94065 (US). **COSTANZO, Simona** [IT/US]; 215 El Monte Avenue, Los Altos, CA 94022 (US). **DEFINA, Steven, Charles**



[US/US]; 1232 Floribunda, #6, Burlingame, CA 94010 (US). **DUBENKO, Larisa** [US/US]; 584 46th Avenue, San Francisco, CA 94121 (US). **FRANZINI, Maurizio** [IT/US]; 1212 10th Avenue, #307, San Francisco, CA 94122 (US). **HUANG, Ping** [US/US]; 117 Whit's Road, Mountain View, CA 94040 (US). **JAMMALAMADAKA, Vasu** [US/US]; 2806 Maria Street, Pleasonton, CA 94588 (US). **KHOURY, Richard George** [US/US]; 225 Poseidon Lane, Redwood City, CA 94065 (US). **KIM, Moon, Hwan** [US/US]; 1128 Oregon Avenue, Palo Alto, CA 94303 (US). **KLEIN, Rhett, Ronald** [US/US]; 1024 1/2 Clayton Street, San Francisco, CA 94117 (US). **LE, Donna, Tra** [US/US]; 1855 Ribisi Way, San Jose, CA 95131 (US). **MAC, Morrison, B.** [US/US]; 2567 30th Avenue, San Francisco, CA 94116 (US). **NUSS, John, M.** [US/US]; 16 Woodranch Circle, Danville, CA 94506 (US). **PARKS, Jason, Jevious** [US/US]; 4005 Cowell Blvd., Apt. 506, Davis, CA 95616 (US). **RICE, Kenneth, D.** [US/US]; 802 Autumn Lane, Mill Valley, CA 94941 (US). **TSANG, Tsze, H.** [US/US]; 8367 Kent Drive, El Cerrito, CA 94530 (US). **TSUHAKO, Amy, Lew** [US/US]; 1232 Madruga Way, Milpitas, CA 95035 (US). **WANG, Yong** [CN/US]; 667 Catamaran Street, Apt. 4, Foster City, CA 94404 (US). **XU, Wei** [US/US]; 327 Glasgow Circle, Danville, CA 94526 (US).

(74) Agents: **ATKINS, Michael, J.** et al.; P. O. Box 511, 170 Harbor Way, South San Francisco, California 94083-0511 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM,

[Continued on next page]

(54) Title: KINASE MODULATORS AND METHODS OF USE



(57) Abstract: The present invention relates to compounds of the Formula I and II wherein R, R₂₁, R₂₅-R₃₃, m, n, X₂₁-X₂₃, and Q₁ are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.

WO 2005/117909 A2



AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PATENT APPLICATION
Kinase Modulators and Method of Use

Assignee: Exelixis, Inc.
Entity: Large

Kinase Modulators and Method of Use

BACKGROUND OF THE INVENTION

Reference to Related Applications

[0001] This application claims priority to U.S. provisional patent application 60/564,908 filed April 23, 2004. The contents of the prior application are hereby incorporated in their entirety.

Field of the Invention

[0002] This invention relates to compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemovasion and metabolism. Even more specifically, the invention relates to compounds which inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

Summary of Related Art

[0003] Improvements in the specificity of agents used to treat cancer is of considerable interest because of the therapeutic benefits which would be realized if the side effects associated with the administration of these agents could be reduced. Traditionally, dramatic improvements in the treatment of cancer are associated with identification of therapeutic agents acting through novel mechanisms.

[0004] Protein kinases are enzymes that catalyze the phosphorylation of proteins at the hydroxy groups of tyrosine, serine and threonine residues of proteins. The kinase complement of the human genome contains 518 putative protein kinase genes [Manning et al, Science, (2002), 298, 1912]. The consequences of this activity include effects on cell differentiation, proliferation, transcription, translation, metabolism, cell cycle progression, apoptosis, metabolism cytoskeletal rearrangement and movement; i.e., protein kinases mediate the majority of signal transduction in eukaryotic cells. Furthermore, abnormal protein kinase activity has been related to a host of disorders, ranging from relatively non-life threatening diseases such as psoriasis to cancer. Chromosomal mapping has revealed that over 200 kinases map to disease loci, including cancer, inflammatory and metabolic disease.

[0005] Tyrosine kinases can be categorized as receptor type or non-receptor type. Receptor-type tyrosine kinases have an extracellular, a transmembrane, and an intracellular portion, while non-receptor type tyrosine kinases are wholly intracellular.

[0006] Receptor-type tyrosine kinases are comprised of a large number of transmembrane receptors with diverse biological activity. In fact, about 20 different subfamilies of receptor-type tyrosine kinases have been identified. One tyrosine kinase subfamily, designated the HER subfamily, is comprised of EGFR (HER1), HER2, HER3, and HER4. Ligands of this subfamily of receptors identified so far include epithelial growth factor, TGF-alpha, amphiregulin, HB-EGF, betacellulin and heregulin. Another subfamily of these receptor-type tyrosine kinases is the insulin subfamily, which includes INS-R, IGF-IR, and IR-R. The PDGF subfamily includes the PDGF-alpha and -beta receptors, CSFIR, c-kit and FLK-II. Then there is the FLK family, which is comprised of the kinase insert domain receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4 (FLK-4) and the fms-like tyrosine kinase-1 (Flt-1). The PDGF and FLK families are usually considered together due to the similarities of the two groups. For a detailed discussion of the receptor-type tyrosine kinases, see Plowman et al., *DN&P* 7(6): 334-339, 1994, which is hereby incorporated by reference.

[0007] The non-receptor type of tyrosine kinases is also comprised of numerous subfamilies, including Src, Frk, Btk, Csk, Abl, Syk/Zap70, Fes/Fps, Fak, Jak, and Ack. Each of these subfamilies is further sub-divided into varying receptors. For example, the Src subfamily is one of the largest and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr, and Yrk. The Src subfamily of enzymes has been linked to oncogenesis. For a more detailed discussion of the non-receptor type of tyrosine kinases, see Bolen, *Oncogene*, 8:2025-2031 (1993), which is hereby incorporated by reference.

[0008] Serine-theoronine kinases play critical roles in intracellular signal transduction and include the multiple families, including STE, CKI, AGC, CAMK, and CMGC. Important subfamilies include, the MAP kinases, p38, JNK and ERK, which modulate signal transduction resulting from such diverse stimuli as mitogenic, stress, proinflammatory and antiapoptotic pathways. Members of the MAP kinase subfamily have been targeted for therapeutic intervention, including p38a, JNK isozymes and Raf.

[0009] Since protein kinases and their ligands play critical roles in various cellular activities, deregulation of protein kinase enzymatic activity can lead to altered cellular properties, such as uncontrolled cell growth associated with cancer. In addition to

oncological indications, altered kinase signaling is implicated in numerous other pathological diseases. These include, but are not limited to: immunological disorders, cardiovascular diseases, inflammatory diseases, and degenerative diseases. Therefore, both receptor and non-receptor protein kinases are attractive targets for small molecule drug discovery.

[0010] One particularly attractive goal for therapeutic use of kinase modulation relates to oncological indications. For example, modulation of protein kinase activity for the treatment of cancer has been demonstrated successfully with the FDA approval of Gleevec® (imatinib mesylate, produced by Novartis Pharmaceutical Corporation of East Hanover, NJ) for the treatment of Chronic Myeloid Leukemia (CML) and gastrointestinal stroma cancers. Gleevec is a selective Abl kinase inhibitor.

[0011] Modulation (particularly inhibition) of cell proliferation and angiogenesis, two key cellular processes needed for tumor growth and survival (Matter A. Drug Disc Technol 2001 6, 1005-1024), is an attractive goal for development of small-molecule drugs. Anti-angiogenic therapy represents a potentially important approach for the treatment of solid tumors and other diseases associated with dysregulated vascularization, including ischemic coronary artery disease, diabetic retinopathy, psoriasis and rheumatoid arthritis. As well, cell antiproliferative agents are desirable to slow or stop the growth of tumors.

[0012] The enzyme, p70S6 kinase (p70S6K) is a serine-theoronine kinase that is a component of the phosphatidylinositol 3 kinase (PI3K)/Akt kinase (AktK) pathway. Both Akt and p70S6K are downstream of phosphatidylinositol-3 kinase (PI3K), and undergo phosphorylation and activation in response to growth factors such as IGF-1, EGF, TGF- α and HGF. The enzyme p70S6K modulates protein synthesis by phosphorylation of the S6 ribosomal protein promoting translation. A role for p70S6K in tumor cell proliferation and protection of cells from apoptosis is supported based on its participation in growth factor receptor signal transduction, overexpression and activation in tumor tissues [Pene et al (2002) Oncogene 21, 6587; Miyakawa et al (2003) Endocrin J. 50, 77, 83; Le et al (2003) Oncogene 22, 484]. Clinical inhibition of p70S6K activation was observed in renal carcinoma patients treated with CCI-779 (rapamycin ester), an inhibitor of the upstream activating kinase, mTOR. A significant linear association between disease progression and inhibition of p70S6K activity was reported [Peralba et al (2003) Clinical Cancer Research 9, 2887].

[0013] Recently, the enzyme p70S6K was found to be implicated in metabolic diseases and disorders. It was reported that the absence of p70S6K protects against age- and diet-induced obesity while enhancing insulin sensitivity [Um et al (2004) *Nature* 431, 200-205 and Pende et al (2000) *Nature* 408, 994-997]. A role for p70S6K in metabolic diseases and disorders such as obesity, diabetes, metabolic syndrome, insulin resistance, hyperglycemia, hyperaminoacidemia, and hyperlipidemia is supported based upon the findings.

[0014] Accordingly, the identification of small-molecule compounds that specifically inhibit, regulate and/or modulate the signal transduction of kinases, particularly p70S6K and/or Akt, is desirable as a means to treat or prevent disease states associated with abnormal cell proliferation and metabolism is an object of this invention.

SUMMARY OF THE INVENTION

[0015] The present invention provides compounds for modulating kinase activity and methods of treating diseases mediated by kinase activity, in particular p70S6 and/or Akt kinase activity, utilizing the compounds and pharmaceutical compositions thereof. Diseases mediated by kinase activity are from herein referred to as "kinase-dependent diseases or conditions" (see definition in detailed description of invention below). Inhibitors that are selective for p70S6 and/or Akt kinase are included in this invention.

[0016] In another aspect, the invention provides methods of screening for modulators of kinase activity. The methods comprise combining a composition of the invention, a kinase, and at least one candidate agent and determining the effect of the candidate agent on the kinase activity.

[0017] In yet another aspect, the invention also provides pharmaceutical kits comprising one or more containers filled with one or more of the ingredients of pharmaceutical compounds and/or compositions of the present invention, including, one or more kinase enzyme activity modulators as described herein. Such kits can also include, for example, other compounds and/or compositions (e.g., diluents, permeation enhancers, lubricants, and the like), a device(s) for administering the compounds and/or compositions, and written instructions in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which instructions can also reflects approval by the agency of manufacture, use or sale for human administration.

[0018] In still yet another aspect, the invention also provides a diagnostic agent comprising a compound of the invention and, optionally, pharmaceutically acceptable adjuvants and excipients.


[0019] These and other features and advantages of the present invention will be described in more detail below.

DETAILED DESCRIPTION OF THE INVENTION

[0020] The compositions of the invention are used to treat diseases associated with abnormal and/or unregulated cellular activities. Disease states which can be treated by the methods and compositions provided herein include, but are not limited to, cancer (further discussed below), immunological disorders such as rheumatoid arthritis, graft-host diseases, multiple sclerosis, psoriasis; cardiovascular diseases such as atherosclerosis, myocardioinfarction, ischemia, pulmonary hypertension, stroke and restenosis; other inflammatory and degenerative diseases such as interbowel diseases, osteoarthritis, macular degeneration, diabetic retinopathy.

[0021] It is appreciated that in some cases the cells may not be in a hyper- or hypo-proliferative and/or migratory state (abnormal state) and still require treatment. For example, during wound healing, the cells may be proliferating "normally," but proliferation and migration enhancement may be desired. Alternatively, reduction in "normal" cell proliferation and/or migration rate may be desired.

[0022] In embodiment A, the present invention comprises a compound for modulating kinase activity, particularly p70S6 and/or Akt kinase activity, of Formula I,



I

- [0023] or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,
- [0024] X_{21} is N or CR₂₂;
- [0025] X_{22} is N or CR₂₃;
- [0026] X_{23} is N or CR₂₄, but when X_{22} is N then X_{23} is CR₂₄;
- [0027] each of R₂₁, R₂₂, R₂₃, R₂₄, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉ and R₃₀, and each R₃₁, R₃₂ and R₃₃ is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -NR₃₅R_{35a}, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -N(R₃₅)SO₂R₃₅, -N(R₃₅)C(O)R₃₅, -N(R₃₅)CO₂R₃₅, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;
- [0028] R is selected from -H, halogen, trihalomethyl, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or
- [0029] two of R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, R₃₀, R₃₁ or R₃₂, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system;
- [0030] each of R₃₅ and R_{35a} is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or
- [0031] R₃₅ and R_{35a}, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl; and
- [0032] m is an integer from 0 to 5;
- [0033] n is an integer from 1 to 2; and
- [0034] with the provisos that when X_{22} is CR₂₃ and X_{23} is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X_{22} is N and X_{23} is CR₂₄ then R is not optional substituted aryl or heteroaryl and R₂₁ is not -NR₃₅R_{35a}, and that when X_{22} is CR₂₃ and X_{23} is CR₂₄ then R₂₁ is not optionally substituted

aryl, and that compounds with CAS Registration Nos. 732271-60-2, 565169-26-8, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-34-2, 47281-43-6, 37425-49-3, 37425-48-2, 24932-89-6 and 24932-78-3 are not included in Formula I.

[0035] In one example, the compound is according to Embodiment A, wherein n is 1.

[0036] In another example, the compound is according to paragraph [0035], wherein X₂₁ is N.

[0037] In another example, the compound is according to paragraph [0036], wherein X₂₃ is N.

[0038] In another example, the compound is according to paragraph [0037], wherein X₂₂ is CR₂₃.

[0039] In another example, the compound is according to paragraph [0038], wherein R is -H.

[0040] In another example, the compound is according to paragraph [0038], wherein R is optionally substituted alkyl.

[0041] In another example, the compound is according to paragraph [0039], wherein R₂₁ is -H.

[0042] In another example, the compound is according to paragraph [0039], wherein R₂₁ is optionally substituted alkyl.

[0043] In another example, the compound is according to paragraph [0041], wherein R₂₅ and R₂₆ are -H.

[0044] In another example, the compound is according to paragraph [0043], wherein R₂₇ and R₂₈ are -H.

[0045] In another example, the compound is according to paragraph [0044], wherein R₂₉ is -H.

[0046] In another example, the compound is according to paragraph [0045], wherein R₃₀ is -H.

[0047] In another example, the compound is according to paragraph [0045], wherein R₃₀ is optionally substituted alkyl.

[0048] In another example, the compound is according to paragraph [0045], wherein R₃₀ is -C(O)R₃₅.

[0049] In another example, the compound is according to paragraph [0045], wherein R₃₀ is -C(O)NR₃₅R_{35a}.

[0050] In another example, the compound is according to paragraph [0046], wherein R₃₁ is -H.

[0051] In another example, the compound is according to paragraph [0050], wherein R₃₂ is -H.

[0052] In another example, the compound is according to paragraph [0050], wherein R₃₂ is -C(O)R₃₅.

[0053] In another example, the compound is according to paragraph [0050], wherein R₂₉, R₃₀, R₃₁, and R₃₂ are -H.

[0054] In another example, the compound is according to paragraph [0051], wherein R₂₃ is optionally substituted alkyl.

[0055] In another example, the compound is according to paragraph [0051], wherein R₂₃ is halogen, preferably F, Cl, or Br, and more preferably Br.

[0056] In another example, the compound is according to paragraph [0051], wherein R₂₃ is -H.

[0057] In another example, the compound is according to paragraph [0051], wherein m is 2.

[0058] In another example, the compound is according to paragraph [0051], wherein m is 3.

[0059] In another example, the compound is according to paragraph [0051], wherein R₃₃ is -H.

[0060] In another example, the compound is according to paragraph [0051], wherein R₃₃ is halogen.


[0061] In another example, the compound is according to paragraph [0051], wherein R₃₃ is optionally substituted alkyl.

[0062] In another example, the compound is according to paragraph [0051], wherein R₃₃ is -NR₃₅R_{35a}.

[0063] In another example, the compound is according to paragraph [0051], wherein R₃₃ is -C(O)R₃₅.

[0064] In another example, the compound is according to paragraph [0051], wherein R₃₃ is trihalomethyl.

[0065] In embodiment B, the present invention also comprises a compound for modulating kinase activity, particularly p70S6 and/or Akt kinase activity according to Formula II,



II

[0066] or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,

[0067] X₂₁ is N or CR₂₂;

[0068] X₂₂ is N or CR₂₃;

[0069] X₂₃ is N or CR₂₄, but when X₂₂ is N then X₂₃ is CR₂₄;

[0070] each of R₂₁, R₂₂, R₂₃, R₂₄, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉ and R₃₀ and each of R₃₁, R₃₂ and R₃₃ is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -NR₃₅R_{35a}, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -N(R₃₅)SO₂R₃₅, -N(R₃₅)C(O)R₃₅, -N(R₃₅)CO₂R₃₅, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, and optionally substituted arylalkyl;

[0071] R is selected from -H, halogen, trihalomethyl, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, and optionally substituted arylalkyl; or

[0072] two of R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, R₃₀, R₃₁ or R₃₂, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system;

[0073] each R₃₅ and R_{35a} is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

[0074] R₃₅ and R_{35a}, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl;

[0075] Q₁ optionally substituted heterocyclyl;

[0076] n is an integer from 1 to 2; and

[0077] with the provisos that when X₂₂ is CR₂₃ and X₂₃ is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X₂₂ is N and X₂₃ is CR₂₄ then R is not optional substituted aryl or heteroaryl and R₂₁ is not -NR₃₅R_{35a}, and that when X₂₂ is CR₂₃ and X₂₃ is CR₂₄ then R₂₁ is not optionally substituted aryl and X₂₁ is N, and that compounds with CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 537667-22-4, 252722-35-3, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 24932-90-9, and 24932-77-2 are not included in Formula II.

[0078] In one example, the compound is according to Embodiment B, wherein n is 1.

[0079] In another example, the compound is according to paragraph [0078], wherein X₂₁ is N.

[0080] In another example, the compound is according to paragraph [0079], wherein X₂₃ is N.

[0081] In another example, the compound is according to paragraph [0080], wherein X₂₂ is CR₂₃.

[0082] In another example, the compound is according to paragraph [0081], wherein R is -H.

[0083] In another example, the compound is according to paragraph [0081], wherein R is optionally substituted alkyl.

[0084] In another example, the compound is according to paragraph [0082], wherein R₂₁ is -H.

[0085] In another example, the compound is according to paragraph [0082], wherein R₂₁ is optionally substituted alkyl.

[0086] In another example, the compound is according to paragraph [0084], wherein R₂₅ and R₂₆ are -H.

[0087] In another example, the compound is according to paragraph [0086], wherein R₂₇ and R₂₈ are -H.

[0088] In another example, the compound is according to paragraph [0087], wherein R₂₉ is -H.

[0089] In another example, the compound is according to paragraph [0088], wherein R₃₀ is -H.

[0090] In another example, the compound is according to paragraph [0088], wherein R₃₀ is optionally substituted alkyl.

[0091] In another example, the compound is according to paragraph [0088], wherein R₃₀ is -C(O)R₃₅.

[0092] In another example, the compound is according to paragraph [0088], wherein R₃₀ is -C(O)NR₃₅R_{35a}.

[0093] In another example, the compound is according to paragraph [0089], wherein R₃₁ is -H.

[0094] In another example, the compound is according to paragraph [0093], wherein R₃₂ is -H.

[0095] In another example, the compound is according to paragraph [0094], wherein R₃₂ is -C(O)R₃₅.

[0096] In another example, the compound is according to paragraph [0094], wherein R₂₉, R₃₀, R₃₁, and R₃₂ are -H.

[0097] In another example, the compound is according to paragraph [0094], wherein R₂₃ is optionally substituted alkyl.

[0098] In another example, the compound is according to paragraph [0094], wherein R₂₃ is halogen.

[0099] In another example, the compound is according to paragraph [0094], wherein R₂₃ is -H.

[0100] In another example, the compound is according to paragraph [0099], wherein Q₁ is a substituted heterocyclyl wherein the heterocyclyl has at least one nitrogen.

[0101] In another example, the compound is according to paragraph [0099], wherein Q₁ is a substituted heterocyclyl wherein the heterocyclyl has at least one oxygen.

[0102] In embodiment C, the present invention comprises molecules of embodiment A except that each R₃₃ is independently selected from:

[0103] (a) H, halo, -OH, NO₂-, CN;

[0104] (b) C₁-C₆- alkyl, optionally substituted with 1-5 moieties independently selected from halo, -OH, -C₁-C₃-alkoxy optionally substituted with 1-3 halo, or aryl;

[0105] (c) C₁-C₈-alkoxy optionally substituted with 1-3 moieties independently selected from halo and C₁-C₃-alkoxy;

[0106] (d) R₉₀-C₀-C₃-alkyl, wherein R₉₀ is N(R₇₃)(R₇₄), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, C₁-C₃-alkyl, C₁-C₃-alkoxy, aryl, and heteroaryl; or R₉₀ is R₉₁-aryl optionally substituted with 1-3 halo;

[0107] (e) R₉₅-C₁-C₃-alkoxy, wherein R₉₅ is N(R₇₃)(R₇₄), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, C₁-C₃-alkyl, aryl, and heteroaryl;

[0108] (f) R₈₀-C₁-C₃-alkyl-(Z)_s-C₀-C₃-alkyl, wherein R₈₀ is N(R₇₅)(R₇₆)- or aryl optionally substituted with C₁-C₃-alkyl;

[0109] (g) R₈₁-C₀-C₆-alkyl-(Z)_s-CO-, wherein R₈₁ is H, C₁-C₆-alkyl optionally substituted with 1-3 halo, C₁-C₆-alkyloxy, N(R₇₀)(R₇₁)-, heteroaryl, or aryl optionally substituted with 1-3 groups independently selected from halo and C₁-C₃-alkyl;

[0110] (h) N(R₇₃)(R₇₄)-C(O)-C₀-C₃-alkoxy;

[0111] (i) trimethylsilyl-C₁-C₃-alkyl; or

[0112] (j) C₁-C₃-alkylS(O)₂;

[0113] and wherein

[0114] R₇₀ and R₇₁ are independently H, C₁-C₃-alkyl, or C₁-C₃-alkoxy, or R₇₀ and R₇₁ together with the nitrogen to which they are attached form a heterocyclyl optionally substituted with 1-3 C₁-C₆-alkyl, provided two oxygen atoms are not adjacent;

[0115] R₇₂ is H or C₁-C₆-alkyl;

[0116] R₇₃ and R₇₄ are independently H or C₁-C₆-alkyl;

[0117] R₇₅ and R₇₆ are independently H or C₁-C₆-alkyl or, together with the nitrogen to which they are attached, form a 5- or 6-membered heterocyclyl optionally substituted with C₁-C₃-alkyl;

[0118] R₉₁ is N(R₇₅)(R₇₆)-C₁-C₃-alkyl-Z-;

[0119] Z is -NR₇₂- or -O-; and

[0120] s is 0 or 1.

[0121] Table A gives particular examples of R₃₃ of groups (b)-(j) (paragraphs [0104] - [0112]), above:

Table A

(b)	methyl, trifluoromethyl, ethyl, propyl, 2,2-dimethylbutyl, 1,1-difluorobutyl, trifluoromethyl, hydroxymethyl, phenylethyl, styryl, ethynyl, 3,3-dimethylbut-1-ynyl, difluoromethoxymethyl, ethoxymethyl, 3-hydroxypropyl, 1-hydroxybutyl, (2,2,2-trifluoroethoxy)methyl, 4,4,4-trifluoro-1,1-dimethoxybutyl
(c)	methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-methoxyethoxy, 4-methylbutoxy, 2-ethylbutoxy, 2,2-dimethylpropoxy, 2-fluoro-2-methylpropoxy, difluoromethoxy, 2,3-difluoro-2-(fluoromethyl)propoxy, (2,2-difluorocyclopropyl)methoxy, ethoxymethoxy, 3,3,3-trifluoroethoxy, 3,3,3-trifluoroproxy
(d)	phenyl, 3,4-difluorophenyl, 3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl, furan-2-yl, thiazol-2-yl, morpholino, pyrrolidinylpropyl, 3-methyl-1,2,4-oxadiazol-5-yl, 3-phenyl-1,2,4-oxadiazol-5-yl, diethylamino, isopentylamino, 2-(2-(pyrrolidin-1-yl)ethoxy)phenyl, 3-(2-(pyrrolidin-1-yl)ethoxy)phenyl, 4-fluoro-2-(2-(pyrrolidin-1-yl)ethoxy)phenyl, 2-(3-(dimethylamino)propoxy)phenyl, 2-(2-morpholinoethoxy)phenyl, 2-(2-(2,5-dioxopyrrolidin-1-yl)ethoxy)phenyl, 3-fluoro-2-(2-(pyrrolidin-1-yl)ethoxy)phenyl
(e)	morpholino-propoxy, piperidinyl-propoxy, (tetrahydrofuran-2-yl)methoxy

(f)	(2-(dimethylamino)ethylamino)methyl, 2-(dimethylamino)ethoxy, 2-(diethylamino)ethoxy, 3-(diethylamino)propyl, 3-(diethylamino)propoxy, 3-(dimethylamino)propoxy, 3-(dimethylamino)-prop-1-enyl, 2-(dimethylamino)ethylamino, 2-(diethylamino)ethylamino, 2-(pyrrolidin-1-yl)ethoxy, 3-(pyrrolidin-1-yl)propyl, 3-(pyrrolidin-1-yl)propoxy, 2-(pyrrolidin-1-yl)ethylamino, 2-(piperidin-1-yl)ethoxy, 3-(piperidin-1-yl)propyl, 3-(piperidin-1-yl)propoxy, 2-(1-methylpiperidin-4-yl)ethoxy, (1-methylpiperidin-4-yl)methoxy, (1-methylpiperidin-4-yl)ethoxy, 2-morpholinoethoxy, 3-morpholinopropoxy, 3-morpholinopropyl, 3-(4-methylpiperazin-1-yl)propyl, 3-(4-methylpiperazin-1-yl)propoxy, 3-(4-ethylpiperazin-1-yl)propoxy, 2-(4-methylpiperazin-1-yl)ethoxy, 2-(4-ethylpiperazin-1-yl)ethoxy, phenylmethoxy, 3-methylbenzyloxy, 2-(isopropyl(methyl)amino)ethylamino
(g)	2-(dimethylamino)ethylcarbamoyl, N-methylpiperizinylcarbonyl, (2-(dimethylamino)ethoxy)carbonyl, methylcarbamoyl, ethylcarbamoyl, isopropylcarbamoyl, isopropyl(methyl)carbamoyl, isobutylcarbamoyl, <i>t</i> -butylcarbamoyl, phenylcarbamoyl, benzylcarbamoyl, 2-chlorophenylcarbamoyl, methoxycarbonyl, pyridin-3-ylcarbamoyl, 4,4,4-trifluorobutanoyl, dimethylcarbamoyl, pyrrolidine-1-carbonyl, 2-(dimethylamino)ethylcarbamoyl, acetyl, propionyl, butyryl, 4,4,4-trifluorobutanoyl, pentoyl, benzoyl, cyclopropylmethoxycarbamoyl, cyclopropanecarbonyl
(h)	2-(ethylamino)-2-oxoethoxy, 2-(cyclopropylamino)-2-oxoethoxy
(i)	2-(trimethylsilyl)ethyl
(j)	methylsulfonyl, ethylsulfonyl

[0122] In some examples of Embodiments A-C, each of R₂₅-R₃₂ is H.

[0123] In some examples according to paragraph [0122], R₂₁ is H.

[0124] In some examples according to paragraph [0122], X₂₁ and X₂₃ are N.

[0125] In some examples according to paragraph [0122] X₂₂ is CR₂₃ and R₂₃ is lower alkyl or halo, preferably Br.

[0126] In some examples of embodiments A and C according to paragraph[0122], m is 3. Preferred R₃₃ in these examples includes lower alkyl (preferably methyl), R₈₀-C₁-C₃-alkyl-(Z)_s-C₀-C₃-alkyl (preferably wherein R₈₀ is heterocyclyl such as pyrrolidinyl; the C₁-C₃-alkyl is ethyl; s is 1; Z is NH; and C₀-C₃-alkyl is C₀, *i.e.*, a bond), and R₈₁-C₀-C₆-alkyl-(Z)_s-CO- (preferably wherein: R₈₁ is C₁-C₆-alkyl optionally substituted with 1-3 halo, more preferably wherein the C₁-C₆-alkyl optionally substituted with 1-3 halo is trihalopropyl (preferably trifluoropropyl, and even more preferably 3,3,3-trifluoropropyl); the C₀-C₆-alkyl is C₀ (*i.e.*, a bond); and s is 0). Preferably the R₈₀-C₁-C₃-alkyl-(Z)_s-C₀-C₃-alkyl and the R₈₁-C₀-C₆-alkyl-(Z)_s-CO- groups are meta to each other and to X₂₁.

[0127] Another preferred embodiment includes Embodiments A and C with R₂₁ according to paragraph [0123], R₂₅-R₃₂ according to paragraph [0122], X₂₁ and X₂₃ are

according to paragraph [0124], X₂₂ according to paragraph [0125] and m and R₃₃ according to paragraph [0126].

[0128] In other examples of embodiments A-C, R₂₅-R₂₈ and R₃₀-R₃₂ are H and R₂₉ is other than H. In such embodiments the annular carbon atom to which R₂₉ is bonded is chiral. In some examples of this embodiment, that chiral center is enantiomerically enriched (greater than 60%, 70%, 80%, 90%, or 95%) or pure. Examples of R₂₉ when the annular carbon is chiral in this embodiment include methyl and hydroxymethyl.

[0129] In a particular embodiment of Embodiment C, when X₂₃ is CR₂₄, m is 1-5, and at least one R₃₃ is selected from:

- [0130] (i) C₁-C₆- alkyl 1-5 moieties independently selected from -OH and -C₁-C₃-alkoxy optionally substituted with 1-3 halo, or aryl;
- [0131] (ii) C₁-C₈-alkoxy optionally substituted with 1-3 C₁-C₃-alkoxy moieties;
- [0132] (iii) R₉₀-C₀-C₃-alkyl, wherein R₉₀ is N(R₇₃)(R₇₄) if the alkyl moiety is C₁-C₃-alkyl, heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, C₁-C₃-alkyl, C₁-C₃-alkoxy, aryl, and heteroaryl; or R₉₀ is R₉₁-aryl optionally substituted with 1-3 halo;
- [0133] (iv) R₉₅-C₁-C₃-alkoxy, wherein R₉₅ is N(R₇₃)(R₇₄), heterocyclyl, aryl, or heteroaryl, each of which is optionally substituted with 1-3 moieties independently selected from halo, C₁-C₃-alkyl, aryl, and heteroaryl;
- [0134] (v) R₈₀-C₁-C₃-alkyl-(Z)_s-C₀-C₃-alkyl, wherein R₈₀ is N(R₇₅)(R₇₆)- or aryl optionally substituted with C₁-C₃-alkyl;
- [0135] (vi) R₈₁-C₀-C₆-alkyl-(Z)_s-CO-, wherein R₈₁ is H, C₁-C₆-alkyl optionally substituted with 1-3 halo, C₁-C₆-alkyloxy, N(R₇₀)(R₇₁)-, heteroaryl, or aryl optionally substituted with 1-3 groups independently selected from halo and C₁-C₃-alkyl;
- [0136] (vii) N(R₇₃)(R₇₄)-C(O)-C₀-C₃-alkoxy;
- [0137] (viii) trimethylsilyl-C₁-C₃-alkyl; or
- [0138] (ix) C₁-C₃-alkylS(O)₂-;

[0139] In each of the aspects, examples, and embodiments of the compounds of the invention, R is preferably H or optionally substituted C₁-C₆-alkyl, more preferably H or unsubstituted C₁-C₆-alkyl, and even more preferably H. In one particular embodiment of embodiments A or C, X₂₂ is CR₂₃, X₂₃ is CR₂₄, and R₂₁ is halogen. In another particular embodiment of embodiments A or C, X₂₂ is N, X₂₃ is CR₂₄, and R₂₁ is halogen.

[0142] In yet another particular embodiment of embodiments A or C, X₂₂ is CR₂₃, X₂₃ is CR₂₄, X₂₁ is nitrogen, R₂₁ is hydrogen, m is 1, 2, 3, 4, or 5 and at least one R₃₃ is not hydrogen.

[0143] In still another particular embodiment of embodiments A or C, X₂₂ is N, X₂₃ is CR₂₄, X₂₁ is nitrogen and R₂₁ is hydrogen, then m is 1, 2, 3, 4, or 5 and at least one R₃₃ is not hydrogen.

[0144] In yet still another particular embodiment of embodiments A or C, X₂₂ is N, X₂₃ is CR₂₄, X₂₁ is N, n is 1, R₂₅-R₃₂ are the same and are H, or only one of R₂₅-R₃₂ is alkyl, and R is H or alkyl, then R₂₄ is H or alkyl.

[0145] In another particular embodiment of embodiments A or C, X₂₂ is CR₂₃, X₂₃ is CR₂₄, X₂₁ is N, n is 1, R₂₅-R₃₂ are the same and are H, or only one of R₂₅-R₃₂ is alkyl, R is H or alkyl, and R₂₄ is H or alkyl.

[0146] In one particular embodiment of embodiment C, Q₁ is not pyrid-2-yl, i.e., when Q₁ is pyridyl it is not attached to the X₂₁ group at position ortho to the pyridyl nitrogen.

[0147] In another particular embodiment of embodiment C, X₂₂ is CR₂₃, X₂₃ is CR₂₄, and R₂₁ is halogen.

[0148] In still another particular embodiment of embodiment C, X₂₂ is N, X₂₃ is CR₂₄, and R₂₁ is halogen.

[0149] In yet another particular embodiment of embodiment C, X₂₂ is CR₂₃, X₂₃ is CR₂₄, X₂₁ is nitrogen, R₂₁ is hydrogen, m is 1, 2, 3, 4, or 5 and at least one R₃₃ is not hydrogen.

[0150] In yet still another particular embodiment of embodiment C, X₂₂ is N, X₂₃ is CR₂₄, X₂₁ is nitrogen, R₂₁ is hydrogen, m is 1, 2, 3, 4, or 5 and at least one R₃₃ is not hydrogen.

[0151] In another particular embodiment of embodiment C, Q₁ is not pyrimidyl or triazinyl.

[0152] In one example, the compound is according to paragraphs [0022]-[0151], wherein the compound is a pharmaceutically acceptable salt.

[0153] In one example, the compound is according to paragraphs [0022]-[0151], wherein the compound is a prodrug.

[0154] In another example, the compound is according to any one of paragraphs [0022]-[0151], selected from Tables 1 or 2 below.

[0155] Another aspect of the invention is a composition comprising the compound according to any one of paragraphs [0022]-[0154] and at least one pharmaceutically acceptable carrier or excipient.

[0156] Another aspect of the invention is a metabolite of the compound according to any one of paragraphs [0022]-[0154].

[0157] Another aspect of the invention is a method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155] and the CAS Registration Nos: 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X₂₂ is CR₂₃ and X₂₃ is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X₂₂ is N and X₂₃ is CR₂₄ then R₂₁ is -NR₃₅R₃₅, and when X₂₂ is CR₂₃ and X₂₃ is CR₂₄ then R₂₁ is optionally substituted aryl and X₂₁ is N.

[0158] Another aspect of the invention is the method according to paragraph [0157], wherein the kinase is p70S6 and/or Akt.

[0159] Another aspect of the invention is the method according to paragraph [0158], wherein modulating the *in vivo* activity of p70S6K and/or AktK comprises inhibition of p70S6K and/or AktK.

[0160] Another aspect of the invention is a method of treating and/or inhibiting diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a

therapeutically effective amount of a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155] and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X_{22} is CR_{23} and X_{23} is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X_{22} is N and X_{23} is CR_{24} then R_{21} is $-NR_{35}R_{35}$, and when X_{22} is CR_{23} and X_{23} is CR_{24} then R_{21} is optionally substituted aryl and X_{21} is N.

[0161] Another aspect of the invention is a method of screening for modulator of a p70S6K and/or AktK, the method comprising combining either a composition comprising at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155], and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X_{22} is CR_{23} and X_{23} is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X_{22} is N and X_{23} is CR_{24} then R_{21} is $-NR_{35}R_{35}$, and when X_{22} is CR_{23} and X_{23} is CR_{24} then R_{21} is optionally substituted aryl and X_{21} is N, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.

[0162] Another aspect of the invention is a method of inhibiting proliferative activity in a cell or a plurality of cells, the method comprising administering an effective amount of at least one of the compound according to any of paragraphs [0022]-[0154] and the pharmaceutical composition according to paragraph [0155], and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1,

252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X_{22} is CR_{23} and X_{23} is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X_{22} is N and X_{23} is CR_{24} then R_{21} is $-NR_{35}R_{35}$, and when X_{22} is CR_{23} and X_{23} is CR_{24} then R_{21} is optionally substituted aryl and X_{21} is N, to said cell or plurality of cells.

[0163] Another aspect of the invention is a method of preparing the compounds according to any of paragraphs [0022]-[-0154].

Definitions


[0164] As used in the present specification, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise or they are expressly defined to mean something different.

[0165] The symbol “-” means a single bond, “=” means a double bond, “≡” means a triple bond. The symbol “~” refers to a group on a double-bond as occupying either position on the terminus of a double bond to which the symbol is attached; that is, the geometry, E- or Z-, of the double bond is ambiguous. When a group is depicted removed from its parent formula, the “~” symbol will be used at the end of the bond which was theoretically cleaved in order to separate the group from its parent structural formula.

[0166] Chemical formulae use descriptors such as “ R^1 ” accompanied by a list of formulae or verbage describing the scope of what is meant by the descriptor. A subsequent descriptor such as “ R^{1a} ” is used to describe some subset of the scope of R^1 , and “ R^{1b} ” is used to describe another subset of the scope of R^1 , and so on. In such subsequent cases, all other formulae containing simply “ R^1 ” are meant to include the entire scope of the descriptor.

[0167] When chemical structures are depicted or described, unless explicitly stated otherwise, all carbons are assumed to have hydrogen substitution to conform to a valence of four. For example, in the structure on the left-hand side of the schematic below there are nine hydrogens implied. The nine hydrogens are depicted in the right-hand structure. Sometimes a particular atom in a structure is described in textual formula as having a hydrogen or hydrogens as substitution (expressly defined hydrogen), for example, - CH_2CH_2- . It is understood by one of ordinary skill in the art that the aforementioned


descriptive techniques are common in the chemical arts to provide brevity and simplicity to description of otherwise complex structures.



[0168] In this application, some ring structures are depicted generically and will be described textually. For example, in the schematic below, if in the structure on the left, ring A is used to describe a “spirocyclyl,” then if ring A is cyclopropyl, there are at most four hydrogens on ring A (when “R” can also be -H). In another example, as depicted on the right side of the schematic below, if ring B is used to describe a “phenylene” then there can be at most four hydrogens on ring B (assuming depicted cleaved bonds are not C-H bonds).




[0169] If a group “R” is depicted as “floating” on a ring system, as for example in the formula:



then, unless otherwise defined, a substituent “R” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly defined hydrogen from one of the ring atoms, so long as a stable structure is formed.

[0170] If a group “R” is depicted as floating on a fused ring system, as for example in the formulae:



then, unless otherwise defined, a substituent “R” may reside on any atom of the fused ring system, assuming replacement of a depicted hydrogen (for example the -NH- in the formula above), implied hydrogen (for example as in the formula above, where the hydrogens are not shown but understood to be present), or expressly defined hydrogen (for

example where in the formula above, "X" equals =CH-) from one of the ring atoms, so long as a stable structure is formed. In the example depicted, the "R" group may reside on either the 5-membered or the 6-membered ring of the fused ring system. In the formula depicted above, when y is 2 for example, then the two "R's" may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied, or expressly defined hydrogen on the ring.

[0171] When a group "R" is depicted as existing on a ring system containing saturated carbons, as for example in the formula:



where, in this example, "y" can be more than one, assuming each replaces a currently depicted, implied, or expressly defined hydrogen on the ring; then, unless otherwise defined, where the resulting structure is stable, two "R's" may reside on the same carbon. A simple example is when R is a methyl group; there can exist a geminal dimethyl on a carbon of the depicted ring (an "annular" carbon). In another example, two R's on the same carbon, including that carbon, may form a ring, thus creating a spirocyclic ring (a "spirocyclyl" group) structure with the depicted ring as for example in the formula:



[0172] "Alkyl" is intended to include saturated and non-saturated (but not aromatic) linear, branched, and cyclic hydrocarbon structures and combinations thereof, inclusively. For example, "C₈ alkyl" may refer to an *n*-octyl, *iso*-octyl, cyclohexylethyl, 3-octenyl, -octa-2,4-dienyl, cyclooctane, cyclooctene, and the like. Lower alkyl refers to alkyl groups of from one to six carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, propenyl, isopropyl, butyl, *s*-butyl, *t*-butyl, isobutyl, pentyl, hexyl, hex-3-ynyl, and the like. Higher alkyl refers to alkyl groups containing more than eight carbon atoms. Exemplary alkyl groups are those of C₂₀ or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from three to thirteen carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In this application, alkyl refers to alkanyl, alkenyl, and alkynyl residues (and combinations thereof); it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus, when an alkyl residue having a specific number of carbons is named, all geometric

isomers having that number of *carbons* are intended to be encompassed; thus, for example, either "butyl" or "C₄alkyl" is meant to include *n*-butyl, *sec*-butyl, isobutyl, *t*-butyl, isobutenyl and but-2-yne radicals; and for example, "propyl" or "C₃alkyl" each include *n*-propyl, propenyl, and isopropyl. Otherwise, if alkenyl and/or alkynyl descriptors *are used* in a particular definition of a group, for example "C₄alkyl" along with "C₄alkenyl," then C₄alkenyl geometric isomers are not meant to be included in "C₄alkyl," but other 4-carbon isomers are, for example C₄alkynyl. For example, a more general description, intending to encompass the invention as a whole may describe a particular group as "C₁₋₈alkyl" while a preferred species may describe the same group as including, "C₁₋₈alkyl," "C₁₋₆alkenyl" and "C₁₋₅alkynyl." As used herein, C₀ is a bond. So, for example NH₂-C₀-C₃-alkyl includes amino as well as aminomethyl, 2-aminoethyl, 1 aminoethyl, etc.

[0173] "Alkylene" refers to straight or branched chain divalent radical consisting solely of carbon and hydrogen atoms, containing no unsaturation and having from one to ten carbon atoms, for example, methylene, ethylene, propylene, *n*-butylene and the like. Alkylene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, fully saturated. Examples of alkylene include ethylene (-CH₂CH₂-), propylene (-CH₂CH₂CH₂-), dimethylpropylene (-CH₂C(CH₃)₂CH₂-), and cyclohexylpropylene (-CH₂CH₂CH(C₆H₁₃)).

[0174] "Alkylidene" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms, having from two to ten carbon atoms, for example, ethylidene, propylidene, *n*-butylidene, and the like. Alkylidene is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, double bond unsaturation. The unsaturation present includes at least one double bond.

[0175] "Alkylidyne" refers to a straight or branched chain unsaturated divalent radical consisting solely of carbon and hydrogen atoms having from two to ten carbon atoms, for example, propylid-2-ynyl, *n*-butylid-1-ynyl, and the like. Alkylidyne is a subset of alkyl, referring to the same residues as alkyl, but having two points of attachment and, specifically, triple bond unsaturation. The unsaturation present includes at least one triple bond.

[0176] Any of the above radicals, "alkylene," "alkylidene" and "alkylidyne," when optionally substituted, may contain alkyl substitution which itself contains unsaturation.

For example, 2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an *n*-butylid-3-ynyl radical with a vinyl substituent at the 2-position of said radical.

[0177] “Alkoxy” or “alkoxyl” refers to the group -O-alkyl, for example including from one to eight carbon atoms of a straight, branched, cyclic configuration, unsaturated chains, and combinations thereof attached to the parent structure through an oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to six carbons.

[0178] “Substituted alkoxy” refers to the group -O-(substituted alkyl), the substitution on the alkyl group generally containing more than only carbon (as defined by alkoxy). One exemplary substituted alkoxy group is “polyalkoxy” or -O-optionally substituted alkylene-optionally substituted alkoxy, and includes groups such as -OCH₂CH₂OCH₃, and glycol ethers such as polyethyleneglycol and -O(CH₂CH₂O)_xCH₃, where x is an integer of between about two and about twenty, in another example, between about two and about ten, and in a further example between about two and about five. Another exemplary substituted alkoxy group is hydroxyalkoxy or -OCH₂(CH₂)_yOH, where y is for example an integer of between about one and about ten, in another example y is an integer of between about one and about four.

[0179] “Acyl” refers to groups of from one to ten carbon atoms of a straight, branched, cyclic configuration, saturated, unsaturated and aromatic and combinations thereof, attached to the parent structure through a carbonyl functionality. One or more carbons in the acyl residue may be replaced by nitrogen, oxygen or sulfur as long as the point of attachment to the parent remains at the carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl, *t*-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers to groups containing one to six carbons.

[0180] “ α -Amino Acids” refer to naturally occurring and commercially available amino acids and optical isomers thereof. Typical natural and commercially available α -amino acids are glycine, alanine, serine, homoserine, threonine, valine, norvaline, leucine, isoleucine, norleucine, aspartic acid, glutamic acid, lysine, ornithine, histidine, arginine, cysteine, homocysteine, methionine, phenylalanine, homophenylalanine, phenylglycine, ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan, glutamine, asparagine, proline and hydroxyproline. A “side chain of an α -amino acid” refers to the radical found on the

α -carbon of an α -amino acid as defined above, for example, hydrogen (for glycine), methyl (for alanine), benzyl (for phenylalanine), and the like.


[0181] “Amino” refers to the group -NH₂. “Substituted amino,” refers to the group -N(H)R or -N(R)R where each R is independently selected from the group: optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl, sulfanyl, sulfinyl and sulfonyl, for example, diethylamino, methylsulfonylamino, and furanyl-oxy-sulfonamino.

[0182] “Aryl” refers to aromatic six- to fourteen-membered carbocyclic ring, for example, benzene, naphthalene, indane, tetralin, fluorene and the like, univalent radicals. As univalent radicals, the aforementioned ring examples are named, phenyl, naphthyl, indanyl, tetralinyl, and fluorenyl.

[0183] “Arylene” generically refers to any aryl that has at least two non-hydrogen groups attached thereto. For a more specific example, “phenylene” refers to a divalent phenyl ring radical. A phenylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto. The terms “ortho-arylene,” “meta-arylene” or “para-arylene” refer to geometrical isomers of a particular arylene wherein, two groups attached to an aryl as depicted in a formula are situated in an ortho, meta or para geometrical relationship about the aryl, respectively.

[0184] “Arylalkyl” refers to a residue in which an aryl moiety is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Both the aryl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of an arylalkyl group may be optionally substituted. “Lower arylalkyl” refers to an arylalkyl where the “alkyl” portion of the group has one to six carbons; this can also be referred to as aryl C₁₋₆alkyl.

[0185] “Exo-alkenyl” refers to a double bond that emanates from an annular carbon, and is not within the ring system, for example the double bond depicted in the formula below.



[0186] In some examples, as appreciated by one of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to form a ring structure.

The fused ring structure may contain heteroatoms and may be optionally substituted with one or more groups. It should additionally be noted that saturated carbons of such fused groups (i.e. saturated ring structures) can contain two substitution groups.

[0187] “Fused-polycyclic” or “fused ring system” refers to a polycyclic ring system that contains bridged or fused rings; that is, where two rings have more than one shared atom in their ring structures. In this application, fused-polycyclics and fused ring systems are not necessarily all aromatic ring systems. Typically, but not necessarily, fused-polycyclics share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydronaphthalene. A spiro ring system is not a fused-polycyclic by this definition, but fused polycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polycyclic.

[0188] “Halogen” or “halo” refers to fluorine, chlorine, bromine or iodine. “Haloalkyl” and “haloaryl” refer generically to alkyl and aryl radicals that are substituted with one or more halogens, respectively. Thus, “dihaloaryl,” “dihaloalkyl,” “trihaloaryl” etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.

[0189] “Heteroarylene” generically refers to any heteroaryl that has at least two groups attached thereto. For a more specific example, “pyridylene” refers to a divalent pyridyl ring radical. A pyridylene, thus may have more than two groups attached, but is defined by a minimum of two non-hydrogen groups attached thereto. For the purposes of this application, the term “ortho-heteroarylene” refers to a geometrical isomer of a particular heteroarylene wherein two groups attached to a heteroaryl as depicted in a formula are situated on contiguous atoms of the heteroaryl.

[0190] “Heteroatom” refers to O, S, N, or P.

[0191] “Heterocyclyl” refers to a stable three- to fifteen-membered ring radical that consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclyl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused or bridged ring systems as well as spirocyclic systems; and the nitrogen, phosphorus, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized to various oxidation states. In a specific example, the group -S(O)₀₋₂₋, refers to -S-

(sulfide), -S(O)- (sulfoxide), and -SO₂- (sulfone). For convenience, nitrogens, particularly but not exclusively, those defined as annular aromatic nitrogens, are meant to include their corresponding *N*-oxide form, although not explicitly defined as such in a particular example. Thus, for a compound of the invention having, for example, a pyridyl ring; the corresponding pyridyl-*N*-oxide is meant to be included as another compound of the invention. In addition, annular nitrogen atoms may be optionally quaternized; and the ring radical may be partially or fully saturated or aromatic. Examples of heterocyclyl radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, quinazolinyl, quinoxaliny, quinolinyl, isoquinolinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2,5-dioxopyrrolidin-1-yl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl, benzothieliyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.

[0192] “Heteroalicyclic” refers specifically to a non-aromatic heterocyclyl radical. A heteroalicyclic may contain unsaturation, but is not aromatic.

[0193] “Heteroaryl” refers specifically to an aromatic heterocyclyl radical.


[0194] “Heterocyclalkyl” refers to a residue in which a heterocyclyl is attached to a parent structure via one of an alkylene, alkylidene, or alkylidyne radical. Examples include (4-methylpiperazin-1-yl) methyl, (morpholin-4-yl) methyl, (pyridine-4-yl) methyl, 2-(oxazolin-2-yl) ethyl, 4-(4-methylpiperazin-1-yl)-2-butetyl, and the like. Both the heterocyclyl, and the corresponding alkylene, alkylidene, or alkylidyne radical portion of a heterocyclalkyl group may be optionally substituted. “Lower heterocyclalkyl” refers to a heterocyclalkyl where the “alkyl” portion of the group has one to six carbons. “Heteroalicyclylalkyl” refers specifically to a heterocyclalkyl where the heterocyclyl

portion of the group is non-aromatic; and “heteroarylalkyl” refers specifically to a heterocyclalkyl where the heterocyclyl portion of the group is aromatic. Such terms may be described in more than one way, for example, “lower heterocyclalkyl” and “heterocycl C₁₋₆alkyl” are equivalent terms.

[0195] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. One of ordinary skill in the art would understand that, with respect to any molecule described as containing one or more optional substituents, that only sterically practical and/or synthetically feasible compounds are meant to be included. “Optionally substituted” refers to all subsequent modifiers in a term, for example in the term “optionally substituted aryl C₁₋₈alkyl,” optional substitution may occur on both the “C₁₋₈alkyl” portion and the “aryl” portion of the molecule; and for example, optionally substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups. A list of exemplary optional substitutions is included below in the definition of “substituted.”

[0196] “Saturated bridged ring system” refers to a bicyclic or polycyclic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturation, but not aromatic or heteroaromatic rings in its core structure (but may have aromatic substitution thereon). For example, hexahydro-furo[3,2-b]furan, 2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane, and 1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the class “saturated bridged ring system.”

[0197] “Spirocycl” or “spirocyclic ring” refers to a ring originating from a particular annular carbon of another ring. For example, as depicted below, a ring atom of a saturated bridged ring system (rings B and B’), but not a bridgehead atom, can be a shared atom between the saturated bridged ring system and a spirocycl (ring A) attached thereto. A spirocycl can be carbocyclic or heteroalicyclic.



[0198] “Substituted” alkyl, aryl, and heterocyclyl, refer respectively to alkyl, aryl, and heterocyclyl, wherein one or more (for example up to about five, in another example, up to about three) hydrogen atoms are replaced by a substituent. Suitable substituents include, without limitation, halo, hydroxy, oxo (e.g., an annular -CH- substituted with oxo is -C(O)-) nitro, halohydrocarbyl, hydrocarbyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, heteroaryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl, sulfonamido, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano, alkylthio, ureido, and ureidoalkyl groups. Preferred substituents, which are themselves not further substituted (unless expressly stated otherwise) are:


[0199] (a) halo, cyano, oxo, alkyl, alkoxy, alkylthio, haloalkoxy, aminoalkyl, aminoalkoxy, carboxy, formyl, nitro, amino, amidino, carbamoyl, guanidino, C₃-C₇ heterocycle, heterocyclalkyl, heterocyclcarbonyl, hydroxyalkyl, alkoxyalkyl,

[0200] (b) C₁-C₅ alkyl or alkenyl or arylalkyl imino, carbamoyl, carbamate, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, C₁-C₈ alkyl, C₁-C₈ alkenyl, C₁-C₈ alkoxy, C₁-C₈ alkoxy carbonyl, aryloxycarbonyl, C₂-C₈ acyl, C₂-C₈ acylamino, C₁-C₈ alkylthio, arylalkylthio, arylthio, heteroarylthio, C₁-C₈ alkylsulfinyl, arylalkylsulfinyl, arylsulfinyl, C₁-C₈ alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, C₀-C₆ N-alkyl carbamoyl, C₂-C₁₅ N,N-dialkylcarbamoyl, C₃-C₇ cycloalkyl, aroyl, aryloxy, heteroaryloxy, arylalkyl ether, C₃-C₇ heterocyclalkylether, aryl, aryl fused to a cycloalkyl or heterocycle or another aryl ring, C₃-C₇ heterocycle, heteroaryl, arylcarbamoyl, or any of these rings fused or spiro-fused to a cycloalkyl, heterocyclyl, or aryl, wherein any of the foregoing which are additionally substitutable is further optionally substituted with one more moieties listed in (a), above; and

[0201] (c) -(CH₂)_s-NR₃₅R_{35a}, wherein s is from 0 (in which case the nitrogen is directly bonded to the moiety that is substituted) to 6, and R₃₅ and R_{35a} are each independently hydrogen, cyano, oxo, carboxamido, amidino, C₁-C₈ hydroxyalkyl, C₁-C₃ alkylaryl, aryl-C₁-C₃ alkyl, C₁-C₈ alkyl, C₁-C₈ alkenyl, C₁-C₈ alkoxy, C₁-C₈ alkoxy carbonyl, aryloxycarbonyl, aryl-C₁-C₃ alkoxy carbonyl, C₂-C₈ acyl, C₁-C₈ alkylsulfonyl, arylalkylsulfonyl, arylsulfonyl, aroyl, aryl, cycloalkyl, heterocyclyl, or heteroaryl, wherein each of the foregoing is further optionally substituted with one more moieties listed in (a), above; or R₃₅ and R_{35a} taken together with the N to

which they are attached form a heterocyclyl or heteroaryl, each of which is optionally substituted with from 1 to 3 substituents from (a), above.

[0202] In addition, substituents on cyclic moieties (i.e., cycloalkyl, heterocyclyl, aryl, heteroaryl) include 5-6 membered mono- and 9-14 membered bi-cyclic moieties fused to the parent cyclic moiety to form a bi- or tri-cyclic fused ring system. For example, an optionally substituted phenyl includes, but not limited to, the following:



[0203] Preferred substituents on cyclic moieties (i.e., cycloalkyl, heterocyclyl, aryl, heteroaryl) also include groups of the formula $-K_1-N(H)(R_{36})$, wherein

[0204] K_1 is a chemical bond or C_1-C_4 alkylene;

[0205] R_{36} is selected from the group consisting of Z' and $-Ak_2-Z'$, wherein

[0206] Ak_2 is C_1-C_4 alkylene; and

[0207] Z' is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which optionally is substituted, and each of which optionally is fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings.

[0208] Particularly preferred substituents on cyclic moieties (such as aryl, heteroaryl, cycloalkyl, heterocyclyl, or any of these rings fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings), include 1, 2, or 3 groups independently selected from the following:

[0209] a) alkoxy, cyano, amino, oxo, haloalkyl, halo, alkyl, $R_{35}-C(O)-N(R_{35})-$, $R_{35}-O-C(O)-N(R_{35})-$, $R_{35}-NH-C(O)-N(R_{35})-$, $R_{35}-NH-C(O)-O-$, $(R_{35a})(R_{35})N-alkyl-$, $(R_{35a})(R_{35})N-alkyl-O-$, $(R_{35})(R_{35a})N-alkenylene-N(R_{35})-$, $N(R_{35})-aryl-N(R_{35})-C(O)-aryl-alkyl-N(R_{35})-$; wherein R_{35} is cycloalkyl, heterocyclyl- C_1-C_6 alkyl-, or alkyl;

[0210] b) aryl- C_0-C_6 alkyl-, heteroaryl- C_0-C_6 alkyl-, cycloalkyl- C_0-C_6 alkyl-, heterocyclyl- C_0-C_6 alkyl-, aryl- C_0-C_6 alkyl- $N(R_{35})-$, aryl- $C(O)-$, heteroaryl- C_0-C_6 alkyl- $N(R_{35})-$, heterocyclyl- C_0-C_6 alkyl- $N(R_{35})-$, aryl- $O-$, heteroaryl- $O-$, aryl- $S-$, heteroaryl- $S-$, aryl- SO_2- , heteroaryl- SO_2 , aryl- $C(O)N(R_{35})-$, heteroaryl- $C(O)N(R_{35})-$, heteroaryl- $C(H)(SO_2-heteroaryl)-N(R_{35})-$; wherein R_{35}

and R_{35a} are independently H or C₁-C₆ alkyl, or R₃₅ and R_{35a} taken together with the N to which they are attached form a heterocycl or heteroaryl;

[0211] c) and wherein any of the rings described in paragraphs (a) and (b) immediately above are further optionally substituted with 1, 2, or 3 groups independently selected from alkyl, alkoxy, thioalkoxy, alkyl-SO₂-, amino, halo, cyano, haloalkyl, hydroxyalkyl, alkoxyalkoxyalkyl, COOH, alkanoyl, alkanoate, NO₂, hydroxy, haloalkoxy, (R_{35a})(R₃₅)N--C₀-C₆ alkyl-, (R_{35a})(R₃₅)N--C₀-C₆ alkyl-O-, (R_{35a})(R₃₅)N--C(O)-, heteroaryl, alkyl-C(O)N(R₃₅)-, aryl-O-, (R_{35a})(R₃₅)N--SO₂-, aryl, and (R_{35a})(R₃₅)N--alkyl-C(O)N(R₃₅)-.

[0212] “Sulfanyl” refers to the groups: -S-(optionally substituted alkyl), -S-(optionally substituted aryl), and -S-(optionally substituted heterocycl).

[0213] “Sulfinyl” refers to the groups: -S(O)-H, -S(O)-(optionally substituted alkyl), -S(O)-optionally substituted aryl), and -S(O)-(optionally substituted heterocycl).

[0214] “Sulfonyl” refers to the groups: -S(O₂)-H, -S(O₂)-(optionally substituted alkyl), -S(O₂)-optionally substituted aryl), -S(O₂)-(optionally substituted heterocycl), -S(O₂)-(optionally substituted alkoxy), -S(O₂)-optionally substituted aryloxy), and -S(O₂)-(optionally substituted heterocyclxy).

[0215] “Yield” for each of the reactions described herein is expressed as a percentage of the theoretical yield.

[0216] Some of the compounds of the invention may have imino, amino, oxo or hydroxy substituents off aromatic heterocycl systems. For purposes of this disclosure, it is understood that such imino, amino, oxo or hydroxy substituents may exist in their corresponding tautomeric form, i.e., amino, imino, hydroxy or oxo, respectively.

[0217] Compounds of the invention are named according to systematic application of the nomenclature rules agreed upon by the International Union of Pure and Applied Chemistry (IUPAC), International Union of Biochemistry and Molecular Biology (IUBMB), and the Chemical Abstracts Service (CAS). Compounds were named using the nomenclature engine published by ACD/Labs of Toronto Canada - ACD/Name Batch 7.00 Release, Product v.7.10, Build 15 Sep 2003.

[0218] The compounds of the invention, or their pharmaceutically acceptable salts, may have asymmetric carbon atoms, oxidized sulfur atoms or quaternized nitrogen atoms in their structure.

[0219] The compounds of the invention and their pharmaceutically acceptable salts may exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. The compounds may also exist as geometric isomers. All such single stereoisomers, racemates and mixtures thereof, and geometric isomers are intended to be within the scope of this invention.

[0220] It is assumed that when considering generic descriptions of compounds of the invention for the purpose of constructing a compound, such construction results in the creation of a stable structure. That is, one of ordinary skill in the art would recognize that there can theoretically be some constructs which would not normally be considered as stable compounds (that is, sterically practical and/or synthetically feasible, *supra*).

[0221] When a particular group with its bonding structure is denoted as being bonded to two partners; that is, a divalent radical, for example, -OCH₂- , then it is understood that either of the two partners may be bound to the particular group at one end, and the other partner is necessarily bound to the other end of the particular group, unless stated explicitly otherwise. Stated another way, divalent radicals are not to be construed as limited to the depicted orientation, for example “-OCH₂-” is meant to mean not only “-OCH₂-” as drawn, but also “-CH₂O-.”

[0222] Methods for the preparation and/or separation and isolation of single stereoisomers from racemic mixtures or non-racemic mixtures of stereoisomers are well known in the art. For example, optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. Enantiomers (R- and S-isomers) may be resolved by methods known to one of ordinary skill in the art, for example by: formation of diastereoisomeric salts or complexes which may be separated, for example, by crystallization; via formation of diastereoisomeric derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantiomers; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support, such as silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where a desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step may be required to liberate the desired enantiomeric form. Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts

or solvents, or by converting one enantiomer to the other by asymmetric transformation. For a mixture of enantiomers, enriched in a particular enantiomer, the major component enantiomer may be further enriched (with concomitant loss in yield) by recrystallization.

[0223] "Patient" for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms. Thus the methods are applicable to both human therapy and veterinary applications. In a preferred embodiment the patient is a mammal, and in a most preferred embodiment the patient is human.

[0224] "Kinase-dependent diseases or conditions" refer to pathologic conditions that depend on the activity of one or more protein kinases. Kinases either directly or indirectly participate in the signal transduction pathways of a variety of cellular activities including proliferation, adhesion, migration, differentiation and invasion. Diseases associated with kinase activities include tumor growth, the pathologic neovascularization that supports solid tumor growth, and associated with other diseases where excessive local vascularization is involved such as ocular diseases (diabetic retinopathy, age-related macular degeneration, and the like) and inflammation (psoriasis, rheumatoid arthritis, and the like).

[0225] While not wishing to be bound to theory, phosphatases can also play a role in "kinase-dependent diseases or conditions" as cognates of kinases; that is, kinases phosphorylate and phosphatases dephosphorylate, for example protein substrates. Therefore compounds of the invention, while modulating kinase activity as described herein, may also modulate, either directly or indirectly, phosphatase activity. This additional modulation, if present, may be synergistic (or not) to activity of compounds of the invention toward a related or otherwise interdependent kinase or kinase family. In any case, as stated previously, the compounds of the invention are useful for treating diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth.

[0226] "Therapeutically effective amount" is an amount of a compound of the invention, that when administered to a patient, ameliorates a symptom of the disease. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease state and its severity, the age of the patient to be treated, and the like. The therapeutically effective amount can be

determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.

[0227] “Cancer” refers to cellular-proliferative disease states, including but not limited to: Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary tract: kidney (adenocarcinoma, Wilm's tumor [neuroblastoma], lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma); Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma; chondromyxofibroma, osteoid osteoma and giant cell tumors; Nervous system: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform, oligodendrogloma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma); Gynecological: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma], granulosa-thecal cell tumors, SertoliLeydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell

carcinoma, botryoid sarcoma [embryonal rhabdomyosarcoma], fallopian tubes (carcinoma); Hematologic: blood (myeloid leukemia [acute and chronic], acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis; and Adrenal glands: neuroblastoma. Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of the above-identified conditions.

[0228] "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

[0229] "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Exemplary salts are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Exemplary organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. (See, for example, S. M. Berge, et al., "Pharmaceutical Salts," *J. Pharm. Sci.*, 1977;66:1-19 which is incorporated herein by reference.)

[0230] “Prodrug” refers to compounds that are transformed (typically rapidly) *in vivo* to yield the parent compound of the above formulae, for example, by hydrolysis in blood. Common examples include, but are not limited to, ester and amide forms of a compound having an active form bearing a carboxylic acid moiety. Examples of pharmaceutically acceptable esters of the compounds of this invention include, but are not limited to, alkyl esters (for example with between about one and about six carbons) wherein the alkyl group is a straight or branched chain. Acceptable esters also include cycloalkyl esters and arylalkyl esters such as, but not limited to benzyl. Examples of pharmaceutically acceptable amides of the compounds of this invention include, but are not limited to, primary amides, and secondary and tertiary alkyl amides (for example with between about one and about six carbons). Amides and esters of the compounds of the present invention may be prepared according to conventional methods. A thorough discussion of prodrugs is provided in T. Higuchi and V. Stella, “Pro-drugs as Novel Delivery Systems,” Vol 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference for all purposes.

[0231] “Metabolite” refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation in the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, reduction, or hydrolysis, or to a conjugate (see Goodman and Gilman, “The Pharmacological Basis of Therapeutics” 8.sup.th Ed., Pergamon Press, Gilman et al. (eds), 1990 for a discussion of biotransformation). As used herein, the metabolite of a compound of the invention or its salt may be the biologically active form of the compound in the body. In one example, a prodrug may be used such that the biologically active form, a metabolite, is released *in vivo*. In another example, a biologically active metabolite is discovered serendipitously, that is, no prodrug design *per se* was undertaken. An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.

[0232] In addition, the compounds of the present invention can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.

[0233] In addition, it is intended that the present invention cover compounds made either using standard organic synthetic techniques, including combinatorial chemistry or by biological methods, such as bacterial digestion, metabolism, enzymatic conversion, and the like.

[0234] "Treating" or "treatment" as used herein covers the treatment of a disease-state in a human, which disease-state is characterized by abnormal cellular proliferation, and invasion and includes at least one of: (i) preventing the disease-state from occurring in a human, in particular, when such human is predisposed to the disease-state but has not yet been diagnosed as having it; (ii) inhibiting the disease-state, i.e., arresting its development; and (iii) relieving the disease-state, i.e., causing regression of the disease-state. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.

[0235] One of ordinary skill in the art would understand that certain crystallized, protein-ligand complexes, in particular p70S6- or Akt-4-ligand complexes, and their corresponding x-ray structure coordinates can be used to reveal new structural information useful for understanding the biological activity of kinases as described herein. As well, the key structural features of the aforementioned proteins, particularly, the shape of the ligand binding site, are useful in methods for designing or identifying selective modulators of kinases and in solving the structures of other proteins with similar features. Such protein-ligand complexes, having compounds of the invention as their ligand component, are an aspect of the invention.

[0236] As well, one of ordinary skill in the art would appreciate that such suitable x-ray quality crystals can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of kinases. Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a kinase in a conformation (e.g. as defined by x-ray structure coordinates obtained from suitable x-ray quality crystals as described above) wherein the computer program creates a model of the three dimensional structures of the ligand binding domain, b) introducing a model of the three dimensional structure of a candidate agent in the computer program, c) superimposing the model of the candidate agent on the model of the ligand binding domain, and d) assessing whether the


candidate agent model fits spatially into the ligand binding domain. Aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling.

[0237] Additionally, one of ordinary skill in the art would appreciate that such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for kinase modulation, and determining whether said candidate agent modulates kinase activity in the assay. Such methods may also include administering the candidate agent, determined to modulate kinase activity, to a mammal suffering from a condition treatable by kinase modulation, such as those described above.


[0238] Also, one of ordinary skill in the art would appreciate that compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a kinase. Such a method may be characterized by the following aspects: a) creating a computer model of a kinase binding pocket using structure coordinates obtained from suitable x-ray quality crystals of the kinase, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket.

[0239] CAS, a division of the American Chemical Society, is one of the world's leader in providing scientists online and web access to chemistry-related research data. CAS produces one of the world's largest and most comprehensive databases of chemical information, indexing abstracts, patents, articles from approximately 9,000 scientific journals, conference proceedings, and other documents pertinent to chemistry, life sciences and many other fields. Certain compounds are set forth in this application using a CAS Registration identifier. The structures of these compounds, as they correspond to the CAS Registration identifier, are set forth below:


749908-53-0




749908-35-8




537667-22-4




749908-52-9




749908-34-7




537667-19-9




749908-36-9




732271-60-2









537667-17-7



565169-26-8







General Administration

[0240] Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration or agents for serving similar utilities. Thus, administration can be, for example, orally, nasally, parenterally (intravenous, intramuscular, or subcutaneous), topically, transdermally, intravaginally, intravesically, intracistemally, or rectally, in the form of solid, semi-solid, lyophilized

powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages.

[0241] The compositions will include a compound of the invention as the/an active agent, and, in addition, may include at least one other conventional pharmaceutical carrier or excipient, such as medicinal agents, pharmaceutical agents, adjuvants, etc. Compositions of the invention may be used in combination with anticancer or other agents that are generally administered to a patient being treated for cancer. Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0242] If desired, a pharmaceutical composition of the invention may also contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorbitan monolaurate, triethanolamine oleate, butylaltered hydroxytoluene, etc.

[0243] Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

[0244] One preferable route of administration is oral, using a convenient daily dosage regimen that can be adjusted according to the degree of severity of the disease-state to be treated.

[0245] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders, as for example, cellulose derivatives, starch, alginates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, croscarmellose sodium, complex silicates, and sodium carbonate, (e) solution retarders, as for example paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol, and glycerol monostearate, magnesium stearate and the like (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

[0246] Solid dosage forms as described above can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, and can also be of such composition that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes. The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0247] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs. Such dosage forms are prepared, for example, by dissolving, dispersing, etc., a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like; solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyleneglycol, dimethylformamide; oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid esters of sorbitan; or mixtures of these substances, and the like, to thereby form a solution or suspension.

[0248] Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

[0249] Compositions for rectal administrations are, for example, suppositories that can be prepared by mixing the compounds of the present invention with for example suitable non-irritating excipients or carriers such as cocoa butter, polyethyleneglycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore, melt while in a suitable body cavity and release the active component therein.

[0250] Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants. The active component is admixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants as may be required. Ophthalmic formulations, eye ointments, powders, and solutions are also contemplated as being within the scope of this invention.

[0251] Generally, depending on the intended mode of administration, the pharmaceutically acceptable compositions will contain about 1% to about 99% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, and 99% to 1% by weight of a suitable pharmaceutical excipient. In one example, the composition will be between about 5% and about 75% by weight of a compound(s) of the invention, or a pharmaceutically acceptable salt thereof, with the rest being suitable pharmaceutical excipients.

[0252] Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing Company, Easton, Pa., 1990). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease-state in accordance with the teachings of this invention.

[0253] The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of the compound, the age, body weight, general health, sex,

diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular disease-states, and the host undergoing therapy. The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 1,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 100 mg per kilogram of body weight per day is an example. The specific dosage used, however, can vary. For example, the dosage can depend on a number of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well known to one of ordinary skill in the art.

Utility of compounds of the invention as screening agents

[0254] To employ the compounds of the invention in a method of screening for candidate agents that bind to, for example p70S6 and/or Akt receptor kinase, the protein is bound to a support, and a compound of the invention is added to the assay. Alternatively, the compound of the invention is bound to the support and the protein is added. Classes of candidate agents among which novel binding agents may be sought include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for candidate agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled *in vitro* protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

[0255] The determination of the binding of the candidate agent to, for example, p70S6K and/or AktK protein may be done in a number of ways. In one example, the candidate agent (the compound of the invention) is labeled, for example, with a fluorescent or radioactive moiety and binding determined directly. For example, thus may be done by attaching all or a portion of the p70S6K and/or AktK protein to a solid support, adding a labeled agent (for example a compound of the invention in which at least one atom has been replaced by a detectable isotope), washing off excess reagent, and determining whether the amount of the label is that present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

[0256] By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, for example, radioisotope,

fluorescent tag, enzyme, antibodies, particles such as magnetic particles, chemiluminescent tag, or specific binding molecules, and the like. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin, and the like. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

[0257] In some embodiments, only one of the components is labeled. For example, p70S6K and/or AktK protein may be labeled at tyrosine positions using ^{125}I , or with fluorophores. Alternatively, more than one component may be labeled with different labels; using ^{125}I for the proteins, for example, and a fluorophor for the candidate agents.

[0258] The compounds of the invention may also be used as competitors to screen for additional drug candidates. "candidate bioactive agent" or "drug candidate" or grammatical equivalents as used herein describe any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for bioactivity. They may be capable of directly or indirectly altering the cellular proliferation phenotype or the expression of a cellular proliferation sequence, including both nucleic acid sequences and protein sequences. In other cases, alteration of cellular proliferation protein binding and/or activity is screened. In the case where protein binding or activity is screened, some embodiments exclude molecules already known to bind to that particular protein. Exemplary embodiments of assays described herein include candidate agents, which do not bind the target protein in its endogenous native state, termed herein as "exogenous" agents. In one example, exogenous agents further exclude antibodies to p70S6K and/or AktK.

[0259] Candidate agents can encompass numerous chemical classes, though typically they are organic molecules having a molecular weight of more than about 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding and lipophilic binding, and typically include at least an amine, carbonyl, hydroxyl, ether, or carboxyl group, for example at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclyl structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents

are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs, or combinations thereof.

[0260] Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.

[0261] In one example, the binding of the candidate agent is determined through the use of competitive binding assays. In this example, the competitor is a binding moiety known to bind to p70S6K and/or AktK, such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding as between the candidate agent and the binding moiety, with the binding moiety displacing the candidate agent.

[0262] In some embodiments, the candidate agent is labeled. Either the candidate agent, or the competitor, or both, is added first to p70S6K and/or AktK protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature that facilitates optimal activity, typically between 4°C and 40°C.

[0263] Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

[0264] In one example, the competitor is added first, followed by the candidate agent. Displacement of the competitor is an indication the candidate agent is binding to p70S6K and/or AktK and thus is capable of binding to, and potentially modulating, the activity of the p70S6K and/or AktK. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates

displacement by the agent. Alternatively, if the candidate agent is labeled, the presence of the label on the support indicates displacement.

[0265] In an alternative embodiment, the candidate agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate the candidate agent is bound to p70S6K and/or AktK with a higher affinity. Thus, if the candidate agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate the candidate agent is capable of binding to p70S6K and/or AktK.

[0266] It may be of value to identify the binding site of p70S6K and/or AktK. This can be done in a variety of ways. In one embodiment, once p70S6K and/or AktK has been identified as binding to the candidate agent, the p70S6K and/or AktK is fragmented or modified and the assays repeated to identify the necessary components for binding.

[0267] Modulation is tested by screening for candidate agents capable of modulating the activity of p70S6K and/or AktK comprising the steps of combining a candidate agent with p70S6K and/or AktK, as above, and determining an alteration in the biological activity of the p70S6K and/or AktK. Thus, in this embodiment, the candidate agent should both bind to (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both *in vitro* screening methods and *in vivo* screening of cells for alterations in cell viability, morphology, and the like.

[0268] Alternatively, differential screening may be used to identify drug candidates that bind to native p70S6K and/or AktK, but cannot bind to modified p70S6K and/or AktK.

[0269] Positive controls and negative controls can be used in the assays. For example, all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of samples is for a time sufficient for the binding of the agent to the protein. Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples can be counted in a scintillation counter to determine the amount of bound compound.

[0270] A variety of other reagents can be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or

background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components can be added in any order that provides for the requisite binding.

[0271] One of ordinary skill in the art would understand that certain crystallized, protein-ligand complexes, in particular p70S6K- and/or AktK-ligand complexes, and their corresponding x-ray structure coordinates can be used to reveal new structural information useful for understanding the biological activity of p70S6K and/or AktK's as described herein. As well, the key structural features of the aforementioned proteins, particularly, the shape of the ligand binding site, are useful in methods for designing or identifying selective modulators of p70S6K and/or AktK's and in solving the structures of other proteins with similar features. Ligands of such complexes may include compounds of the invention as described herein.

[0272] As well, one of ordinary skill in the art would appreciate that such suitable x-ray quality crystals can be used as part of a method of identifying a candidate agent capable of binding to and modulating the activity of p70S6K and/or AktKs. Such methods may be characterized by the following aspects: a) introducing into a suitable computer program, information defining a ligand binding domain of a p70S6K and/or AktK in a conformation (e.g. as defined by x-ray structure coordinates obtained from suitable x-ray quality crystals as described above) wherein the computer program creates a model of the three dimensional structures of the ligand binding domain, b) introducing a model of the three dimensional structure of a candidate agent in the computer program, c) superimposing the model of the candidate agent on the model of the ligand binding domain, and d) assessing whether the candidate agent model fits spatially into the ligand binding domain. Aspects a-d are not necessarily carried out in the aforementioned order. Such methods may further entail: performing rational drug design with the model of the three-dimensional structure, and selecting a potential candidate agent in conjunction with computer modeling.

[0273] Additionally, one of ordinary skill in the art would appreciate that such methods may further entail: employing a candidate agent, so-determined to fit spatially into the ligand binding domain, in a biological activity assay for p70S6K and/or AktK modulation, and determining whether said candidate agent modulates p70S6K and/or AktK activity in the assay. Such methods may also include administering the candidate

agent, determined to modulate p70S6K and/or AktK activity, to a mammal suffering from a condition treatable by p70S6K and/or AktK modulation, such as those described above.

[0274] Also, one of ordinary skill in the art would appreciate that compounds of the invention can be used in a method of evaluating the ability of a test agent to associate with a molecule or molecular complex comprising a ligand binding domain of a p70S6K and/or AktK. Such a method may be characterized by the following aspects: a) creating a computer model of a p70S6K and/or AktK binding pocket using structure coordinates obtained from suitable x-ray quality crystals of the p70S6K and/or AktK, b) employing computational algorithms to perform a fitting operation between the test agent and the computer model of the binding pocket, and c) analyzing the results of the fitting operation to quantify the association between the test agent and the computer model of the binding pocket.

Abbreviations and their Definitions

[0275] The following abbreviations and terms have the indicated meanings throughout:

Abbreviation	Meaning
Ac	Acetyl
CAN	Acetonitrile
ATP	adenosine triphosphate
BNB	4-bromomethyl-3-nitrobenzoic acid
Boc	T-butyloxycarbonyl
Br	Broad
Bu	Butyl
°C	degrees Celsius
c-	Cyclo
CBZ	CarboBenZoxy = benzyloxycarbonyl
D	Doublet
Dd	doublet of doublet
Dt	doublet of triplet
DBU	Diazabicyclo[5.4.0]undec-7-ene
DCM	dichloromethane = methylene chloride = CH ₂ Cl ₂
DCE	Dichloroethylene
DEAD	diethyl azodicarboxylate
DIC	Diisopropylcarbodiimide
DIEA	N,N-diisopropylethyl amine
DMAP	4-N,N-dimethylaminopyridine
DMF	N,N-dimethylformamide
DMSO	dimethyl sulfoxide

Abbreviation	Meaning
DVB	1,4-divinylbenzene
EEDQ	2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
EI	Electron Impact ionization
Et	Ethyl
Fmoc	9-fluorenylmethoxycarbonyl
G	gram(s)
GC	gas chromatography
H or hr	hour(s)
HATU	O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
HMDS	Hexamethyldisilazane
HOAc	acetic acid
HOBt	Hydroxybenzotriazole
HPLC	high pressure liquid chromatography
L	liter(s)
M	molar or molarity
M	Multiplet
Me	Methyl
Mesyl	Methanesulfonyl
Mg	milligram(s)
MHz	megahertz (frequency)
Min	minute(s)
ML	milliliter(s)
MM	Millimolar
Mmol	millimole(s)
Mol	mole(s)
MS	Mass spectral analysis
MTBE	methyl t-butyl ether
N	normal or normality
NBS	N-bromosuccinimide
NCS	N-chlorosuccinimide
NM	Nanomolar
NMO	N-methylmorpholine oxide
NMR	nuclear magnetic resonance spectroscopy
PEG	Polyethylene glycol
PEY	poly-glutamine, tyrosine
Ph	Phenyl
PhOH	Phenol
Pfp	Pentafluorophenol
PfpY	Pentafluoropyridine
PPTS	Pyridinium p-toluenesulfonate
Py	Pyridine


Abbreviation	Meaning
PyBroP	bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
Q	Quartet
RT	Room temperature
Sat'd	Saturated
S	Singlet
s-	Secondary
t-	Tertiary
T or tr	Triplet
TBDMS	t-butyldimethylsilyl
TES	Triethylsilane
TFA	trifluoroacetic acid
THF	Tetrahydrofuran
TMOF	trimethyl orthoformate
TMS	Trimethylsilyl
Tosyl	p-toluenesulfonyl
Trt	Triphenylmethyl
µL	microliter(s)
µM	Micromole(s) or micromolar

Synthesis of Compounds

[0276] Scheme 1 depicts a general synthetic route for compounds of the invention and is not intended to be limiting. Specific examples are described subsequently to this general synthetic description. In the generalizations below, specific reaction conditions or details, for example, added reagents, catalysts, solvents, reaction temperature, and the like are not described. The general routes depicted in conjunction with the specific examples provided contain sufficient information to allow one of ordinary skill in the art to synthesize compounds of the invention.

[0277] Scheme 1 shows that in general, compounds of Formulas I and II can be made, for example via a linear route. For example, an amino-substituted pyrazolopyrimidine (or purine or pyrrolopyrimidine) of 1 having leaving group "L" is reacted with a substituted piperazine/piperidine of 2, substituted with B which can be an optionally substituted as in Formulas I and II, in an anhydrous solvent such that the leaving group is displaced by the substituted piperazine/piperidine. After heating for a sufficient period of time, the reaction gives compounds of 3, wherein L is an amine and X₂₁, X₂₂, X₂₃, n, R and R₂₁-R₃₂ are as described above.

Scheme 1



[0278] One of ordinary skill in the art would recognize that the descriptions associated with Scheme 1 is a generalization, and that there are other combinations of steps and approaches that can be used to make compounds of the invention. The examples that follow provide much more detailed descriptions of making exemplary compounds of the invention.

Examples

[0279] The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are incorporated by reference in their entirety. Generally, each example is set out below with a corresponding multi-step synthesis scheme. Following specific examples are lists of compounds that were made in a similar way.

EXAMPLE 1: 6-(4-phenylpiperazin-1-yl)-9H-purine

[0281] To 6-chloro-9H-purine (60 mg, 0.39 mmol) in ethanol (2 mL) was added diisopropylethylamine (50 mg, 0.39 mmol) and 1-phenylpiperazine (63 mg, 0.39 mmol). The reaction mixture was stirred at 70 °C for 3 h, and then cooled to room temperature. The precipitation was filtered, washed with ethanol, and dried to give 6-(4-phenylpiperazin-1-yl)-9H-purine (77 mg, 71% yield) as a colorless solid. ¹H NMR (400 MHz, d₆-DMSO) δ 13.09 (br s, 1H), 8.25 (s, 1H), 8.16 (s, 1H), 7.24 (m, 2H), 7.01 (m, 2H), 6.82 (m, 1H), 4.37 (br s, 4H), 3.26 (m, 4H); MS (ESI) for C₁₅H₁₆N₆: 281 (MH⁺).

[0282] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0283] 6-[4-(3-chlorophenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.10 (br s, 1H), 8.25 (s, 1H), 8.17 (s, 1H), 7.24 (m, 1H), 7.03 (m, 1H), 6.97 (m, 1H), 6.82 (m, 1H), 4.36 (br s, 4H), 3.32 (m, 4H); MS (ESI) for $\text{C}_{15}\text{H}_{16}\text{N}_6$: 281 (MH^+); MS (ESI) for $\text{C}_{15}\text{H}_{15}\text{ClN}_6$: 315 (MH^+).

[0284] 6-[4-(2-chlorophenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.05 (br s, 1H), 8.22 (s, 1H), 8.13 (s, 1H), 7.43 (d, 1H), 7.31-7.27 (m, 1H), 7.18 (s, 1H), 7.07-7.03 (m, 1H), 4.39 (br s, 4H), 3.09 (m, 4H); MS (ESI) for $\text{C}_{15}\text{H}_{15}\text{ClN}_6$: 315 (MH^+).

[0285] 6-[4-(2-fluorophenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.05 (br s, 1H), 8.22 (s, 1H), 8.14 (s, 1H), 7.17-6.96 (m, 4H), 4.38 (br s, 4H), 3.12 (m, 4H); MS (ESI) for $\text{C}_{15}\text{H}_{15}\text{FN}_6$: 299 (MH^+).

[0286] 6-[4-(4-methoxyphenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.05 (br s, 1H), 8.22 (s, 1H), 8.13 (s, 1H), 6.95 (d, 2H), 6.83 (d, 2H), 4.35 (br s, 4H), 3.68 (s, 3H), 3.12 (m, 4H); MS (ESI) for $\text{C}_{16}\text{H}_{18}\text{N}_6\text{O}$: 311 (MH^+).

[0287] 6-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.03 (br s, 1H), 8.21 (s, 1H), 8.12 (s, 1H), 6.99-6.84 (m, 4H), 4.35 (br s, 4H), 3.81 (s, 3H), 3.06 (m, 4H); MS (ESI) for $\text{C}_{16}\text{H}_{18}\text{N}_6\text{O}$: 311 (MH^+).

[0288] 6-[4-(4-chlorophenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.05 (br s, 1H), 8.22 (s, 1H), 8.14 (s, 1H), 7.24 (d, 2H), 7.01 (d, 2H), 4.35 (br s, 4H), 3.26 (m, 4H); MS (ESI) for $\text{C}_{15}\text{H}_{15}\text{ClN}_6$: 315 (MH^+).

[0289] 6-[4-(4-fluorophenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.05 (br s, 1H), 8.22 (s, 1H), 8.14 (s, 1H), 7.09-6.99 (m, 4H), 4.35 (br s, 4H), 3.20 (m, 4H); MS (ESI) for $\text{C}_{15}\text{H}_{15}\text{FN}_6$: 299 (MH^+).

[0290] 6-[4-(3-trifluoromethylphenyl)piperazin-1-yl]-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.11 (br s, 1H), 8.26 (s, 1H), 8.18 (s, 1H), 7.45 (m, 1H), 7.30 (d, 1H), 7.26 (s, 1H), 7.11 (d, 1H), 4.38 (br s, 4H), 3.38 (m, 4H); MS (ESI) for $\text{C}_{16}\text{H}_{15}\text{F}_3\text{N}_6$: 349 (MH^+).

[0291] 6-(4-o-tolyl)piperazin-1-yl)-9H-purine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.09 (br s, 1H), 8.24 (s, 1H), 8.15 (s, 1H), 7.20 (d, 1H), 7.15 (m, 1H), 7.04 (d, 1H), 6.98

(m, 1H), 4.38 (br s, 4H), 2.97-2.94 (m, 4H), 2.33 (s, 3H); MS (ESI) for C₁₆H₁₈N₆: 295 (MH⁺).

[0292] EXAMPLE 2: 4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine

[0293] To 4-chloro-7H-pyrrolo[2,3-d]pyrimidine (60 mg, 0.39 mmol) in ethanol (2 mL) was added diisopropylethylamine (50 mg, 0.39 mmol) and 1-phenylpiperazine (63 mg, 0.39 mmol). The reaction mixture was stirred at 70 °C for 16 h, and then cooled to room temperature. The precipitation was filtered, washed with methanol, and dried to give 4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine (74 mg, 68% yield) as a colorless solid. ¹H NMR (400 MHz, d₆-DMSO) δ 11.76 (br s, 1H), 8.18 (s, 1H), 7.24 (m, 3H), 6.98 (m, 2H), 6.81 (m, 1H), 6.68 (d, 1H), 4.03 (m, 4H), 3.29 (m, 4H); MS (ESI) for C₁₆H₁₇N₅: 280 (MH⁺).

[0294] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0295] 4-[4-(3-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 11.76 (br s, 1H), 8.18 (s, 1H), 7.24 (m, 2H), 6.98 (m, 1H), 6.94 (m, 1H), 6.81 (m, 1H), 6.64 (d, 1H), 4.02 (m, 4H), 3.35 (m, 4H); MS (ESI) for C₁₆H₁₆ClN₅: 314 (MH⁺).

[0296] 4-[4-(2-methylphenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 11.71 (br s, 1H), 8.15 (s, 1H), 7.21-7.11 (m, 3H), 7.02 (m, 1H), 6.96 (m, 1H), 6.46 (m, 1H), 4.02 (m, 4H), 2.95 (m, 4H), 2.32 (s, 3H); MS (ESI) for C₁₇H₁₉N₅: 294 (MH⁺).

[0297] 4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 11.70 (br s, 1H), 8.14 (s, 1H), 7.18 (m, 1H), 7.00-6.84 (m, 4H), 6.64 (m, 1H), 4.00 (m, 4H), 3.81 (s, 3H), 3.07 (m, 4H); MS (ESI) for C₁₇H₁₉N₅O: 310 (MH⁺).

[0298] 4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 11.71 (br s, 1H), 8.15 (s, 1H), 7.20 (m, 1H), 7.11 (m, 1H), 6.63 (m, 1H), 6.55 (m, 1H), 6.48 (m, 1H), 6.38 (m, 1H), 4.00 (m, 4H), 3.27 (s, 3H), 3.28 (m, 4H); MS (ESI) for C₁₇H₁₉N₅O: 310 (MH⁺).

[0299] 4-{4-[4-(methyloxy)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 11.71 (br s, 1H), 8.15 (s, 1H), 7.20 (m, 1H), 6.93 (m, 2H),

6.83 (m, 2H), 6.63 (m, 1H), 3.99 (m, 4H), 3.68 (s, 3H), 3.13 (m, 4H); MS (ESI) for C₁₇H₁₉N₅O: 310 (MH⁺).

[0300] 4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 11.73 (br s, 1H), 8.16 (s, 1H), 7.44 (m, 1H), 7.26-7.17 (m, 3H), 7.08 (m, 1H), 6.63 (m, 1H), 4.03 (m, 4H), 3.41 (m, 4H); MS (ESI) for C₁₇H₁₆F₃N₅: 314 (MH⁺).

[0301] 4-[4-(4-fluorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO): δ 11.75 (s, 1H), 8.20 (s, 1H), 7.42-7.00 (m, 5H), 6.60 (s, 1H), 4.08-3.98 (t, 4H), 3.26-3.18 (t, 4H); MS (ESI) for C₁₆H₁₆FN₅: 298 (MH⁺).

[0302] 4-[4-(4-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO): δ 11.70 (s, 1H), 8.40 (s, 1H), 7.30-7.20 (m, 3H), 7.02-6.92 (d, 2H), 6.62 (s, 1H), 4.00 (s, 4H), 3.20 (s, 4H); MS (ESI) for C₁₆H₁₆CIN₅: 314 (MH⁺).

[0303] 4-[4-(2-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO): δ 11.65 (s, 1H), 8.18 (s, 1H), 7.48-7.42 (s, 1H), 7.34-7.26 (m, 1H), 7.22-7.16 (m, 2H), 7.10-7.04 (m, 1H), 6.68 (s, 1H), 4.04 (t, 4H), 3.12 (t, 4H); MS (ESI) for C₁₆H₁₆CIN₅: 314 (MH⁺).

[0304] 4-[4-(2-fluorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO): δ 11.70 (s, 1H), 8.20 (s, 1H), 7.22-6.84 (m, 5H), 6.50 (s, 1H), 4.08 (s, 4H), 3.18 (s, 4H); MS (ESI) for C₁₆H₁₆FN₅: 298 (MH⁺).

[0305] EXAMPLE 3: 4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine

[0306] To 4-chloro-1H-pyrazolo[3,4-d]pyrimidine (60 mg, 0.39 mmol, R.K. Robins, *J. Am. Chem. Soc.* 1956, 78, 784-790) in ethanol (2 mL) was added diisopropylethylamine (50 mg, 0.39 mmol) and 1-phenylpiperazine (63 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 4 h. The precipitation was filtered, washed with methanol, and dried to give 4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine (68 mg, 62% yield) as a colorless solid. ¹H NMR (400 MHz, d₆-DMSO) δ 13.59 (br s, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 7.26 (m, 2H), 6.98 (m, 2H), 6.82 (m, 1H), 4.09 (m, 4H), 3.33 (m, 4H); MS (ESI) for C₁₅H₁₆N₆: 281 (MH⁺).

[0307] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0308] 4-[4-(3-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₆-DMSO) δ 13.59 (br s, 1H), 8.31 (s, 1H), 8.28 (s, 1H), 7.25 (m, 1H), 6.98 (m, 1H), 6.93 (m, 1H), 6.81 (m, 1H), 4.09 (m, 4H), 3.41 (m, 4H); MS (ESI) for C₁₅H₁₅ClN₆: 281 (MH⁺).

[0309] 4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₆-DMSO) δ 13.60 (br s, 1H), 8.31 (s, 1H), 8.29 (s, 1H), 7.47 (m, 1H), 7.26 (m, 1H), 7.20 (m, 1H), 7.10 (m, 1H), 4.11 (m, 4H), 3.47 (m, 4H); MS (ESI) for C₁₆H₁₅F₃N₆: 349 (MH⁺).

[0310] 4-[4-(2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₆-DMSO) δ 13.59 (br s, 1H), 8.33 (s, 1H), 8.28 (s, 1H), 7.21 (m, 1H), 7.16 (m, 1H), 7.05 (m, 1H), 6.99 (m, 1H), 4.09 (m, 4H), 2.98 (m, 4H), 2.33 (s, 3H); MS (ESI) for C₁₆H₁₈N₆: 295 (MH⁺).

[0311] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₆-DMSO) δ 13.60 (br s, 1H), 8.32 (s, 1H), 8.28 (s, 1H), 7.23 (m, 1H), 7.05 (m, 2H), 4.08 (m, 4H), 3.01 (m, 4H), 2.30 (s, 3H); MS (ESI) for C₁₆H₁₇ClN₆: 329 (MH⁺).

[0312] EXAMPLE 4: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine

[0313] To 4-hydroxy-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (270 mg, 1.80 mmol, R. Badger, *Aust. J. Chem.* 1965, 18, 1267-1270) in chloroform (5 mL) was added oxalyl chloride (0.23 mL, 2.68 mmol) and DMF (0.05 mL), and the mixture was refluxed for 8 h. Over the first 4 h reaction time, more oxalyl chloride (1.7 mL) and DMF (1.0 mL) was added in portions. The mixture was added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (130 mg, 43% yield) as a brown solid. ^1H NMR (400 MHz, d₆-DMSO) δ 8.75 (s, 1H), 2.64 (s, 3H); MS (ESI) for C₆H₅ClN₄: 169 (MH⁺).

[0314] To 4-chloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (125 mg, 0.74 mmol) in THF (5 mL) was added diisopropylethylamine (96 mg, 0.75 mmol) and 1-(5-chloro-2-methylphenyl)piperazine (156 mg, 0.74 mmol). The reaction mixture was stirred at room temperature for 2 h. The precipitation was filtered, washed with methanol, and dried to

give 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine (36 mg, 14% yield) as an off-white solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 13.27 (br s, 1H), 8.27 (s, 1H), 7.20 (m, 1H), 7.03 (m, 2H), 3.86 (m, 4H), 3.00 (m, 4H), 2.59 (s, 3H), 2.29 (s, 3H); MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{ClN}_6$: 343 (MH^+).

[0315] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0316] 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO): δ 8.40 (br s, 1H), 7.23 (t, 1H), 6.99 (m, 1H), 6.90 (dd, 1H), 6.80 (dd, 1H), 3.98 (s, 4H), 3.40 (s, 4H), 2.68 (s, 3H); MS (ESI) for $\text{C}_{16}\text{H}_{17}\text{ClN}_6$: 390 (MH^+)

[0317] 3-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_4 -methanol): δ 8.50 (s, 1H), 7.22-6.88 (m, 5H), 4.22 (s, 4H), 3.22 (s, 4H), 2.80 (s, 3H), 2.40 (s, 3H); MS (ESI) for $\text{C}_{17}\text{H}_{20}\text{N}_6$: 310 (MH^+).

[0318] EXAMPLE 5: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine

[0319] To 3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (82 mg, 0.50 mmol, DE 1966640, 1973) in thionyl chloride (5 mL) was added DMF (76 mg, 1.02 mmol) and the reaction mixture was refluxed for 3 h. The mixture was concentrated, the residue added to saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine (65 mg, 90% yield) as a yellow solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 8.73 (s, 1H), 3.05 (q, 2H), 1.32 (t, 3H); MS (ESI) for $\text{C}_7\text{H}_7\text{ClN}_4$: 183 (MH^+).

[0320] To 4-chloro-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine (60 mg, 0.33 mmol) in THF (5 mL) was added diisopropylethylamine (45 mg, 0.34 mmol) and 1-(5-chloro-2-methylphenyl)piperazine (83 mg, 0.39 mmol) and the reaction mixture was stirred at 50 °C for 5 h. The mixture was concentrated, and the remaining solid washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine (53 mg, 45% yield) as an off-white solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 13.35 (br s, 1H), 8.32 (s, 1H), 7.22 (m, 1H), 7.05 (m, 2H), 3.81 (m, 4H), 3.00 (m, 6H), 2.28 (s, 3H), 1.30 (t, 3H); MS (ESI) for $\text{C}_{18}\text{H}_{21}\text{ClN}_6$: 357 (MH^+).

[0321] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0322] 4-[4-(3-chlorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.36 (s, 1H), 8.32 (s, 1H), 7.25 (t, 1H), 7.01 (t, 1H), 6.96 (dd, 1H), 6.83 (dd, 1H), 3.80 (m, 4H), 3.34 (m, 4H), 2.98 (q, 2H), 1.29 (t, 3H); MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{ClN}_6$: 343 (MH^+).

[0323] 4-{4-[5-chloro-2-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.34 (s, 1H), 8.31 (s, 1H), 7.03 (dd, 1H), 6.98 (d, 1H), 6.93 (d, 1H), 3.82 (s, 3H), 3.79 (m, 4H), 3.14 (m, 4H) 2.97 (q, 2H), 1.29 (t, 3H); MS (ESI) for $\text{C}_{18}\text{H}_{21}\text{ClN}_6\text{O}$: 373 (MH^+).

[0324] 4-[4-(3-chlorophenyl)-1,4-diazepan-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 12.36 (br s, 1H), 8.36 (s, 1H), 7.09 (t, 1H), 6.67 (t, 1H), 6.62 (dd, 1H), 6.58 (dd, 1H), 4.08 (m, 2H), 3.85 (m, 2H), 3.75 (m, 2H), 3.50 (m, 2H), 3.04(q, 2H), 2.16 (m, 2H), 1.38 (t, 3H); MS (ESI) for $\text{C}_{18}\text{H}_{21}\text{ClN}_6$: 357 (MH^+).

[0325] 4-[5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 12.52 (br s, 1H), 8.39 (s, 1H), 7.08 (m, 1H), 6.63 (dd, 1H), 6.53 (m, 1H), 6.42 (dd, 1H), 5.30 (s, 1H), 4.55 (s, 1H), 4.06 (dd, 1H), 3.72 (m, 2H), 3.43 (d, 1H), 3.09-2.91 (m, 2H), 2.16 (q, 2H), 1.36 (t, 3H); MS (ESI) for $\text{C}_{18}\text{H}_{19}\text{ClN}_6$: 356 (MH^+).

[0326] 4-(4-{3-chloro-4-[(2-morpholin-4-yl-ethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_4 -methanol) δ 8.48 (s, 1H), 7.21 (d, 1H), 7.16 (d, 1H), 7.07 (dd, 1H), 4.43 (m, 2H), 4.35 (m, 4H), 4.10 (m, 2H), 3.88-3.81 (m, 2H), 3.73-3.65 (m, 4H), 3.42-3.37 (m, 6H), 3.23 (q, 2H), 1.44 (t, 3H).

[0327] 2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenol: ^1H NMR (400 MHz, CDCl_3) δ 8.36 (s, 1H), 6.96 (s, 1H), 6.73 (s, 1H), 4.08 (br s, 4H), 3.02 (q, 2H), 2.99 (m, 4H), 2.30 (s, 3H), 1.39 (t, 3H); MS (ESI) for $\text{C}_{18}\text{H}_{21}\text{ClN}_6\text{O}$: 373 (MH^+).

[0328] 3-({2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-N,N-dimethylpropan-1-amine trifluoroacetate: ^1H NMR (400 MHz, d_4 -methanol) δ 8.43 (s, 1H), 7.12 (s, 1H), 6.99 (s, 1H), 4.20 (br s, 4H), 4.15 (t, 2H), 3.39

(t, 2H), 3.16 (q, 2H), 3.02 (t, 4H), 2.96 (s, 6H), 2.38 (s, 3H), 2.25 (m, 2H), 1.40 (t, 3H); MS (ESI) for C₂₃H₃₂ClN₇O: 458 (MH⁺).

[0329] 2-(2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-N,N-dimethylethanamine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.43 (s, 1H), 7.14 (s, 1H), 7.07 (s, 1H), 4.38 (t, 2H), 4.21 (br s, 4H), 3.63 (t, 2H), 3.16 (q, 2H), 3.02 (m, 10H), 2.40 (s, 3H), 1.40 (t, 3H); MS (ESI) for C₂₂H₃₀ClN₇O: 444 (MH⁺).

[0330] 4-{4-[5-chloro-2-methyl-4-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 7.08 (s, 1H), 6.94 (s, 1H), 4.25 (br s, 4H), 3.83 (s, 3H), 3.18 (q, 2H), 3.02 (t, 4H), 2.39 (s, 3H), 1.41 (t, 3H); MS (ESI) for C₁₉H₂₃ClN₆O: 387 (MH⁺).

[0331] 4-[4-(3,6-dimethylpyrazin-2-yl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.35 (s, 1H), 8.35 (s, 1H), 8.00 (s, 1H), 3.81 (m, 4H), 3.30 (m, 4H), 2.99 (q, 2H), 2.47 (s, 3H), 2.35 (s, 3H) 1.29 (t, 3H); MS (ESI) for C₁₇H₂₂N₈: 339 (MH⁺).

[0332] 1-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]isoquinoline: ¹H NMR (400 MHz, d₆-DMSO) δ 13.31 (s, 1H), 8.31 (s, 1H), 8.18 (d, 1H), 8.12 (d, 1H), 7.89 (d, 1H), 7.71 (m, 1H), 7.62 (m, 1H), 7.41 (d, 1H), 3.94 (m, 4H), 3.48 (m, 4H), 3.00 (q, 2H), 1.30 (t, 3H); MS (ESI) for C₂₀H₂₁N₇: 360 (MH⁺).

[0333] 4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.34 (s, 1H), 8.31 (s, 1H), 6.46 (s, 1H), 3.90 (m, 4H), 3.72 (m, 4H), 2.99 (q, 2H), 2.26 (s, 6H), 1.29 (t, 3H); MS (ESI) for C₁₇H₂₂N₈: 339 (MH⁺).

[0334] 2-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carboxamide: ¹H NMR (400 MHz, d₆-DMSO) δ 8.46 (s, 1H), 8.26 (m, 1H), 7.96 (s, 1H), 7.81 (m, 1H), 7.62 (s, 1H), 6.95 (dd, 1H), 3.96 (br s, 4H), 3.52 (br s, 4H), 3.05 (br s, 2H), 1.29 (t, 3H); C₁₇H₂₀N₈O: 353 (MH⁺).

[0335] N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N-methyl-N-(1-methylethyl)ethane-1,2-diamine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.55 (s, 2H), 4.20 (br s, 4H), 3.69 (m, 1H),

3.58 (m, 2H), 3.48 (m, 1H), 3.24 (m, 1H), 3.16 (q, 2H), 3.04 (br s, 4H), 2.88 (s, 3H), 2.24 (s, 3H), 1.42 (t, 3H), 1.36 (m, 6H); MS (ESI) for C₂₄H₃₅ClN₈: 471 (MH⁺).

[0336] N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N-ethyl-N-methylethane-1,2-diamine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.55 (s, 2H), 4.17 (br s, 4H), 3.57 (m, 2H), 3.47 (m, 1H), 3.35 (m, 1H), 3.25 (m, 2H), 3.15 (q, 2H), 3.02 (br s, 4H), 2.93 (s, 3H), 2.21 (s, 3H), 1.40 (t, 3H), 1.34 (t, 3H); MS (ESI) for C₂₃H₃₃ClN₈: 457 (MH⁺).

[0337] methyl 4-(3-chlorophenyl)-1-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate: ¹H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 7.24 (t, 1H), 6.98 (m, 1H), 6.89 (dd, 1H), 5.97 (br s, 1H), 4.43-4.30 (m, 2H), 4.12 (m, 1H), 3.79 (s, 3H), 3.75 (m, 1H), 3.33-3.14 (m, 4H), 3.03 (dt, 1H), 1.43 (t, 3H); MS (ESI) for C₁₉H₂₁ClN₆O₂: 401 (MH⁺).

[0338] 4-(3-chlorophenyl)-1-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-methylpiperazine-2-carboxamide: ¹H NMR (400 MHz, CDCl₃) δ 12.44 (br s, 1H), 8.51 (s, 1H), 7.20 (t, 1H), 6.99 (br m, 1H), 6.94 (dd, 1H), 6.86 (dd, 1H), 6.72-6.65 (br m, 1H), 5.24 (br s, 1H), 4.33 (d, 1H), 4.26 (d, 1H), 3.81-3.70 (m, 1H), 3.58-3.51 (m, 1H), 3.18-2.96 (m, 4H), 2.89 (m, 3H), 1.47 (t, 3H); MS (ESI) for C₁₉H₂₂ClN₇O: 400 (MH⁺).

[0339] 4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.36 (s, 1H), 6.78 (br s, 1H), 6.73 (br s, 1H), 4.34 (t, 2H), 4.15 (br s, 4H), 4.05-3.69 (br m, 4H), 3.62 (t, 2H), 3.58-3.26 (br m, 4H), 3.09 (q, 2H), 3.03-2.96 (br m, 4H), 2.19 (s, 3H), 1.32 (t, 3H); MS (ESI) for C₂₄H₃₂ClN₇O₂: 486 (MH⁺).

[0340] 4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.36 (s, 1H), 6.76 (m, 1H), 6.71 (m, 1H), 4.30 (t, 2H), 4.24-4.11 (br m, 4H), 3.62-3.50 (br m, 4H), 3.17-2.95 (br m, 8H), 2.18 (s, 3H), 1.94-1.71 (br m, 5H), 1.54-1.41 (br m, 1H), 1.32 (t, 3H); MS (ESI) for C₂₅H₃₄ClN₇O: 484 (MH⁺).

[0341] 4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.38 (s, 1H), 6.74 (m, 1H), 6.68 (m, 1H), 4.30 (t, 2H), 4.23 (br m, 6H), 3.70-2.88 (m, 18H), 2.18 (s, 3H), 1.37-1.25 (m, 6H); MS (ESI) for C₂₆H₃₇ClN₈O: 513 (MH⁺).

[0342] 4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.38 (s, 1H), 6.70 (m, 1H), 6.67 (m, 1H), 4.20 (br m, 4H), 4.08-3.92 (m, 4H), 3.82-3.65 (br m, 2H), 3.56-3.43 (br m, 2H), 3.40-3.27 (br m, 2H), 3.20-3.06 (br m., 4H), 3.03-2.95 (br m, 4H), 2.28-2.18 (br m, 2H), 2.18-2.14 (br m, 3H), 1.39-1.28 (t, 3H); MS (ESI) for C₂₅H₃₄ClN₇O₂: 500 (MH⁺).

[0343] 4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 6.78 (m, 1H), 6.75 (m, 1H), 4.33-4.16 (br m, 4H), 4.15-4.07 (m, 2H), 3.79-3.67 (m, 2H), 3.49-3.38 (m, 2H), 3.24-3.04 (m, 8H), 2.35-1.98 (m, 9H), 1.42 (t, 3H); MS (ESI) for C₂₅H₃₄ClN₇O: 484 (MH⁺).

[0344] 4-[4-(5-chloro-2-methyl-3-[(3-(4-methylpiperazin-1-yl)propyl)oxy]phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.36 (s, 1H), 6.67 (m, 1H), 6.63 (m, 1H), 4.26-4.15 (br m, 4H), 4.04-3.96 (m, 2H), 3.60-3.27 (m, 6H), 3.20-3.07 (m, 4H), 3.03-2.92 (m, 4H), 2.88-2.85 (m, 3H), 2.22-2.10 (m, 4H), 1.33 (t, 3H); MS (ESI) for C₂₆H₃₇ClN₈O: 513 (MH⁺).

[0345] 4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.33 (s, 1H), 6.69 (m, 1H), 6.67 (m, 1H), 4.18-4.04 (br m, 4H), 4.02 (t, 2H), 3.57-3.49 (m, 2H), 3.27-3.23 (m, 2H), 3.12-3.02 (m, 2H), 3.01-2.86 (m, 6H), 2.24-2.17 (m, 2H), 2.15 (br s, 3H), 1.94-1.84 (m, 2H), 1.82-1.64 (m, 3H), 1.52-1.40 (m, 1H), 1.32 (t, 3H); MS (ESI) for C₂₆H₃₆ClN₇O: 498 (MH⁺).

[0346] 4-[4-(5-chloro-3-[(3-(4-ethylpiperazin-1-yl)propyl)oxy]-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.37 (s, 1H), 6.68 (m, 1H), 6.64 (m, 1H), 4.27-4.13 (br m, 4H), 4.00 (t, 2H), 3.54-3.23 (m, 6H), 3.20-3.05 (m, 8H), 3.01-2.94 (m, 4H), 2.19-2.07 (m, 5H), 1.35-1.24 (m, 6H); MS (ESI) for C₂₇H₃₉ClN₈O: 527 (MH⁺).

[0347] 3-({5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)-N,N-diethylpropan-1-amine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.46 (s, 1H), 6.79 (m, 1H), 6.76 (m, 1H), 4.33-4.21 (m, 4H), 4.11 (t, 2H),

3.42-3.35 (m, 2H), 3.24-3.15 (m, 2H), 3.10-3.03 (m, 4H), 2.32-2.19 (m, 5H), 1.46-1.30 (m, 9H); MS (ESI) for C₂₅H₃₆ClN₇O: 486 (MH⁺).

[0348] N-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N',N'-trimethylethane-1,2-diamine: ¹H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 6.83 (m, 1H), 6.77 (m, 1H), 4.06-3.81 (br m, 4H), 3.11-3.01 (m, 8H), 2.69 (s, 3H), 2.53 (m, 2H), 2.31 (s, 3H), 2.27 (s, 6H), 1.37 (t, 3H); MS (ESI) for C₂₃H₃₃ClN₈: 457 (MH⁺).

[0349] 3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.33 (s, 1H), 6.02 (m, 1H), 5.99 (m, 1H), 4.34-3.92 (m, 4H), 3.69-3.55 (m, 4H), 3.47 (t, 2H), 3.36 (t, 2H), 3.12-2.99 (m, 4H), 2.98-2.88 (m, 4H), 2.12-1.84 (m, 8H), 1.31 (t, 3H), 0.91 (d, 6H); MS (ESI) for C₂₃H₃₃ClN₈: 457 (MH⁺).

[0350] 3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline: ¹H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 7.15 (m, 1H), 7.04 (m, 1H), 4.09-3.80 (br m, 4H), 3.51 (t, 2H), 3.16-2.94 (m, 14H), 2.26 (s, 3H), 2.00-1.93 (m, 4H), 1.71-1.61 (m, 2H), 1.46-1.33 (m, 5H), 0.95 (t, 3H); MS (ESI) for C₂₉H₄₂ClN₈O: 519 (MH⁺).

[0351] N,N-diethyl-2-({3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)ethanamine: ¹H NMR (400 MHz, CD₃OD) δ 8.43 (s, 1H), 7.24-7.20 (t, 1H), 6.70 (dd, 1H), 6.64 (t, 1H), 6.55 (dd, 1H), 4.33 (t, 2H), 4.20 (br s, 4H), 3.59 (t, 2H), 3.41 (t, 4H), 3.35 (t, 4H), 3.18 (m, 2H), 1.42-1.35 (m, 9H); MS (ESI) for C₂₃H₃₃N₇O: 424 (MH⁺).

[0352] N,N-diethyl-2-({3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)ethanamine: ¹H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 7.17 (t, 1H), 6.81 (d, 1H), 6.80 (d, 1H), 4.31 (t, 2H), 4.26 (br s, 4H), 3.68 (t, 2H), 3.40 (m, 4H), 3.18 (m, 2H), 3.08 (t, 4H), 2.31 (s, 3H), 1.40 (m, 9H); MS (ESI) for C₂₄H₃₅N₇O: 438 (MH⁺).

[0353] 3-ethyl-4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.35 (s, 1H), 8.32 (s, 1H), 7.18 (m, 2H), 7.10 (d, 1H), 7.07 (s, 1H), 6.94 (m, 1H), 3.81 (t, 3H), 3.31 (t, 4H), 2.98 (m, 2H), 1.29 (t, 3H); MS (EI) for C₁₇H₂₀N₆: 309 (MH⁺).

- [0354] 3-ethyl-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.43 (s, 1H), 7.17 (t, 1H), 6.61 (dd, 1H), 6.55 (t, 1H), 6.48 (dd, 1H), 4.24 (br s, 4H), 3.78 (s, 3H), 3.41 (t, 4H), 3.20 (m, 2H), 1.42 (t, 3H); MS (ESI) for C₁₈H₂₂N₆O: 339 (MH⁺).
- [0355] Ethyl-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)pyrimidine-5-carboxylate: ^1H NMR (400 MHz, d₄-methanol) δ 8.81 (s, 1H), 8.48 (s, 1H), 4.43 (m, 2H), 4.30 (t, 4H), 3.96 (t, 4H), 3.21 (q, 2H), 1.42 (m, 6H); MS (ESI) for C₁₉H₂₁F₃N₈O₂: 451 (MH⁺).
- [0356] 4-{4-[3-chloro-5-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 6.61 (s, 1H), 6.46 (t, 3H), 4.23 (br s, 4H), 3.78 (s, 3H), 3.44 (t, 4H), 3.19 (q, 2H), 1.42 (t, 3H); MS (ESI) for C₁₈H₂₁ClN₆O: 373 (MH⁺).
- [0357] 3-ethyl-4-{4-[4-trifluoromethyl]pyridin-2-yl}piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.46 (s, 1H), 8.34 (d, 1H), 7.08 (s, 1H), 6.93 (dd, 1H), 4.27 (t, 4H), 3.92 (m, 4H), 3.21 (q, 2H), 1.43 (t, 3H); MS (ESI) for C₁₇H₁₈F₃N₇: 378 (MH⁺).
- [0358] 4-{4-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.43 (s, 1H), 6.75 (d, 1H), 4.25 (br s, 4H), 3.83 (s, 3H), 3.19 (q, 2H), 3.07 (t, 4H), 2.21 (s, 3H), 1.42 (t, 3H); MS (ESI) for C₁₉H₂₃ClN₆O: 388 (MH⁺).
- [0359] 3-ethyl-4-{4-[2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 7.11 (t, 1H), 6.71 (t, 2H), 4.28 (br s, 4H), 3.81 (s, 3H), 3.19 (q, 2H), 3.07 (t, 4H), 2.24 (s, 3H), 1.41 (t, 3H); MS (ESI) for C₁₉H₂₄N₆O: 353 (MH⁺).
- [0360] 2-((3-chloro-5-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl)oxy)-N,N-diethylethanamine: ^1H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.70 (s, 1H), 6.55 (m, 2H), 4.87 (t, 2H), 3.60 (br s, 4H), 3.60-3.43 (t, 2H), 3.31 (m, 4H), 1.42-1.35 (m, 6H); MS (EI) for C₂₃H₃₂ClN₇O: 458 (MH⁺).
- [0361] 4-(4-(3-chloro-4-[(2-piperidin-1-ylethyl)oxy]phenyl)piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 7.13 (d, 1H), 7.10 (d, 1H), 6.98 (dd, 1H), 4.36 (m, 2H), 4.19 (br s, 4H), 3.74 (m,

2H), 3.59 (m, 2H), 3.33 (m, 4H), 3.20-3.11 (m, 4H), 2.00 (m, 2H), 1.88-1.81 (m, 3H), 1.57 (m, 1H), 1.41 (t, 3H); MS (ESI) for C₂₄H₃₁CIN₇O: 470 (MH⁺).

[0362] 4-[4-(5-chloro-2-methyl-3-morpholin-4-ylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.31 (s, 1H), 8.29 (s, 1H), 6.78 (d, 1H), 6.74 (d, 1H), 3.79 (m, 4H), 3.73 (m, 4H), 3.01 (m, 4H), 2.96 (q, 2H), 2.85 (m, 4H), 2.25 (s, 3H), 1.29 (t, 3H); MS (ESI) for C₂₂H₂₈CIN₇O: 442 (MH⁺).

[0363] 2-{[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine trifluoroacetate: ¹H NMR (400 MHz, d₆-DMSO) δ 9.65 (br s, 1H), 8.36 (br s, 1H), 6.90 (d, 1H), 6.69 (d, 1H), 4.33 (m, 2H), 3.87 (br s, 2H), 3.77 (s, 3H), 3.48 (4H buried under water peak), 3.20 (br s, 4H), 3.00 (q, 2H), 2.90 (m, 6H), 1.30 (t, 3H); MS (ESI) for C₂₂H₃₀CIN₇O₂: 260 (MH⁺).

[0364] 3-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-dimethylprop-2-yn-1-amine trifluoroacetate: ¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (br s, 1H), 7.32 (d, 1H), 7.20 (d, 1H), 4.39 (s, 2H), 3.87 (br s, 2H), 3.46 (2H buried under water peak), 3.07-2.99 (m, 6H), 2.90 (s, 6H), 2.40 (s, 3H), 1.30 (t, 3H); MS (ESI) for C₂₃H₂₇CIN₇: 438 (MH⁺).

[0365] N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-dimethylethane-1,2-diamine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.48 (s, 1H), 6.56 (m, 2H), 4.34 (br s, 4H), 3.58 (t, 2H), 3.41 (t, 2H), 3.21 (q, 2H), 3.07 (br s, 4H), 2.96 (s, 6H), 2.24 (s, 3H), 1.42 (t, 3H); MS (ESI) for C₂₂H₃₀CIN₈: 443 (MH⁺).

[0366] 3-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-diethylpropan-1-amine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.48 (s, 1H), 7.06 (d, 1H), 7.00 (d, 1H), 4.34 (br s, 4H), 3.28-3.20 (m, 8H), 3.09 (m, 4H), 2.76 (m, 2H), 2.40 (s, 3H), 2.00 (m, 2H), 1.44 (t, 3H), 1.33 (t, 6H); MS (ESI) for C₂₅H₃₆CIN₇: 470 (MH⁺).

[0367] 4-(4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 7.04 (d, 1H), 6.99 (d, 1H), 4.34 (br s, 4H), 3.67 (m, 2H), 3.29-3.19 (m, 6H), 3.14-3.06 (m, 6H), 2.76 (m, 2H), 2.39 (s, 3H), 2.19-2.14 (m, 2H), 2.06-1.98 (m, 4H), 1.44 (t, 3H); MS (ESI) for C₂₅H₃₄CIN₇: 468 (MH⁺).

[0368] 2-(5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl)oxy)-N,N-dimethylethanamine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 6.87 (d, 1H), 6.81 (d, 1H), 4.38 (m, 2H), 4.33 (br s, 4H), 3.67 (m, 2H), 3.22 (q, 2H), 3.10 (m, 4H), 3.04 (s, 6H), 2.30 (s, 3H), 1.43 (t, 3H); MS (ESI) for C₂₂H₃₀ClN₇O: 444 (MH⁺).

[0369] 2-(5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl)oxy)-N,N-diethylethanamine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 6.87 (d, 1H), 6.81 (d, 1H), 4.38 (m, 2H), 4.34 (br s, 4H), 3.69 (m, 2H), 3.43-3.37 (m, 4H), 3.22 (q, 2H), 3.10 (m, 4H), 2.29 (s, 3H), 1.45-1.39 (m, 9H); MS (ESI) for C₂₄H₃₄ClN₇O: 472 (MH⁺).

[0370] 4-(4-(5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl)piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) 8.47 (s, 1H), 6.86 (d, 1H), 6.81 (d, 1H), 4.36-4.30 (m, 6H), 3.79 (m, 2H), 3.73 (m, 2H), 3.27 (m, 2H), 3.22 (q, 2H), 3.10 (m, 4H), 2.31 (s, 3H), 2.22 (m, 2H), 2.08 (m, 2H), 1.43 (t, 3H); MS (ESI) for C₂₄H₃₂ClN₇O: 470 (MH⁺).

[0371] 5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 6.53 (s, 2H), 3.71 (m, 2H), 3.57 (t, 2H), 3.46 (t, 2H), 3.23-3.13 (m, 4H), 3.04 (br s, 4H), 2.23 (s, 3H), 2.18 (m, 2H), 2.05 (m, 2H), 1.42 (t, 3H); MS (ESI) for C₂₄H₃₃ClN₈: 469 (MH⁺).

[0372] 4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 7.05 (s, 1H), 6.99 (s, 1H), 4.33 (br s, 4H), 4.06 (d, 2H), 3.79 (t, 2H), 3.52 (d, 2H), 3.26-3.04 (m, 10H), 2.76 (m, 2H), 2.40 (s, 3H), 2.06 (m, 2H), 1.44 (t, 3H); MS (ESI) for C₂₅H₃₄ClN₇O: 484 (MH⁺).

[0373] N'-(5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl)-N,N-diethylethane-1,2-diamine: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 6.55 (m, 2H), 4.31 (br s, 4H), 3.60 (t, 2H), 3.40 (t, 2H), 3.32 (4H buried under solvent), 3.22 (q, 2H), 3.07 (br s, 4H), 2.24 (s, 3H), 1.43 (t, 3H), 1.35 (t, 6H); MS (ESI) for C₂₄H₃₅ClN₈: 471 (MH⁺).

[0374] 4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ

8.39 (s, 1H), 7.03 (s, 1H), 7.00 (s, 1H), 4.14 (br s, 4H), 3.55 (d, 2H), 3.16 (m, 4H), 3.06 (br s, 4H), 2.94 (t, 2H), 2.74 (t, 2H), 2.38 (s, 3H), 2.06-1.95 (m, 4H), 1.85 (m, 1H), 1.78 (m, 2H), 1.54 (m, 1H), 1.43 (t, 3H); MS (ESI) for C₂₆H₃₆ClN₇: 482 (MH⁺).

[0375] 4-[4-(3-bromo-2-chloro-5-fluorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, CDCl₃) δ 11.21 (s, 1H), 8.44 (s, 1H), 7.12 (dd, 1H), 6.76 (dd, 1H), 3.95 (m, 4H), 3.18 (m, 4H), 3.02 (q, 2H), 1.41 (t, 3H); MS (ESI) for C₁₇H₁₇BrClFN₆: 439 (MH⁺).

[0376] 2-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 6.44 (dd, 1H), 6.34 (dd, 1H), 4.32 (br s, 4H), 3.73 (m, 2H), 3.62 (t, 2H), 3.45 (t, 2H), 3.26 -3.11 (m, 8H), 2.16 (m, 2H), 2.04 (m, 2H), 1.41 (t, 3H); MS (ESI) for C₂₃H₃₀ClFN₈: 473 (MH⁺).

[0377] 4-[4-(2,5-difluorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.31 (s, 1H), 8.30 (s, 1H), 7.19 (m, 1H), 6.93 (m, 1H), 6.78 (m, 1H), 3.81 (m, 4H), 3.19 (m, 4H), 2.97 (q, 2H), 1.29 (t, 3H); MS (ESI) for C₁₇H₁₈F₂N₆: 345 (MH⁺).

[0378] 3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(phenylmethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.49 (s, 1H), 7.41 (m, 2H), 7.35 (m, 2H), 7.30 (m, 1H), 5.08 (s, 2H), 4.39 (br s, 4H), 3.71 (br s, 2H), 3.60 (t, 2H), 3.42 (t, 2H), 3.27-3.06 (m, 8H), 2.25 (s, 3H), 2.17 (br s, 2H), 2.05 (br s, 2H), 1.44 (t, 3H); MS (ESI) for C₃₁H₄₀N₈O: 542 (M+2).

[0379] methyl 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 7.21 (m, 1H), 6.94 (s, 1H), 6.87-6.79 (m, 2H), 5.11-5.04 (d, 2H), 4.64-4.56 (d, 1H), 4.04-3.96 (d, 2H), 3.86-3.59 (m, 3H), 3.52 (s, 3H), 3.22-3.15 (m, 2H), 1.42-1.37 (m, 3H); MS (ESI) for C₁₉H₂₁ClN₆O₂: 401 (MH⁺).

[0380] 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylic acid: ¹H NMR (400 MHz, d₆-DMSO) δ 13.34 (s, 1H), 12.75 (s, 1H), 8.30 (s, 1H), 7.22-7.17 (m, 1H), 6.91 (s, 1H), 6.85 (d, 1H), 6.75 (d, 1H), 4.85 (s, 1H), 4.66 (d, 1H), 4.24 (d, 1H), 3.71-3.64 (d, 1H), 3.61-3.51 (m, 2H), 3.03-2.90 (m, 2H), 1.30-1.25 (m, 3H); MS (ESI) for C₁₈H₁₉ClN₆O₂: 387 (MH⁺).

- [0381] 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-methylpiperazine-2-carboxamide trifluoroacetate: ^1H NMR (400 MHz, d₆-DMSO) δ 13.34 (s, 1H), 12.75 (s, 1H), 8.30 (s, 1H), 7.20 (m, 1H), 6.91 (s, 1H), 6.85 (d, 1H), 6.75 (d, 1H), 4.85 (s, 1H), 4.66 (d, 1H), 4.24 (d, 1H), 3.71-3.64 (d, 1H), 3.61-3.51 (m, 2H), 3.03-2.90 (m, 2H), 1.30-1.25 (m, 3H); MS (ESI) for C₁₉H₂₂ClN₇O: 400 (MH⁺).
- [0382] 1-(3-chlorophenyl)-N-[2-(dimethylamino)ethyl]-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxamide trifluoracetate: ^1H NMR (400 MHz, d₆-DMSO) δ 9.37 (s, 1H), 8.50 (s, 1H), 8.28 (s, 1H), 7.25 (m, 1H), 6.80 (m, 2H), 4.70-3.56 (m, 7H), 3.04-2.90 (m, 4H), 2.73 (d, 6H), 1.29-1.22 (m, 3H); MS (ESI) for C₂₂H₂₉ClN₈O: 457 (MH⁺).
- [0383] [1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2-yl]methanol trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.48 (s, 1H), 7.25-7.19 (m, 1H), 6.96 (s, 1H), 6.88 (d, 1H), 6.80 (d, 1H), 4.73 (br s, 1H), 4.52 (br s, 1H), 4.13 (br s, 1H), 4.05-3.98 (m, 1H), 3.69-3.57 (m, 2H), 3.53-3.41 (m, 2H), 3.27-3.20 (m, 2H), 1.45-1.40 (m, 3H); MS (ESI) for C₁₈H₂₁ClN₆O: 373 (MH⁺).
- [0384] 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)piperazine-2-carboxamide trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.43 (s, 1H), 7.25 (m, 1H), 6.90-6.78 (m, 3H), 4.80 (d, 1H), 4.42 (s, 1H), 4.38-4.27 (m, 2H), 4.07 (br s, 1H), 3.85 (br s, 2H), 3.77-3.69 (m, 1H), 3.49 (d, 2H), 3.24-3.15 (m, 2H), 3.08-2.97 (m, 2H), 2.80 (s, 3H), 1.91 (br s, 2H), 1.80-1.64 (m, 2H), 1.42-1.36 (m, 3H); MS (ESI) for C₂₄H₃₁ClN₈O: 484 (MH⁺).
- [0385] 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(2-morpholin-4-ylethyl)piperazine-2-carboxamide trifluoracetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.40 (s, 1H), 7.17 (m, 1H), 6.85 (s, 1H), 6.77 (d, 2H), 4.77 (d, 1H), 4.52 (s, 1H), 4.25 (m, 2H), 4.07 (m, 1H), 3.88 (br s, 2H), 3.77-3.59 (m, 2H), 3.56-3.47 (m, 2H), 3.37 (m, 2H), 3.18-3.07 (m, 4H), 2.99 (br s, 2H), 1.33-1.28 (m, 3H); MS (ESI) for C₂₄H₃₁ClN₈O₂: 499 (MH⁺).
- [0386] 4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 6.77 (s, 1H), 6.72 (s, 1H), 4.24 (br s, 4H), 4.06 (m, 2H), 3.52 (d, 2H), 3.17 (m, 2H), 3.06 (m, 4H), 2.99 (d, 2H),

2.86 (s, 3H), 2.21 (s, 3H), 2.08 (d, 2H), 1.85 (m, 3H), 1.52 (m, 2H), 1.43-1.37 (m, 3H); MS (ESI) for C₂₆H₃₆ClN₇O: 499 (MH⁺).

[0387] 4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 6.79 (s, 1H), 6.75 (s, 1H), 4.26 (br s, 4H), 4.15 (m, 2H), 3.47 (m, 2H), 3.25 (m, 2H), 3.18 (m, 2H), 3.13 (m, 2H), 3.07 (m, 4H), 3.00 (m, 4H), 2.88 (s, 3H), 2.22 (s, 3H), 1.43-1.38 (m, 3H); MS (ESI) for C₂₅H₃₅ClN₈O: 500 (MH⁺).

[0388] 4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: MS (ESI) for C₂₇H₃₆ClN₅O: 483 (MH⁺).

[0389] 4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.48 (s, 1H), 7.06 (s, 1H), 6.99 (s, 1H), 4.33 (br s, 2H), 3.87 (br s, 4H), 3.62 (br s, 4H), 3.36 (m, 2H), 3.21 (m, 4H), 3.09 (m, 2H), 3.02 (m, 2H), 2.76 (m, 2H), 2.39 (s, 3H), 2.12 (m, 2H), 1.45-1.38 (m, 3H), 1.35-1.27 (m, 3H); MS (ESI) for C₂₆H₃₇ClN₈: 498 (MH⁺).

[0390] 5-bromo-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylaniline: ¹H NMR (400 MHz, d₆-DMSO) δ 13.29 (s, 1H), 8.28 (s, 1H), 6.58 (s, 1H), 6.39 (s, 1H), 5.13 (s, 2H), 3.79 (br s, 4H), 3.00-2.93 (m, 2H), 2.92-2.88 (m, 4H), 1.99 (s, 3H), 1.31-1.26 (m, 3H); MS (ESI) for C₁₈H₂₂BrN₇: 417 (MH⁺).

[0391] 4-{4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 7.63 (d, 1H), 7.41 (s, 1H), 7.39 (d, 1H), 4.26 (br s, 4H), 3.30 (m, 4H), 3.21-3.15 (m, 2H), 1.46-1.40 (m, 4H); MS (ESI) for C₁₈H₁₈ClF₃N₆: 411(MH⁺).

[0392] 3-bromo-5-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide trifluoroacetate: ¹H NMR (400 MHz, d₆-DMSO) δ 13.31 (s, 1H), 10.22 (s, 1H), 8.31 (s, 1H), 7.94 (s, 1H), 7.73-7.68 (d, 2H), 7.64 (s, 1H), 7.37-7.31 (m, 2H), 7.12-7.07 (m, 1H), 3.86 (br s, 4H), 3.07 (br s, 4H), 3.02-2.95 (m, 2H), 2.46 (s, 3H), 1.33-1.27 (m, 3H); MS (ESI) for C₂₅H₂₆BrN₇O: 521 (MH⁺).

[0393] 4-[4-(3-Ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6,7-bis(methoxy)quinazoline hydrochloride ^1H NMR (400 MHz, d₄-methanol) δ 8.83 (s, 1H), 8.36 (s, 1H), 7.49 (s, 1H), 7.25 (s, 1H), 4.37-4.32 (m, 4H), 4.07-4.02 (m, 4H), 4.00 (s, 3H), 3.96 (s, 3H), 3.04-2.98 (q, 2H), 1.30-1.26 (t, 3H); MS (ESI) for C₂₁H₂₄N₈O₂: 421 (MH⁺).

[0394] EXAMPLE 6: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propyl-1H-pyrazolo[3,4-d]pyrimidine

[0395] To a suspension of sodium hydride (60% in mineral oil, 2.0 g, 50.0 mmol) in anhydrous THF (35 mL) was added dropwise a solution of malononitrile (3.0 g, 45.4 mmol) in THF (5 mL) at 0 °C. The reaction was stirred at room temperature for 20 min, then cooled to 0 °C. A solution of butyryl chloride (4.84 g, 45.4 mmol) in THF (10 mL) was added dropwise over 1 h, and the reaction mixture was stirred at room temperature for an additional 16 h. The reaction was concentrated, acidified with 2 N hydrochloric acid (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were dried over magnesium sulfate, and concentrated to give crude (1-hydroxybutylidene)propanedinitrile (3.12 g) as a brown oil.

[0396] To a solution of (1-hydroxybutylidene)propanedinitrile (288 mg, 2.12 mmol) in diethyl ether (1.5 mL) and methanol (1.5 mL) was added dropwise a solution of TMS-diazomethane in hexanes (2.0M, 483 mg, 4.24 mmol) at 0 °C. The reaction was stirred at 0 °C for 3 h, and then quenched with glacial acetic acid (0.5 mL). The solution was basified with saturated sodium bicarbonate (100 mL), and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 1:1) afforded [1-(methoxy)-butylidene]propanedinitrile (128 mg) as a tan oil.

[0397] A mixture of [1-(methoxy)-butylidene]propanedinitrile (128 mg, 1.87 mmol) and hydrazine hydrate (187 mg, 3.74 mmol) in ethanol (3 mL) was stirred at 80 °C for 3 h, and then concentrated to give 5-amino-3-propyl-1H-pyrazole-4-carbonitrile (115 mg) as a tan oil. ^1H NMR (400 MHz, d₆-DMSO) δ 5.87 (br s, 1H), 3.85 (s, 1H), 2.48-2.44 (m, 2H), 1.62-1.57 (m, 2H), 0.90-0.87 (m, 3H); MS (ESI) for C₇H₁₀N₄: 151 (MH⁺).

[0398] A solution of 5-amino-3-propyl-1H-pyrazole-4-carbonitrile (115 mg, 0.77 mmol) in formic acid (4 mL) was heated at 110 °C for 4 h. The solution was concentrated,

ethyl acetate (5 mL) was added, and the precipitate was filtered, and dried to afford 3-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (43.0 mg) as a tan solid.

[0399] A suspension of 3-propyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (43.0 mg, 0.24 mmol) in thionyl chloride (5 mL) and DMF (0.05 ml) was refluxed for 2 h under nitrogen. The solution was concentrated, added into saturated sodium bicarbonate (10 mL), and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with 5% lithium chloride (50 mL), dried with sodium sulfate, and concentrated to give 4-chloro-3-propyl-1H-pyrazolo[3,4-d]pyrimidine (37 mg). ¹H NMR (400 MHz, d₆-DMSO) δ 8.76 (s, 1H), 7.93 (br s, 1H), 3.03-2.99 (m, 2H), 1.82-1.73 (m, 2H), 0.99-0.95 (m, 3H); MS (ESI) for C₈H₉ClN₄: 197 (MH⁺).

[0400] A solution of 4-chloro-3-propyl-1H-pyrazolo[3,4-d]pyrimidine (35 mg, 0.18 mmol), diisopropylethylamine (24 mg, 0.19 mmol), and 1-(5-chloro-2-methylphenyl)piperazine (40 mg, 0.19 mmol) in THF (5 mL) was stirred at 50 °C for 2 h. The mixture was concentrated, and the remaining solid washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propyl-1H-pyrazolo[3,4-d]pyrimidine (6 mg) as an off-white solid. ¹H NMR (400 MHz, d₄-methanol) δ 8.31 (br s, 1H), 7.19 (d, 1H), 7.04 (s, 1H), 6.99 (d, 1H), 3.95-3.92 (m, 4H), 3.05 (m, 4H), 3.00 (d, 2H), 2.34 (s, 3H), 1.87-1.77 (m, 2H), 1.00-0.96 (m, 3H); MS (ESI) for C₁₉H₂₃ClN₆: 371 (MH⁺).

[0401] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0402] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.38 (br s, 1H), 8.37 (s, 1H), 7.22 (d, 1H), 7.05 (m, 2H), 3.80 (br s, 4H), 3.38 (m, 1H), 3.02 (m, 4H), 2.29 (s, 3H), 1.34 (d, 6H); MS (ESI) for C₁₉H₂₃ClN₆: 371 (MH⁺).

[0403] 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.84 (m, 2H), 4.40 (br s, 4H), 4.34 (t, 2H), 3.78 (m, 2H), 3.71 (t, 2H), 3.25 (m, 2H), 3.10 (m, 4H), 2.31 (m, 1H), 2.28 (s, 3H), 2.21 (m, 2H), 2.06 (m, 2H), 1.24 (m, 2H), 1.12 (m, 2H); MS (ESI) for C₂₅H₃₂ClN₇O: 482 (MH⁺).

[0404] 5-chloro-3-[4-(3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline trifluoroacetate: ¹H NMR (400 MHz, d₄-

methanol) δ 8.41 (s, 1H), 6.54 (m, 2H), 4.40 (br s, 4H), 3.72 (m, 2H), 3.56 (t, 2H), 3.46 (t, 2H), 3.15 (m, 2H), 3.06 (br s, 4H), 2.30 (m, 1H), 2.21 (s, 3H), 2.16 (m, 2H), 2.03 (m, 2H), 1.23 (m, 2H), 1.11 (m, 2H); MS (ESI) for C₂₅H₃₃ClN₈: 481 (MH⁺).

[0405] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.5 (s, 1H), 8.33 (s, 1H), 7.34-7.26 (m, 2H), 7.24-7.17 (m, 4H), 7.07-7.00 (m, 1H), 6.99-6.96 (m, 1H), 4.39 (s, 2H), 3.75 (br s, 4H), 2.82 (br s, 4H), 2.24 (s, 3H); MS (ESI) for C₂₃H₂₃ClN₆: 419(MH⁺).

[0406] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 13.38 (s, 1H), 8.32 (s, 1H), 7.24 (s, 1H), 7.04 (m, 2H), 3.83-3.77 (br s, 4H), 3.03-2.98 (br s, 4H), 2.83 (d, 2H), 2.29 (s, 1H), 2.19-2.08 (m, 1H), 0.89-0.84 (d, 6H); MS (ESI) for C₂₂H₂₇ClN₄: 383 (MH⁺).

[0407] 5-chloro-2-methyl-3-{4-[3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-N-(2-pyrrolidin-1-ylethyl)aniline trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.53 (s, 2H), 4.29-4.01 (br s, 4H), 3.75-3.68 (m, 2H), 3.59-3.54 (m, 2H), 3.48-3.42 (m, 2H), 3.21-3.11 (m, 2H), 3.04-2.96 (m, 6H), 2.21 (s, 3H), 2.19-2.14 (d, 2H), 2.10 (m, 1H), 2.06-1.99 (m, 2H), 0.93-0.89 (d, 6H); MS (ESI) for C₂₆H₃₇ClN₈: 498 (MH⁺).

[0408] 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.44-8.39 (s, 1H), 6.87-6.84 (s, 1H), 6.81-6.78 (s, 1H), 4.36-4.30 (m, 2H), 4.21-4.09 (br s, 4H), 3.82-3.74 (m, 2H), 3.73-3.69 (m, 2H), 3.08-3.03 (m, 6H), 3.01-2.96 (d, 2H), 2.30-2.27 (s, 3H), 2.24-2.18 (m, 2H), 2.15-2.00 (m, 3H), 0.94-0.89 (d, 6H); MS (ESI) for C₂₆H₃₆ClN₇O: 499 (MH⁺).

[0409] 4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.85 (s, 1H), 6.81 (s, 1H), 4.35 (m, 2H), 4.20-4.11 (br s, 4H), 3.83-3.75 (m, 2H), 3.72 (m, 2H), 3.58-3.49 (m, 1H), 3.30-3.24 (m, 2H), 3.10-3.05 (m, 4H), 2.29 (s, 3H), 2.26-2.17 (m, 2H), 2.13-2.04 (m, 2H), 1.48-1.43 (d, 6H); MS (ESI) for C₂₅H₃₄ClN₇O: 485 (MH⁺).

[0410] 5-chloro-2-methyl-3-{4-[3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-N-(2-pyrrolidin-1-ylethyl)aniline trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.54 (d, 2H), 4.29-4.00 (br s, 4H), 3.78-3.68 (m, 2H), 3.62-

3.44 (m, 5H), 3.58-3.49 (m, 1H), 3.23-3.13 (m, 2H), 3.08-2.99 (br s, 4H), 2.23 (s, 3H), 2.21-2.15 (m, 2H), 2.09-2.01 (m, 2H), 1.48-1.42 (d, 6H); MS (ESI) for C₂₅H₃₅ClN₈: 484 (MH⁺).

[0411] EXAMPLE 7: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidine

[0412] To a suspension of sodium hydride (60% in mineral oil, 1.21 g, 30.3 mmol) in THF (20 mL) was added dropwise a solution of malononitrile (1.00 g, 15.1 mmol) in THF (5 mL) at 0 °C. The resulting mixture was stirred at room temperature for 1 h, and then cooled to 0 °C. A solution of 2-(2-methoxyethoxy)acetyl chloride (2.31 g, 15.1 mmol) in THF (5 mL) was added slowly. The reaction mixture was stirred at room temperature for another 3 h, then added into 1N hydrochloric acid (50 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with water (25 mL), and brine (25 mL), dried with sodium sulfate, and concentrated to give (1-hydroxy-2-{{[2-(methyloxy)ethyl]oxy}ethylidene)propanedinitrile (3.03 g) as a brown oil. ¹H NMR (400 MHz, d₆-DMSO) δ 4.03 (s, 2H), 3.52 (m, 2H), 3.43 (m, 2H), 3.23 (s, 3H).

[0413] To a suspension of sodium hydride (60% in mineral oil, 0.27 g, 6.75 mmol) in DMF (5 mL) was added dropwise a solution of (1-hydroxy-2-{{[2-(methyloxy)ethyl]oxy}ethylidene)propanedinitrile (1.23 g, 6.75 mmol) in DMF (5 mL) at 0 °C. The resulting mixture was stirred at room temperature for 30 min, and then cooled to 0 °C. A solution of dimethylsulfate (0.85 g, 6.75 mmol) in DMF (5 mL) was added slowly, and the reaction mixture was stirred at room temperature for 24 h. More dimethylsulfate (0.85 g, 6.75 mmol) was added, and the reaction mixture was stirred at 50 °C for 12 h, and then at room temperature for 3 d. The resulting suspension was added into 1N hydrochloric acid (100 mL), and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with 5% lithium chloride (50 mL), water (50 mL), and brine (50 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 1:1) afforded impure (1-(methyloxy)-2-{{[2-(methyloxy)ethyl]oxy}ethylidene)propanedinitrile (0.44 g) as a brown oil. ¹H NMR (400 MHz, d₆-DMSO) δ 4.57 (s, 2H), 4.17 (s, 3H), 3.66 (m, 2H), 3.50 (m, 2H), 3.26 (s, 3H).

[0414] A solution of (1-(methyloxy)-2-{{[2-(methyloxy)ethyl]oxy}ethylidene)propanedinitrile (436 mg, 2.22 mmol) and hydrazine monohydrate (206 mg, 4.12 mmol) in ethanol (5 mL) was stirred at room temperature for

19 h, and then concentrated to give crude 5-amino-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazole-4-carbonitrile.

[0415] A solution of 5-amino-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazole-4-carbonitrile in formic acid (5 mL) was refluxed for 24 h, and then concentrated to afford crude 3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol.

[0416] Crude 3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol was suspended in thionyl chloride (5 mL), DMF (188 mg, 2.57 mmol) was added, and the reaction mixture was refluxed for 90 min. The mixture was concentrated, the residue added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford crude 4-chloro-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidine (36 mg).

[0417] A solution of 4-chloro-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidine (36 mg), diisopropylethylamine (22 mg, 0.17 mmol), and 1-(5-chloro-2-methylphenyl)piperazine (30 mg, 0.14 mmol) in THF (5 mL) was stirred at 50 °C for 3 h. The mixture was concentrated, and the remaining solid washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidine (6 mg) as an off-white solid. ¹H NMR (400 MHz, d₆-DMSO) δ 8.28 (s, 1H), 7.17 (d, 1H), 7.05 (d, 1H), 6.98 (dd, 1H) 4.81 (s, 2H), 4.11 (m, 4H), 3.67 (m, 2H), 3.55 (m, 2H), 3.31 (s, 3H), 3.05 (m, 4H), 2.35 (s, 3H); MS (ESI) for C₂₀H₂₅ClN₆O₂: 417 (MH⁺).

[0418] EXAMPLE 8: 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine

[0419] To 3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (200 mg, 0.86 mmol, T.Y.H. Wu, P.G. Schultz, S.Ding, *Org. Lett.* 2003, 5, 3587-3590) in anhydrous dioxane (5 mL) was added triethylamine (0.17 mL, 1.20mmol) and 1-(5-chloro-2-methylphenyl)piperazine (254 mg, 1.20 mmol). The reaction mixture was stirred at 85 °C for 30 min, concentrated, and the solid residue was suspended in 2-propanol. The solid was filtered, washed with water and 2-propanol, and dried to provide 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine (150 mg, 43% yield) as a white solid. ¹H NMR (400 MHz, d₆-DMSO) δ 8.37 (s, 1H), 7.22 (d, 1H), 7.08-7.03 (m, 2H), 3.94 (m, 4H), 3.05 (m, 4H), 2.29 (s, 3H); MS (ESI) for C₁₆H₁₆BrClN₆: 407 (MH⁺).

[0420] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0421] N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-dimethylethane-1,2-diamine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 6.58 (d, 1H), 6.54 (d, 1H), 4.07 (br s, 4H), 3.57 (t, 2H), 3.40 (t, 2H), 3.03 (m, 4H), 2.96 (s, 6H), 2.20 (s, 3H); MS (ESI) for C₂₀H₂₆BrClN₈: 495 (MH⁺).

[0422] N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N-methyl-N-(1-methylethyl)ethane-1,2-diamine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 6.58 (m, 2H), 4.28 (br s, 4H), 3.68 (m, 1H), 3.59 (m, 2H), 3.47 (m, 1H), 3.24 (m, 1H), 3.11 (m, 4H), 2.87 (s, 3H), 2.22 (s, 3H), 1.37 (d, 3H), 1.32 (d, 3H); MS (ESI) for C₂₂H₃₀BrClN₈: 523 (MH⁺).

[0423] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopropylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.20 (s, 1H), 4.12 (br s, 4H), 3.51 (d, 2H), 3.43 (m, 2H), 3.33 (m, 2H), 3.20 (m, 2H), 3.10 (br s, 4H), 2.86 (m, 2H), 1.97 (s, 3H), 1.85 (m, 2H), 1.74 (m, 2H), 0.90 (m, 1H), 0.28 (m, 2H), 0.01 (m, 2H); MS (ESI) for C₂₆H₃₅BrN₈O: 555, 557 (MH⁺).

[0424] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(3-methylbutyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.49 (s, 1H), 4.40 (br s, 4H), 4.00 (t, 2H), 3.74 (m, 2H), 3.63 (t, 2H), 3.50 (t, 2H), 3.38 (br s, 4H), 3.16 (m, 2H), 2.26 (s, 3H), 2.17 (m, 2H), 2.06 (m, 2H), 1.83 (m, 1H), 1.64 (m, 2H), 0.96 (d, 6H); MS (ESI) for C₂₇H₃₉BrN₈O: 551, 553 (MH⁺).

[0425] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclohexylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 4.32 (br s, 4H), 3.76 (m, 4H), 3.60 (t, 2H), 3.48 (t, 2H), 3.17 (m, 2H), 2.23 (s, 3H), 2.18 (m, 2H), 2.07 (m, 2H), 1.87 (m, 2H), 1.76 (m, 4H), 1.30 (m, 4H), 1.10 (m, 2H); MS (ESI) for C₂₉H₄₁BrN₈O: 597, 599 (MH⁺).

[0426] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopentylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 6.11 (d, 1H), 6.05 (d, 1H), 4.09 (br s, 4H), 3.80 (d, 2H), 3.28 (m, 2H), 3.06 (br s, 4H), 2.85 (m, 2H), 2.62 (br s, 4H), 2.14 (m, 1H), 2.10 (s, 3H), 1.82 (m, 6H), 1.61 (m, 4H), 1.35 (m, 2H); MS (ESI) for C₂₈H₃₉BrN₈O: 583, 585 (MH⁺).

- [0427]** 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 8.18 (m, 2H), 7.51 (m, 3H), 7.39 (s, 1H), 7.24 (s, 1H), 4.65 (s, 1H), 4.12 (br s, 4H), 3.40 (br s, 2H), 3.17 (m, 4H), 2.91 (m, 2H), 2.65 (br s, 4H), 2.25 (s, 3H), 1.84 (br s, 4H); MS (ESI) for $\text{C}_{30}\text{H}_{33}\text{BrN}_{10}\text{O}$: 629, 631 (MH^+).
- [0428]** 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl_3) δ 8.44 (s, 1H), 7.29 (s, 1H), 7.12 (s, 1H), 4.72 (s, 1H), 4.08 (br s, 4H), 3.39 (br s, 2H), 3.13 (m, 4H), 2.94 (br s, 2H), 2.68 (br s, 4H), 2.47 (s, 3H), 2.25 (s, 3H), 1.86 (br s, 4H); MS (ESI) for $\text{C}_{25}\text{H}_{31}\text{BrN}_{10}\text{O}$: 567, 569 (MH^+).
- [0429]** 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethylsulfonyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 7.01 (s, 1H), 6.88 (s, 1H), 4.75 (s, 1H), 4.08 (br s, 4H), 3.30 (m, 2H), 3.11 (m, 6H), 2.86 (m, 2H), 2.61 (br s, 4H), 2.21 (s, 3H), 1.83 (br s, 4H), 1.30 (t, 3H); MS (ESI) for $\text{C}_{24}\text{H}_{33}\text{BrN}_8\text{O}_2\text{S}$: 577, 579 (MH^+).
- [0430]** 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methylsulfonyl)-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 7.05 (s, 1H), 6.91 (s, 1H), 4.80 (s, 1H), 4.09 (br s, 4H), 3.32 (m, 2H), 3.11 (m, 4H), 3.05 (s, 3H), 2.88 (m, 2H), 2.63 (br s, 4H), 2.21 (s, 3H), 1.83 (br s, 4H); MS (ESI) for $\text{C}_{23}\text{H}_{31}\text{BrN}_8\text{O}_2\text{S}$: 563, 565 (MH^+).
- [0431]** 5-bromo-3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl_3) δ 8.44 (s, 1H), 6.63 (d, 1H), 6.55 (s, 1H), 4.56 (s, 1H), 4.08 (br s, 4H), 3.26 (br s, 2H), 3.05 (m, 4H), 2.86 (br s, 2H), 2.61 (br s, 4H), 2.11 (s, 3H), 1.84 (br s, 4H); MS (ESI) for $\text{C}_{22}\text{H}_{28}\text{Br}_2\text{N}_8$: 565 (MH^+).
- [0432]** 3-bromo-4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d_4 -methanol) δ 8.48 (s, 1H), 6.89 (m, 1H), 6.85 (m, 1H), 4.53-4.46 (m, 2H), 4.41-4.31 (m, 4H), 4.07-3.64 (m, 10H), 3.23-3.16 (m, 4H), 3.05 (s, 3H), 2.31 (s, 3H); MS (ESI) for $\text{C}_{23}\text{H}_{30}\text{BrClN}_8\text{O}$: 549 (MH^+).
- [0433]** 3-bromo-4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR

(400 MHz, d₄-methanol) δ 8.49 (s, 1H), 6.90 (m, 1H), 6.86 (m, 1H), 4.55-4.44 (m, 2H), 4.42-4.30 (m, 4H), 4.16-3.52 (m, 10H), 3.44-3.35 (m, 2H), 3.24-3.12 (m, 4H), 2.33 (s, 3H), 1.51-1.33 (m, 3H); MS (ESI) for C₂₄H₃₂BrClN₈O: 563 (MH⁺).

[0434] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-ethylbutyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.37 (s, 1H), 6.20 (br m, 1H), 6.12 (br m, 1H), 4.48-3.93 (m, 4H), 3.85 (d, 2H), 3.81-3.63 (m, 2H), 3.58 (t, 2H), 3.46 (t, 2H), 3.24-3.03 (m, 6H), 2.25-1.96 (m, 8H), 1.66-1.36 (m, 5H), 0.95 (t, 6H); MS (ESI) for C₂₈H₄₁BrN₈O: 585 (MH⁺).

[0435] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-ethylbutyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.50 (s, 1H), 4.67-4.14 (br m, 4H), 3.98 (t, 2H), 3.81-3.68 (br m, 2H), 3.64 (t, 2H), 3.50 (t, 2H), 3.45-3.33 (m, 4H), 3.23-3.09 (m, 2H), 2.27 (s, 3H), 2.24-1.97 (m, 4H), 1.73 (m, 2H), 1.49 (m, 2H), 0.97 (t, 3H); MS (ESI) for C₂₆H₃₇BrN₈O: 557 (MH⁺).

[0436] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,2-dimethylpropyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ¹H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 6.10 (m, 1H), 6.04 (m, 1H), 4.57-3.73 (br m, 4H), 3.56 (br m, 2H), 3.38-3.29 (br m, 2H), 3.12-2.99 (br m, 4H), 2.95-2.85 (br m, 2H), 2.77-2.63 (br m, 4H), 2.10 (s, 3H), 1.91-1.78 (br m, 4H), 1.32-1.16 (br m, 1H), 1.02 (m, 9H); MS (ESI) for C₂₇H₃₉BrN₈O: 571 (MH⁺).

[0437] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(tetrahydrofuran-2-ylmethyl)oxy]aniline acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 6.14 (m, 1H), 6.09 (m, 1H), 4.29-3.72 (m, 10H), 3.42 (t, 2H), 3.14-2.93 (m, 10H), 2.16-1.84 (m, 12H), 1.83-1.71 (m, 1H); MS (ESI) for C₂₇H₃₇BrN₈O₂: 585 (MH⁺).

[0438] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methoxyethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 6.12 (m, 1H), 6.05 (m, 1H), 4.24-3.83 (m, 6H), 3.74-3.54 (m, 6H), 3.48 (t, 2H), 3.37 (t, 2H), 3.32 (s, 3H), 3.17-2.90 (m, 5H), 2.17-1.86 (m, 6H); MS (ESI) for C₂₅H₃₅BrN₈O₂: 559 (MH⁺).

[0439] 1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one: ¹H NMR (400 MHz, d₄-methanol) δ 8.31 (s, 1H), 7.16 (m, 1H), 7.05 (m, 1H), 4.41-3.76 (m, 4H), 3.49-3.43 (m, 2H), 3.15-

3.04 (m, 4H), 3.03-2.96 (m, 4H), 2.93-2.83 (m, 4H), 2.26 (s, 3H), 2.00-1.85 (m, 4H), 1.72-1.60 (m, 2H), 1.46-1.34 (m, 2H), 0.95 (t, 3H), MS (ESI) for C₂₇H₃₇BrN₈O: 569 (MH⁺).

[0440] {3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(phenyl)methanone trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 7.80-7.76 (m, 2H), 7.67-7.60 (m, 1H), 7.56-7.49 (m, 2H), 6.92 (m, 2H), 4.25-3.93 (m, 4H), 3.78-3.67 (m, 2H), 3.61 (t, 2H), 3.47 (t, 2H), 3.22-3.10 (m, 2H), 3.09-3.00 (m, 4H), 2.34 (s, 3H), 2.26-1.94 (m, 4H); MS (ESI) for C₂₉H₃₃BrN₈O: 589 (MH⁺).

[0441] 1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}propan-1-one acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.26 (s, 1H), 7.19 (br s, 1H), 7.05 (br s, 1H), 4.36-3.81 (br m, 4H), 3.56 (t, 2H), 3.25 (t, 2H), 3.21-3.12 (m, 4H), 3.11-2.96 (m, 6H), 2.27 (s, 3H), 2.04-1.98 (m, 4H), 1.91 (s, 3H), 1.16 (t, 3H); MS (ESI) for C₂₅H₃₃BrN₈O: 541 (MH⁺).

[0442] 1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 7.16 (br s, 1H), 7.05 (br s, 1H), 4.41-3.71 (br m, 4H), 3.46 (t, 2H), 3.16-3.04 (m, 4H), 3.03-2.92 (m, 4H), 2.91-2.80 (m, 4H), 2.25 (s, 3H), 1.99-1.86 (m, 4H), 1.79-1.63 (m, 2H), 0.99 (t, 3H); MS (ESI) for C₂₆H₃₅BrN₈O: 555 (MH⁺).

[0443] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-N-(methoxy)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide: ¹H NMR (400 MHz, d₄-methanol) δ 8.31 (s, 1H), 6.80 (br s, 1H), 6.70 (br s, 1H), 4.37-3.77 (br m, 4H), 3.6 (s, 3H), 3.49 (t, 2H), 3.33 (s, 3H), 3.23-2.97 (m, 10H), 2.24 (s, 3H), 2.03-1.94 (m, 4H); MS (ESI) for C₂₅H₃₄BrN₉O₂: 572 (MH⁺).

[0444] 1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}ethanone trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.34 (s, 1H), 7.23 (s, 1H), 7.07 (s, 1H), 4.36-3.88 (br m, 4H), 3.79-3.69 (m, 2H), 3.65 (t, 2H), 3.50 (t, 2H), 3.24-3.03 (m, 6H), 2.59 (s, 3H), 2.30 (s, 3H), 2.24-1.96 (m, 4H); MS (ESI) for C₂₄H₃₁BrN₈O: 527 (MH⁺).

[0445] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{{(2,2-difluorocyclopropyl)methyl}oxy}-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ¹H NMR (400 MHz, d₄-methanol) δ 8.21 (s, 1H), 6.04 (s, 1H), 5.99 (s, 1H), 4.05-3.95 (m, 1H), 3.88-

3.77 (m, 1H), 3.31 (t, 2H), 3.02-2.77 (m, 10H), 2.06-1.90 (m, 4H), 1.89-1.82 (m, 4H), 1.56-1.41 (m, 1H), 1.27-1.13 (m, 1H); MS (ESI) for $C_{26}H_{33}BrF_2N_8O$: 591 (MH^+).

[0446] 1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}-4,4,4-trifluorobutan-1-one hydrochloride: 1H NMR (400 MHz, d_4 -methanol) δ 8.39 (s, 1H), 7.27 (m, 1H), 7.09 (m, 1H), 4.51-3.88 (m, 4H), 3.80-3.71 (m, 2H), 3.67 (t, 2H), 3.52 (t, 2H), 3.36-3.29 (m, 2H), 3.24-3.08 (m, 6H), 2.69-2.51 (m, 2H), 2.33 (s, 3H), 2.27-1.96 (m, 4H); MS (ESI) for $C_{26}H_{32}BrF_3N_8O$: 609 (MH^+).

[0447] {3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(cyclopropyl)methanone trifluoroacetate: 1H NMR (400 MHz, d_4 -methanol) δ 8.33 (s, 1H), 7.33 (s, 1H), 7.08 (s, 1H), 4.42-3.85 (br m, 4H), 3.78-3.68 (m, 2H), 3.65 (t, 2H), 3.50 (t, 2H), 3.23-3.05 (m, 6H), 2.91-2.78 (m, 1H), 2.31 (s, 3H), 2.24-1.94 (m, 4H), 1.18-1.00 (m, 4H); MS (ESI) for $C_{26}H_{33}BrN_8O$: 553 (MH^+).

[0448] 3-bromo-4-[4-(5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methyl]oxy]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d_4 -methanol) δ 8.36 (s, 1H), 6.76 (m, 2H), 4.14 (br s, 4H), 3.93 (d, 2H), 3.60 (d, 2H), 3.10 (m, 6H), 2.90 (s, 3H), 2.23 (s, 3H), 2.17 (m, 3H), 1.72 (q, 2H); MS (ESI) for $C_{23}H_{29}BrClN_7O$: 536 (MH^+).

[0449] 3-bromo-4-[4-(5-chloro-2-methyl-3-[(2-(1-methylpiperidin-4-yl)ethyl]oxy]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: 1H NMR (400 MHz, d_4 -methanol) δ 8.41 (s, 1H), 6.76 (m, 2H), 4.22 (br s, 4H), 4.07 (t, 2H), 3.53 (m, 2H), 3.12 (m, 4H), 3.03 (m, 2H), 2.87 (s, 3H), 2.22 (s, 3H), 2.10 (m, 2H), 2.04-1.83 (m, 3H), 1.53 (m, 2H); MS (ESI) for $C_{24}H_{31}BrClN_7O$: 550 (MH^+).

[0450] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-fluoro-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: 1H NMR (400 MHz, d_4 -methanol) δ 8.47 (s, 1H), 6.45 (dd, 1H), 6.38 (dd, 1H), 4.31 (br s, 4H), 3.73 (m, 2H), 3.62 (t, 2H), 3.45 (t, 2H), 3.26 (m, 4H), 3.15 (m, 2H), 2.17 (m, 2H), 2.03 (m, 2H); MS (ESI) for $C_{21}H_{25}BrClFN_8$: 523 (MH^+).

[0451] 3-bromo-4-[4-(2,5-difluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 7.19 (m, 1H), 6.93 (m, 1H), 6.79 (m, 1H), 3.94 (m, 4H), 3.22 (m, 4H); MS (ESI) for $C_{15}H_{13}F_2N_6$: 397 (MH^+).

[0452] 3-((3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl)oxy)-N,N-diethylpropan-1-amine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.74 (s, 1H), 6.71 (s, 1H), 4.11-4.08 (t, 2H), 3.98-3.93 (m, 4H), 3.55-3.35 (m, 4H), 3.28-3.16 (m, 4H), 3.01-3.00 (t, 2H), 2.24-2.17 (m, 5H), 1.39-1.35 (t, 6H); MS (ESI) for C₂₃H₃₁BrCl N₇O: 536 (MH⁺).

[0453] 3-Bromo-4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 6.80 (s, 2H), 6.71 (s, 1H), 4.37-4.33 (m, 4H), 4.13-4.10 (t, 2H), 3.77-3.72 (m, 2H), 3.46-3.32 (m, 2H), 3.18-3.14 (m, 6H), 2.31-2.20 (m, 7H), 2.11-2.03 (m, 2H); MS (ESI) for C₂₃H₂₉BrCl N₇O: 534 (MH⁺).

[0454] 3-Bromo-4-[4-(5-chloro-2-methyl-3-[(3-(4-methylpiperazin-1-yl)propyl)oxy]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 6.81-6.79 (m, 2H), 4.33-4.27 (m, 4H), 4.15-4.13 (t, 2H), 4.00-3.45 (m, 12H), 3.17-3.14 (t, 4H), 3.05 (s, 3H), 2.39-2.33 (m, 2H), 2.26 (s, 3H); MS (ESI) for C₂₄H₃₂BrCl N₈O: 563 (MH⁺).

[0455] 3-Bromo-4-[4-(5-chloro-3-[(3-(4-ethylpiperazin-1-yl)propyl)oxy]-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 6.81-6.79 (m, 2H), 4.34-4.29 (m, 4H), 4.15-4.13 (t, 2H), 4.00-3.48 (m, 8H), 3.40-3.35 (q, 2H), 3.27-3.25 (m, 2H), 3.17-3.14 (t, 4H), 2.39-2.33 (m, 2H), 2.26 (s, 3H), 1.45-1.42 (t, 3H); MS (ESI) for C₂₅H₃₄BrCl N₈O: 577 (MH⁺).

[0456] 3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide: ^1H NMR (400 MHz, d₆-DMSO) δ 10.26 (s, 1H), 8.39 (s, 1H), 7.97 (s, 1H), 7.74 (d, 2H), 7.67 (s, 1H), 7.39-7.33 (m, 2H), 7.14-7.09 (m, 1H), 4.05-3.95 (br s, 4H), 3.15-3.09 (m, 4H), 2.47 (s, 3H); MS (ESI) for C₂₃H₂₁Br₂N₇O: 572 (MH⁺).

[0457] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclobutylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 6.11 (s, 1H), 6.05 (s, 1H), 4.40-4.32 (br s, 1H), 4.16-4.09 (m, 2H), 3.93-3.89 (d, 2H), 3.30-3.22 (br s, 2H), 3.09-3.03 (m, 2H), 2.87-2.80 (br s, 2H), 2.79-2.71 (m, 1H), 2.64-2.53 (br s, 4H), 2.19-2.12 (m, 2H), 2.11-2.09 (s, 3H), 1.97-1.87 (m, 2H), 1.84-1.78 (m, 4H), 1.29-1.24 (m, 2H); MS (ESI) for C₂₇H₃₇BrN₈O: 570 (MH⁺).

[0458] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethyoxy)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: ^1H NMR (400 MHz, d₄-

methanol) δ 8.31 (s, 1H), 6.10 (s, 1H), 6.05 (s, 1H), 4.10-3.94 (m, 6H), 3.04-2.98 (br s, 4H), 2.89-2.85 (m, 2H), 2.77-2.72 (br s, 4H), 2.11 (s, 3H), 1.90-1.86 (m, 4H), 1.37-1.31 (m, 3H); MS (ESI) for C₂₄H₃₃BrN₈O: 530 (MH⁺).

[0459] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(1-methylethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₂₅H₃₅BrN₈O: 544 (MH⁺).

[0460] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(propyloxy)-N-(2-pyrrolidin-1-ylethyl)aniline acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 6.14 (s, 1H), 6.07 (s, 1H), 4.28-3.91 (br s, 4H), 3.90-3.86 (m, 2H), 3.45-3.39 (m, 2H), 3.12-3.06 (m, 2H), 3.06-2.96 (m, 8H), 2.13-2.12 (s, 3H), 1.99-1.93 (m, 4H), 1.80-1.70 (m, 2H), 1.05-1.00 (m, 3H); MS (ESI) for C₂₅H₃₅BrN₈O: 544 (MH⁺).

[0461] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(phenylethynyl)-N-(2-pyrrolidin-1-ylethyl)aniline: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 7.49-7.46 (d, 2H), 7.36-7.32 (m, 3H), 6.76 (s, 1H), 6.69 (s, 1H), 3.78-3.66 (m, 4H), 3.63-3.59 (m, 2H), 3.50-3.45 (m, 2H), 3.26-3.19 (m, 4H), 3.09-3.04 (m, 4H), 2.27 (s, 3H), 2.14-2.07 (m, 4H); MS (ESI) for C₃₀H₃₃BrN₈: 586 (MH⁺).

[0462] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethynyl-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 6.72 (s, 1H), 6.63 (s, 1H), 4.17-3.95 (br s, 4H), 3.75-3.69 (br s, 2H), 3.59-3.55 (m, 2H), 3.49-3.44 (m, 2H), 2.28 (s, 1H), 3.20-3.12 (m, 2H), 3.07-3.01 (br s, 4H), 2.24 (s, 3H), 2.21-2.14 (m, 2H), 2.07-2.00 (m, 2H); MS (ESI) for C₂₄H₂₉BrN₈: 510 (MH⁺).

[0463] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline trifluoracetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 6.59 (s, 1H), 6.50 (s, 1H), 4.30-3.86 (br s, 4H), 3.76-3.68 (br s, 2H), 3.59-3.54 (m, 2H), 3.49-3.43 (m, 2H), 3.21-3.12 (m, 2H), 3.05-2.98 (br s, 4H), 2.22 (s, 3H), 2.19-2.13 (m, 2H), 2.07-1.98 (m, 2H), 1.31-1.28 (s, 9H); MS (ESI) for C₂₈H₃₇BrN₈: 566 (MH⁺).

[0464] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 6.42 (s, 1H), 6.34 (s, 1H), 4.30-3.84 (br s, 4H), 3.75-3.67 (m, 2H), 3.54 (m, 2H), 3.35 (m, 2H), 3.25-3.19 (m, 2H), 3.03 (br s, 4H), 2.53-2.47 (m, 2H),

2.19 (s, 3H), 2.06 (m, 4H), 1.52-1.45 (m, 2H), 0.97 (s, 9H); MS (ESI) for C₂₈H₄₁BrN₈: 570 (MH⁺).

[0465] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethyl-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.34 (s, 1H), 6.49 (s, 1H), 6.40 (s, 1H), 4.22-3.90 (br s, 4H), 3.80-3.67 (br s, 2H), 3.62-3.56 (m, 2H), 3.54-3.48 (m, 2H), 3.22-3.06(m, 4H), 2.62-2.50 (m, 2H), 2.19 (s, 3H), 2.07-2.00 (m, 4H), 1.22-1.19 (m, 3H); MS (ESI) for C₂₄H₃₃BrN₈: 514 (MH⁺).

[0466] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[2-(trimethylsilyl)ethyl]aniline trifluouroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.39 (s, 1H), 6.47 (s, 1H), 6.41 (s, 1H), 4.22-3.90 (br s, 4H), 3.80-3.65 (m, 2H), 3.50-3.46 (m, 2H), 3.15 (br s, 6H), 2.60 (m, 2H), 2.21 (s, 3H), 2.20-2.00 (m, 4H), 0.84-0.81 (m, 2H), 0.02 (s, 9H); MS (ESI) for C₂₇H₄₁BrN₈Si: 586 (MH⁺).

[0467] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethyl)-N-(2-pyrrolidin-1-ylethyl)aniline acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.29 (s, 1H), 7.23-7.17 (m, 2H), 7.12-7.09 (m, 3H), 6.29 (s, 1H), 6.24 (s, 1H), 4.18-3.77 (br s, 4H), 3.35-3.32 (m, 2H), 2.97-2.78 (m, 14H), 2.13 (s, 3H), 1.93-1.88 (m, 4H); MS (ESI) for C₃₀H₃₇BrN₈: 590 (MH⁺).

[0468] 3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 6.48 (s, 1H), 6.35 (s, 1H), 6.21 (s, 1H), 4.03-3.98 (m, 4H), 3.42-3.37 (m, 2H), 3.36-3.32 (m, 4H), 3.14-3.06 (m, 6H), 2.02-1.96 (m, 4H); MS (ESI) for C₂₁H₂₆Br₂N₈: 551 (MH⁺).

[0469] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-N-(2-pyrrolidin-1-ylethyl)aniline acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.31 (s, 1H), 6.32 (s, 1H), 6.17 (s, 2H), 4.03-3.99 (m, 4H), 3.35-3.32 (m, 4H), 2.88 (m, 2H), 2.80-2.77 (m, 4H), 1.91-1.87 (m, 6H); MS (ESI) for C₂₁H₂₆BrClN₈: 506 (MH⁺).

[0470] 1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one acetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.24 (s, 1H), 6.91 (s, 1H), 6.72 (s, 1H), 6.48 (s, 1H), 4.54 (br s, 2H), 3.99-3.94 (m, 4H), 3.48-3.42 (m, 2H), 3.34-3.24 (m, 8H), 2.89-2.84 (m, 2H), 2.01-1.93 (br s, 4H), 1.67-1.57 (m, 2H, 0.92-0.86 (m, 3H); MS (ESI) for C₂₅H₃₃BrN₈O: 542 (MH⁺).

[0471] 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline: ^1H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 6.10 (s, 1H), 4.19-4.15 (m, 2H), 3.41-3.36 (m, 2H), 3.02 (br s, 4H), 2.83-2.79 (m, 2H), 2.71-2.59 (m, 6H), 2.11 (s, 3H), 1.88-1.84 (m, 4H), 1.29 (m, 2H), 0.91-0.82 (m, 2H); MS (ESI) for C₂₅H₃₂BrF₃N₈O: 598 (MH⁺).

[0472] EXAMPLE 9: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine

[0473] A solution of 5-amino-3-phenyl-1H-pyrazole-4-carbonitrile (341mg, 1.85 mmol, R.J. Bantems, J.D. Anderson, D.F. Smee, A. Jin, H.A. Alaghmandan, B.S. Sharma, W.B. Jolley, R.K. Robins, H.B. Cottam, *J. Med. Chem.* **1990**, *33*, 2174-2178) in formic acid (5 mL) was refluxed for 12 h. After cooling to room temperature, methanol (5 mL) was added, the precipitate was filtered, washed with methanol (2 x 3 mL), and dried to give 3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (190 mg, 48% yield) as a tan solid. ^1H NMR (400 MHz, d₆-DMSO) δ 13.90 (br s, 1H), 12.21 (br s, 1H), 8.36 (d, 2H), 8.05 (s, 1H), 7.50-7.36 (m, 3H); MS (ESI) for C₁₁H₈N₄O: 213 (MH⁺).

[0474] A mixture of 3-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (95 mg, 0.45 mmol) and DMF (0.5 mL) in 5 ml of thionyl chloride was refluxed for 3 h. The reaction mixture was concentrated, the residue was added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with 5% lithium chloride (20 mL), water (20 mL), and brine (20 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine (104 mg, 100% yield) as a brown solid. ^1H NMR (400 MHz, d₆-DMSO) δ 8.86 (s, 1H), 7.78 (m, 2H), 7.54 (m, 3H); MS (ESI) for C₁₁H₇ClN₄: 231 (MH⁺).

[0475] A mixture of 4-chloro-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine (100 mg, 0.43 mmol), diisopropylethylamine (67 mg, 0.52 mmol), and 1-(5-chloro-2-methylphenyl)-piperazine (91 mg, 0.43 mmol) in dry THF (5 mL) was stirred at 50 °C for 5 h, and then concentrated. The remaining solid was washed with methanol and dried to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine (90 mg, 51% yield) as a pale yellow solid. ^1H NMR (400 MHz, d₆-DMSO) δ 13.91 (br s, 1H), 8.44 (s, 1H), 7.70 (m, 2H), 7.55 (m, 2H), 7.46 (m, 1H), 7.15 (d, 1H), 7.00 (dd, 1H), 6.92 (d, 1H), 3.53 (m, 4H), 2.74 (m, 4H), 2.15 (s, 3H); MS (ESI) for C₂₂H₂₁ClN₆: 405 (MH⁺).

[0476] EXAMPLE 10: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-3-amine

[0477] A mixture of 4-hydroxy-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-3-amine (102 mg, 0.45 mmol, Y. Tominaga, Y. Honkawa, M. Hara, A. Hosami, *J. Heterocycl. Chem.* 1990, 27, 775-783) and phosphoryl chloride (5 mL) was refluxed for 2 h. The reaction mixture was concentrated, the residue was added into saturated sodium bicarbonate (50 mL), and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine (30 mL), dried with sodium sulfate, and concentrated to afford 4-chloro-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-3-amine (67 mg, 61% yield) as a yellow solid. ¹H NMR (400 MHz, d₆-DMSO) δ 13.60 (s, 1H), 8.70 (s, 1H), 8.20 (s, 1H), 7.59 (m, 2H), 7.29 (m, 2H), 6.91 (m, 1H); MS (ESI) for C₁₁H₈ClN₅: 246 (MH⁺).

[0478] A mixture of 4-chloro-N-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (60 mg, 0.24 mmol), diisopropylethylamine (37 mg, 0.29 mmol), and 1-(5-chloro-2-methylphenyl)piperazine (50 mg, 0.24 mmol) in anhydrous THF (5 mL) was stirred at 50 °C for 2 h. The reaction mixture was concentrated, and the remaining solid washed with methanol and purified by reverse phase HPLC to provide 4-[4-(5-chloro-2-methylphenyl)-piperazin-1-yl]-N-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3-amine (18 mg, 17% yield) as a yellow solid. ¹H NMR (400 MHz, d₆-DMSO) δ 13.14 (s, 1H), 8.63 (s, 1H), 8.29 (s, 1H), 7.20 (m, 3H), 7.00 (dd, 1H), 6.93 (d, 2H), 6.82 (t, 1H), 6.76 (d, 1H), 3.87 (br s, 4H), 2.59 (m, 4H), 2.19 (s, 3H); MS (ESI) for C₂₂H₂₂ClN₇: 420 (MH⁺).

[0479] EXAMPLE 11: 4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenol

[0480] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine (50.0 mg, 0.12 mmol), 4-hydroxyphenylboronic acid (51.0mg, 0.37 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (1:1) (20mg, 0.025 mmol), and triethylamine (0.051 mL, 0.37 mmol) in dry DMF (1 mL) was stirred at 140 °C for 16 h. The reaction mixture was cooled, diluted with ethyl acetate (10 mL), and filtered over celite. The filtrate was washed with water and brine, dried over sodium sulfate, and concentrated. The oily residue was purified by reverse phase HPLC. The product containing fraction was concentrated and isolated as the hydrochloride salt by evaporating three times with a solution of 4N hydrochloric acid in dioxane to give 4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]-pyrimidin-3-yl}phenol hydrochloride (25 mg, 44% yield) as a white solid. ¹H NMR (400

MHz, d₆-DMSO) δ 9.73 (br s, 1H), 8.41 (s, 1H), 7.52 (d, 2H), 7.16 (d, 1H), 7.02-6.97 (dd, 1H), 6.94-6.90 (m, 3H), 3.55 (m, 4H), 2.78 (m, 4H), 2.17 (s, 3H); MS (ESI) for C₂₂H₂₁ClN₆O: 421 (MH⁺).

[0481] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0482] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenol hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 7.39 (t, 1H), 7.13 (dd, 2H), 7.07 (m, 1H), 6.96 (m, 3H), 3.75 (m, 4H), 2.81 (m, 4H), 2.22 (s, 3H); MS (ESI) for C₂₂H₂₁ClN₆O: 421 (MH⁺).

[0483] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{3-[(phenylmethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.45 (s, 1H), 7.52 (t, 1H), 7.44 (d, 1H), 7.36-7.21 (m, 6H), 7.14 (d, 1H), 6.98 (dd, 1H), 6.92 (d, 1H), 5.20 (s, 2H), 3.77 (br s, 4H), 2.78 (m, 4H), 2.22 (s, 3H); MS (ESI) for C₂₉H₂₇ClN₆O: 511 (MH⁺).

[0484] 3-(1,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₆-DMSO) δ 8.45 (s, 1H), 7.26 (d, 1H), 7.17 (d, 2H), 7.12 (d, 1H), 02 (dd, 1H), 6.94 (d, 1H), 6.11 (s, 2H), 3.58 (m, 4H), 2.80 (m, 4H), 2.19 (s, 3H); MS (ESI) for C₂₃H₂₁ClN₆O₂: 449 (MH⁺).

[0485] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-thienyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₆-DMSO) δ 8.45 (s, 1H), 7.68 (d, 1H), 7.44 (d, 1H), 7.26 (t, 1H), 7.17 (d, 1H), 7.01 (dd, 1H), 6.97 (d, 1H), 3.61 (m, 4H), 2.84 (m, 4H), 2.12 (s, 3H); MS (ESI) for C₂₀H₁₉ClN₆S: 411 (MH⁺).

[0486] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}aniline hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.96 (br s, 2H), 8.52 (s, 1H), 7.52 (t, 1H), 7.20 (d, 1H), 7.12 (d, 1H), 7.08 (d, 1H), 7.02 (dd, 1H), 6.97 (m, 2H), 3.88 (m, 4H), 2.83 (m, 4H), 2.22 (s, 3H); MS (ESI) for C₂₂H₂₂ClN₇: 420 (MH⁺).

[0487] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}benzoic acid hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.51 (s, 1H), 8.37 (s, 1H), 8.20 (d, 1H), 7.99 (d, 1H), 7.72 (t, 1H), 7.11 (d, 1H), 6.97-6.90 (m, 2H), 3.77 (m, 4H), 2.81 (m, 4H), 1.93 (s, 3H); MS (ESI) for C₂₃H₂₁ClN₆O₂: 449 (MH⁺).

- [0488] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.53 (s, 1H), 7.56 (d, 2H), 7.45 (d, 2H), 7.12 (d, 1H), 6.97 (dd, 1H), 6.92 (d, 1H), 3.89 (m, 4H), 2.81 (m, 4H), 2.22 (s, 6H); MS (ESI) for C₂₂H₂₃ClN₆: 421 (MH⁺).
- [0489] N-(4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenyl)acetamide hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.52 (s, 1H), 7.83 (d, 2H), 7.63 (d, 2H), 7.12 (d, 1H), 6.96 (dd, 1H), 6.93 (d, 1H), 3.89 (m, 4H), 2.82 (m, 4H), 2.22 (s, 3H), 2.16 (s, 3H); MS (ESI) for C₂₄H₂₄ClN₇O: 462 (MH⁺).
- [0490] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3{4-[2-morphholin-4-ylethyl]oxy}phenyl]-1H-pyrazolo[3,4-d] pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 7.70 (s, 1H), 7.68 (s, 1H), 7.26 (s, 1H), 7.24 (s, 1H), 7.13 (d, 1H), 6.97 (dd, 1H), 6.94 (s, 1H), 4.48 (t, 4H), 4.04 (s, 2H), 3.76 (s, 4H), 3.68 (t, 4H), 2.80 (s, 4H), 2.12 (s, 3H); MS (ESI) for C₂₈H₃₂ClN₇O₂ : 534 (MH⁺).
- [0491] 3-[(4-{4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenyl)oxy]-NN-dimethylpropan-1-amine: ^1H NMR (400 MHz, d₄-methanol) δ 8.48 (s, 1H), 7.65 (s, 1H), 7.63 (s, 1H), 7.20 (s, 1H), 7.18 (s, 1H), 7.13 (d, 1H), 6.97 (dd, 1H), 6.93 (d, 1H), 4.21 (t, 4H), 3.38 (t, 2H), 2.95 (s, 6H), 2.81 (s, 4H), 2.27 (m, 3H), 2.22 (s, 4H); MS (ESI) for C₂₇H₃₂ClN₇O: 506 (MH⁺).
- [0492] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 7.17 (d, 1H), 7.00 (m, 2H), 6.23 (s, 1H), 3.98 (s, 6H), 3.53 (t, 4H), 3.00 (t, 4H); MS (ESI) for C₂₁H₂₄ClN₇: 411 (MH⁺).
- [0493] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 7.09 (d, 1H), 6.97-6.89 (m, 2H), 4.03 (br.s, 4H), 3.32-3.24 (m, 2H), 3.07-2.95 (m, 6H), 2.89 (t, 2H), 2.26 (s, 3H), 2.16-2.00 (m, 1H), 1.83-1.68 (m, 2H), 1.46-1.30 (m, 2H), MS (ESI) for C₂₂H₂₈ClN₇: 426(MH⁺).
- [0494] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.51 (s, 1H), 7.60 (d, 2H), 7.17 (d, 2H), 7.12 (d, 1H), 6.98-6.95 (d,d 1H), 6.92 (s 1H), 3.93-3.88 (m, 4H), 3.89 (s, 3H), 2.87-2.82 (m, 4H), 2.24 (s, 3H); MS (ESI) for C₂₃H₂₃Cl N₆O: 435 (MH⁺).

- [0495] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d_4 -methanol) δ 8.54 (s, 1H), 7.73 (m, 2H), 7.41-7.36 (m, 2H), 7.13 (d, 1H), 6.98-6.95 (d,d 1H), 6.92 (s 1H), 3.93-3.89 (m, 4H), 2.86-2.81 (m, 4H), 2.23 (s, 3H); MS (ESI) for $C_{22}\text{H}_{20}\text{Cl FN}_6$: 423 (MH^+).
- [0496] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(phenyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d_4 -methanol) δ 8.53 (s, 1H), 7.65 (d, 2H), 7.38-7.35 (m, 2H), 7.20-7.14 (m, 4H), 7.06 (m, 1H), 6.99 (d,d 1H), 6.93 (s 1H), 3.98-3.88 (m, 4H), 2.89-2.83 (m, 4H), 2.27 (s, 3H); MS (ESI) for $C_{28}\text{H}_{25}\text{Cl N}_6\text{O}$: 497 (MH^+).
- [0497] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(piperidin-4-ylmethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d_4 -methanol) δ 8.50 (s, 1H), 7.63-7.60 (d, 2H), 7.18 (d, 2H), 7.13 (d, 1H), 6.97 (d,d, 1H), 6.92 (d, 1H), 4.02 (d, 2H), 3.94-3.84 (m, 4H), 3.47-3.44 (d, 2H), 3.09-3.03 (t,d, 2H), 2.87-2.80 (m, 4H), 2.24 (s, 3H), 2.23-2.18 (m, 1H), 2.14-2.10 (d, 2H), 1.71-1.06 (q,d, 2H); MS (ESI) for $C_{28}\text{H}_{32}\text{Cl N}_7\text{O}$: 518 (MH^+).
- [0498] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-[2-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d_4 -methanol) δ 8.40 (s, 1H), 7.53-7.48 (d, d, d, 1H), 7.45-7.43 (d,d, 1H), 7.14-7.10 (d, 1H), 7.10-7.06 (t,d, 1H), 7.01 (d,d, 1H), 6.87-6.84 (d,d, 1H), 6.80 (d, 1H), 3.82-3.74 (m, 7H), 2.88-2.81 (m, 4H), 2.11 (s, 3H); MS (ESI) for $C_{23}\text{H}_{23}\text{Cl N}_6\text{O}$: 435 (MH^+).
- [0499] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-pyridin-4-yl-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d_4 -methanol) δ 8.82 (b, 2H), 8.40 (s, 1H), 8.26 (d, 2H), 7.01 (d, 1H), 6.86-6.83 (m, 2H), 3.69-3.63 (m, 4H), 2.79-2.74 (m, 4H), 2.14 (s, 3H); MS (ESI) for $C_{21}\text{H}_{20}\text{Cl N}_7$: 406 (MH^+).
- [0500] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d_4 -methanol) δ 8.53 (s, 1H), 7.56-7.52 (t, 1H), 7.24-7.17 (m, 3H), 7.13 (d,d 1H), 6.99-6.96 (d,d, 2H), 6.93 (d, 1H), 3.94-3.88 (m, 7H), 2.86-2.78 (m, 4H), 2.23 (s, 3H); MS (ESI) for $C_{23}\text{H}_{23}\text{Cl N}_6\text{O}$: 435 (MH^+).
- [0501] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]benzonitrile trifluoroacetate: ^1H NMR (400 MHz, d_4 -methanol) δ 8.53

(s, 1H), 7.99-7.96 (d, 2H), 7.89 (d, 2H), 7.12 (d, 1H), 6.98-6.93 (m, 2H), 3.88-3.81 (m, 4H), 2.87-2.82 (m, 4H), 2.24 (s, 3H); MS (ESI) for C₂₃H₂₀Cl N₇O: 430 (MH⁺).

[0502] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-(3-fluoropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.63 (s, 1H), 8.53 (d, 1H), 8.37 (s, 1H), 7.73 (t, 1H), 7.03 (d, 1H), 6.88-6.85 (d,d, 1H), 6.83 (d, 1H), 3.74-3.69 (m, 4H), 2.73-2.69 (m, 4H), 2.13 (s, 3H); MS (ESI) for C₂₁H₁₉ClF N₇: 424 (MH⁺).

[0503] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-(3-chloropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.83 (s, 1H), 8.70 (d, 1H), 8.45 (s, 1H), 7.75 (d, 1H), 7.12 (d, 1H), 6.98-6.95 (d,d, 1H), 6.91 (d, 1H), 3.78-3.71 (m, 4H), 2.80-2.74 (m, 4H), 2.22 (s, 3H); MS (ESI) for C₂₁H₁₉Cl₂ N₇: 440 (MH⁺).

[0504] EXAMPLE 12: 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propan-1-ol trifluoroacetate

[0505] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine (0.50 g, 1.2 mmol), p-toluenesulfonic acid monohydrate (0.49 g, 2.6 mmol), and dihydropyran (0.18 g, 2.1 mmol) in DMF (3 mL) was stirred at 90 °C for 15 h. The reaction mixture was cooled, diluted with ethyl acetate (30 mL), washed with saturated sodium bicarbonate, water, and brine (30 mL each), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 85:15 to 7:3) gave 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (0.30 g, 50% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 7.13 (d, 1H), 7.00 (m, 2H), 5.98 (d,d, 1H), 4.14 (m, 1H), 4.03-3.98 (m, 4H), 3.82-3.76 (m, 1H), 3.07 (m, 4H), 2.60-2.51 (m, 1H), 2.32 (s, 3H), 2.12 (m, 1H), 1.95-1.92 (m, 1H), 1.81-1.73 (m, 2H), 1.61 (m, 1H); MS (ESI) for C₂₁H₂₄BrClN₆O: 491 (MH⁺).

[0506] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (0.26g, 0.52 mmol), potassium phosphate (0.56 g, 2.6 mmol), tert-butyl acrylate (0.30 g, 2.3 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichlormethane (0.86g, 0.11 mmol) in DMF (3 mL) was degassed with nitrogen for 5 min, and then stirred at 90 °C for 15 h. The reaction mixture was cooled, diluted with ethyl acetate (30 mL), filtered through celite, and the filtrate was washed with water and brine (30 mL each),

dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 85:15 to 7:3) provided 1,1-dimethylethyl (2*E*)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2*H*-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoate (0.13 g, 0.23 mmol, 43% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.48 (s, 1H), 7.75-7.71 (d, 1H), 7.10 (d, 1H), 6.97 (m, 2H), 6.72 (d, 1H), 6.04-6.01 (d,d, 1H), 4.14-4.01 (m, 1H), 3.96-3.92 (m, 1H), 3.86-3.81 (m, 4H), 3.07-3.02 (m, 4H), 2.60-2.51 (m, 1H), 2.29 (s, 3H), 2.12 (m, 1H), 1.95-1.92 (m, 1H), 1.81-1.73 (m, 2H), 1.53 (s, 9H), 1.61 (m, 1H); MS (ESI) for $\text{C}_{28}\text{H}_{35}\text{ClN}_6\text{O}_3$: 539 (MH^+).

[0507] A solution of 1,1-dimethylethyl (2*E*)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2*H*-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoate (20 mg, 0.037 mmol) in 4N hydrogen chloride in dioxane (1.0 mL) was stirred at 60 °C for 15 min. The reaction mixture was concentrated, and the residue partitioned between sodium bicarbonate and ethyl acetate. The organic layer was concentrated and the residue was purified by reverse phase HPLC to give 1,1-dimethylethyl (2*E*)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoate trifluoroacetate (8.6 mg, 40% yield). ^1H NMR (400 MHz, $d_6\text{-DMSO}$) δ 8.44 (s, 1H), 7.69-7.65 (d, 1H), 7.21 (d, 1H), 7.05-7.02 (m, 2H), 6.57-6.63 (d, 1H), 3.75-3.72 (m, 4H), 3.06-3.03 (m, 4H), 2.27 (s, 3H), 1.48 (s, 9H); MS (ESI) for $\text{C}_{23}\text{H}_{27}\text{ClN}_6\text{O}_2$: 455 (MH^+).

[0508] A solution of 1,1-dimethylethyl (2*E*)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2*H*-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoate (100 mg, 0.19 mmol) in trifluoroacetic acid was stirred at room temperature for 1 h. The reaction mixture was concentrated and the residue was purified by reverse phase HPLC to yield (2*E*)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoic acid trifluoroacetate (36 mg, 48% yield). ^1H NMR (400 MHz, $d_6\text{-DMSO}$) δ 8.42 (s, 1H), 7.72-7.68 (d, 1H), 7.20 (d, 1H), 7.02 (m, 2H), 6.57-6.63 (d, 1H), 3.78-3.75 (m, 4H), 3.03-2.99 (m, 4H), 2.26 (s, 3H); MS (ESI) for $\text{C}_{19}\text{H}_{19}\text{ClN}_6\text{O}_2$: 399 (MH^+).

[0509] Sodium borohydride (90 mg, 2.4 mmol) was added to a mixture of the 1,1-dimethylethyl (2*E*)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2*H*-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoate (127 mg, 0.24 mmol) and cobalt(II) chloride (310 mg, 2.4 mmol) in methanol (5 mL), and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL),

concentrated, and ethyl acetate (5 mL) was added. The organic layer was washed with water, and brine (5 mL each), dried over sodium sulfate, and concentrated. The residue was dissolved in trifluoroacetic acid and stirred at room temperature for 15 min. The solution was concentrated and the residue was purified by reverse phase HPLC to provide 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propanoic acid trifluoroacetate (30 mg, 31% yield). ¹H NMR (400 MHz, d₆-DMSO) δ 8.41 (s, 1H), 7.18 (d, 1H), 7.05 (d, 1H), 7.02-6.99 (d,d, 1H), 4.24-4.21(m, 4H), 3.43-3.39 (t , 2H), 3.12-3.09 (m, 4H), 2.89-2.85 (t, 1H), 2.37 (s, 3H); MS (ESI) for C₁₉H₂₁ClN₆O₂: 401 (MH⁺).

[0510] Sodium borohydride (14 mg, 0.37 mmol) was added to a mixture of the 1,1-dimethylethyl (2E)-3-[4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoate (20 mg, 0.037 mmol) and cobalt(II) chloride (49mg, 0.37 mmol) in methanol (5 mL), and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water (5 mL), concentrated, diluted with ethyl acetate (5 mL), washed with water and brine solution (5 mL each), dried over sodium sulfate, and concentrated. The residue was dissolved in THF (2 mL), and a solution of lithium aluminum hydride in THF (1.0 M, 37 uL, 0.037 mmol) was added. The resulting mixture was stirred at room temperature for 1 h, and then quenched with 2N aqueous sodium hydroxide (0.2 mL), diluted with ethyl ether (10 mL), and filtered through celite. The filtrate was washed with brine (2 mL), dried over sodium sulfate, and concentrated. The residue was dissolved in trifluoroacetic acid (1 mL), stirred at room temperature of 15 min, and then concentrated. The residue was purified by reverse phase HPLC to give 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propan-1-ol trifluoroacetate (5.2 mg, 35% yield). ¹H NMR (400 MHz, d₆-DMSO) δ 8.33 (s, 1H), 7.08-7.06 (d, 1H), 6.94-6.93 (d, 1H), 6.91-6.88 (d,d, 1H), 4.16-4.16 (m, 4H), 3.54-3.51 (t, 2H), 3.16-3.12 (m, 2H), 3.01-2.98. (m, 4H), 2.89-2.85 (t, 1H), 2.56 (s, 3H), 1.92-1.85 (m, 2H); MS (ESI) for C₁₉H₂₃ClN₆O: 387 (MH⁺).

[0511] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:

[0512] methyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate: ¹H NMR (400 MHz, d₆-DMSO) δ 8.42 (s, 1H), 7.82-7.76 (d, 1H), 7.20 (d, 1H), 7.05-7.01 (m, 2H), 6.64 (d, 1H), 3.78-3.74 (m, 7H), 3.03-2.99 (m, 4H), 2.27 (s, 3H); MS (ESI) for C₂₀H₂₁ClN₆O₂: 413 (MH⁺).

[0513] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N,N-diethylpropan-1-amine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.37 (s, 1H), 7.19 (d, 1H), 7.06 (d, 1H), 7.00 (dd, 1H), 4.02 (m, 4H), 3.28-3.18 (m, 8H), 3.07 (m, 4H), 2.35 (s, 3H), 2.27 (m, 2H), 1.32 (t, 6H); MS (ESI) for C₂₃H₃₁ClN₇: 442 (MH⁺).

[0514] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylpropyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 7.19 (d, 1H), 7.08-6.99 (m, 2H), 4.11 (br s, 4H), 3.68 (br s, 2H), 3.37 (m, 1H), 3.27 (m, 1H), 3.21 (t, 2H), 3.13-3.07 (m, 6H), 2.35 (s, 3H), 2.27 (m, 2H), 2.15 (br s, 2H), 2.02 (br s, 2H).

[0515] 3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₆-DMSO) δ 8.40 (s, 1H), 7.23 (d, 1H), 7.11-7.08 (m, 1H), 7.05 (dd, 1H), 6.67-6.63 (m, 1H), 5.20-4.48 (m, 5H), 3.83 (br.m, 4H), 3.02 (br.m, 4H), 2.29 (s, 3H), MS (ESI) for C₂₀H₂₂ClN₇: 396(MH⁺).

[0516] Phenylmethyl (3aR,6aS)-5-({4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}methylidene)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.44 (s, 1H), 7.27-7.12 (m, 6H), 7.00 (m, 2H), 5.19 (s, 1H), 4.95-4.83 (br s, 2H), 4.22-4.10 (m, 4H), 3.88 (m, 2H), 3.68-3.63 (m, 1H), 3.46-3.36 (m, 3H), 3.02-2.93 (m, 6H), 2.73-2.68 (d,d, 1H), 2.33-2.31 (d, 3H), 2.20-2.16 (d,d, 1H); MS (ESI) for C₃₂H₃₄Cl N₇O₂: 584 (MH⁺).

[0517] 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-3-[(E)-(3aR,6aS)-hexahydrocyclopenta[c]pyrrol-5(1H)-ylidenemethyl]-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 7.19 (d, 1H), 7.05-7.00 (m, 2H), 5.27 (s, 1H), 4.13-4.08 (m, 4H), 3.92 (m, 2H), 3.64-3.59 (m, 1H), 3.48-3.42 (d,d, 1H), 3.34 (m, 1H), 3.16 (m, 2H), 3.07-3.03 (m, 5H), 2.78-2.71 (m, 1H), 2.35 (s, 3H), 2.34 (m, 1H); MS (ESI) for C₂₄H₂₈Cl N₇: 450 (MH⁺).

[0518] EXAMPLE 13: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate

[0519] To a solution of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (150 mg, 0.305 mmol) in DMF (3 mL) and triethylamine (0.45 mL) was added (1,1-dimethylethyl)(dimethyl)(prop-2-yn-1-yloxy)silane (156 mg, 0.915 mmol), copper(I) iodide (17.5 mg, 0.092 mmol) and

tetrakis(triphenylphosphine)palladium(0) (36 mg, 0.036 mmol). The mixture was stirred in a sealed tube at 105 °C for 3 h, then cooled to room temperature and concentrated. Column chromatography on silica (hexanes:ethyl acetate 3:2) provided 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-[(1,1-dimethylethyl)(dimethyl)silyl]oxy)prop-1-yn-1-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (164 mg, 93% yield) as an orange oil. ¹H NMR (400 MHz, CDCl₃) δ 8.29 (s, 1H), 7.16 (s, 1H), 7.01 (m, 1H), 6.89-6.86 (m, 2H), 5.91 (dd, 1H), 4.54 (s, 2H), 4.08 (m, 4H), 4.02 (m, 1H), 3.69 (m, 1H), 2.95 (m, 4H), 2.47 (m, 1H), 2.22 (s, 3H), 2.03 (m, 1H), 1.82 (m, 1H), 1.67 (m, 2H), 1.51 (m, 1H), 0.78 (s, 9H), 0.00 (s, 6H).

[0520] To a solution of 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-[(1,1-dimethylethyl)(dimethyl)silyl]oxy)prop-1-yn-1-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (164 mg, 0.28 mmol) in THF (2 mL) was added tetrabutylammonium fluoride in THF (1.0 M, 340 μL, 0.34 mmol). The mixture was stirred at room temperature for 80 min, then diluted with ethyl acetate, washed with water, and brine, dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexane:ethyl acetate 1:1) afforded 3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol (118 mg, 90% yield) as a colorless syrup. ¹H NMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 7.11 (d, 1H), 6.99 (m, 2H), 6.01 (dd, 1H), 4.54 (s, 2H), 4.16 (m, 4H), 4.09 (m, 1H), 3.79 (m, 1H), 3.03 (m, 4H), 2.71 (br s, 1H), 2.53 (m, 1H), 2.31 (s, 3H), 2.10 (m, 1H), 1.93 (m, 1H), 1.75 (m, 2H), 1.60 (m, 1H).

[0521] To a solution of 3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol (85 mg, 0.18 mmol) in dichloromethane (4 mL) was added triethylamine (38 μL, 0.27 mmol) and methanesulfonyl chloride (18 μL, 0.23 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature over 1 h before diluting with dichloromethane. The organic solution was washed with 10% citric acid followed by saturated sodium bicarbonate. The organic layer was dried over magnesium sulfate, and concentrated to give 3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-yl methanesulfonate (86.5 mg, 88% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 7.11 (m, 1H), 6.98 (m, 2H), 6.02 (d, 1H), 5.09 (s, 2H), 4.18 (m, 4H), 4.13 (m, 1H), 3.79 (m, 1H), 3.09 (s, 3H), 3.04 (m, 4H), 2.54 (m, 1H), 2.33 (s, 3H), 2.13 (m, 1H), 1.92 (m, 1H), 1.77 (m, 2H), 1.63 (m, 1H).

[0522] To a solution of 3-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-yl methanesulfonate (43 mg, 0.08 mmol) in DMF (1 mL) was added pyrrolidine (33 μ L, 0.4 mmol). The mixture was stirred for 1 h at room temperature, and then concentrated to provide 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine. 1 H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 7.13 (d, 1H), 7.01 (d, 1H), 6.98 (m, 1H), 6.01 (dd, 1H), 4.21 (m, 4H), 4.12 (m, 1H), 3.80 (m, 1H), 3.74 (s, 2H), 3.33 (m, 4H), 3.04 (m, 4H), 2.57 (m, 1H), 2.32 (s, 3H), 2.13 (m, 1H), 2.01 (m, 4H), 1.93 (m, 1H), 1.77 (m, 2H), 1.61 (m, 1H).

[0523] A solution of 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine in methanol (2 mL) and 4M hydrochloric acid in dioxane (2 mL) was stirred at 60 °C for 30 min and then concentrated. Purification by reverse phase HPLC provided 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate as a yellow syrup. 1 H NMR (400 MHz, d₄-methanol) δ 8.39 (s, 1H), 7.18 (d, 1H), 7.07 (d, 1H), 7.00 (dd, 1H), 4.54 (s, 2H), 4.32 (m, 4H), 3.53 (br s, 4H), 3.11 (m, 4H), 2.37 (s, 3H), 2.16 (br s, 4H); MS (ESI) for C₂₃H₂₅ClN₇: 436 (MH⁺).

[0524] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:

[0525] N-(3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-yl)acetamide: 1 H NMR (400 MHz, d₆-DMSO) δ 8.47 (t, 1H), 8.34 (s, 1H), 7.23 (d, 1H), 7.10 (d, 1H), 7.04 (dd, 1H), 4.18 (d, 2H), 4.12 (br s, 4H), 3.04 (m, 4H), 2.31 (s, 3H), 1.77 (s, 3H); MS (ESI) for C₂₁H₂₂ClN₇O: 424 (MH⁺).

[0526] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N,N-diethylprop-2-yn-1-amine trifluoroacetate: 1 H NMR (400 MHz, d₆-DMSO) δ 9.97 (br s, 1H), 8.34 (s, 1H), 7.21 (d, 1H), 7.05 (m, 1H), 7.02 (d, 1H), 4.54 (br s, 2H), 4.14 (m, 4H), 3.26 (m, 4H), 3.03 (m, 4H), 2.30 (s, 3H), 1.26 (t, 6H); MS (ESI) for C₂₃H₂₈ClN₇: 438 (MH⁺).

[0527] 3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-ol: 1 H NMR (400 MHz, d₆-DMSO) δ 8.31 (s, 1H), 7.20 (d, 1H), 7.05 (d, 1H), 7.02 (dd, 1H), 4.37 (s, 2H), 4.11 (m, 4H), 3.04 (m, 4H), 2.29 (s, 3H); MS (ESI) for C₁₉H₁₉ClN₆O: 383 (MH⁺).

[0528] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.47 (s, 1H), 7.20 (d, 1H), 7.08 (d, 1H), 7.02 (dd, 1H), 4.45 (m, 4H), 3.85 (s, 2H), 3.16 (m, 4H), 3.00 (br s, 8H), 2.89 (s, 3H), 2.37 (s, 3H); MS (ESI) for C₂₄H₂₈ClN₈: 465 (MH⁺).

[0529] EXAMPLE 14: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate

[0530] To 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (50 mg, 0.11 mmol) in anhydrous toluene (0.4 mL) was added Pd₂(dba)₃ (10 mg, 0.011 mmol), 2-(di-*t*-butylphosphino-1, 1'-binaphthyl (10 mg, 0.033 mmol), sodium *tert*-butoxide (15 mg, 0.15 mmol), and Boc-piperazine (25 mg, 0.13 mmol). The reaction mixture was stirred at 100 °C for 16 h under nitrogen, and then concentrated. Column chromatography on silica (hexanes:ethyl acetate 2:1) provided 1,1-dimethylethyl 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]piperazine-1-carboxylate (14 mg, 21% yield). MS (ESI) for C₃₀H₄₁ClN₈O₃: 597 (MH⁺).

[0531] To 1,1-dimethylethyl 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]piperazine-1-carboxylate (14 mg, 0.023 mmol) in methanol (1 mL) was added 4N hydrogen chloride in dioxane (0.1 ml), and the mixture was refluxed for 2 min. Purification by reversed phase HPLC yielded 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate (6 mg, 49% yield) as a white solid. ^1H NMR (400 MHz, d₄-methanol) δ 8.30 (s, 1H), 7.17 (d, 1H), 7.04-7.01 (m, 1H), 6.99 (dd, 1H), 4.16 (br s, 4H), 3.58-3.37 (m, 8H), 3.08-2.96 (m, 4H), 2.34 (s, 3H); MS (ESI) for C₂₀H₂₅ClN₈: 413 (MH⁺).

[0532] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0533] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d₄-methanol) δ 8.29 (s, 1H), 7.16 (d, 1H), 7.03 (m, 1H), 6.99 (dd, 1H), 4.14 (br s, 4H), 3.90-3.79 (m, 2H), 3.65-3.53 (m, 2H), 3.45-3.34 (m, 2H), 3.28-3.16 (m, 2H), 3.06-3.00 (m, 4H), 2.98 (s, 3H), 2.34 (s, 3H); MS (ESI) for C₂₁H₂₇ClN₈: 427 (MH⁺).

[0534] EXAMPLE 15: 2-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-N,N-diethylethanamine trifluoroacetate

[0535] A mixture of ethyl 2-cyano-4,4,4-trifluoro-3-oxobutanoate (18.2 g, 78 mmol, EP 1067121A2), tert-butylhydrazine hydrochloride (17.4g, 140 mmol), trifluoroacetic acid (12.3 mL, 160 mmol), molecular sieves (3A, 28 g) and dimethyl carbonate (165 mL) was stirred at 80 °C for 18 h. The reaction mixture was cooled, diluted with ethyl acetate (200 mL), and filtered. The filtrate was concentrated and ethyl acetate (200 mL) was added. The organic layer was washed with 5% bicarbonate, 5% sodium hydroxide, water and brine (100 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 95:5 to 4:1) gave ethyl 5-amino-1-(1,1-dimethyl-ethyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (7.3g, 33% yield); MS (ESI) for C₁₁H₁₆F₃N₃O: 280 (MH⁺).

[0536] A mixture of ethyl 5-amino-1-(1,1-dimethyl-ethyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate (16.0, 57 mmol) and ammonium carbonate (5.4g, 69 mmol) in formamide (48 mL) was stirred at 170 °C for 3 d. The reaction mixture was cooled, diluted with ethyl acetate (200 mL), washed with water and brine (200 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 65:35 to 3:1) provided 1-(1,1-dimethyl-ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol (7.3g, 52% yield); MS (ESI) for C₁₀H₁₁F₃N₄O₂: 261 (MH⁺).

[0537] DMF (3.0 mL, 38 mmol) was added drop wise to a mixture of 4-hydroxypyrazolopyrimidine (5.0, 19 mmol) and thionyl chloride (50 mL). The resulting mixture was stirred at 75 °C for 2 h. The reaction mixture was cooled, concentrated, and partitioned between aqueous sodium bicarbonate (100 mL) and ethyl acetate (100 mL). The organic layer was washed with water and brine (100 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 95:5) afforded 4-chloro-1-(1,1-dimethyl-ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine (5.0g, 95% yield); ¹H NMR (400 MHz, CDCl₃) δ 8.80 (s, 1H), 1.85 (m, 9H); MS (ESI) for C₁₀H₁₀ClF₃N₄: 279 (MH⁺).

[0538] A mixture of 4-chloro-1-(1,1-dimethyl-ethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine (85 mg, 0.31 mmol), 2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]-N,N-diethylethanamine (200mg, 0.61 mmol), and triethylamine (0.21 mL, 1.5 mmol), in dioxane (5 mL) was stirred at 75 °C for 18 h. The reaction mixture was

cooled, diluted with ethyl acetate (50 mL), washed with water and brine (30 mL each), dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane: methanol:ammonia 95:4:1) gave 2-[(5-chloro-3-{4-[1-(1,1-dimethylethyl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl}-2-methylphenyl)oxy]-*N,N*-diethylethanamine (105 mg, 61% yield). ¹H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.83 (s, 1H), 6.79 (s, 1H), 4.36-4.33 (t, 2H), 3.92-3.89 (m, 4H), 3.68-3.66 (t, 2H), 3.41-3.37 (q,d, 4H), 3.01-2.98 (t, 4H), 2.24 (s, 3H), 1.81 (m, 9H), 1.42-1.38 (t, 6H); MS (ESI) for C₂₇H₃₇Cl F₃N₇O: 568 (MH⁺).

[0539] A mixture of 2-[(5-chloro-3-{4-[1-(1,1-dimethylethyl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl}-2-methylphenyl)oxy]-*N,N*-diethylethanamine (105 mg, 0.19 mmol) and methanesulfonic acid (1.0 mL) was stirred at 55 °C for 2 h, then poured into ice (10 g), and basified with solid sodium bicarbonate to pH 8. The aqueous layer was extracted with ethyl acetate (3x10 mL). The organic layer was washed with water and brine (20 mL each), dried over sodium sulfate, and concentrated. The residue was purified by reverse phase HPLC to give 2-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-*N,N*-diethylethanamine trifluoroacetate (85 mg, 74% yield). ¹H NMR (400 MHz, d₄-methanol) δ 8.40 (s, 1H), 6.74 (s, 1H), 6.71 (s, 1H), 4.11-4.09 (t, 2H), 3.96-3.93 (m, 4H), 3.03-2.99 (m, 6H), 2.79-2.74 (q, 4H), 2.02 (s, 3H), 1.17-1.14 (t, 6H); MS (ESI) for C₂₃H₂₉Cl F₃N₇O: 512 (MH⁺).

[0540] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0541] 4-(4-{5-Chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.83 (s, 1H), 6.79 (s, 1H), 4.34-4.32 (t, 2H), 3.97-3.93 (m, 4H), 3.69-3.66 (m, 2H), 3.72-3.70 (t, 2H), 3.26-3.23 (m, 2H), 3.02-2.99 (t, 4H), 2.26 (s, 3H), 2.23-2.19 (m, 2H), 2.09-2.05 (m, 2H); MS (ESI) for C₂₃H₂₇Cl F₃N₇O: 510 (MH⁺).

[0542] 4-(4-{5-Chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1*H*-pyrazolo[3,4-*d*]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.32 (s, 1H), 6.67 (s, 1H), 6.64 (s, 1H), 4.03-4.00 (t, 4H), 3.89-3.85 (m, 4H), 3.70-3.64 (t, 2H), 3.50-3.47 (d, 2H), 3.33-3.29 (d,d, 2H), 3.16-3.11 (t, d, 2H),

2.91-2.89 (t, 4H), 2.22-2.17 (m, 2H), 2.12 (s, 3H); MS (ESI) for C₂₄H₂₉Cl F₃N₇O₂: 540 (MH⁺).

[0543] 4-(4-{5-Chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.83 (s, 1H), 6.79 (s, 1H), 4.39 (t, 2H), 4.10-4.07 (m, 2H), 3.97-3.93 (m, 4H), 3.88 (m, 2H), 3.69 (t, 2H), 3.64-3.61 (m, 2H), 3.36-3.33 (m, 2H), 3.25 (m, 2H), 3.01-2.99 (t, d, 4H), 2.24 (s, 3H); MS (ESI) for C₂₃H₂₇Cl F₃N₇O₂: 526 (MH⁺).

[0544] 4-(4-{5-Chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.51 (s, 1H), 6.85 (s, 1H), 6.80 (s, 1H), 4.39-4.37 (t, 2H), 4.11-4.07 (m, 4H), 3.68-3.60 (m, 4H), 3.17-3.12 (t,d, 2H), 3.07-3.05 (t, 4H), 2.26 (s, 3H), 2.01-1.97 (m, 2H), 1.87-1.81 (m, 3H), 1.60-1.56 (m, 1H); MS (ESI) for C₂₄H₂₉Cl F₃N₇O: 524 (MH⁺).

[0545] 4-(4-{5-Chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.76 (s, 1H), 6.73 (s, 1H), 4.12-4.09 (t, 2H), 3.98-3.94 (m, 4H), 3.76-3.70 (m, 2H), 3.46-3.42 (d,d, 2H), 3.18-3.13 (m, 2H), 3.02-2.99 (t, 4H), 2.29-2.19 (m, 7H), 2.09-2.04 (m, 2H); MS (ESI) for C₂₄H₂₉Cl F₃N₇O: 524 (MH⁺).

[0546] 4-(4-{5-Chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.76 (s, 1H), 6.73 (s, 1H), 4.12-4.09 (t, 2H), 3.98-3.94 (m, 4H), 3.63-3.60 (m, 2H), 3.02-2.98 (m, 6H), 2.31-2.25 (m, 2H), 2.29-2.19 (s, 3H), 2.02-1.96 (m, 2H), 1.90-1.70 (m, 4H), 1.58-1.50 (m, 2H); MS (ESI) for C₂₅H₃₁Cl F₃N₇O: 538 (MH⁺).

[0547] 4-[4-(5-Chloro-2-methyl-3-{[3-(4-methylpiperazin-1-yl)propyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.74(s, 1H), 6.71 (s, 1H), 4.11-4.08 (t, 2H), 3.98-3.94 (m, 4H), 3.52-3.36 (m, 8H), 3.26-3.22 (d,d, 2H), 3.01-2.99 (m, 4H), 2.95 (s, 3H), 2.26-2.20 (m, 5H); MS (ESI) for C₂₅H₃₂Cl F₃N₈O: 553 (MH⁺).

[0548] 4-[4-(5-Chloro-3-{[3-(4-ethylpiperazin-1-yl)propyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine

hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.41 (s, 1H), 6.74 (s, 1H), 6.71 (s, 1H), 4.11-4.08 (t, 2H), 3.98-3.94 (m, 4H), 3.52-3.36 (m, 8H), 3.26-3.21 (t, 2H), 3.19-3.17 (d,d, 2H), 3.02-2.99 (m, 4H), 2.22 (m, 5H), 1.39-1.35 (t, 3H); MS (ESI) for C₂₆H₃₄Cl F₃N₈O: 567 (MH⁺).

[0549] N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-dimethylethane-1,2-diamine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.50 (s, 1H), 6.58-6.53 (m, 2H), 4.36-3.79 (br m, 4H), 3.58 (t, 2H), 3.40 (t, 2H), 3.09-2.98 (m, 4H), 2.96 (s, 6H), 2.22 (s, 3H); MS (ESI) for C₂₁H₂₆ClF₃N₈: 483(MH⁺).

[0550] 3-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-N,N-diethylpropan-1-amine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.40 (s, 1H), 6.69 (d, 1H), 6.65 (d, 1H), 4.04-3.95 (m, 6H), 3.29 (m, 2H), 2.95 (t, 4H), 2.16 (m, 2H), 2.13 (s, 3H), 1.27 (t, 6H); MS (ESI) for C₂₄H₃₁ClF₃N₇O: 526(MH⁺).

[0551] 4-[4-(5-chloro-2-methyl-3-{[2-(4-methylpiperazin-1-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.55 (s, 1H), 6.86 (m, 1H), 6.81 (m, 1H), 4.52-4.45 (m, 2H), 4.24-4.14 (m, 4H), 4.09-3.60 (m, 10H), 3.15-3.08 (m, 4H), 3.05 (s, 3H), 2.30 (s, 3H); MS (ESI) for C₂₄H₃₀ClF₃N₈O: 539(MH⁺).

[0552] 4-[4-(5-chloro-3-{[2-(4-ethylpiperazin-1-yl)ethyl]oxy}-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ^1H NMR (400 MHz, d₄-methanol) δ 8.57 (s, 1H), 6.88 (br s, 1H), 6.81 (br s, 1H), 4.55-4.42 (m, 2H), 4.26-4.12 (br s, 4H), 4.11-3.49 (m, 10H), 3.37 (q, 2H), 3.17-3.04 (m, 4H), 2.29 (s, 3H), 1.43 (t, 3H); MS (ESI) for C₂₅H₃₂ClF₃N₈O: 553(MH⁺).

[0553] 3-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-diethylpropan-1-amine trifluoroacetate: ^1H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 7.02 (br s, 1H), 6.97 (br s, 1H), 4.09-3.84 (m, 4H), 3.28-3.15 (m, 6H), 3.02-2.94 (m, 4H), 2.73 (t, 2H), 2.35 (s, 3H), 2.02-1.89 (m, 2H), 1.30 (t, 6H); MS (ESI) for C₂₄H₃₁ClF₃N₇: 510(MH⁺).

[0554] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR(400 MHz, d₄-methanol) δ 8.30 (s, 1H), 7.06 (d, 1H),

6.91 (d, 1H), 6.88 (d, 1H), 6.86 (d, 1H), 3.86 (t, 4H), 2.92 (t, 4H), 2.24 (s, 3H); MS (ESI) for C₁₇H₁₆ClF₃N₆: 399 (MH⁺).

[0555] 4-[4-(5-chloro-2-methyl-3-{[(1-methylpiperidin-4-yl)methyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.42 (s, 1H), 6.74 (d, 1H), 6.72 (d, 1H), 3.98 (br s, 4H), 3.92 (d, 2H), 3.60 (d, 2H), 3.08 (m, 2H), 3.01 (m, 4H), 2.90 (s, 3H), 2.22 (s, 3H), 2.17 (m, 3H), 1.72 (m, 2H); MS (ESI) for C₂₄H₂₉ClF₃N₇O: 524 (MH⁺).

[0556] 4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₄-methanol) δ 8.43 (s, 1H), 6.74 (d, 1H), 6.70 (d, 2H), 4.06 (t, 2H), 3.99 (br s, 4H), 3.52 (m, 2H), 3.05-2.98 (m, 6H), 2.87 (s, 3H), 2.21 (s, 3H), 2.11 (m, 2H), 1.91-1.82 (m, 3H), 1.52 (m, 2H); MS (ESI) for C₂₅H₃₁ClF₃N₇O: 538 (MH⁺).

[0557] N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-diethylethane-1,2-diamine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.57 (s, 1H), 6.60 (s, 1H), 6.58 (s, 1H), 4.28-4.14 (br s, 4H), 3.63-3.58 (m, 2H), 3.42-3.38 (m, 2H), 3.36-3.30 (m, 4H), 3.15-3.09 (br s, 4H), 2.24-2.22 (s, 3H), 1.37-1.32 (m, 6H); MS (ESI) for C₂₅H₃₂ClF₃N₆: 510 (MH⁺).

[0558] 5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline: ¹H NMR (400 MHz, d₄-methanol) δ 8.58 (s, 1H), 6.58 (s, 2H), 6.58 (s, 1H), 4.28-4.14 (br s, 4H), 3.77-3.70 (m, 2H), 3.61-3.56 (m, 2H), 3.48-3.44 (m, 2H), 3.19-3.09 (m, 6H), 2.25-2.23 (s, 3H), 2.19-2.13 (m, 2H), 2.09-2.01 (m, 2H); MS (ESI) for C₂₃H₂₈ClF₃N₈: 509 (MH⁺).

[0559] 4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride: ¹H NMR (400 MHz, d₄-methanol) δ 8.51 (s, 1H), 7.03 (s, 1H), 6.99 (s, 1H), 4.15-4.07 (br s, 4H), 3.69-3.62 (m, 2H), 3.28-3.23 (m, 2H), 3.13-3.02 (m, 6H), 2.77-2.17 (m, 2H), 2.37-2.35 (s, 3H), 2.19-2.12 (m, 4H), 2.04-1.96 (m, 4H); MS (ESI) for C₂₄H₂₉ClF₃N₇: 508 (MH⁺).

[0560] 4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₂₄H₂₉ClF₃N₇: 538 (MH⁺).

[0561] 4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine trifluoroacetate: ¹H NMR (400 MHz, d₄-

methanol) δ 8.41 (s, 1H), 7.01 (s, 1H), 6.97 (s, 1H), 4.04-3.91 (br s, 4H), 3.58-3.53 (m, 2H), 3.18-3.13 (m, 2H), 3.02-2.98 (m, 4H), 2.97-2.89 (m, 2H), 2.76-2.70 (m, 2H), 2.37-2.35 (s, 3H), 2.04-1.94 (m, 4H), 1.89-1.82 (m, 2H), 1.80-1.67 (m, 2H); MS (ESI) for C₂₅H₃₁ClF₃N₇: 523 (MH⁺).

[0562] EXAMPLE 16: 4-[4-(5-Chloro-2-methylphenyl)piperazin-1-yl]-6-methyl-1*H*-pyrazolo[3,4-d]pyrimidine

[0563] 3-Amino-4-pyrazolecarboxamide hemisulfate salt (250 mg, 1.4 mmol.) was taken into 1:1 polyphosphoric acid and glacial acetic acid (2 mL) and the mixture was heated at 120 °C over six hours. The mixture was cooled to room temperature then taken into water (10 mL) and the pH adjusted to approximately 5 by dropwise addition of 50% aqueous sodium hydroxide. The resulting white precipitate was collected by filtration and washed with additional water. The solid was then suspended in methanol and collected by filtration then washed with ethyl ether. Drying in vacuo afforded 6-methyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one (154 mg) as a colorless solid. ¹H-NMR (400MHz, d₆-DMSO): 13.55 (s, 1H), 11.95 (s, 1H), 8.03 (s, 1H), 2.34 (s, 3H).

[0564] 6-Methyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one (134 mg, 0.89 mmol.) was taken into thionyl chloride (3 mL) followed by addition of DMF (0.2 mL) and the mixture was brought to reflux over 30 minutes. The resulting solution was concentrated and the residue partitioned with ethyl acetate and saturated aqueous sodium bicarbonate. The organic phase was washed with brine then dried over anhydrous sodium sulfate, filtered and concentrated to afford a yellow oil. The oil was taken into THF (3 mL) followed by addition of 1-(5-Chloro-2-methylphenyl)-piperazine (390 mg, 1.87 mmol.) and catalytic DMAP then the mixture was brought to reflux over one hour. The resulting suspension was filtered and the filtrate was then concentrated. The residue was then suspended in methanol, filtered again and the resulting methanolic solution purified by preparative reverse phase HPLC. The pure fraction were combined and lyophilized to give 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-methyl-1*H*-pyrazolo[3,4-d]pyrimidine (10.7 mg) as a colorless solid. MS (ESI) for C₁₇H₁₉ClN₆: 343 (MH⁺).

[0565] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0566] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-ethyl-1*H*-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₁₈H₂₁ClN₆: 357 (MH⁺).

- [0567] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $C_{19}H_{23}ClN_6$: 371 (MH^+).
- [0568] 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-6-phenyl-1H-pyrazolo[3,4-d]pyrimidine: 1H NMR (400 MHz, d_6 -DMSO) δ 8.41 (m, 2H), 7.52 (m, 3H), 7.23 (d, 1H), 7.10 (d, 1H), 7.05 (dd, 1H), 4.01 (br s, 4H), 3.08 (m, 4H), 2.62 (s, 3H), 2.32 (s, 3H); MS (ESI) for $C_{23}H_{23}ClN_6$: 419 (MH^+).
- [0569] EXAMPLE 17: 1-(3-chlorophenyl)-1,4-diazepane
- [0570] A mixture of 1-chloro-3-iodobenzene (240 mg, 1 mmol), homopiperazine (600 mg, 6 mmol), sodium *tert*-butoxide (135 mg, 1.4 mmol), $Pd_2(dbu)_3$ (23 mg, 0.025 mmol), and XANTPHOS (29 mg, 0.05 mmol) in dioxane (3 mL) was heated to 60 °C for 6 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. Concentration *in vacuo* and column chromatography of the residue (dichloromethane:methanol 8:2 to 7:3) gave 1-(3-chlorophenyl)-1,4-diazepane (46 mg, 22% yield) as a yellow-brown film. 1H NMR (400 MHz, $CDCl_3$) δ 7.11 (t, 1H), 6.64 (m, 2H), 6.56 (m, 1H), 3.61 (m, 2H), 3.56 (m, 2H), 3.10 (m, 2H), 2.93 (m, 2H), 2.89 (br s, 1H), 2.04-1.98 (m, 2H).
- [0571] EXAMPLE 18: 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane
- [0572] A mixture of 3-bromo-1-chlorobenzene (191 mg, 1.0 mmol), 2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid *tert*-butyl ester (240 mg, 1.2 mmol), sodium *tert*-butoxide (135 mg, 1.4 mmol), $Pd_2(dbu)_3$ (27 mg, 0.03 mmol), and BINAP (56 mg, 0.09 mmol) in toluene (3 mL) was heated to 110 °C for 15 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. The solvents were removed *in vacuo*. Column chromatography on silica (hexanes:ethyl acetate 4:1) of the residue afforded 5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid *tert*-butyl ester (240 mg, 78% yield) as a yellow solid. 1H NMR (400 MHz, $CDCl_3$, mixture of rotamers) δ 7.10 (q, 1H), 6.65 (d, 1H), 6.50 (m, 1H), 6.40 (d, 1H), 4.62 (s, 0.5H), 4.48 (s, 0.5H), 3.53 (m, 1H), 3.47-3.67 (m, 2H), 3.20-3.08 (dd, 1H), 1.98-1.91 (m, 2H), 1.45 (s, 4.5H), 1.41 (s, 4.5H).
- [0573] To 5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid *tert*-butyl ester (240 mg, 0.78 mmol) was added 4N HCl in dioxane (3 mL). The mixture was heated with a heat gun for two minutes, cooled to room temperature, and concentrated to provide 2-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptane hydrochloride as a yellow

solid, which was used without further purification. ^1H NMR (400 MHz, d₄-methanol) δ 7.18 (t, 1H), 6.69 (m, 2H), 6.60 (m, 1H), 4.66 (s, 1H), 4.50 (s, 1H), 3.71 (m, 2H), 3.40-3.33 (m, 2H), 2.27 (d, 1H), 2.10 (d, 1H).

[0574] EXAMPLE 19: 4-[2-(2-chloro-4-piperazin-1-ylphenoxy)ethyl]morpholine hydrochloride

[0575] A mixture of 4-bromo-2-chlorophenol (5.0 g, 24 mmol), cesium carbonate (15.7 g, 48 mmol), and benzyl bromide in DMF (50 mL) was stirred at room temperature for 30 min. Water was added and the resulting mixture was extracted with ether. The organic layer was washed with water and brine, dried over magnesium sulfate, and concentrated. The residue was triturated with hexanes to provide 1-benzyloxy-4-bromo-2-chlorobenzene (5.91 g, 83% yield) as a white solid. ^1H NMR (400 MHz, CDCl₃) δ 7.52 (d, 1H), 7.45-7.27 (m, 6H), 6.84-6.82 (d, 1H), 5.14 (s, 2H).

[0576] A mixture of 1-benzyloxy-4-bromo-2-chlorobenzene (300 mg, 1 mmol), piperazine (517 mg, 6 mmol), sodium *tert*-butoxide (135 mg, 1.4 mmol), Pd₂(dba)₃ (23 mg, 0.025 mmol), and BINAP (62 mg, 0.1 mmol) in toluene (3 mL) was heated to 110 °C for 14 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. The filtrate was concentrated. Column chromatography of the residue (dichloromethane:methanol 4:1) afforded 1-(4-benzyloxy-3-chlorophenyl)piperazine (147 mg, 48% yield) as a yellow film. ^1H NMR (400 MHz, CDCl₃) δ 7.45 (m, 2H), 7.40-7.35 (m, 2H), 7.30 (m, 1H), 6.98 (d, 1H), 6.88 (d, 1H), 6.73 (dd, 1H), 5.08 (s, 2H), 3.03-2.98 (m, 8H), 1.73 (br s, 1H).

[0577] A mixture of 1-(4-benzyloxy-3-chlorophenyl)piperazine (147 mg, 0.48 mmol) in trifluoroacetic acid (1 mL) was stirred at 65 °C for 2 h, and then concentrated. The residue was dissolved in ethyl acetate, and washed with saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate, and concentrated to give 2-chloro-4-piperazin-1-yl-phenol as a brown sticky film, which was used without further purification. ^1H NMR (400 MHz, d₄-methanol) δ 7.12 (m, 1H), 6.86 (m, 2H), 3.34 (m, 4H), 3.25 (m, 4H).

[0578] A solution of 2-chloro-4-piperazin-1-yl-phenol (0.47 mmol) and Boc-anhydride (110 mg, 0.5 mmol) in THF (5 mL) was stirred at room temperature for 3 d. Concentration and column chromatography on silica (hexanes:ethyl acetate 3:2) provided 1,1-dimethylethyl 4-(3-chloro-4-hydroxyphenyl)-piperazine-1-carboxylate (112 mg, 75%

yield) as a yellow sticky film. ^1H NMR (400 MHz, d₄-methanol) δ 6.95 (m, 1H), 6.85-6.79 (m, 2H), 3.53 (m, 4H), 2.97-2.94 (m, 4H), 1.47 (s, 9H).

To a mixture of 1,1-dimethylethyl 4-(3-chloro-4-hydroxyphenyl)-piperazine-1-carboxylate (56 mg, 0.18 mmol) and cesium carbonate (176 mg, 0.54 mmol) in DMF (1.8 mL) was added *N*-(2-chloroethyl)-morpholine hydrochloride (67 mg, 0.36 mmol). The suspension was stirred at 60 °C for 4 h, and then cooled to room temperature. Water and ethyl acetate were added, and the layers were separated. The organic phase was washed with brine, dried over magnesium sulfate, and concentrated to provide 1,1-dimethylethyl 4-[3-chloro-4-(2-morpholin-4-yl-ethoxy)phenyl]piperazine-1-carboxylate (68 mg, 89% yield) as an orange oil. ^1H NMR (400 MHz, CDCl₃) δ 6.97 (d, 1H), 6.88 (d, 1H), 6.78 (dd, 1H), 4.12 (t, 2H), 3.73 (m, 4H), 3.56 (m, 4H), 3.01 (m, 4H), 2.86 (t, 2H), 2.63 (m, 4H), 1.48 (s, 9H).

[0579] A solution of 1,1-dimethylethyl 4-[3-chloro-4-(2-morpholin-4-yl-ethoxy)phenyl]piperazine-1-carboxylate (68 mg, 0.16 mmol) in 4N hydrochloric acid in dioxane was refluxed for 2 min, and then concentrated to give 4-[2-(2-chloro-4-piperazin-1-ylphenoxy)ethyl]morpholine hydrochloride as a yellow film. ^1H NMR (400 MHz, d₄-methanol) δ 7.38 (m, 1H), 7.22 (m, 2H), 4.50 (m, 2H), 4.08 (m, 2H), 3.92-3.85 (m, 2H), 3.72-3.66 (m, 4H), 3.55-3.49 (m, 8H), 3.42-3.35 (m, 2H).

[0580] EXAMPLE 20: 1,1-dimethylethyl 4-(3-chlorophenyl)-3-{[(2-morpholin-4-yl-ethoxy)amino]carbonyl}piperazine-1-carboxylate

[0581] To 1-(1,1-dimethylethyl) 3-methyl piperazine-1,3-dicarboxylate (1.00g, 4.09 mmol) in dry toluene (15 mL) was added 3-bromo-chlorobenzene (653 mg, 3.41 mmol), Pd₂(dba)₃ (93.0 mg, 0.102 mmol), BINAP (191 mg, 0.307 mmol), and cesium carbonate (1.11 g, 4.77 mmol). The reaction mixture was stirred at 100 °C for 42 h, then cooled to room temperature and filtered through celite. The filter cake was washed with ethanol, and the filtrate was concentrated. Column chromatography on silica (hexanes:ethyl acetate 3:1) provided 1-(1,1-dimethylethyl) 3-methyl 4-(3-chlorophenyl)piperazine-1,3-dicarboxylate (310 mg, 21% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl₃) δ 7.20-7.13 (t, 1H), 6.84-6.79 (m, 2H), 6.73-6.78 (d, 1H), 4.63-4.50 (br s, 1H), 4.41-4.32 (br s, 1H), 4.24-4.02 (br s, 2H), 3.71-3.65 (s, 3H), 3.55-3.46 (br s, 1H), 3.42-3.26 (br s, 1H), 3.16-2.97 (br s, 1H), 1.49-1.42 (s, 9H); MS (ESI) for C₁₇H₂₃ClN₂O₄: 355 (MH⁺).

[0582] To 1-(1,1-dimethylethyl) 3-methyl 4-(3-chlorophenyl)piperazine-1,3-dicarboxylate (184 mg, 0.519 mmol) in methanol (6 mL) was added 1M potassium hydroxide (3 mL). The reaction mixture was stirred at 50 °C for 5 h. The pH was adjusted to 5, and the mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated to provide 1-(3-chlorophenyl)-4-[(1,1-dimethylethyl)oxy]carbonyl)piperazine-2-carboxylic acid (159 mg, 76% yield) as a colorless oil. MS (ESI) for $C_{16}H_{21}ClN_2O_4$: 341 (MH^+).

[0583] To 1-(3-chlorophenyl)-4-[(1,1-dimethylethyl)oxy]carbonyl)piperazine-2-carboxylic acid (67 mg, 0.291 mmol) in DMF (4 mL) was added 2-morpholin-4-ylethylamine (379 mg, 2.91 mmol), HATU (111 mg, 0.291 mmol), HOAt (48 mg, 0.349 mmol), and N-methyl morpholine (0.170 mL, 1.45 mmol). The reaction mixture was stirred at 25 °C for 21 h. Water and saturated sodium bicarbonate were added, and the solution was extracted with diethyl ether. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. The residue was suspended in acetonitrile and filtered. The filtrate was concentrated to provide 1,1-dimethylethyl 4-(3-chlorophenyl)-3-[(2-morpholin-4-ylethyl)amino]carbonyl)piperazine-1-carboxylate (81 mg, 62% yield) as a colorless oil. MS (ESI) for $C_{22}H_{33}ClN_4O_4$: 453 (MH^+).

[0584] To 1,1-dimethylethyl 4-(3-chlorophenyl)-3-[(2-morpholin-4-ylethyl)amino]carbonyl)piperazine-1-carboxylate (81 mg, 0.18 mmol) in methanol (5 mL) was added 4N hydrochloric acid in dioxane (0.1 mL). The reaction mixture was refluxed for 2 min, and then concentrated to provide 1-(3-chlorophenyl)-N-(2-morpholin-4-ylethyl)piperazine-2-carboxamide hydrochloride (69 mg, 100% yield) as a colorless oil. MS (ESI) for $C_{17}H_{25}ClN_4O_2$: 353 (MH^+).

[0585] Using the same or analogous synthetic techniques and/or substitution with alternative reagents, the following compounds of the invention were prepared:

[0586] 1-(3-chlorophenyl)-N-(1-methylpiperidin-4-yl)piperazine-2-carboxamide: MS (ESI) for $C_{17}H_{25}ClN_4O$: 337 (MH^+).

[0587] [1-(3-chlorophenyl)piperazin-2-yl]methanol: MS (ESI) for $C_{11}H_{15}ClN_2O$: 227 (MH^+).

[0588] 1-(3-chlorophenyl)-N-[2-(dimethylamino)ethyl]piperazine-2-carboxamide: MS (ESI) for $C_{15}H_{23}ClN_4O$: 311 (MH^+).

[0589] 1-(3-chlorophenyl)-N-methylpiperazine-2-carboxamide: MS (ESI) for C₁₂H₁₆ClN₃O: 254 (MH⁺).

[0590] methyl 4-(3-chlorophenyl)piperazine-2-carboxylate: MS (ESI) for C₁₂H₁₅ClN₂O₂: 255 (MH⁺).

[0591] 4-(3-chlorophenyl)-N-methylpiperazine-2-carboxamide: MS (ESI) for C₁₂H₁₆ClN₃O: 254 (MH⁺).

[0592] EXAMPLE 21: 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-en-1-yl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride

[0593] A mixture of 3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine (20 mg, 0.050 mmol), 3-methyl-2-butenyltributylstannane (19 mg, 0.055 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichlormethane (8.0 mg, 0.010 mmol), and hexamethylphosphoramide (1mL) was de-gassed with nitrogen for 5 min, and then stirred at 140 °C for 18 h. The reaction mixture was cooled, and diluted with ethyl acetate (10 mL). The organic layer was washed with water (3 x 5 mL), and brine (5 mL), dried over sodium sulfate, and concentrated. The residue was purified by reversed phase HPLC to give a powder, which was azoetroped with a mixture of 4M hydrogen chloride in dioxane:methanol 95:5 (3 x 1 mL) to give 4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-en-1-yl)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride (3.1 mg, 16% yield). ¹H NMR (400 MHz, d₄-methanol) δ 8.39 (s, 1H), 7.18 (d, 1H), 7.03 (d, 1H), 7.00 (d, d, 1H); 5.35 (t, 1H), 4.17-4.08 (m, 4H), 3.84 (d, 1H), 3.07-3.02 (m, 4H), 2.34 (s, 3H), 1.78 (s, 3H), 1.75 (s, 3H); MS (ESI) for C₂₁H₂₅Cl N₆: 397 (MH⁺).

[0594] EXAMPLE 22: [5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methanol

[0595] To a degassed solution of methyl 3-bromo-5-chloro-2-(methyloxy)benzoate (1.57 g, 5.64 mmol) in toluene (60 mL) was added cesium carbonate (2.57 g, 7.89 mmol), BINAP (351 mg, 0.564 mmol), tris(dibenzylideneacetone)dipalladium(0) (130 mg, 0.141 mmol), and Boc-piperazine (1.4 g, 7.33 mmol). The mixture was refluxed for 24 h, then cooled to room temperature, and filtered through celite. The filtrate was concentrated and the residue was purified by column chromatography on silica (hexanes:ethyl acetate 4:1) to afford of 1,1-dimethylethyl 4-[5-chloro-2-(methyloxy)-3-[(methyloxy)carbonyl]phenyl]piperazine-1-carboxylate (1.13g, 52% yield) as a white

solid. ^1H NMR (400 MHz, CDCl_3) δ 7.37 (d, 1H), 6.97 (d, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.58-3.56 (m, 4H), 3.06-3.03 (m, 4H), 1.48 (s, 9H); MS (ESI) for $\text{C}_{18}\text{H}_{25}\text{ClN}_2\text{O}_5$: 385 (MH^+).

[0596] A solution of 1,1-dimethylethyl-4-{5-chloro-2-(methyloxy)-3-[(methyloxy)carbonyl]phenyl}piperazine-1-carboxylate (300mg, 0.78 mmol) in THF (8 mL) was cooled to 0 °C, and lithium aluminum hydride (1.17 mL, 1.17 mmol) was added. The solution was stirred at 0 °C for 1 h, followed by the addition of water (150 μL), 15% sodium hydroxide (150 μL), and finally water (300 μL). The mixture was stirred at 0 °C for 10 min, then filtered through celite and concentrated. Column chromatography on silica (hexanes:ethyl acetate 3:2) gave 1,1-dimethylethyl-4-[5-chloro-3-(hydroxymethyl)-2-(methyloxy)phenyl]piperazine-1-carboxylate (264 mg, 95% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 7.00 (d, 1H), 6.82 (d, 1H), 4.65 (d, 2H), 3.87 (s, 3H), 3.60-3.57 (m, 4H), 3.05-3.02 (m, 4H), 1.48 (s, 9H); MS (ESI) for $\text{C}_{17}\text{H}_{25}\text{ClN}_2\text{O}_4$: 357 (MH^+).

[0597] A solution of 1,1-dimethylethyl-4-[5-chloro-3-(hydroxymethyl)-2-(methyloxy)phenyl]piperazine-1-carboxylate (40 mg, 0.11 mmol) in dioxane (2 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 3 min, and then concentrated. The solid residue was dissolved in THF (5 mL), and triethylamine (50 μl , 0.34 mmol) and 4-chloro-3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidine (20 mg, 0.11 mmol) were added. The solution was stirred at 50 °C for 24 h, then cooled to room temperature and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5 to 9:1) afforded [5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methanol (7.3 mg, 16% yield) as a white solid. ^1H NMR (400 MHz, CDCl_3) δ 3.31 (s, 1H), 8.30 (s, 1H), 7.04 (d, 1H), 6.88 (d, 1H), 5.19 (t, 1H), 4.49 (d, 2H), 3.85-3.78 (m, 7H), 3.21-3.16 (m, 4H), 2.97 (q, 2H), 1.29 (t, 3H); MS (ESI) for $\text{C}_{19}\text{H}_{24}\text{ClN}_6\text{O}_2$: 403 (MH^+).

[0598] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0599] methyl 5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate: ^1H NMR (400 MHz, CDCl_3) δ 13.35 (s, 1H), 8.30 (s, 1H), 7.22 (d, 1H), 7.19 (d, 1H), 3.85-3.81 (m, 10H), 3.23-3.20 (m, 4H), 2.97 (q, 2H), 1.30 (t, 3H); MS (ESI) for $\text{C}_{20}\text{H}_{23}\text{ClN}_6\text{O}_3$: 431 (MH^+).

[0600] EXAMPLE 23: 5-chloro-N-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzamide

[0601] To a solution of 1,1-dimethylethyl-4-{5-chloro-2-(methyloxy)-3-[(methyloxy)-carbonyl]phenyl}piperazine-1-carboxylate (Example 22, 290 mg, 0.75 mmol) in methanol (6 mL) was added 1N aqueous potassium hydroxide (3.75 mL, 3.75 mmol). The solution was stirred at 60 °C for 15 h, then cooled to 0 °C and acidified to pH 2 using aqueous 1N hydrochloric acid. The solution was diluted with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated to afford 5-chloro-3-(4-{{(1,1-dimethylethyl)oxy}carbonyl}piperazin-1-yl)-2-(methyloxy)benzoic acid (268 mg, 96% yield) as a yellow solid. ¹H NMR (400 MHz, d₄-methanol) δ 7.26 (br s, 1H), 7.08 (d, 1H), 3.88 (s, 3H), 3.61-3.57 (m, 4H), 3.06-3.03 (m, 4H), 1.48 (s, 9H); MS (ESI) for C₁₇H₂₃ClN₂O₅: 393 (M+Na⁺).

[0602] To a solution of 5-chloro-3-(4-{{(1,1-dimethylethyl)oxy}carbonyl}piperazin-1-yl)-2-(methyloxy)benzoic acid (95 mg, 0.26 mmol) in DMF (5 mL) was added N,N-dimethylethylenediamine (25 μl, 0.23 mmol), triethylamine (75 μl, 0.51 mmol), and HATU (146 mg, 0.38 mmol). The solution was stirred at room temperature for 17 h, and then partitioned between ethyl acetate and 5% aqueous lithium chloride. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) provided 1,1-dimethylethyl 4-[5-chloro-3-({{[2-(dimethylamino)ethyl]amino}carbonyl}-2-(methyloxy)phenyl]piperazine-1-carboxylate (108 mg, 96% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.63 (br s, 1H), 7.71 (d, 1H), 7.00 (d, 1H), 3.93 (s, 3H), 3.66-3.63 (m, 2H), 3.62-3.58 (m, 4H), 3.04-3.01 (m, 4H), 2.90-2.87 (m, 2H), 2.58 (s, 6H), 1.49 (s, 9H); MS (ESI) for C₂₁H₃₃ClN₄O₄: 441 (MH⁺).

[0603] A solution of 1,1-dimethylethyl 4-[5-chloro-3-({{[2-(dimethylamino)ethyl]amino}carbonyl}-2-(methyloxy)phenyl]piperazine-1-carboxylate (108 mg, 0.25 mmol) in dioxane (2 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 3 min and then concentrated. The residue was dissolved in THF (3 mL), and triethylamine (103 μl, 0.75 mmol) and 4-chloro-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine (45 mg, 0.25 mmol) were added. The mixture was stirred at 50 °C for 24 h, then cooled to room temperature and concentrated. The residue was diluted with sodium bicarbonate, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. Column chromatography

on silica (dichloromethane:methanol 85:15) yielded 5-chloro-N-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzamide (15 mg, 13% yield) as a white solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 13.32 (br s, 1H), 8.37-8.34 (m, 1H), 8.30 (s, 1H), 7.22 (d, 1H), 7.12 (d, 1H), 3.85-3.81 (m, 7H), 3.22-3.20 (m, 4H), 2.39 (q, 2H), 2.19 (s, 6H), 1.99 (t, 3H); MS (ESI) for $C_{23}H_{31}ClN_8O_2$: 488 (MH^+).

[0604] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0605] 4-(4-{5-chloro-2-(methyloxy)-3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.31 (br s, 1H), 8.30 (s, 1H), 7.03 (d, 1H), 6.87 (d, 1H), 3.85-3.75 (m, 7H), 3.64-3.58 (m, 2H), 3.18-3.10 (m, 4H), 2.96 (q, 2H), 2.36-2.30 (m, 2H), 2.23-2.19 (m, 5H), 1.30 (t, 3H); MS (ESI) for $C_{24}H_{31}ClN_8O_2$: 499 (MH^+).

[0606] 2-(dimethylamino)ethyl 5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.32 (br s, 1H), 8.30 (s, 1H), 7.19 (m, 2H), 4.30 (t, 2H), 3.84-3.80 (m, 7H), 3.25-3.20 (m, 4H), 2.99 (q, 2H), 2.58 (t, 2H), 2.19 (s, 6H), 1.29 (t, 3H); MS (ESI) for $C_{23}H_{30}ClN_7O_3$: 488 (MH^+).

[0607] EXAMPLE 24: 1-[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]-N,N-dimethylmethanamine

[0608] To a solution of 1,1-dimethylethyl-4-[5-chloro-3-(hydroxymethyl)-2-(methyloxy)phenyl]piperazine-1-carboxylate (82 mg, 0.23 mmol) in dichloromethane (5 mL) was added Dess-Martin periodinane (117 mg, 0.28 mmol). The solution was stirred at room temperature for 1 h, followed by the addition of a 10% aqueous sodium thiosulfate pentahydrate solution (10 mL) and saturated sodium bicarbonate (10 mL). The mixture was stirred at room temperature for 15 minutes, the layers were separated, and the aqueous layer was extracted with more dichloromethane. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 4:1) afforded 1,1-dimethylethyl 4-[5-chloro-3-formyl-2-(methoxy)phenyl]piperazine-1-carboxylate (69 mg, 85% yield) as a yellow oil. ^1H NMR (400 MHz, $CDCl_3$) δ 10.35 (s, 1H), 7.44 (d, 1H), 7.08 (d, 1H), 3.97 (s, 3H), 3.63-3.60 (m, 4H), 3.09-3.06 (m, 4H), 1.49 (s, 9H); MS (ESI) for $C_{17}H_{23}ClN_2O_4$: 377 ($M+Na^+$).

[0609] To a solution of 1,1-dimethylethyl 4-[5-chloro-3-formyl-2-(methoxy)phenyl]piperazine-1-carboxylate (95 mg, 0.27 mmol) in ethanol (2 mL) was

added triethylamine (75 μ L, 0.54 mmol), dimethylamine hydrochloride (44 mg, 0.54 mmol), and Titanium(IV) isopropoxide (160 μ L, 0.54 mmol). The mixture was stirred at room temperature for 15 h. Sodium borohydride (16 mg, 0.42 mmol) was added, and the mixture was stirred at room temperature for additional 3 h. The mixture was quenched by the addition of a 2N ammonia solution (3 mL), and the resulting precipitate was filtered and washed with dichloromethane. The filtrate was partitioned between water and dichloromethane, and the aqueous layer was extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-[5-chloro-3-[(dimethylamino)methyl]-2-(methoxy)phenyl]piperazine-1-carboxylate (59 mg, 57% yield) as a white solid. 1 H NMR (400 MHz, CDCl₃) δ 7.01 (d, 1H), 6.75 (d, 1H), 3.80 (s, 3H), 3.60-3.52 (m, 4H), 3.38 (s, 2H), 3.06-2.99 (m, 4H), 2.24 (s, 6H), 1.48 (s, 9H); MS (ESI) for C₁₉H₃₀ClN₃O₃: 384 (MH⁺).

[0610] To a solution of 1,1-dimethylethyl 4-[5-chloro-3-[(dimethylamino)methyl]-2-(methoxy)phenyl]piperazine-1-carboxylate (59 mg, 0.15 mmol) in dioxane (2 mL) was added 4N hydrochloric acid in dioxane (1 mL). The solution was refluxed for 2 min, and then concentrated. The residue was dissolved in THF (5 mL) and triethylamine (65 μ L, 0.46 mmol) and 4-chloro-3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidine (28 mg, 0.15 mmol) were added. The solution was stirred at 50 °C for 24 h, cooled to room temperature and concentrated. The residue was added into saturated sodium bicarbonate, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 85:15) yielded 1-[5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl]-2-(methoxy)phenyl]-N,N-dimethylmethanamine (21 mg, 33% yield) as a white solid. 1 H NMR (400 MHz, d₆-DMSO) δ 13.31 (br s, 1H), 8.30 (s, 1H), 6.99 (d, 1H), 6.89 (d, 1H), 3.82-3.78 (m, 7H), 3.37 (s, 2H), 3.22-3.17 (m, 4H), 2.97 (q, 2H), 2.16 (s, 6H), 1.30 (t, 3H); MS (ESI) for C₂₁H₂₈ClN₇O: 430 (MH⁺).

[0611] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0612] N'-{[5-chloro-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl]-2-(methoxy)phenyl]methyl}-N,N-dimethylethane-1,2-diamine: 1 H NMR (400 MHz, CD₃OD) δ 8.30 (s, 1H), 7.02 (d, 1H), 6.93 (d, 1H), 3.97-3.93 (m, 7H), 3.76 (s, 2H), 3.27-3.24 (m, 4H), 3.06 (q, 2H), 2.69 (t, 2H), 2.48 (t, 2H), 2.22 (s, 6H), 1.38 (t, 3H); MS (ESI) for C₂₃H₃₃ClN₈O: 474 (MH⁺).

[0613] EXAMPLE 25: 1-[5-chloro-2-methyl-4-(methyloxy)phenyl]piperazine trifluoroacetate

[0614] A mixture of 2-chloro-5-methyl-4-nitrosophenol (11.6 g, 67.9 mmol, M.E. Falugh, T.A. Crowell, J.A. Clemens, B.D. Sawyer, *J. Med. Chem.* 1979, 22, 63-69), benzyl bromide (11.6 g, 67.9 mmol), and potassium carbonate (14.1 g, 102.2 mmol) in DMSO was stirred at 60 °C for 6 h. The reaction mixture was partitioned between water and ethyl acetate, filtered through celite, and the layers were separated. The organic layer was washed with saturated sodium bicarbonate, water, and brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 97:3) afforded 1-chloro-4-methyl-5-nitroso-2-[(phenylmethyl)oxy]benzene (1.55 g, 9% yield).

[0615] A mixture of 1-chloro-4-methyl-5-nitroso-2-[(phenylmethyl)oxy]benzene (1.55 g, 5.92 mmol) and tin(II) chloride (5.05 g, 22.38 mmol) in ethanol was refluxed for 4 h. The reaction mixture was concentrated and the residue partitioned between ethyl acetate and saturated sodium bicarbonate. The layers were separated, the organic layer was washed with water, and brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 9:1) gave 1-chloro-4-methyl-2-[(phenylmethyl)oxy]aniline (1.32 g, 90% yield).

[0616] A mixture of 1-chloro-4-methyl-2-[(phenylmethyl)oxy]aniline (1.10 g, 4.44 mmol), bis(2-chloroethyl)amine hydrochloride (0.79 g, 4.43 mmol), and potassium carbonate (0.61 g, 4.42 mmol) in diglyme was refluxed for 18 h. The reaction mixture was diluted with hexanes, decanted, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5 to 92:9) provided 1-[5-chloro-2-methyl-4-[(phenylmethyl)oxy]phenyl]piperazine (0.23 g, 16% yield).

[0617] A solution of 1-[5-chloro-2-methyl-4-[(phenylmethyl)oxy]phenyl]piperazine (0.23 mg, 0.73 mmol) in trifluoroacetic acid (3 mL) was refluxed for 3 h and then concentrated. The residue was dissolved in ethyl acetate, treated with activated charcoal, and filtered. Concentration gave 2-chloro-5-methyl-4-piperazine-1-ylphenol (159 mg, 96% yield).

[0618] A solution of 2-chloro-5-methyl-4-piperazine-1-ylphenol (49 mg, 0.22 mmol) and Boc-anhydride (48 mg, 0.22 mmol) in ethyl acetate was stirred at 50 °C for 2 h. Concentration and column chromatography on silica (dichloromethane:methanol 95:5 to

9:1) afforded 1,1-dimethylethyl 4(5-chloro-4-hydroxy-2-methylphenyl)piperazine-1-carboxylate (49 mg, 68% yield).

[0619] A mixture of 1,1-dimethylethyl 4(5-chloro-4-hydroxy-2-methylphenyl)piperazine-1-carboxylate (16 mg, 0.05 mmol), methyl iodide (14 mg, 0.10 mmol), and cesium carbonate (32 mg, 0.10 mmol) in DMF was stirred at 60 °C for 5 h. The reaction mixture was diluted with ethyl acetate, washed with water, 1N sodium hydroxide, and water, dried over sodium sulfate, and concentrated. The residue was dissolved in dichloromethane/trifluoroacetic acid/water (75:20:5) and stirred at room temperature for 12 h. Concentration provided 1-[5-chloro-2-methyl-4-(methyloxy)-phenyl]piperazine trifluoroacetate (8 mg, 47% yield), which was used without further purification.

[0620] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0621] 3-[(2-chloro-5-methyl-4-piperazin-1-ylphenyl)oxy]-N,N-dimethylpropan-1-amine

[0622] 2-[(2-chloro-5-methyl-4-piperazin-1-ylphenyl)oxy]-N,N-dimethylethanamine

[0623] EXAMPLE 26: 2-{[5-chloro-2-(methyloxy)-3-piperazin-1-ylphenyl]oxy}-N,N-dimethylethanamine

[0624] To a solution of methyl 3-bromo-5-chloro-2-(methyloxy)benzoate (2.86 g, 10.6 mmol) in THF (30 mL) was added methanol (620 µL, 15.3 mmol) followed by 2 M lithium borohydride in THF (7.7 mL, 15.4 mmol). The resulting mixture was heated to 50 °C for 2 h. The residual hydride was quenched with 1M hydrochloric acid at 0 °C. The mixture was diluted with ethyl acetate and neutralized with sodium bicarbonate. The layers were separated, the organic layer was dried over magnesium sulfate, and concentrated to give [3-bromo-5-chloro-2-(methyloxy)phenyl]methanol as a white solid.
¹H NMR (400 MHz, CDCl₃) δ 7.47 (d, 1H), 7.34 (d, 1H), 4.71 (d, 2H), 3.85 (s, 3H), 2.03 (t, 1H).

[0625] A biphasic mixture of [3-bromo-5-chloro-2-(methyloxy)phenyl]methanol, potassium bromide (122 mg, 1.02 mmol), and TEMPO (16 mg, 0.10 mmol) in dichloromethane (25 mL) and water (10 mL) was cooled to 0 °C. A solution of bleach saturated with sodium bicarbonate (5% sodium hypochlorite, 18.7 mL, 12.5 mmol) was added, and the mixture was stirred for 20 min. Water was then added followed by dichloromethane.

The layers were separated, and the aqueous layer was extracted with dichloromethane. The organic extracts were combined, dried over magnesium sulfate, and concentrated to afford 3-bromo-5-chloro-2-(methyloxy)benzaldehyde (2.2 g, 87% yield over 2 steps) as a pale yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 10.26 (s, 2H), 7.78 (d, 1H), 7.75 (d, 1H), 3.97 (s, 3H).

[0626] A mixture of 3-bromo-5-chloro-2-(methyloxy)benzaldehyde (1.22 g, 4.9 mmol), and 3-chloroperbenzoic acid (2.4 g, 9.8 mmol) in dichloromethane (20 mL) was refluxed for 26 h, and then concentrated. The residue was dissolved in ethyl acetate, washed twice with saturated sodium bicarbonate, dried over magnesium sulfate, and concentrated. The residue was dissolved in methanol, and 1M potassium hydroxide (5 mL) was added. The mixture was stirred for 1 h at room temperature, and then acidified with 1M hydrochloric acid (5 mL). The methanol was removed in vacuo, and the resulting mixture was extracted with ethyl acetate. The organic extracts were dried with magnesium sulfate, and concentrated. Silica gel column chromatography (hexanes:ethyl acetate 4:1) provided 3-bromo-5-chloro-2-(methyloxy)phenol (123 mg, 11% yield) as a colorless oil. ^1H NMR (400 MHz, CDCl_3) δ 7.08 (d, 1H), 6.94 (d, 1H), 3.89 (s, 3H).

[0627] To a solution of 3-bromo-5-chloro-2-(methyloxy)phenol (123 mg, 0.52 mmol) in DMF (1 mL) was added cesium carbonate (678 mg, 2.08 mmol) and 2-chloro-N,N-dimethylethylamine hydrochloride (150 mg, 1.04 mmol). The mixture was stirred at room temperature for 4 h and then at 70 °C for additional 2 h. After cooling to room temperature, water and ethyl acetate were added. The layers were separated, and the organic layer was washed with brine, dried over sodium sulfate, and concentrated to give crude 2-{{[3-bromo-5-chloro-2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine as a yellow film, which was used without further purification. ^1H NMR (400 MHz, CDCl_3) δ 7.14 (d, 1H), 6.86 (d, 1H), 4.09 (t, 2H), 3.84 (s, 3H), 2.78 (t, 2H), 2.35 (s, 6H).

[0628] To a solution of crude 2-{{[3-bromo-5-chloro-2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine in toluene (2 mL) was added tri(dibenzylideneacetone)dipalladium(0) (12 mg, 0.013 mmol), BINAP (16 mg, 0.026 mmol), sodium *tert*-butoxide (70 mg, 0.73 mmol), and piperazine (270 mg, 3.12 mmol). The resulting mixture was refluxed for 5 h. After cooling to room temperature, the mixture was filtered through celite, and the filter cake was rinsed with ethyl acetate. The filtrate was concentrated and the residue purified by column chromatography on silica (dichloromethane:methanol:aqueous ammonia 80:19:1) to provide 2-{{[5-chloro-2-(methyloxy)-3-piperazin-1-ylphenyl]oxy}-N,N-

dimethylethanamine (84.3 mg, 52% yield for 2 steps) as a yellow film. ^1H NMR (400 MHz, CDCl_3) δ 6.57 (d, 1H), 6.50 (d, 1H), 4.05 (t, 2H), 3.79 (s, 3H), 3.02 (m, 8H), 2.75 (t, 2H), 2.34 (s, 6H); MS (ESI) for $\text{C}_{15}\text{H}_{24}\text{ClN}_3\text{O}_2$: 314 (MH^+).

[0629] EXAMPLE 27: 3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-*N,N*-dimethylprop-2-yn-1-amine hydrochloride

[0630] A mixture of 5-chloro-1-iodo-2-methyl-3-nitrobenzene (3.0 g, 10.1 mmol) and tin(II) chloride dihydrate (9.1 g, 40.4 mmol) in acetic acid (10 mL) was stirred for 1 h at room temperature, and was then diluted with ether. The mixture was cooled to 0 °C and 50% aqueous sodium hydroxide was added slowly. A clumpy white solid formed, and was removed by filtration. The filtrate was concentrated and the residue purified by column chromatography on silica (hexane:ethyl acetate 4:1) to provide 5-chloro-3-iodo-2-methylaniline (1.81 g, 67% yield) as a pale yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 7.25 (d, 1H), 6.64 (d, 1H), 3.78 (br s, 2H), 2.28 (s, 3H).

[0631] To a solution of 5-chloro-3-iodo-2-methylaniline (1.32 g, 4.9 mmol) in diglyme (5 mL) was added potassium carbonate (677 mg, 4.9 mmol) and bis(2-chloroethyl)amine hydrochloride (875 mg, 4.9 mmol). The mixture was refluxed for 24 h and then cooled to room temperature. Water and ethyl acetate were added. The layers were separated, the organic layer was dried over sodium sulfate, filtered, and concentrated. Column chromatography on silica (dichloromethane:methanol 4:1) provided 1-(5-chloro-3-iodo-2-methylphenyl)piperazine as a white solid (660 mg, 40% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, 1H), 6.97 (d, 1H), 3.03 (m, 4H), 2.83 (m, 4H), 2.39 (s, 3H), 1.73 (br s, 1H); MS (ESI) for $\text{C}_{11}\text{H}_{14}\text{ClIN}_2$: 337 (MH^+).

[0632] A mixture of 1-(5-chloro-3-iodo-2-methylphenyl)piperazine (660 mg, 2.0 mmol) and Boc-anhydride (437 mg, 2.0 mmol) in THF (20 mL) was stirred at room temperature for 15 h, and then concentrated to give 1,1-dimethylethyl 4-(5-chloro-3-iodo-2-methylphenyl)piperazine-1-carboxylate (784 mg, 92% yield) as a pale yellow syrup. ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, 1H), 6.93 (d, 1H), 3.55 (br s, 4H), 2.80 (m, 4H), 2.38 (s, 3H), 1.48 (s, 9H).

[0633] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-iodo-2-methylphenyl)piperazine-1-carboxylate (106 mg, 0.24 mmol) in THF (1 mL) was added bis(triphenylphosphine)palladium(II) chloride (35 mg, 0.012 mmol), 3-dimethylamino-1-propyne (40 μL , 0.36 mmol), triethylamine (50 μL , 0.36 mmol), and copper(I) iodide (5

mg, 0.024 mmol). The mixture was stirred at room temperature for 20 h, and then concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) provided 1,1-dimethylethyl 4-{5-chloro-3-[3-(dimethylamino)prop-1-yn-1-yl]-2-methylphenyl}piperazine-1-carboxylate (41.1 mg, 44% yield) as a yellow film. ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, 1H), 6.89 (d, 1H), 3.56 (br s, 4H), 3.52 (s, 2H), 2.80 (m, 4H), 2.37 (s, 6H), 2.36 (s, 3H), 1.48 (s, 9H); MS (ESI) for C₂₁H₃₀ClN₃O₂: 392 (MH⁺).

[0634] A mixture of 1,1-dimethylethyl 4-{5-chloro-3-[3-(dimethylamino)prop-1-yn-1-yl]-2-methylphenyl}piperazine-1-carboxylate (41.1 mg, 0.105 mmol) in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 2 min and then concentrated to provide 3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N,N-dimethylprop-2-yn-1-amine hydrochloride as a solid. MS (ESI) for C₁₆H₂₂ClN₃: 292 (MH⁺).

[0635] EXAMPLE 28: N'-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N,N-dimethylethane-1,2-diamine hydrochloride

[0636] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-iodo-2-methylphenyl)piperazine-1-carboxylate (92 mg, 0.21 mmol) in dioxane (1 mL) was added sodium *tert*-butoxide (28 mg, 0.29 mmol), tri(dibenzylideneacetone)dipalladium(0) (6 mg, 0.006 mmol), XANTPHOS (8 mg, 0.013 mmol), and N,N-dimethylethylenediamine (28 μL, 0.25 mmol). The mixture was refluxed for 5 h, then cooled to room temperature and concentrated. Column chromatography on silica (dichloromethane: methanol 9:1) gave 1,1-dimethylethyl 4-(5-chloro-3-{[2-(dimethylamino)ethyl]amino}-2-methylphenyl)piperazine-1-carboxylate (33.3 mg, 0.084 mmol, 40% yield) as a yellow film. ¹H NMR (400 MHz, CDCl₃) δ 6.43 (d, 1H), 6.38 (d, 1H), 4.43 (br s, 1H), 3.56 (br s, 4H), 3.15 (m, 2H), 2.79 (br s, 4H), 2.62 (m, 2H), 2.28 (s, 6H), 2.07 (s, 3H), 1.48 (s, 9H); MS (ESI) for C₂₀H₃₃ClN₄O₂: 397 (MH⁺).

[0637] A solution of 1,1-dimethylethyl 4-(5-chloro-3-{[2-(dimethylamino)ethyl]amino}-2-methylphenyl)piperazine-1-carboxylate (33.3 mg, 0.084 mmol) in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 2 min and then concentrated to provide N'-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N,N-dimethylethane-1,2-diamine hydrochloride as a solid. MS (ESI) for C₁₅H₂₅ClN₄: 297 (MH⁺).

[0638] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:

- [0639] N'-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N-methyl-N-(1-methylethyl)ethane-1,2-diamine: MS (ESI) for C₁₇H₂₉ClN₄: 325 (MH⁺).
- [0640] N'-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N-ethyl-N-methylethane-1,2-diamine: MS (ESI) for C₁₆H₂₇ClN₄: 311 (MH⁺).
- [0641] 1-(3-bromo-2-chloro-5-fluorophenyl)piperazine: MS (ESI) for C₁₀H₁₁BrClFN₂: 295 (MH⁺)
- [0642] 2-chloro-5-fluoro-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for C₁₆H₂₄ClFN₄: 327 (MH⁺).
- [0643] N-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N,N',N'-trimethylethane-1,2-diamine: MS (ESI) for C₁₆H₂₇ClN₄: 311 (MH⁺).
- [0644] 5-bromo-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₁₇H₂₇BrN₄: 368 (MH⁺).
- [0645] 5-chloro-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₁₇H₂₇ClN₄: 323 (MH⁺).
- [0646] EXAMPLE 29: 3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N,N-diethylpropan-1-amine hydrochloride
- [0647] To a solution 1,1-dimethylethyl 4-(5-chloro-3-iodo-2-methylphenyl)piperazine-1-carboxylate (111 mg, 0.25 mmol) in DMF (0.5 mL) was added tetrabutylammonium chloride (70 mg, 0.25 mmol), sodium bicarbonate (53 mg, 0.63 mmol), palladium(II) acetate (1 mg, 0.005 mmol), and allylalcohol (26 µL, 0.38 mmol). The resulting mixture was heated to 50 °C for 4 h before cooling to room temperature. Brine and ethyl acetate were added, the organic layer was dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexane:ethyl acetate 4:1) afforded 1,1-dimethylethyl 4-[5-chloro-2-methyl-3-(3-oxopropyl)phenyl]piperazine-1-carboxylate (63.0 mg, 69% yield) as a colorless film. ¹H NMR (400 MHz, CDCl₃) δ 9.82 (m, 1H), 6.88-6.85 (m, 2H), 3.56 (br s, 4H), 2.91 (t, 2H), 2.78 (m, 4H), 2.73 (m, 2H), 2.22 (s, 3H), 1.48 (s, 9H).
- [0648] To a solution of 1,1-dimethylethyl 4-[5-chloro-2-methyl-3-(3-oxopropyl)phenyl]piperazine-1-carboxylate (31 mg, 0.085 mmol) in 1,2-dichloroethane (1 mL) was added diethylamine (44 µL, 0.43 mmol) and sodium triacetoxyborohydride (36 mg, 0.17 mmol). The mixture was stirred for 45 min at room temperature. The residual hydride was quenched with 1N hydrochloric acid, and water and dichloromethane were

added. The mixture was neutralized with sodium bicarbonate. The organic layer was dried over magnesium sulfate, and concentrated to provide 1,1-dimethylethyl 4-{5-chloro-3-[3-(diethylamino)propyl]-2-methylphenyl}piperazine-1-carboxylate (27.5 mg, 76% yield) as a colorless film. ^1H NMR (400 MHz, CDCl_3) δ 6.92 (d, 1H), 6.89 (d, 1H), 3.56 (br s, 4H), 2.79 (br s, 4H), 2.60-2.49 (m, 8H), 2.22 (s, 3H), 1.70 (m, 2H), 1.49 (s, 9H), 1.03 (t, 6H).

[0649] A solution of 1,1-dimethylethyl 4-{5-chloro-3-[3-(diethylamino)propyl]-2-methylphenyl}piperazine-1-carboxylate (27.5 mg, 0.065 mmol) in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 4 min and then concentrated to provide 3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)-N,N-diethylpropan-1-amine hydrochloride as a solid. MS (ESI) for $\text{C}_{18}\text{H}_{30}\text{ClN}_3$: 324 (MH^+).

[0650] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:

[0651] 1-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazine: MS (ESI) for $\text{C}_{18}\text{H}_{28}\text{ClN}_3$: 295 (MH^+).

[0652] 1-[3-(5-chloro-2-methyl-3-piperazin-1-ylphenyl)propyl]-4-methylpiperazine hydrochloride: MS (ESI) for $\text{C}_{19}\text{H}_{31}\text{ClN}_4$: 351 (MH^+).

[0653] EXAMPLE 30: 2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]-N,N-dimethylethanamine hydrochloride

[0654] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-iodo-2-methylphenyl)piperazine-1-carboxylate (384 mg, 0.88 mmol) in DMSO (5 mL) was added potassium acetate (259 mg, 2.64 mmol), bis(pinacolato)diboron (226 mg, 0.97 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (72 mg, 0.088 mmol). The mixture was stirred at 80 °C for 24 h, and cooled to room temperature. Water and ethyl acetate were added, and the suspension was filtered through celite. The layers were separated, the organic layer was washed with brine, dried over magnesium sulfate, and concentrated. Column chromatography on silica (hexane: ethyl acetate 9:1) provided 1,1-dimethylethyl 4-[5-chloro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (185 mg, 48% yield) as a pale yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 7.43 (d, 1H), 7.01 (d, 1H), 3.55 (br s, 4H), 2.79 (m, 4H), 2.44 (s, 3H), 1.48 (s, 9H), 1.34 (s, 12H).

[0655] To a solution of 1,1-dimethylethyl 4-[5-chloro-2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine-1-carboxylate (185 mg, 0.42 mmol) in THF (5 mL) was added 7.5 M sodium hydroxide (170 μ L, 1.26 mmol) and 30% hydrogen peroxide solution (242 μ L, 2.52 mmol) at 0 °C. The mixture was stirred for 30 min before adding 10% citric acid and ethyl acetate. The layers were separated, the organic layer was dried over magnesium sulfate, and concentrated to give 1,1-dimethylethyl 4-(5-chloro-3-hydroxy-2-methylphenyl)piperazine-1-carboxylate (139 mg, 100% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl₃) δ 6.61 (d, 1H), 6.53 (d, 1H), 6.23 (br s, 1H), 3.56 (br s, 4H), 2.79 (m, 4H), 2.13 (s, 3H), 2.13 (s, 3H), 1.49 (s, 9H).

[0656] To a solution of 1,1-dimethylethyl 4-(5-chloro-3-hydroxy-2-methylphenyl)piperazine-1-carboxylate (45 mg, 0.122 mmol) in DMF was added 2-chloro-N,N-dimethylethylamine hydrochloride (35 mg, 0.244 mmol) and cesium carbonate (159 mg, 0.488 mmol). The mixture was stirred at room temperature for 16 h. Water was added and the resulting aqueous mixture was extracted twice with ethyl acetate. The organic extracts were combined, washed with water and brine, dried over magnesium sulfate, and concentrated to afford 1,1-dimethylethyl 4-(5-chloro-3-{[2-(dimethylamino)ethyl]oxy}-2-methylphenyl)piperazine-1-carboxylate as a colorless film which was used without further purification. 1 H NMR (400 MHz, CDCl₃) δ 6.61 (d, 1H), 6.59 (d, 1H), 4.06 (t, 2H), 3.55 (br s, 4H), 2.80 (m, 6H), 2.39 (s, 6H), 2.11 (s, 3H), 1.48 (s, 9H).

[0657] A solution of 1,1-dimethylethyl 4-(5-chloro-3-{[2-(dimethylamino)ethyl]oxy}-2-methylphenyl)piperazine-1-carboxylate in methanol (1 mL) and 4N hydrochloric acid in dioxane (1 mL) was refluxed for 4 min and then concentrated to provide 2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]-N,N-dimethylethanamine hydrochloride as a solid. MS (ESI) for C₁₅H₂₄ClN₃O: 298 (MH⁺).

[0658] Using the analogous synthetic techniques and substituting with alternative reagents, the following compounds of the invention were prepared:

[0659] 1-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazine: MS (ESI) for C₁₂H₁₇ClN₂O: 241 (MH⁺).

[0660] 2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]-N,N-diethylethanamine: MS (ESI) for C₁₇H₂₈ClN₃O: 326 (MH⁺).

- [0661] 1-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazine: MS (ESI) for C₁₇H₂₆ClN₃O: 324 (MH⁺).
- [0662] 4-{2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]ethyl}morpholine: MS (ESI) for C₁₇H₂₆ClN₃O₂: 340(MH⁺).
- [0663] 1-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazine: MS (ESI) for C₁₈H₂₈ClN₃O: 338(MH⁺).
- [0664] 1-{2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]ethyl}-4-ethylpiperazine: MS (ESI) for C₁₉H₃₁ClN₄O: 367(MH⁺).
- [0665] 4-{3-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]propyl}morpholine: MS (ESI) for C₁₈H₂₈ClN₃O₂: 354(MH⁺).
- [0666] 1-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazine: MS (ESI) for C₁₈H₂₈ClN₃O: 338(MH⁺).
- [0667] 1-{3-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]propyl}-4-methylpiperazine: MS (ESI) for C₁₉H₃₁ClN₄O: 367 (MH⁺).
- [0668] 1-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazine: MS (ESI) for C₁₉H₃₀ClN₃O: 352 (MH⁺).
- [0669] 1-{3-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]propyl}-4-ethylpiperazine: MS (ESI) for C₂₀H₃₃ClN₄O: 381 (MH⁺).
- [0670] 3-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]-N,N-diethylpropan-1-amine: MS (ESI) for C₁₈H₃₀ClN₃O: 340 (MH⁺).
- [0671] 1-{2-[(5-chloro-2-methyl-3-piperazin-1-ylphenyl)oxy]ethyl}-4-methylpiperazine hydrochloride: MS (ESI) for C₁₈H₂₉ClN₄O: 353 (MH⁺).
- [0672] EXAMPLE 31: N,N-diethyl-2-[(3-piperazin-1-ylphenyl)oxy]ethanamine hydrochloride
- [0673] A mixture of 3-hydroxyphenylpiperazine (0.41g, 2.25 mmol) and Boc-anhydride (0.49g, 2.25 mmol) in dry THF (15 mL) was stirred at room temperature for 5 h. The reaction mixture was concentrated to provide 1,1-dimethylethyl 4-(3-hydroxyphenyl)piperazine-1-carboxylate (100% yield) as a beige solid. MS (ESI) for C₁₅H₂₂N₂O₃: 223 (M-56).

[0674] A mixture of 1,1-dimethylethyl 4-(3-hydroxyphenyl)piperazine-1-carboxylate (0.13g, 0.46 mmol), potassium carbonate (256 mg, 1.9 mmol), and 2-(diethylamino)ethyl chloride hydrochloride (0.16g, 0.92 mmol) in DMF (3 mL) was stirred at 110 °C for 1 h. The reaction mixture was poured into ice water, and extracted several times with ether. The organic layer was washed with water, dried over sodium sulfate, and concentrated to give crude 1,1-dimethylethyl 4-(3-{[2-(diethylamino)ethyl]oxy}phenyl)piperazine-1-carboxylate. MS (ESI) for C₂₁H₃₅N₃O₃ : 378 (MH⁺).

[0675] A solution of 1,1-dimethylethyl 4-(3-{[2-(diethylamino)ethyl]oxy}phenyl)piperazine-1-carboxylate (0.17 g, 0.45 mmol) in MeOH (2 mL) and 4N hydrochloric acid in dioxane (2 mL) was refluxed for 1 min. The reaction mixture was concentrated, the residue was triturated with ether, and dried to afford N,N-diethyl-2-[(3-piperazin-1-ylphenyl)oxy]ethanamine hydrochloride (100% yield) as an oil. MS (ESI) for C₁₆H₂₇N₃O: 278 (MH⁺).

[0676] EXAMPLE 32: N,N-diethyl-2-[(2-methyl-3-piperazin-1-ylphenyl)oxy]ethanamine hydrochloride

[0677] A mixture of 2-methyl-3-nitrophenol (672 mg, 4.4 mmol), cesium carbonate (2.1 g, 6.44 mmol); and benzyl bromide (751 mg, 4.4 mmol) in DMF (6 mL) was stirred at room temperature for 3 h. The reaction mixture was poured into ice water. The light yellow precipitation was filtered off, washed several times with water, and dried, to provide 1-nitro-2-methyl-3-[(phenylmethyl)oxy]benzene (930 mg, 87% yield). ¹HNMR (400 MHz, d₄-methanol): δ 7.47 (d, 1H), 7.45 (s, 1H), 7.40 (s, 1H), 7.39 (d, 1H), 7.37 (d, 1H), 7.34 (m, 1H), 7.32 (s, 1H), 7.29 (d, 1H), 4.90 (s, 2H), 2.35 (s, 3H).

[0678] To a solution of 1-nitro-2-methyl-3-[(phenylmethyl)oxy]benzene (0.92g, 3.8 mmol) in ethyl acetate (50 mL) was added tin(II) chloride monohydrate (3.5g, 15.2 mmol) and the reaction mixture was stirred at 70 °C for 5 h. The reaction mixture was cooled to room temperature, diluted with ether (50 mL), and sodium bicarbonate was added until pH 8. The semi-solid byproduct was filtered off, washed with ethyl acetate, the organic layer was dried with sodium sulfate, and concentrated. Trituration with ether gave 2-methyl-3-[(phenylmethyl)oxy]aniline (0.35g, 44% yield) as a light yellow solid. MS (ESI) for C₁₄H₁₅NO: 214 (MH⁺).

[0679] A mixture of 2-methyl-3-[(phenylmethyl)oxy]aniline (0.34g, 1.6 mmol), potassium carbonate (0.44 g, 3.2 mmol), and bis(2-chloroethyl)amine hydrochloride (1.6

mmol) diglyme (5 mL) was refluxed for 4 h. The reaction mixture was cooled to room temperature, water was added, and the pH of the aqueous layer was adjusted to pH 13. The aqueous layer was extracted with ethyl acetate (3 x 20 mL), dried with sodium sulfate, and concentrated to provide 1-{2-methyl-3-[(phenylmethyl)oxy]phenyl}piperazine (0.43g, 96% yield) as a dark oil. MS (ESI) for C₁₈H₂₂N₂O: 283 (MH⁺).

[0680] A mixture of 1-{2-methyl-3-[(phenylmethyl)oxy]phenyl}piperazine (0.42g 1.5 mmol) and Boc-anhydride (0.33g, 1.5 mmol) in THF (10 mL) was stirred at room temperature for 30 h. The reaction mixture was concentrated, diluted with ethyl acetate (30 ml), the organic layer was washed with water, brine, dried with sodium sulfate, and concentrated. Column chromatography on silica provided 1,1-dimethylethyl 4-{2-methyl-3-[(phenylmethyl)oxy]phenyl}piperazine-1-carboxylate (0.18g, 32% yield). MS (ESI) for C₂₃H₃₀N₂O₃: 384 (MH⁺) and 327 (MH-56).

[0681] To a solution of 1,1-dimethylethyl 4-{2-methyl-3-[(phenylmethyl)oxy]phenyl}piperazine-1-carboxylate (0.18g, 0.5 mmol) in ethanol (15 mL) was added palladium on carbon (0.11g, 10%, contains 50% water), and the reaction mixture was stirred under an hydrogen atmosphere for 15 h. The reaction mixture was filtered through celite, and the filter cake was washed with ethanol. The filtrate was concentrated to give 1,1-dimethylethyl 4-(3-hydroxy-2-methylphenyl)piperazine-1-carboxylate (0.075g, 54% yield). MS (ESI) for C₁₆H₂₄N₂O₃: 293 (MH⁺).

[0682] A mixture of 1,1-dimethylethyl 4-(3-hydroxy-2-methylphenyl)piperazine-1-carboxylate (0.07g, 0.24 mmol), potassium carbonate (0.134g, 0.96 mmol), and 2-(diethylamino)ethylchloride hydrochloride (0.083g, 0.48 mmol) in DMF (2 mL) was stirred at 100 °C for 1 h. The reaction mixture was cooled to room temperature, poured into ice water, and extracted with ethyl acetate (3 x 20 ml). The organic layer was dried with sodium sulfate, and concentrated to afford 1,1-dimethylethyl 4-(3-{[2-(diethylamino)ethyl]oxy}-2-methylphenyl)piperazine-1-carboxylate (0.07g, 76% yield). MS (ESI) for C₂₂H₃₇N₃O₃: 392 (MH⁺).

[0683] A solution of 1,1-dimethylethyl 4-(3-{[2-(diethylamino)ethyl]oxy}-2-methylphenyl)piperazine-1-carboxylate (0.07g, 0.18 mmol) in MeOH (2 mL) and 4N hydrochloric acid in dioxane (2 mL) was refluxed for 1 min. The reaction mixture was concentrated to give N,N-diethyl-2-[(2-methyl-3-piperazin-1-ylphenyl)oxy]ethanamine hydrochloride (0.04 g, 77% yield), which was used without further purification. MS (ESI) for C₁₇H₂₉N₃O: 292 (MH⁺).

[0684] EXAMPLE 33: 5-(ethylsulfonyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride

[0685] To a solution of 3,5-dibromo-4-methylphenol (5.24 g, 19.70 mmol) in DMF (30 mL) was added sodium hydride (60% in mineral oil, 0.79 g, 19.75 mmol) at room temperature under nitrogen. The resulting mixture was stirred at 60 °C for 15 min, cooled to room temperature, and dimethythiocarbamoyl chloride (2.30 g, 18.61 mmol) was added. The resulting mixture was stirred at 60 °C for 1 h, and then diluted with ethyl acetate (100 mL). The organic layer was washed with 1N sodium hydroxide (2 x 50 mL), water (50 mL), 5% lithium chloride (50 mL), and brine (50 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 9:1) afforded O-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (5.11 g, 78% yield) as a colorless solid. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (s, 2H), 3.44 (s, 3H), 3.32 (s, 3H), 2.55 (s, 3H).

[0686] O-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (4.00 g, 11.33 mmol) was stirred at 200 °C for 23 h under nitrogen. Column chromatography on silica (hexanes:ethyl acetate 9:1) gave S-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (3.05 g, 76% yield) as a colorless solid. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, 2H), 3.07 (br s, 3H), 3.03 (br s, 3H), 2.57 (s, 3H).

[0687] A solution of S-(3,5-dibromo-4-methylphenyl)dimethylthiocarbamate (3.73 g, 10.56 mmol) in methanol (50 mL) and 2N sodium hydroxide (20 mL) was refluxed for 90 min. The reaction mixture was diluted with water (100 mL), acidified with 1N hydrochloric acid to pH 3, and then extracted with ethyl acetate (100 mL). The organic layer was washed with water (50 mL), and brine (50 mL), dried with sodium sulfate, and concentrated to give 3,5-dibromo-4-methylbenzenethiol (2.85 g, 96% yield) as a colorless solid. ¹H NMR (400 MHz, d₆-DMSO) δ 7.61 (s, 2H), 6.94 (s, 1H), 2.43 (s, 3H).

[0688] A mixture of 3,5-dibromo-4-methylbenzenethiol (0.88 g, 3.12 mmol), cesium carbonate (2.03 g, 6.24 mmol), and ethyl iodide (0.72 g, 4.63 mmol) in DMF (7 mL) mixture was stirred at 60 °C for 1 h, and then diluted with ethyl acetate (100 mL). The organic layer was washed with water (30 mL), 5% lithium chloride (2 x 30 mL), and brine (30 mL), dried with sodium sulfate, and concentrated to afford 1,3-dibromo-5-(ethylthio)-2-methylbenzene (0.90 g, 93% yield) as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.54 (s, 2H), 2.92 (q, 2H), 2.52 (s, 3H), 1.31 (t, 3H).

[0689] To a solution of 1,3-dibromo-5-(ethylthio)-2-methylbenzene (0.88 g, 2.84 mmol) in dichloromethane (30 mL) was added m-chloroperbenzoic acid (70%, 2.80 g) at 0 °C. The ice batch was removed and the resulting mixture was stirred at room temperate for 5 h. The mixture was diluted with ethyl acetate (200 mL), washed with saturated sodium bicarbonate (3 x 50 mL), and brine (30 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 9:1) provided 1,3-dibromo-5-(ethylsulfonyl)-2-methylbenzene (0.57 g, 59% yield) as a colorless solid. ¹H NMR (400 MHz, CDCl₃) δ 8.03 (s, 2H), 3.14 (q, 2H), 2.66 (s, 3H), 1.31 (t, 3H).

[0690] A mixture of 1,3-dibromo-5-(ethylsulfonyl)-2-methylbenzene (400 mg, 1.17 mmol), Boc-piperazine (218 mg, 1.17 mmol), sodium *tert*-butoxide (160 mg, 1.66 mmol), Pd₂(dba)₃ (55 mg, 0.06 mmol), and BINAP (110 mg, 0.18 mmol) in toluene (5 mL) was stirred at 100 °C for 17 h. Column chromatography of the mixture on silica (hexanes: ethyl acetate 4:1) gave 1,1-dimethylethyl 4-[3-bromo-5-(ethylsulfonyl)-2-methylphenyl]piperazine-1-carboxylate (184 mg, 35% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (d, 3H), 7.43 (d, 1H), 3.60 (br s, 4H), 3.11 (q, 2H), 2.18 (m, 4H), 2.46 (s, 3H), 1.49 (s, 9H), 1.29 (t, 3H).

[0691] A mixture of 1,1-dimethylethyl 4-[3-bromo-5-(ethylsulfonyl)-2-methylphenyl]-piperazine-1-carboxylate (220 mg, 0.49 mmol), 1-(2-aminoethyl)pyrrolidine (90 mg, 0.79 mmol), sodium *tert*-butoxide (95 mg, 0.98 mmol), Pd₂(dba)₃ (22 mg, 0.02 mmol), and BINAP (46 mg, 0.07 mmol) in toluene (3 mL) was stirred in a sealed pressure vessel at 100 °C for 2 h. Column chromatography of the mixture on silica (dichloromethane: methanol 95:5) afforded 1,1-dimethylethyl 4-{5-(ethylsulfonyl)-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (158 mg, 67% yield) as a yellow oil. ¹H NMR (400 MHz, d₄-methanol) δ 6.95 (d, 1H), 6.88 (d, 1H), 3.58 (br s, 4H), 3.52 (t, 2H), 3.30 (m, 4H), 3.09 (br s, 4H), 2.84 (br s, 4H), 2.23 (s, 3H), 1.99 (m, 4H), 1.48 (s, 9H), 1.21 (t, 3H); MS (ESI) for C₂₄H₄₀N₄O₄S: 481 (MH⁺).

[0692] A mixture of 1,1-dimethylethyl 4-{5-(ethylsulfonyl)-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (155 mg, 0.32 mmol), methanol (5 mL), and 4N hydrochloric acid in dioxane (5 mL) was refluxed for 1 min. The mixture was concentrated to 5-(ethylsulfonyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)-aniline hydrochloride (170 mg, 100% yield) which was used without further purification. MS (ESI) for C₁₉H₃₂N₄O₂S: 381 (MH⁺).

[0693] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0694] 2-methyl-5-(methylsulfonyl)-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₁₈H₃₀N₄O₂S: 367 (M⁺).

[0695] EXAMPLE 34: 5-bromo-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride

[0696] A mixture of 3,5-dibromo-4-methylbenzoic acid (6.3 g, 21.4 mmol), potassium carbonate (4.4 g, 32.1 mmol), and benzyl bromide (3.7 g, 21.7 mmol) in acetone (100 mL) was refluxed for 3 h. The resulting mixture was partitioned between ethyl acetate (300 mL) and water (100 mL). The organic layer was washed with water (2 x 100 mL), and brine (100 mL), dried with sodium sulfate, and concentrated to give phenylmethyl 3,5-dibromo-4-methylbenzoate (7.5 g, 91% yield) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 2H), 7.41 (m, 5H), 5.35 (s, 2H), 2.62 (s, 3H).

[0697] A mixture of phenylmethyl 3,5-dibromo-4-methylbenzoate (7.50 mg, 19.53 mmol), Boc-piperazine (3.64 g, 19.53 mmol), cesium carbonate (8.91 g, 27.34 mmol), Pd₂(dba)₃ (0.89 g, 0.98 mmol), and BINAP (1.82 g, 2.93 mmol) in toluene (100 mL) was stirred at 100 °C for 16 h. The reaction mixture was filtered through celite and concentrated. Column chromatography on silica (hexanes: ethyl acetate 9:1) gave 1,1-dimethylethyl 4-(3-bromo-2-methyl-5-[(phenylmethyl)oxy]carbonyl)phenyl)piperazine-1-carboxylate (4.04, 42% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, 1H), 7.64 (d, 1H), 7.40 (m, 5H), 5.35 (s, 2H), 3.58 (br s, 4H), 2.85 (m, 4H), 2.43 (s, 3H), 1.49 (s, 9H).

[0698] A mixture of 1,1-dimethylethyl 4-(3-bromo-2-methyl-5-[(phenylmethyl)oxy]carbonyl)phenyl)piperazine-1-carboxylate (2.10 g, 4.29 mmol), 1-(2-aminoethyl)pyrrolidine (0.74 g, 6.44 mmol), cesium carbonate (2.80 g, 8.58 mmol), Pd₂(dba)₃ (0.20 g, 0.21 mmol), and BINAP (0.40 g, 0.64 mmol) in toluene (40 mL) was stirred at 100 °C for 16 h. The reaction mixture was filtered through celite and concentrated. Column chromatography on silica (dichloromethane: methanol 95:5 to 90:10) afforded 1,1-dimethylethyl 4-{2-methyl-5-[(phenylmethyl)oxy]carbonyl}-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (0.91 g, 41% yield) as a brown foam. ¹H NMR (400 MHz, CDCl₃) δ 7.40 (m, 5H), 7.20 (d, 1H), 7.13 (d, 1H), 5.35

(s, 2H), 4.41 (s, 1H), 3.58 (br s, 4H), 3.26 (m, 2H), 2.83 (br s, 4H), 2.79 (t, 2H), 2.53 (m, 4H), 2.15 (s, 3H), 1.77 (m, 4H), 1.49 (s, 9H).

[0699] A solution of 1,1-dimethylethyl 4-{2-methyl-5-[(phenylmethyl)-oxy]carbonyl}-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (3.94 g, 7.54 mmol) in dichloromethane (30 mL) and trifluoroacetic acid (30 mL) was stirred at room temperature for 90 min and then concentrated. Dichloromethane (60 mL) and diisopropylethylamine (10 mL) was added to the residue, and the resulting solution was cooled to 0 °C. Trifluoroacetic anhydride (3.56 g, 16.95 mmol) was added dropwise, and the mixture was stirred at 0 °C for 30 min and then at room temperature for 1 h. The reaction mixture was diluted with ethyl acetate (300 mL), washed with water (100 mL), saturated sodium bicarbonate (100 mL), water (100 mL), and brine (100 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane: methanol 97:3) provided phenylmethyl 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoate (3.60 g, 78% yield) as a yellow foam. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 7.76 (s, 1H), 7.40 (m, 5H), 5.39 (d, 1H), 5.34 (d, 1H), 4.43 (m, 1H), 3.80 (br s, 4H), 3.13 (m, 1H), 2.99 (m, 4H), 2.72 (m, 1H), 2.61 (m, 1H), 2.46 (m, 4H), 2.27 (s, 3H), 1.68 (br s, 4H).

[0700] A mixture of phenylmethyl 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoate (3.60 g, 5.86 mmol) and palladium on carbon (0.60 g, 10%, contains 50% water) was stirred under an hydrogen atmosphere for 3 h. The raction mixture was filtered through celite, and concentrated to give 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoic acid (3.13 g, 100% yield) as yellow semisolid. ¹H NMR (400 MHz, CDCl₃) δ 7.91 (s, 1H), 7.61 (s, 1H), 4.48 (m, 1H), 3.68 (br s, 4H), 3.51 (m, 2H), 3.25 (br s, 4H), 2.90 (m, 5H), 2.16 (s, 3H), 2.06 (m, 4H).

[0701] A solution of 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoic acid (0.98 g, 1.87 mmol) and pyridine (0.15 g, 1.85 mmol) in dichloromethane (10 mL) was cooled to 0 °C, and cyanuric fluoride (0.27 g, 2.01 mmol) was added dropwise. The mixture was stirred at 0 °C for 2.5 h, and then partitioned between dichloromethane (20 mL) and water (30 mL). The aqueous layer was extracted with more dichloromethane (2 x 20 mL), dried with sodium sulfate, and concentrated to afford 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-

(trifluoroacetyl)piperazin-1-yl]benzoyl fluoride (1.05 g, 100% yield) as a yellow foam. MS (ESI) for C₂₂H₂₅F₇N₄O₃: 527 (MH⁺).

[0702] A solution of 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoyl fluoride (1.05 g, 1.87 mmol) in dichloromethane (20 mL) was cooled to 0 °C, and sodium azide (1.20 g, 18.46 mmol) was added. The mixture was stirred at 0 °C for 3 h, and then partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted with more ethyl acetate (2 x 50 mL), washed with brine (50 mL), dried with sodium sulfate, and concentrated to give 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]-benzoyl azide (0.88 g, 85% yield) as a yellow foam. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (s, 1H), 7.69 (s, 1H), 4.45 (m, 1H), 3.87 (br s, 2H), 3.80 (m, 4H), 3.01 (m, 4H), 2.76 (br s, 4H), 2.29 (s, 3H), 1.88 (br s, 4H).

[0703] A solution of *tert*-butanol (2 mL) in toluene (20 mL) was heated to 100 °C, and a solution of 4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]benzoyl azide (0.88 g, 1.60 mmol) and *tert*-butanol (2 mL) in toluene (20 mL) was added at that temperature. The mixture was stirred at 100 °C for 2 h, and then concentrated. Column chromatography on silica (dichloromethane: methanol 95:5) provided 1,1-dimethylethyl {4-methyl-3-[(2-pyrrolidin-1-ylethyl)(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}carbamate (0.42 g, 44% yield) as a yellow foam. ¹H NMR (400 MHz, d₄-methanol) δ 7.26 (s, 1H), 7.18 (s, 1H), 4.39 (m, 1H), 3.82 (br s, 2H), 3.22 (m, 1H), 2.96 (m, 4H), 2.80 (m, 1H), 2.70 (m, 1H), 2.61 (m, 4H), 2.17 (s, 3H), 1.80 (m, 4H), 1.51 (s, 9H).

[0704] A solution of 1,1-dimethylethyl {4-methyl-3-[(2-pyrrolidin-1-ylethyl)-(trifluoroacetyl)amino]-5-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}carbamate (0.42 g, 0.71 mmol) in dichloromethane (5 mL) and trifluoroacetic acid (5 mL) was stirred at room temperature for 3.5 h, and then concentrated. The residue was dissolved in ethyl acetate (50 mL), and washed with saturated sodium bicarbonate (50 mL). The aqueous layer was further extracted with ethyl acetate (2 x 30 mL), the combined organic layers were washed with brine (50 mL), dried with sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane: methanol 95:5) gave N-{5-amino-2-methyl-3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-1-ylethyl)acetamide (0.23 g, 66% yield) as a yellow glass. ¹H NMR (400 MHz, d₄-methanol) δ 6.55 (d, 1H), 6.39 (s,

1H), 4.35 (m, 1H), 3.80 (br s, 4H), 3.18 (m, 1H), 2.93 (m, 4H), 2.77 (m, 1H), 2.68 (m, 1H), 2.58 (m, 4H), 2.08 (s, 3H), 1.80 (m, 4H).

[0705] A mixture of copper(II) bromide (120 mg, 0.54 mmol) and *tert*-butyl nitrite (76 mg, 0.66 mmol) in acetonitrile (8 mL) was cooled to 0 °C, and a solution of N-{5-amino-2-methyl-3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-1-ylethyl)acetamide (220 mg, 0.44 mmol) in acetonitrile (2 mL) was added dropwise. The mixture was stirred at room temperature for 2 h, and then added into 1N hydrochloric acid (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 30 mL), washed with brine (30 mL), dried with sodium sulfate, and concentrated. Purification by reverse phase HPLC afforded N-{5-bromo-2-methyl-3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-1-ylethyl)acetamide (42 mg, 17% yield) as a yellow oil. MS (ESI) for C₂₁H₂₅BrF₆N₄O₂: 559, 561 (MH⁺).

[0706] A mixture of N-{5-bromo-2-methyl-3-[4-(trifluoroacetyl)piperazin-1-yl]phenyl}-2,2,2-trifluoro-N-(2-pyrrolidin-1-ylethyl)acetamide (42 mg, 0.08 mmol) and potassium carbonate (100 mg, 0.72 mmol) in methanol (5 mL) and water (0.5 mL) was stirred at 60 °C for 19 h, then concentrated and azeotroped with 2-propanol (2 x 5 mL) to give crude 5-bromo-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride, which was used without further purification. MS (ESI) for C₁₇H₂₇BrN₄: 367, 369 (MH⁺).

[0707] EXAMPLE 35: 2-[(3-chloro-5-piperazin-1-ylphenyl)oxy]-N,N-diethylethanamine trifluoroacetate

[0708] A mixture of dichlorophenol (2.30 g, 14 mmol), cesium carbonate (7.00 g, 21 mmol), and benzyl bromide (2.43 g, 14 mmol) in DMF (20 mL) was stirred at room temperature for 4 h. The reaction mixture was poured into ice water, and extracted several times with ether. The organic layer was dried with sodium sulfate, and concentrated to provide 1,3-dichloro-5-[(phenylmethyl)oxy]benzene (100% yield). ¹H NMR (CDCl₃): δ 6.97 (s, 1H), 6.88 (m, 2H), 5.03 (s, 2H).

[0709] A mixture of 1,3-dichloro-5-[(phenylmethyl)oxy]benzene (0.56 g, 2.2 mmol), Boc-piperazine (0.5g, 2.64 mmol), sodium *tert*-butoxide (0.30 g, 3.12 mmol), Pd(dba)₃ (0.02g, 1 mol%), and 2-(di-*tert*-butylphosphino)biphenyl (0.03g, 4 mol%) in toluene (4ml), was stirred at 90 °C for 15 h. Column chromatography on silica (ethyl acetate:hexanes 1:8) afforded 1,1-dimethyl 4-(3-chloro-5-

[(phenylmethyl)oxy]phenyl}piperazine-1-carboxylate (0.70 g, 78% yield). MS (ESI) for C₂₂H₂₇ClN₂O₃: 347 (M-56).

[0710] A solution of 1,1-dimethylethyl 4-{3-chloro-5-[(phenylmethyl)oxy]phenyl}piperazine-1-carboxylate (190 mg, 0.47 mmol) in trifluoroacetic acid (4 mL) was refluxed for 5 h. The reaction mixture was concentrated to give 3-chloro-5-piperazin-1-ylphenol (98 mg, 98% yield). MS (ESI) for C₁₀H₁₃ClN₂O: 213 (MH⁺).

[0711] A solution of 3-chloro-5-piperazin-1-ylphenol (98 mg, 0.46 mmol) and Boc-anhydride (101 mg, 0.46 mmol) in THF (4 mL) was stirred at room temperature for 48 h. The reaction mixture was concentrated, the residue was dissolved in ethyl acetate, washed with water, and brine, dried with sodium sulfate, and concentrated to provide 1,1-dimethylethyl 4-(3-chloro-5-hydroxyphenyl)piperazine-1-carboxylate (150 mg, 100% yield). MS (ESI) for C₁₅H₂₁ClN₂O₃: 257 (M-56).

[0712] A mixture of 1,1-dimethylethyl 4-(3-chloro-5-hydroxyphenyl)piperazine-1-carboxylate (150 mg, 0.46 mmol), potassium carbonate (0.26 g, 1.84 mmol), and 2-(diethylamino)ethyl hydrochloride (160 mg, 0.92 mmol) in DMF (3 mL) was stirred at 100 °C for 6 h. The reaction mixture was poured into ice water, and extracted several times with ethyl acetate. The organic layer was washed with water, brine, dried with sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-(3-chloro-5-{[2-(diethylamino)ethyl]oxy}phenyl)piperazine-1-carboxylate yield (73 mg, 38% yield). MS (ESI) for C₂₁H₃₄ClN₃O₃: 412 (MH⁺).

[0713] A solution of 1,1-dimethylethyl 4-(3-chloro-5{[2-(diethylamino)ethyl]oxy}phenyl)piperazine-1-carboxylate (73 mg, 0.18 mmol) in trifluoroacetic acid (4 mL) was stirred at room temperature for 30 min. The reaction mixture was concentrated, and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, water, dried with sodium sulfate, and concentrated to afford 2-[(3-chloro-5-piperazin-1-ylphenyl)oxy]-N,N-diethylethanamine trifluoroacetate (100% yield). MS (ESI) for C₁₆H₂₆ClN₃O: 312 (MH⁺).

[0714] Using the analogous synthetic techniques and substituting with alternative reagents, the following compound of the invention was prepared:

[0715] 1-[3-chloro-5-(methyloxy)phenyl]piperazine: MS (ESI) for C₁₁H₁₅ClN₂O: 228 (MH⁺).

[0716] EXAMPLE 36: 5-[(2-ethylbutyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride

[0717] A mixture of 3,5 dibromo-4-methylphenol (250 mg, 0.94 mmol), cesium carbonate (919 mg, 2.82 mmol) and 3-(bromomethyl)pentane (197 μ L, 1.41 mmol) were stirred in DMF (5 mL) at 60 °C for 16 h under nitrogen. The reaction mixture was diluted with ethyl acetate (50 mL), washed with water (20 mL), 5% lithium chloride (20 mL), and brine (20 mL), dried over sodium sulfate, and concentrated to give 1,3-dibromo-5-[(2-ethylbutyl)oxy]-2-methylbenzene (300 mg, 91% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl₃) δ 7.10-7.08 (br s, 2H), 3.80-3.77 (m, 2H), 2.48 (s, 3H), 1.69-1.57 (m, 1H), 1.51-1.36 (m, 4H), 0.92 (t, 6H).

[0718] To 1,3-dibromo-5-[(2-ethylbutyl)oxy]-2-methylbenzene (289 mg, 0.83 mmol) in dry toluene (3 mL) was added Pd₂(dba)₃ (76 mg, 0.083 mmol), BINAP (154 mg, 0.25 mmol), sodium *tert*-butoxide (109 mg, 1.16 mmol), and Boc-piperazine (163 mg, 0.87 mmol). The reaction mixture was stirred at 110 °C for 16 h under nitrogen, cooled to room temperature, diluted with ethyl acetate (30 mL), filtered, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 95:5) provided 1,1-dimethylethyl 4-{3-bromo-5-[(2-ethylbutyl)oxy]-2-methylphenyl}piperazine-1-carboxylate (200 mg, 53% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl₃) δ 6.87 (d, 1H), 6.52 (d, 1H), 3.78 (d, 2H), 3.64-3.47 (br m, 4H), 2.86-2.75 (br m, 4H), 2.30 (s, 3H), 1.68-1.59 (m, 1H), 1.51-1.38 (m, 13H), 0.92 (t, 6H).

[0719] To 1,1-dimethylethyl 4-{3-bromo-5-[(2-ethylbutyl)oxy]-2-methylphenyl}piperazine-1-carboxylate (193 mg, 0.42 mmol) in anhydrous toluene (2 mL) was added Pd₂(dba)₃ (39 mg, 0.042 mmol), BINAP (79 mg, 0.13 mmol), sodium *tert*-butoxide (56 mg, 0.59 mmol) and 1-(2-aminoethyl)pyrrolidine (64 μ L, 0.51 mmol). The reaction mixture was refluxed for 4 h under nitrogen, diluted with ethyl acetate (20 mL), filtered and concentrated. Column chromatography on silica (dichloromethane:methanol 94:6) gave 1,1-dimethylethyl 4-{5-[(2-ethylbutyl)oxy]-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (147 mg, 53% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl₃) δ 6.06 (d, 1H), 6.01 (d, 1H), 3.81 (d, 2H), 3.73-3.35 (br m, 4H), 3.34-3.22 (m, 2H), 2.94-2.73 (m, 6H), 2.72-2.53 (m, 4H), 2.05 (s, 3H), 1.83 (m, 4H), 1.72-1.56 (m, 1H), 1.55-1.35 (m, 13H), 0.93 (t, 6H); MS (ESI) for C₂₈H₄₈N₄O₃: 489 (MH⁺).

[0720] A solution of 1,1-dimethylethyl 4-{5-[(2-ethylbutyl)oxy]-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (141 mg, 0.29 mmol) in methanol (2mL) and 4N hydrogen chloride in dioxane (0.3ml) was refluxed for 2 min, and then concentrated to yield 5-[(2-ethylbutyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride (130 mg, 99% yield). MS (ESI) for $C_{23}H_{40}N_4O$: 389(MH $^+$).

[0721] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0722] 2-methyl-5-[(2-methylpropyl)oxy]-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{21}H_{36}N_4O$: 361 (MH $^+$).

[0723] 5-(butyloxy)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{21}H_{36}N_4O$: 361(MH $^+$).

[0724] 5-[(2,2-dimethylpropyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{22}H_{38}N_4O$: 375 (MH $^+$).

[0725] 2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)-5-[(tetrahydrofuran-2-ylmethyl)oxy]aniline hydrochloride: MS (ESI) for $C_{22}H_{36}N_4O_2$: 389 (MH $^+$).

[0726] 2-methyl-5-{{[2-(methyloxy)ethyl]oxy}}-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{20}H_{34}N_4O_2$: 363 (MH $^+$).

[0727] 5-{{[(2,2-difluorocyclopropyl)methyl]oxy}}-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{21}H_{32}F_2N_4O$: 395 (MH $^+$).

[0728] 5-[(cyclopropylmethyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{21}H_{34}N_4O$: 359 (MH $^+$).

[0729] 2-methyl-5-[(3-methylbutyl)oxy]-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{22}H_{38}N_4O$: 375 (MH $^+$).

[0730] 5-[(cyclohexylmethyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{24}H_{40}N_4O$: 401 (MH $^+$).

[0731] 5-[(cyclopentylmethyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for $C_{23}H_{38}N_4O$: 387 (MH $^+$).

[0732] 2-methyl-5-[(phenylmethyl)oxy]-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for $C_{24}H_{34}N_4O$: 395 (MH $^+$).

[0733] 5-[(cyclobutylmethyl)oxy]-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₂₂H₃₆N₄O: 373 (MH⁺).

[0734] 5-(ethyloxy)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₁₉H₃₂N₄O: 333 (MH⁺).

[0735] 2-methyl-5-[(1-methylethyl)oxy]-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₂₀H₃₄N₄O: 347 (MH⁺).

[0736] 2-methyl-3-piperazin-1-yl-5-(propyloxy)-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for C₂₀H₃₄N₄O: 347 (MH⁺).

[0737] 2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline hydrochloride: MS (ESI) for C₂₀H₃₁F₃N₄O: 401 (MH⁺).

[0738] EXAMPLE 37: 3-bromo-4-methyl-N-phenyl-5-piperazin-1-ylbenzamide hydrochloride

[0739] To 1,1-dimethylethyl 4-{3-bromo-2-methyl-5-[(methyloxy)carbonyl]phenyl}piperazine-1-carboxylate (1.05 g, 2.54 mmol) in methanol (10 mL) and water (3 mL) was added potassium hydroxide (713 mg, 12.7 mmol). The reaction mixture was stirred at 60 °C for 2 hours. The pH was adjusted to 5 with 10% citric acid, and the mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and concentrated to give 3-bromo-5-(4-{[(1,1-dimethylethyl)oxy]carbonyl}piperazin-1-yl)-4-methylbenzoic acid (849 mg, 84% yield) as a white solid. MS (ESI) for C₁₇H₂₃BrN₂O₄: 400 (MH⁺).

[0740] To 3-bromo-5-(4-{[(1,1-dimethylethyl)oxy]carbonyl}piperazin-1-yl)-4-methylbenzoic acid (25 mg, 0.06 mmol) in DMF (3 mL) was added aniline (58 mg, 0.63 mmol), HATU (24 mg, 0.06 mmol), HOAT (11 mg, 0.08 mmol), and N-methyl morpholine (34 mg, 0.31 mmol). The reaction mixture was stirred at room temperature for 17 h, and then diluted with water. The pH was adjusted to 10 with saturated sodium bicarbonate. The mixture was extracted with diethyl ether, the organic layer was dried over magnesium sulfate, and concentrated to provide 1,1-dimethylethyl 4-{3-bromo-2-methyl-5-[(phenylamino)carbonyl]phenyl}piperazine-1-carboxylate (30 mg, 100% yield) as a colorless oil. MS (ESI) for C₂₃H₂₈BrN₃O₃: 475 (MH⁺).

[0741] To 1,1-dimethylethyl 4-{3-bromo-2-methyl-5-[(phenylamino)carbonyl]phenyl}piperazine-1-carboxylate (106 mg, 0.22 mmol) in methanol (5 mL) was added 4N hydrochloric acid in dioxane (1 mL). The reaction

mixture was refluxed for 3 min, and then concentrated to yield 3-bromo-4-methyl-N-phenyl-5-piperazin-1-ylbenzamide hydrochloride (84 mg, 100% yield) as a colorless oil. MS (ESI) for $C_{18}H_{20}BrN_3O$: 375 (MH^+).

[0742] EXAMPLE 38: 1-{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one hydrochloride

[0743] To methyl-3,5 dibromo-4-methylbenzoate (7.13 g, 23.2 mmol) in dry toluene (90 mL) was added $Pd_2(dbu)_3$ (1.06 g, 1.16 mmol), BINAP (2.17 g, 3.48 mmol), cesium carbonate (10.6 g, 32.5 mmol) and Boc-piperazine (4.36 g, 23.2 mmol). The reaction mixture was stirred at 110 °C for 16 h under nitrogen, cooled to room temperature, diluted with ethyl acetate (300 mL), filtered and concentrated. Column chromatography on silica (hexanes: ethyl acetate 9:1) provided 1,1-dimethylethyl 4-(3-bromo-2-methyl-5-[(methyloxy)carbonyl]phenyl)piperazine-1-carboxylate (5.5 g, 57% yield) as a light yellow oil. MS (ESI) for $C_{18}H_{25}BrN_2O_4$: 313 ($MH^+ - 100$).

[0744] To 1,1-dimethylethyl 4-(3-bromo-2-methyl-5-[(methyloxy)carbonyl]phenyl)piperazine-1-carboxylate (5.5 g, 13.3 mmol) in dry toluene (50 mL) was added $Pd_2(dbu)_3$ (610 mg, 0.66 mmol), BINAP (1.24g, 2.0 mmol), cesium carbonate (6.06 g, 18.6 mmol) and 1-(2-aminoethyl)pyrrolidine (2.02 mL, 16.0 mmol). The reaction mixture was stirred at 100°C for 16 h under nitrogen, diluted with ethyl acetate (200 mL), filtered and concentrated. Column chromatography on silica (dichloromethane:methanol 93:7) afforded 1,1-dimethylethyl 4-(2-methyl-5-[(methyloxy)carbonyl]-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (3.0 g, 50% yield) as an orange solid. MS (ESI) for $C_{24}H_{38}N_4O_4$: 447 (MH^+).

[0745] To 1,1-dimethylethyl 4-(2-methyl-5-[(methyloxy)carbonyl]-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (2.6 g, 5.8 mmol) in methanol (12 mL) was added 4N sodium hydroxide (4.4 ml, 17.5 mmol), and the reaction mixture was stirred at room temperature for 16 h. To the solution was added 1.5N hydrogen chloride until pH 4, and the water layer was extracted with chloroform (2 x 100 mL). The combined organic layers were washed with brine (2 x 50 mL), dried over sodium sulfate, and concentrated to yield 3-(4-{{(1,1-dimethylethyl)oxy}carbonyl}piperazin-1-yl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid (2.5 g, 99% yield). MS (ESI) for $C_{23}H_{36}N_4O_4$: 433 (MH^+).

[0746] To 3-(4-[(1,1-dimethylethyl)oxy]carbonyl)piperazin-1-yl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid (1.5 g, 3.47 mmol) in dry DMF (9 mL) was added N-methyl morpholine (1.53 mL, 13.90 mmol), N,O-dimethylhydroxylamine hydrochloride (406 mg, 4.16 mmol), HATU (1.32 g, 3.47 mmol) and HOAt (570 mg, 4.16 mmol). The reaction mixture was stirred at room temperature for 16 h, and then partitioned between ethyl acetate (100 mL) and water (50 mL). The organic layer was washed with 5% lithium chloride (50 mL), brine (50 mL), dried over sodium sulfate and concentrated. Column chromatography on silica (dichloromethane:methanol 93:7) gave 1,1-dimethylethyl 4-{2-methyl-5-[(methyl(methyloxy)amino]carbonyl}-3-[(2-pyrrolidin-1-ylethyl)amino]-phenyl}piperazine-1-carboxylate (919 mg, 56% yield). MS (ESI) for $C_{25}H_{41}N_5O_4$: 476 (MH^+).

[0747] A solution of 1,1-dimethylethyl 4-{2-methyl-5-[(methyl(methyloxy)amino]carbonyl}-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (300 mg, 0.63 mmol) in anhydrous THF (3 mL) was cooled to 0 °C, and a 2M solution of propylmagnesium bromide in THF (1.6 ml, 3.16 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature and stirred for 3 h. The solution was cooled again to 0 °C and 1.5N hydrogen chloride was added until pH 2. Then, saturated sodium bicarbonate was added until basic pH. The water layer was extracted with ethyl acetate (2 x 50 mL), washed with brine (50 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 95:5) yielded 1,1-dimethylethyl 4-{5-butanoyl-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (196 mg, 68% yield). MS (ESI) for $C_{26}H_{42}N_4O_3$: 459 (MH^+):

[0748] A mixture of 1,1-dimethylethyl 4-{5-butanoyl-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (30 mg, 0.07 mmol) in methanol (2 mL) and 4N hydrogen chloride in dioxane (0.2 ml) was refluxed for 2 min, and then concentrated to afford 1-{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one hydrochloride (28 mg, 99% yield). MS (ESI) for $C_{21}H_{34}N_4O$: 359 (MH^+).

[0749] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0750] 1-{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one hydrochloride: MS (ESI) for $C_{22}H_{36}N_4O$: 373 (MH^+).

- [0751] {4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(phenyl)methanone hydrochloride: MS (ESI) for $C_{24}H_{32}N_4O$: 393 (MH^+).
- [0752] 1-{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}propan-1-one hydrochloride: MS (ESI) for $C_{20}H_{32}N_4O$: 345 (MH^+).
- [0753] 1-{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}ethanone hydrochloride: MS (ESI) for $C_{19}H_{30}N_4O$: 331 (MH^+).
- [0755] 4,4,4-trifluoro-1-{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one hydrochloride: MS (ESI) for $C_{21}H_{31}F_3N_4O$: 413 (MH^+).
- [0756] cyclopropyl{4-methyl-3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}methanone hydrochloride: MS (ESI) for $C_{21}H_{32}N_4O$: 395 (MH^+).
- [0757] EXAMPLE 39: 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-*N*-(2-pyrrolidin-1-ylethyl)aniline hydrochloride
- [0758] To 3,5-dibromo-4-methylphenol (19.0 g, 71.4 mmol) in toluene (200 mL) was added 1,1-dimethylethyl piperazine-1-carboxylate (11.9 g, 63.9 mmol), $Pd_2(dbu)_3$ (1.63 g, 1.8 mmol), sodium tert-butoxide (19.3 g, 201 mmol), and BINAP (4.40 g, 7.1 mmol). The reaction mixture was heated to 110 °C in a sealed tube for 16 h, and then partitioned between water and ethyl acetate. The organic layer was diluted with ether, filtered, dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes: ethyl acetate 8:2) provided 1,1-dimethylethyl 4-(3-bromo-5-hydroxy-2-methylphenyl)piperazine-1-carboxylate (9.75 g, 41.1% yield) as a white solid. MS (ESI) for $C_{16}H_{23}BrN_2O_3$: 372 (MH^+).
- [0759] To 1,1-dimethylethyl 4-(3-bromo-5-hydroxy-2-methylphenyl)piperazine-1-carboxylate (990 mg, 2.67 mmol) in toluene (5 mL) was added 2-pyrrolidin-1-ylethylamine (623 mg, 5.33 mmol), sodium tert-butoxide (512 mg, 5.33 mmol), $Pd_2(dbu)_3$ (123 mg, 0.13 mmol), and 2-(di-t-butylphosphino)biphenyl (159 mg, 0.53 mmol). The reaction mixture was stirred at 110 °C for 16 h, and filtered through celite. The filtrate was diluted with water, extracted with ethyl acetate, dried over sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-{5-hydroxy-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (1.08 g, 100% yield) as a brown oil, which was used without further purification. MS (ESI) for $C_{22}H_{36}N_4O_3$: 405 (MH^+).

[0760] To 1,1-dimethylethyl 4-(5-hydroxy-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (1.08 g, 2.67 mmol) in methylene chloride (10 mL), was added triethylamine (540 mg, 5.34 mmol), and triflic anhydride (829 mg, 2.94 mmol) at -78 °C. The reaction mixture was stirred at -78 °C for 30 min and then at room temperature for 16 h. The reaction was quenched with water, extracted with methylene chloride, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 9:1) afforded 1,1-dimethylethyl 4-(2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]-5-[(trifluoromethyl)sulfonyl]oxy}phenyl)piperazine-1-carboxylate (873 mg, 61% yield) as a light brown oil. MS (ESI) for $C_{23}H_{35}F_3N_4O_5S$: 537 (MH^+).

[0761] To 1,1-dimethylethyl 4-(2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]-5-[(trifluoromethyl)sulfonyl]oxy}phenyl)piperazine-1-carboxylate (256 mg, 0.48 mmol) in DMF (3 mL) was added 3,3-dimethyl-but-1-yne (588 mg, 7.16 mmol), $PdCl_2(PPh_3)_2$ (50 mg, 0.07 mmol), copper(I) iodide (41 mg, 0.22 mmol), and triethylamine (965 mg, 9.54 mmol). The reaction mixture was stirred in a sealed tube at 100 °C for 16 h, and filtered. The filtrate was diluted with water, extracted with ethyl acetate, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 9:1) provided 1,1-dimethylethyl 4-(5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (224 mg, 100% yield) as a pink oil. MS (ESI) for $C_{28}H_{44}N_4O_2$: 469 (MH^+).

[0762] To a solution of 1,1-dimethylethyl 4-(5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (200 mg, 0.43 mmol) in ethyl acetate (40 mL) and glacial acetic acid (4 mL) was added palladium on carbon (100 mg, 10%, contains 50% water), and the reaction mixture was stirred under an hydrogen atmosphere for 3 h. The reaction mixture was filtered through celite, and concentrated. The filtrate was diluted with water, the pH adjusted to 10, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated to give 1,1-dimethylethyl 4-(5-(3,3-dimethylbutyl)-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (202 mg, 100% yield) as a light tan oil. MS (ESI) for $C_{28}H_{48}N_4O_2$: 473 (MH^+).

[0763] To 1,1-dimethylethyl 4-(5-(3,3-dimethylbutyl)-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazine-1-carboxylate (210 mg, 0.44 mmol) in methanol (5 mL) was added 4N hydrochloric acid in dioxane (1 mL). The reaction mixture was refluxed for

3 min and then concentrated to provide 5-(3,3-dimethylbutyl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride (166 mg, 100% yield) as a colorless oil. MS (ESI) for C₂₃H₄₀N₄: 373 (MH⁺).

[0764] Using the same or analogous synthetic techniques and/or substitution with alternative reagents, the following compounds of the invention were prepared:

[0765] 2-methyl-5-(phenylethynyl)-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for C₂₅H₃₂N₄: 389 (MH⁺).

[0766] 5-ethynyl-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for C₁₉H₂₈N₄: 313 (MH⁺).

[0767] 5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for C₂₃H₃₆N₄: 369 (MH⁺).

[0768] 5-ethyl-2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for C₁₉H₃₂N₄: 317 (MH⁺).

[0769] 2-methyl-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)-5-[2-(trimethylsilyl)ethyl]aniline: MS (ESI) for C₂₂H₄₀N₄Si: 389 (MH⁺).

[0770] 2-methyl-5-(2-phenylethyl)-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline: MS (ESI) for C₂₅H₃₆N₄: 393 (MH⁺).

[0771] EXAMPLE 40: 2-Methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride

[0772] To a solution of 3,5-dibromo-4-methylbenzoic acid (500 mg, 1.70 mmol) in DMF (10 mL) was added HATU (951 mg, 2.50 mmol), benzamidineoxime (272 mg, 2.00 mmol) and diisopropylethylamine (505 mg, 3.90 mmol). The reaction mixture was stirred at room temperature for 3 h, then diluted with ethyl acetate (100 mL), washed with saturated sodium bicarbonate (50 mL), 5% lithium chloride (2 x 50 mL), and brine (50 mL), dried over sodium sulfate, and concentrated. Column chromatography on silica (hexanes:ethyl acetate 4:1) afforded N'-{[(3,5-dibromo-4-methylphenyl)carbonyl]oxy}-benzenecarboximidamide (630 mg, 90% yield) as a yellow solid. ¹H NMR (400 MHz, d₆-DMSO) δ 8.39 (s, 2H), 7.75 (m, 2H), 7.50 (m, 3H), 7.16 (s, 2H), 2.60 (s, 3H).

[0773] To a solution of N'-{[(3,5-dibromo-4-methylphenyl)carbonyl]oxy}benzenecarboximidamide (620 mg, 1.50 mmol) in THF (10 mL) was added a 1.0 M solution of tetrabutylammonium fluoride in THF (1.50 mL). The reaction mixture was stirred at room

temperature for 17 h, then diluted with ethyl acetate (100 mL), washed with water (50 mL), and brine (50 mL), dried over sodium sulfate, and concentrated. Trituration with ethyl acetate provided 5-(3,5-dibromo-4-methylphenyl)-3-phenyl-1,2,4-oxadiazole (311 mg, 52% yield) as a colorless solid. ^1H NMR (400 MHz, d_6 -DMSO) δ 8.36 (s, 2H), 8.11 (m, 2H), 7.62 (m, 3H), 2.63 (s, 3H).

[0774] A mixture of 5-(3,5-dibromo-4-methylphenyl)-3-phenyl-1,2,4-oxadiazole (162 mg, 0.41 mmol), Boc-piperazine (76 mg, 0.41 mmol), sodium *tert*-butoxide (56 mg, 0.58 mmol), $\text{Pd}_2(\text{dba})_3$ (19 mg, 0.02 mmol), and BINAP (38 mg, 0.06 mmol) in toluene (4 mL) was stirred at 110 °C for 16 h. Column chromatography of the mixture on silica (hexanes: ethyl acetate 9:1) gave 1,1-dimethylethyl 4-[3-bromo-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]piperazine-1-carboxylate (76 mg, 37% yield) as a colorless solid. ^1H NMR (400 MHz, CDCl_3) δ 8.17 (m, 3H), 7.78 (s, 1H), 7.53 (m, 3H), 3.63 (br s, 4H), 2.95 (m, 4H), 2.49 (s, 3H), 1.50 (s, 9H).

[0775] A mixture of 1,1-dimethylethyl 4-[3-bromo-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)phenyl]piperazine-1-carboxylate (111 mg, 0.22 mmol), 1-(2-aminoethyl)pyrrolidine (51 mg, 0.45 mmol), sodium *tert*-butoxide (49 mg, 0.51 mmol), $\text{Pd}_2(\text{dba})_3$ (15 mg, 0.02 mmol), and BINAP (30 mg, 0.05 mmol) in toluene (4 mL) was stirred in a sealed pressure vessel at 100 °C for 12 h. Column chromatography of the mixture on silica (dichloromethane:methanol 95:5) gave 1,1-dimethylethyl 4-[2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl]piperazine-1-carboxylate (27 mg, 23% yield) as a yellow oil. ^1H NMR (400 MHz, d_4 -methanol) δ 8.13 (m, 2H), 7.95 (m, 1H), 7.55 (m, 2H), 7.34 (s, 1H), 7.27 (s, 1H), 3.61 (m, 4H), 3.19 (br s, 4H), 2.90 (br s, 4H), 2.26 (s, 3H), 2.02 (m, 4H), 1.50 (s, 9H); MS (ESI) for $\text{C}_{30}\text{H}_{40}\text{N}_6\text{O}$: 533 (MH^+).

[0776] A mixture of 1,1-dimethylethyl 4-[2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl]piperazine-1-carboxylate (27 mg, 0.05 mmol), methanol (2 mL), and 4N hydrochloric acid in dioxane (2 mL) was refluxed for 1 min. The mixture was concentrated to give 2-Methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride (31 mg, 100% yield) as a yellow oil, which was used without further purification. MS (ESI) for $\text{C}_{25}\text{H}_{32}\text{N}_6\text{O}$: 433 (MH^+).

[0777] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0778] 2-Methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-3-piperazin-1-yl-N-(2-pyrrolidin-1-ylethyl)aniline hydrochloride: MS (ESI) for $C_{20}H_{30}N_6O$: 371 (MH^+).

[0779] EXAMPLE 41: 1-{3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one hydrochloride

[0780] To 1,1-dimethylethyl 4-{3-bromo-5-[(methyloxy)carbonyl]phenyl}piperazine-1-carboxylate (2.65 g, 6.64 mmol) in toluene (70 mL) was added 2-tyrrolidin-1-yl-ethyl-amine (1.55 g, 13.3 mmol), cesium carbonate (8.65 g, 26.5 mmol), $Pd_2(dba)_3$ (486 mg, 0.531 mmol), and BINAP (992 mg, 1.59 mmol). The reaction mixture was stirred at 110 °C in a sealed tube for 16 h, filtered, and concentrated. Column chromatography on silica (dichloromethane:methanol 9:1) gave 1,1-dimethylethyl 4-{3-[(methyloxy)carbonyl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (1.53 g, 53% yield) as a tan oil. MS (ESI) for $C_{23}H_{36}N_4O_4$: 433 (MH^+).

[0781] To 1,1-dimethylethyl 4-{3-[(methyloxy)carbonyl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (924 mg, 2.13 mmol) in methanol (10 mL) and water (3 mL), was added potassium hydroxide (600 mg, 10.7 mmol). The reaction mixture was stirred at 60 °C for 1 h. The pH was adjusted to 4 with 10% citric acid. The reaction mixture was extracted with chloroform, and concentrated to provide 3-(4-{[(1,1-dimethylethyl)oxy]carbonyl}piperazin-1-yl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid (262 mg, 29% yield) as a white solid. MS (ESI) for $C_{22}H_{34}N_4O_4$: 419 (MH^+).

[0782] To 3-(4-{[(1,1-dimethylethyl)oxy]carbonyl}piperazin-1-yl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid (802 mg, 1.92 mmol), in DMF (5 mL) was added O,N-dimethyl-hydroxylamine (224 mg, 2.30 mmol), HATU (730 mg, 1.92 mmol), HOAT (313 mg, 2.30 mmol), and N-methyl morpholine (583 mg, 5.76 mmol). The reaction mixture was stirred at 60 °C for 22 h, diluted with water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 92:8) gave 1,1-dimethylethyl 4-{3-[(methyl(methyloxy)amino)carbonyl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (316 mg, 36% yield) as an orange solid. MS (ESI) for $C_{24}H_{39}N_5O_4$: 462 (MH^+).

[0783] To 1,1-dimethylethyl 4-{3-[(methyl(methyloxy)amino)carbonyl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (150 mg, 0.33 mmol) in

anhydrous THF (2 mL) was added propyl magnesium bromide (240 mg, 1.63 mmol). The reaction mixture was stirred at 0 °C for 10 min, and then at room temperature for 2 h. Excess Grignard reagent was quenched with 1N aqueous hydrogen chloride. The pH was adjusted to 10 with sodium bicarbonate, and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated. Column chromatography on silica (dichloromethane:methanol 93:7) provided 1,1-dimethylethyl 4-{3-butanoyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}-piperazine-1-carboxylate (20 mg, 14% yield) as a white solid. MS (ESI) for C₂₅H₄₀N₄O₃: 445 (MH⁺).

[0784] To 1,1-dimethylethyl 4-{3-butanoyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazine-1-carboxylate (45 mg, 0.10 mmol) in methanol (5 mL) was added 4N hydrogen chloride in dioxane (1 mL). The reaction mixture was refluxed for 3 min, and then concentrated to give 1-{3-piperazin-1-yl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one hydrochloride (35 mg, 100% yield) as a clear oil. MS (ESI) for C₂₀H₃₂N₄O: 345 (MH⁺).

[0785] EXAMPLE 42: 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine.

[0786] To a 50 mL recovery flask was added 4-(5-chloro-3-iodo-2-methyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.25 g, 2.87 mmol, 1.0 eq.), tetra-*n*-butylammonium chloride (799 mg, 2.87 mmol, 1.0 eq.), sodium bicarbonate (604 mg, 7.18 mmol, 2.5 eq.), palladium (II) acetate (13 mg, 0.02 eq.), and DMF (10 mL). Allyl alcohol (295 µL, 4.31 mmol, 1.5 eq.) was added and the reaction was heated at 50°C for 4h. The reaction mixture was filtered through Celite and the Celite cake was rinsed with EtOAc. The organic phase was washed with water (50 mL), 10% aq LiCl (2 x 50 mL), and saturated aq. sodium chloride (50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give black oil. The crude material was purified via column chromatography (20% EtOAc/Hex) to give 4-[5-chloro-2-methyl-3-(3-oxo-propyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as yellow oil (489 mg, 47%).

[0787] To a 25 mL recovery flask was added 4-[5-chloro-2-methyl-3-(3-oxo-propyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (240 mg, 0.655 mmol, 1.0 eq.), pyrrolidine (274 µL, 3.28 mmol, 5.0 eq.), and 1,2-dichloroethane (5 mL). Upon stirring, NaBH(OAc)₃ (278 mg, 1.31 mmol, 2.0 eq.) was added and the reaction was stirred at

room temperature for 1h. 1N HCl (2 mL) was added and the reaction mixture was diluted with water (50 mL) and EtOAc (50 mL). The organic phase was washed with saturated aq. NaHCO₃ (30 mL) and saturated aq. NaCl (30 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give 4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as a gray paste that was used in the next step without further purification.

[0788] To a 25 mL recovery flask was added 4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (278 mg, 0.665 mol, 1.0 eq.) and methanol (3 mL). 4N HCl/dioxane (4 mL) was added and the reaction was stirred for 2h at room temperature. LC/MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material of 1-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazine was used in the next reaction without further purification.

[0789] To a 25 mL recovery flask was added 1-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazine dihydrochloride (280 mg, 0.713 mmol, 1.1 eq.), 3-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol (193 mg, 0.648 mmol, 1.0 eq.), N-methylmorpholine (285 µL, 2.59 mmol, 4.0 eq.), and DMF (5 mL). With stirring, PyBOP (506 mg, 0.972 mmol, 1.5 eq.) was added whereupon the reaction was heated at 80°C overnight. The reaction mixture was diluted with H₂O (50 mL) and EtOAc (50 mL). The organic phase was washed with 10% aq. LiCl (2 x 30 mL) saturated aq. NaCl (30 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude material was purified via column chromatography (1% to 4% CH₃OH/CH₂Cl₂) to give 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine as a white solid (186 mg).

[0790] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine. To a 25 mL recovery flask was added 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidine (186 mg, 0.309 mol, 1.0 eq.) and methanol (7.5 mL). 4N HCl/dioxane (2.5 mL) was added and the reaction was stirred for 30 min at room temperature. LC/MS analysis indicated that the

deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material was purified via reverse-phase HPLC to give pure product, 3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine as the TFA salt (60 mg, 31%). ^1H NMR (400 MHz, d_6 -DMSO) δ 10.55 (br s, 1H), 8.38 (s, 1H), 7.04 (s, 1H), 7.00 (s, 1H), 3.54-3.50 (m, 2H), 3.17-3.12 (m, 2H), 3.02-2.94 (m, 6H), 2.67-2.63 (t, 2H), 2.54 (s, 2H), 2.27 (s, 3H), 1.98-1.85 (m, 6H). MS (ESI) for $\text{C}_{23}\text{H}_{29}\text{BrClN}_7$: 518 (MH^+).

[0791] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0792] 3-{3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-diethylpropan-1-amine: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.03 (br s, 1H), 8.38 (s, 1H), 7.07 (d, 1H), 7.00 (d, 1H), 3.14-3.05 (m, 6H), 3.02-3.00 (m, 4H), 2.66-2.62 (t, 2H), 2.27 (s, 3H), 1.89 (m, 2H), 1.20 (t, 6H). MS (ESI) for $\text{C}_{23}\text{H}_{31}\text{BrClN}_7$: 520 (MH^+).

[0793] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.61 (br. s, 1H), 8.39 (s, 1H), 7.04 (s, 1H), 7.00 (s, 1H), 3.98 (d, 4H), 3.75 (t, 2H), 3.49 (m, 2H), 3.31 (m, 2H), 3.13 (m, 2H), 3.09 (m, 2H), 3.01 (m, 4H), 2.63 (t, 2H), 2.28 (s, 3H), 1.97 (m, 2H). MS (ESI) for $\text{C}_{23}\text{H}_{29}\text{BrClN}_7\text{O}$: 536 (MH^+).

[0794] 3-Bromo-4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 11.43 (br. s, 1H), 8.36 (s, 1H), 6.99 (s, 1H) 7.02 (s, 1H), 3.95 (m, 4H), 3.79 (m, 2H), 3.67 (m, 2H), 3.52 (m, 2H), 3.35 (m, 2H), 3.19 (m, 2H), 3.01 (m, 4H), 2.83 (s, 3H), 2.64 (m, 2H), 2.28 (s, 3H), 1.98 (m, 2H). MS (ESI) for $\text{C}_{24}\text{H}_{32}\text{BrClN}_8$: 549 (MH^+).

[0795] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.01 (br. s, 1H), 8.40 (s, 1H), 7.07 (s, 1H), 7.02 (s, 1H), 3.98 (m, 4H), 3.43 (d, 2H), 3.09 (m, 2H), 3.04 (m, 4H), 2.85 (m, 2H), 2.62 (t, 2H), 2.28 (s, 3H), 1.96 (m, 2H), 1.79 (m, 2H), 1.71 (m, 2H), 1.39 (m, 2H). MS (ESI) for $\text{C}_{24}\text{H}_{31}\text{BrClN}_7$: 534 (MH^+).

[0796] 4-{4-[5-Chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 9.43 (br. s, 1H), 8.19 (s, 1H), 6.99 (s, 1H), 6.96 (s, 1H), 4.03 (m, 2H), 3.31 (m, 2H), 3.10 (m, 2H), 2.93 (m, 4H),

2.58 (m, 2H), 2.43 (m, 2H), 2.40 (m, 2H), 2.21 (m, 3H), 1.93 (m, 2H), 1.81 (m, 4H). MS (ESI) for C₂₃H₃₀ClN₇: 440 (MH⁺).

[0797] 3-Bromo-4-{4-[5-fluoro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 9.80 (br. s, 1H), 8.89 (s, 1H), 6.72 (m, 2H), 3.88 (m, 4H), 3.08 (m, 2H), 2.92 (m, 6 H), 2.57 (m, 2H), 2.39 (m, 2H), 2.17 (s, 3H), 1.92 (m, 2H), 1.79 (m, 4H). MS (ESI) for C₂₃H₂₉BrFN₇: 504 (MH⁺).

[0798] 3-Bromo-4-{4-[4-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine. MS (ESI) for C₂₃H₃₀BrN₇: 486 (MH⁺).

[0799] (2E)-3-(4-{4-[5-Chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-enoic acid: ¹H NMR (400 MHz, d₆-DMSO) δ 9.51 (br. s, 1H), 8.47 (s, 1H), 7.72 (d, 1H), 7.05 (s, 1H), 6.98 (s, 1H), 6.60 (d, 1H), 3.80 (m, 4H), 3.52 (m, 4H), 3.19 (m, 2H), 3.0 (m, 4H), 2.63 (m, 2H), 2.25 (s, 3H), 2.02 (m, 2H), 1.86 (m, 4H). MS (ESI) for C₂₆H₃₂ClN₇O₂: 510 (MH⁺).

[0800] 3-(4-{4-[5-Chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-yn-1-ol: ¹H NMR (400 MHz, d₆-DMSO) δ 9.51 (br. s, 1H), 8.32 (s, 1H), 7.05 (s, 1H), 7.02 (s, 1H), 4.40 (s, 2H), 4.13 (m, 2H), 3.50 (m, 2H), 3.20 (m, 2H), 3.02 (m, 6H), 2.65 (m, 2H), 2.28 (s, 3H), 2.03 (m, 2H), 1.89 (m, 4H). MS (ESI) for C₂₆H₃₂ClN₇O: 494 (MH⁺).

[0801] EXAMPLE 43: 3-Bromo-4-{4-[5-Chloro-2-methyl-3-(2-pyrrolidin-1-ylethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine.

[0802] 4-(5-Chloro-3-iodo-2-methyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester was synthesized as in a previous procedure.

[0803] To a pressure vessels was added 4-(5-chloro-3-iodo-2-methyl-phenyl)-Boc piperazine (4.0g, 9.2 mmol), dry DMSO (18.0 mL), potassium acetate (2.7g mg, 27.6 mmol), bis-(pinacolato)diboron (2.5 mg, 10.1 mmol), and Pd(dppf)Cl₂ dichloromethane complex (751 mg, 0.92 mmol). The reaction was sealed and heated to 80°C overnight. The reaction was then cooled to rt, filtered through celite, and flushed with EtOAc. The combined organic flushes were washed with water, brine, and dried with Na₂SO₄, and concentrated. Column chromatography on silica gel with 10:90 EtOAc: hexanes gave 2.3 g of 4-[5-chloro-2-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as an oil that crystallizes to 4-[5-chloro-2-

methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as a white solid (57% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.49 (d, 1H), 7.05 (d, 1H), 3.60 (br s, 4H), 2.85 (br m, 4H), 2.42 (s, 3H), 1.50 (s, 9H), 1.4-1.2 (s, 12H). MS (ESI) for $\text{C}_{22}\text{H}_{34}\text{BClN}_2\text{O}_4$: 437 (MH^+).

[0804] To a round bottom flask cooled to 0°C was added 4-[5-chloro-2-Methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (2.3g, 5.3 mmol), THF (50.0 mL), 12.5M NaOH (1.25mL, 15.8 mmol), and 30% aq H_2O_2 (3.03 mL mg, 31.6 mmol). The reaction was stirred at 0°C for 30 min (or until complete) before quenching with 10% citric acid and EtOAc. The reaction was partitioned, and the EtOAc layer was dried with Na_2SO_4 , and concentrated to obtain 4-(5-chloro-3-Hydroxy-2-methyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester as a white solid (1.8g, 100% yield). ^1H NMR (400 MHz, CDCl_3) δ 6.62 (d, 1H), 6.58 (d, 1H), 6.22 (br s, 1H), 3.60 (br s, 4H), 2.80 (br m, 4H), 2.18 (s, 3H), 1.50 (s, 9H). MS (ESI) for $\text{C}_{16}\text{H}_{23}\text{BClN}_2\text{O}_3$: 327 (MH^+).

[0805] To a round bottom flask was added 4-(5-chloro-3-hydroxy-2-methyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (150 mg, 0.46 mmol), DMF (4.0 mL), 1-(2-chloroethyl pyrrolidine) HCl (156 mg, 0.92 mmol), and Cs_2CO_3 (598 mg, 1.84 mmol). The reaction was stirred at 60°C for 5 hr (or until complete) before quenching with 10% LiCl and EtOAc. The reaction was partitioned, and the EtOAc layer was dried with Na_2SO_4 , and concentrated to obtain 4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as a brown oil (279 mg, 100% yield) which was taken to the next step without further purification. ^1H NMR, (400 MHz, CDCl_3) δ 6.62 (br d, 2H), 4.10 (t, 2H), 3.80 (br s, 4H), 2.80 (br t, 4H), 2.60 (m, 4H), 2.18 (s, 3H), 1.80 (br m, 4H), 1.50 (s, 9H). MS (ESI) for $\text{C}_{22}\text{H}_{34}\text{BClN}_3\text{O}_3$: 424 (MH^+).

[0806] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: To a round bottom flask was added 4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (279 mg, 0.65 mmol), MeOH (4.0 mL), and 4M HCl in dioxane. The reaction was stirred at RT for 1 hr (or until complete) before concentrating to obtain free-base as brown oil. The brown oil was dissolved in DMF (4.0 mL) before adding N-methylmorpholine (0.31 mL, 2.8 mmol), PyBop (436 mg, 0.84 mmol), and 3-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol (229 mg, 0.77 mmol). The reaction was heated to 60°C overnight. The reaction was then quenched with 50 mL

EtOAc and 5 mL 10% LiCl, partitioned, dried with Na₂SO₄, concentrated and columned with 90:10 EtOAc: hexane to give 3-bromo-4-{4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine. The THP group was removed by dissolving in MeOH (7.5 mL) and 4M HCl in dioxanes (2.5 mL), and heating to 60°C for 15 min. The reaction was concentrated and prep purified, and then converted to the HCl salt to give 65 mg of 3-bromo-4-{4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine (65 mg). ¹H NMR (400MHz, d₆-DMSO) δ 11.3 (br s, 1H), 8.40 (s, 1H), 6.81 (d, 2H), 4.20 (t, 2H), 4.0 (br s, 4H), 3.60 (br q, 4H), 3.00 (m, 6H), 2.18 (s, 3H), 1.80-2.0 (br m, 4H). MS (ESI) for C₂₂H₂₇BrClN₇O: 518 (MH⁺).

[0807] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0808] (2-{3-[4-(3-Bromo-1H-pyrazolo[3,4-d] pyrimidin-4-yl)-piperazin-1-yl]-5-chloro-2-methyl-phenoxy}-ethyl)-diethyl-amine: ¹H NMR (400MHz, d₆-DMSO) δ 10.7 (br s, 1H), 8.40 (s, 1H), 6.81 (d, 2H), 4.20 (buried t, 2H), 3.8 (br q, 2H), 3.20 (m, 4H), 3.00 (br t, 4H), 2.18 (s, 3H), 1.25 (t, 6H). MS (ESI) for C₂₂H₂₉BrClN₇O: 520 (MH⁺).

[0809] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(2-piperidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ¹H NMR (400MHz, d₆-DMSO) δ 9.9 (br s, 1H), 8.40 (s, 1H), 6.81 (d, 2H), 4.40 (t, 2H), 4.0 (br s, 4H), 3.6 (m, 4H), 3.00 (m, 8H), 2.18 (s, 3H), 1.80 (m, 6H). MS (ESI) for C₂₃H₂₉BrClN₇O: 532 (MH⁺).

[0810] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(2-morpholin-4-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ¹H NMR (400MHz, d₆-DMSO) δ 10.8 (br s, 1H), 8.40 (s, 1H), 6.81 (d, 2H), 4.40 (br t, 1H), 4.0 (br m, 4H), 3.8 (t, 2H), 3.4 (m, 6H), 3.00 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C₂₂H₂₇BrClN₇O₂: 536 (MH⁺).

[0811] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-yl-propoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ¹H NMR (400MHz, d₆-DMSO) δ 9.4 (br s, 1H), 8.40 (s, 1H), 6.81 (d, 2H), 4.15 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 2H), 3.0 (br s, 4H), 2.8 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C₂₄H₃₁BrClN₇O: 548 (MH⁺).

[0812] 3-Bromo-4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-yl-propoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ¹H NMR (400MHz, d₆-DMSO) δ 10.5 (br s, 1H), 8.40 (s, 1H), 6.81 (d, 2H), 4.15 (br t, 2H), 4.0 (br m, 4H), 3.8 (t, 2H), 3.21 (m, 2H), 3.0 (m, 8H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for C₂₃H₂₉BrClN₇O₂: 548 (MH⁺).

- [0813] 3-Bromo-4-{4-[4-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 10.4 (br s, 1H), 8.40 (s, 1H), 7.05 (d, 1H), 6.75 (s, 1H), 6.6 (d, 1H), 4.15 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for $\text{C}_{22}\text{H}_{28}\text{BrN}_7\text{O}$: 486 (MH^+).
- [0814] 4-{4-[4-Methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 7.9, 7.4 (d, 1H), 7.05 (d, 1H), 6.75 (s, 1H), 6.6 (d, 1H), 4.20 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for $\text{C}_{22}\text{H}_{29}\text{N}_7\text{O}$: 406 (MH^+).
- [0815] 3-Methyl-4-{4-[4-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 8.5 (s, 1H), 7.9, 7.4 (d, 1H), 7.05 (d, 1H), 6.75 (s, 1H), 6.6 (d, 1H), 4.20 (br t, 2H), 4.0 (br s, 4H), 3.2 (m, 4H), 2.8 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for $\text{C}_{23}\text{H}_{32}\text{N}_7\text{O}$: 422 (MH^+).
- [0816] 4-{4-[5-Chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-1H-pyrazolo[3,4-d] pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 10.6 (br s, 1H), 6.8 (d, 2H), 4.40 (br t, 2H), 4.10 (br s, 4H), 3.8 (m, 4H), 3.2 (m, 4H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for $\text{C}_{22}\text{H}_{28}\text{ClN}_7\text{O}$: 442 (MH^+).
- [0817] 4-{4-[5-Chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-piperazin-1-yl}-3-methyl-1H-pyrazolo[3,4-d] pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 10.9 (br s, 1H), 8.6 (br s, 1H), 6.8 (d, 2H), 4.20 (br t, 2H), 4.10 (br s, 4H), 3.8 (m, 4H), 3.2 (m, 8H), 2.80 (br s, 2H), 2.18 (s, 3H), 1.80 (m, 4H). MS (ESI) for $\text{C}_{23}\text{H}_{30}\text{ClN}_7\text{O}$: 456 (MH^+).
- [0818] EXAMPLE 44: 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline.
- [0819] To a 15 mL pressure vessel was added 4-(5-chloro-3-iodo-2-methyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (450 mg, 1.03 mmol, 1.0 eq.), Xant phos (36 mg, 0.062 mmol, 0.06 eq.), 2-pyrrolidinoethylamine (157 μL , 1.24 mmol, 1.2 eq.), and dioxane (4 mL). The suspension was bubbled with N_2 upon which $\text{Pd}_2(\text{dba})_3$ (28 mg, 0.031 mmol, 0.03 eq.) and sodium *tert*-butoxide (139 mg, 1.44 mmol, 1.4 eq.) was added. The vessel was sealed and heated at 100°C overnight. The crude reaction mixture was concentrated and chromatographed (3% to 10% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$) to afford pure product 4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as an oil (312 mg, 72%).

[0820] To a 25 mL recovery flask was added 4-[5-chloro-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (308 mg, 0.729 mol, 1.0 eq.) and CH₃OH (4 mL). 4N HCl/dioxane (4 mL) was added and the reaction was stirred for 2h at room temperature. LC/MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material of (5-chloro-2-methyl-3-piperazin-1-yl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine was used in the next reaction without further purification.

[0821] To a 25 mL recovery flask was added (5-chloro-2-methyl-3-piperazin-1-yl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine dihydrochloride (287 mg, 0.728 mmol, 1.1 eq.), 3-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol (197 mg, 0.662 mmol, 1.0 eq.), N-methylmorpholine (364 µL, 3.31 mmol, 5.0 eq.), and DMF (7 mL). With stirring, PyBOP (689 mg, 1.32 mmol, 2.0 eq.) was added whereupon the reaction was heated at 80°C overnight. The reaction mixture was diluted with H₂O (50 mL) and EtOAc (50 mL). The organic phase was washed with 10% aq. LiCl (4 x 30 mL) saturated aq. NaCl (30 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude material of (3-{4-[3-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl}-5-chloro-2-methyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine was purified via column chromatography (2% to 5% CH₃OH/CH₂Cl₂) to give a white solid (470 mg).

[0822] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: To a 25 mL recovery flask was added (3-{4-[3-bromo-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl}-5-chloro-2-methyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine (438 mg, 0.727 mol, 1.0 eq.) and methanol (5 mL). 4N HCl/dioxane (5 mL) was added and the reaction was stirred for 30 min at room temperature. LC/MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material was purified via reverse-phase HPLC to give pure product 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline as the TFA salt (60 mg, 13%). ¹H NMR (400 MHz, d₆-DMSO) δ10.76 (br s, 1H), 8.38 (s, 1H), 6.47 (d, 2H), 3.96 (br s, 3H), 3.61 (m, 2H), 3.51-3.48 (m, 2H), 3.34-3.31 (m, 2H), 3.03-2.97 (m, 6H), 2.12 (s, 3H), 2.01-1.96 (m, 2H), 1.90-1.87 (m, 2H). MS (ESI) for C₂₂H₂₈BrClN₈: 521 (MH⁺).

[0823] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0824] N'-{3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-diethylethane-1,2-diamine: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.43 (br s, 1H), 8.38 (s, 1H), 6.50 (s, 1H), 6.46 (s, 1H), 3.96 (m, 4H), 3.52 (t, 2H), 3.22-3.16 (m, 6H), 2.97 (m, 4H), 2.10 (s, 3H), 1.22 (t, 6H). MS (ESI) for $C_{22}\text{H}_{30}\text{BrClN}_8$: 523 (MH^+).

[0825] 5-Chloro-2-methyl-3-[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.64 (s, 1H), 8.55 (s, 1H), 6.48 (d, 1H), 6.43 (s, 1H), 4.19 (m, 4H), 3.51 (t, 2H), 3.34-3.31 (2H), 2.98 (m, 6H), 2.14 (s, 3H), 2.00 (m, 2H), 1.89 (m, 2H). MS (ESI) for $C_{22}\text{H}_{29}\text{ClN}_8$: 441 (MH^+).

[0826] 5-Chloro-2-methyl-3-[4-(3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.96 (s, 1H), 8.57 (s, 1H), 6.46 (d, 1H), 6.40 (d, 1H), 3.59 (m, 2H), 3.49 (m, 2H), 3.30 (m, 2H), 2.98 (m, 6H), 2.76 (s, 3H), 2.14 (s, 3H), 2.00 (m, 2H), 1.89 (m, 2H). MS (ESI) for $C_{23}\text{H}_{31}\text{ClN}_8$: 455 (MH^+).

[0827] 5-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.14 (br s, 1H), 8.40 (d, 1H), 6.94 (m, 1H), 6.50 (m, 2H), 4.02 (m, 4H), 3.34 (m, 4H), 3.05 (m, 2H), 2.07 (m, 3H), 2.01 (m, 2H), 1.89 (m, 2H). MS (ESI) for $C_{22}\text{H}_{29}\text{BrClN}_8$: 485 (MH^+).

[0828] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 10.33 (br s, 1H), 8.37 (s, 1H), 6.27 (td, 2H), 3.95 (m, 4H), 3.46 (t, 4H), 3.31 (m, 2H), 3.02 (m, 2H), 2.95 (m, 3H), 2.09 (s, 3H), 2.00 (m, 2H), 1.89 (m, 2H). MS (ESI) for $C_{22}\text{H}_{28}\text{BrFN}_8$: 505 (MH^+).

[0829] 3-Bromo-4-(4-pyridin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.40 (s, 1H), 8.07-8.05 (m, 2H), 7.43 (d, 1H), 7.00 (t, 1H), 4.07-4.04 (m, 4H), 3.97-3.94 (m, 4H). MS (ESI) for $C_{14}\text{H}_{14}\text{BrN}_7$: 360 (MH^+).

[0830] 3-Bromo-4-[4-(2,4-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.36 (s, 1H), 7.00 (s, 1H), 6.95 (s, 1H),

3.94 (m, 4H), 2.97 (t, 4H), 2.27 (s, 3H), 2.22 (s, 3H). MS (ESI) for C₁₇H₁₉BrN₆: 389 (MH⁺).

[0831] 3-Bromo-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.44 (s, 1H), 7.29 (t, 1H), 6.98-6.95 (m, 2H), 6.68 (d, 1H), 4.14 (m, 4H), 3.77 (s, 3H), 3.54 (t, 4H). MS (ESI) for C₁₆H₁₇BrN₆O: 391 (MH⁺).

[0832] 3-Bromo-4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.37 (s, 1H), 7.00-6.97 (m, 2H), 6.92-6.90 (m, 1H), 3.96 (m, 4H), 3.82 (s, 3H), 3.18 (m, 4H). MS (ESI) for C₁₆H₁₇BrN₆O: 391 (MH⁺).

[0833] 3-[4-(3-Ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ¹H NMR (400 MHz, d₆-DMSO) δ 11.10 (s, 1H), 8.57 (s, 1H), 6.30 (dd, 1H), 6.21 (dd, 1H), 4.13 (br s, 4H), 3.49-3.48 (m, 2H), 3.51-3.48 (m, 2H), 3.32-3.29 (m, 2H), 3.15-3.10 (m, 2H), 3.00-2.96 (m, 6H), 2.12 (s, 3H), 2.02-1.97 (m, 2H), 1.91-1.87 (m, 2H), 1.31 (t, 3H). MS (ESI) for C₂₄H₃₃FN₈: 453 (MH⁺).

[0834] 5-Fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline: ¹H NMR (400 MHz, d₆-DMSO) HCl salt δ 10.49 (br s, 1H), 8.48 (s, 1H), 6.28 (dd, 1H), 6.21 (dd, 1H), 3.84 (m, 4H), 3.61-3.59 (m, 2H), 3.48 (t, 2H), 3.32-3.29 (m, 2H), 3.02 (m, 2H), 2.89 (m, 4H), 2.09 (s, 3H), 2.03-1.97 (m, 2H), 1.93-1.87 (m, 2H). MS (ESI) for C₂₃H₂₈F₄N₈: 493 (MH⁺).

[0835] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-[(cyclopropylmethyl)oxy]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide: ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 7.26 (s, 1H), 6.90 (s, 1H), 6.81 (s, 1H), 4.47 (s, 1H), 4.12 (s, 1H), 3.87 (s, 2H), 3.33 (s, 2H), 3.06 (s, 4H), 2.86 (s, 2H), 2.64 (s, 4H), 2.15 (s, 3H), 2.05 (s, 1H), 1.83 (s, 4H), 1.26-1.20 (m, 2H), 0.60 (s, 2H), 0.33 (s, 2H). MS (ESI) for C₂₇H₃₆BrN₉O₂: 600 (MH⁺).

[0836] EXAMPLE 45: 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide.

[0837] To 4-[5-carboxy-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (118 mg, 0.27 mmol) in DMF (3 mL) was added triethylamine (82 mg, 0.81 mmol), HOBT (93 mg, 0.68 mmol), EDCI (136 mg, 0.68 mmol) and phenylamine (46 mg, 0.49 mmol). After heating the reaction mixture at

70°C for 1 hour the reaction was cooled to room temperature. Ethyl Acetate was added and the organic layer was washed twice with water (50 ml), once with 1N HCl (50 ml), twice with 5% LiCl (50 ml), and once with brine (50 ml). The organic layer was dried over sodium sulfate and the solvent was removed to yield 4-[2-methyl-5-phenylcarbamoyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (133 mg, 96% yield). ^1H NMR (400 MHz, d₆-DMSO) δ 8.91 (s, 1H), 7.89 (d, 2H), 7.35 (t, 2H), 7.14 (m, 3H), 6.74 (d, 1H), 4.60 (m, 1H), 3.86 (m, 3H), 3.58 (br, s, 1H), 3.24 (t, 3H), 2.84 (m, 6H), 2.17 (s, 3H), 2.10 (m, 5H), 1.49 (s, 9H), 1.28 (m, 3H), 0.90 (t, 1H). MS (ESI) for C₂₉H₄₁N₅O₃: 508 (MH⁺).

[0838] To 4-[2-methyl-5-phenylcarbamoyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (106.1 mg, 0.21 mmol) in THF (3 mL) was added excess triethylamine and 3-Bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (60 mg, 0.25 mmol. The reaction was heated to reflux for 1hour upon which the reaction was cooled to room temperature. Water 50ml was added and the product was extracted into ethyl acetate (50ml). After extraction the organic layer was washed once with water (50 ml) and once with brine (50ml). The organic layer was dried over sodium sulfate and the solvent removed under vacuum. Purification was carried out by column chromatography starting with straight DCM then a 5% MeOH/DCM solution and ending with a 10% MeOH/DCM solution. The product of 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide was isolated and precipitated out of hexane (59.7 mg, 46% yield). ^1H NMR (400 MHz, d₆-DMSO) δ 10.88 (br, s, 1H), 10.15 (s, 1H), 8.41 (s, 1H), 7.78 (d, 2H), 7.34 (m, 3H), 7.08 (m, 3H), 4.07 (br, s, 3H), 3.64 (m, 4H), 3.38 (m, 2H), 3.07 (m, 6H), 2.24 (s, 3H), 2.01 (m, 2H), 1.88 (m, 2H). MS (ESI) for C₂₉H₃₄BrN₉O: 602 (MH⁺).

[0839] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0840] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N,4-trimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide. ^1H NMR (400 MHz, d₆-DMSO) δ 8.49 (s, 1H), 6.62 (s, 1H), 6.58 (s, 1H), 3.78 (m, 1H), 3.65 (s, 1H), 3.61 (t, 1H), 3.22 (s, 6H), 3.09 (br, s, 4H), 3.02 (br, s, 4H), 2.30 (s, 3H), 2.18 (m, 2H), 2.05 (m, 3H), 1.29, (t, 2H), 0.91 (t, 2H). MS (ESI) for C₂₅H₃₄BrN₉O: 556 (MH⁺).

[0841] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(pyrrolidin-1-ylcarbonyl)-N-(2-pyrrolidin-1-ylethyl)aniline. ^1H NMR (400 MHz, d₆-

DMSO) δ 14.18 (br, s, 1H), 10.42 (br, s, 1H), 8.38 (s, 1H), 6.58 (s, 1H), 6.38 (s, 1H), 3.61 (m, 3H), 3.51 (t, 2H), 3.42 (m, 4H), 3.33 (m, 3H), 2.99 (br, s, 7H), 2.17 (s, 3H), 2.01 (m, 2H), 1.83 (m, 4H), 1.76 (m, 3H). MS (ESI) for C₂₇H₃₆BrN₉O: 582 (MH⁺).

[0842] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide. ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 8.26 (m, 1H), 6.92 (s, 1H), 6.85 (s, 1H), 4.91 (t, 1H), 3.96 (br, s, 3H), 3.22 (m, 4H), 2.98 (m, 4H), 2.75 (d, 3H), 2.58 (m, 4H), 2.10 (s, 3H), 1.72 (m, 4H), 1.23 (m, 2H). MS (ESI) for C₂₄H₃₂BrN₉O: 542 (MH⁺).

[0843] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(4-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide. ¹H NMR (400 MHz, d₆-DMSO) δ 10.11 (s, 1H), 8.37 (s, 1H), 7.81 (d, 2H), 7.41 (d, 2H), 7.06 (s, 1H), 6.97 (s, 1H), 4.03 (m, 3H), 3.45 (m, 2H), 3.03 (m, 10H), 2.18 (s, 3H), 1.84 (m, 5H), 1.17 (m, 2H). MS (ESI) for C₂₉H₃₃BrClN₉O: 638 (MH⁺).

[0844] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide. ¹H NMR (400 MHz, d₆-DMSO) δ 10.14 (s, 1H), 8.45 (s, 1H), 7.87 (s, 2H), 7.62 (d, 1H), 7.39 (t, 1H), 7.12 (d, 1H), 7.03 (s, 1H), 6.91 (s, 1H), 5.09 (m, 1H), 3.99 (m, 3H), 3.33 (m, 5H), 3.06 (m, 5H), 2.85 (m, 2H), 2.69 (m, 3H), 2.18 (s, 3H), 1.76 (m, 4H). MS (ESI) for C₂₉H₃₃BrClN₉O: 638 (MH⁺).

[0845] Methyl-3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate. ¹H NMR (400 MHz, d₆-DMSO) δ 14.08 (br, s, 1H), 8.38 (s, 1H), 7.85 (s, 1H), 7.61 (s, 1H), 3.97 (br, s, 4H), 3.85 (s, 3H), 3.08 (br, s, 4H), 2.46 (s, 3H). MS (ESI) for C₁₈H₁₈Br₂N₆O₂: 511 (MH⁺).

[0846] Methyl-3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoate. ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 7.22 (s, 1H), 7.11 (s, 1H), 4.50 (br, s, 1H), 3.89 (s, 3H), 3.33 (m, 2H), 3.08 (m, 4H), 2.87 (m, 2H), 2.62 (m, 4H), 2.02 (s, 3H), 1.82 (m, 4H), 1.28 (m, 4H), 0.88 (t, 3H). MS (ESI) for C₂₄H₃₁BrN₈O₂: 543 (MH⁺).

[0847] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide. ¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (s, 1H), 8.00 (d, 1H), 6.84 (s, 1H), 6.92 (s, 1H), 4.89 (m, 1H), 4.06 (m,

1H), 4.00 (m, 4H), 3.26 (m, 2H), 2.96 (m, 4H), 2.77 (m, 2H), 2.61 (m, 4H), 2.10 (s, 3H), 1.72 (m, 4H), 1.13 (d, 6H). MS (ESI) for C₂₆H₃₆BrN₉O: 570 (MH⁺).

[0848] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-N-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide. ¹H NMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 6.50 (s, 1H), 6.40 (s, 1H), 4.49 (m, 1H), 4.06 (m, 3H), 3.28 (m, 2H), 3.05 (m, 4H), 2.86 (m, 4H), 2.62 (m, 3H), 2.17 (s, 3H), 1.83 (m, 4H), 1.19 (m, 8H), 0.88 (m, 2H). MS (ESI) for C₂₇H₃₈BrN₉O: 584 (MH⁺).

[0849] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin-1-yl]-4-methyl-N-phenylbenzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 14.18 (br s, 1 H), 10.21 (s, 1 H), 8.43 (s, 1 H), 7.88 (m, 2 H), 7.75 (m, 2 H), 7.46 (m, 1 H), 7.35 (m, 2 H), 7.12 (m, 1 H), 4.59 (m, 2 H), 4.42 (m, 1 H), 4.25 (m, 1 H), 3.95 (m, 1 H), 3.68 (m, 1 H), 2.21 (s, 3 H). MS (ESI) for C₂₃H₂₀BrN₇O₂: 506 (MH⁺).

[0850] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(1,1-dimethylethyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 8.37 (s, 1H), 7.52 (s, 1H), 6.87 (s, 1H), 6.79 (s, 1H), 4.86 (m, 1H), 3.26 (m, 6H), 2.99 (m, 4H), 2.72 (m, 2H), 2.55 (m, 4H), 2.10 (s, 3H), 1.72 (m, 4H), 1.36 (s, 9H). MS (ESI) for C₂₇H₃₈BrN₉O: 584 (MH⁺).

[0851] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-pyridin-3-yl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 10.21 (s, 1H), 8.89 (s, 1H), 8.36 (d, 1H), 8.29 (d, 1H), 8.14 (d, 1H), 7.38 (m, 1H), 7.06 (s, 1H), 6.97 (s, 1H), 4.98 (m, 1H), 3.28 (m, 4H), 3.04 (m, 4H), 2.98 (m, 2H), 2.69 (m, 2H), 2.51 (m, 4H), 2.15 (s, 3H), 1.70 (m, 4H). MS (ESI) for C₂₈H₃₃BrN₁₀O: 605 (MH⁺).

[0852] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-ethyl-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 8.34 (s, 1H), 8.28 (m, 1H), 6.91 (s, 1H), 6.84 (s, 1H), 4.86 (m, 1H), 3.24 (m, 6H), 2.97 (br s, 6H), 2.71 (t, 2H), 2.54 (br s, 4H), 2.10 (s, 3H), 1.71 (br s, 4H), 1.08 (t, 3H). MS (ESI) for C₂₅H₃₄BrN₉O: 556 (MH⁺).

[0853] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-(dimethylamino)ethyl)amino]-4-methyl-N-phenylbenzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 10.02 (s, 1H), 8.32 (s, 1H), 7.66 (d, 2H), 7.32 (t, 2H), 7.07 (t, 1H), 7.01 (s, 1H),

6.91 (s, 1H), 4.90 (m, 1H), 3.52 (m, 4H), 3.25 (m, 2H), 3.00 (br s, 4H), 2.63 (m, 2H), 2.28 (s, 6H), 2.12 (s, 3H). MS (ESI) for C₂₇H₃₂BrN₉O: 578 (MH⁺).

[0854] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-{[2-(dimethylamino)ethyl]amino}-4-methyl-N-(1-methylethyl)benzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 8.32 (s, 1H), 8.06 (d, 1H), 6.90 (s, 1H), 6.82 (s, 1H), 4.82 (m, 1H), 4.03 (m, 1H), 3.21 (m, 4H), 2.95 (m, 4H), 2.90 (m, 2H), 2.61 (t, 2H), 2.27 (s, 6H), 2.08 (s, 3H), 1.11 (d, 6H). MS (ESI) for C₂₄H₃₄BrN₉O: 544 (MH⁺).

[0855] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid: ¹H NMR (400 MHz, d₆-DMSO) δ 9.58 (br s, 1H), 8.33 (s, 1H), 7.06 (s, 1H), 6.95 (s, 1H), 3.76 (br s, 4H), 3.59 (m, 2H), 3.46 (m, 2H), 3.35 (br s, 2H), 3.03 (m, 2H), 2.96 (br s, 4H), 2.15 (s, 3H), 2.00 (m, 2H), 1.85 (m, 2H). MS (ESI) for C₂₃H₂₉BrN₈O: 529 (MH⁺).

[0856] 3-[(2S)-4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-N-phenylbenzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 10.1 (s, 1H), 8.37 (s, 1H), 7.81 (s, 1H), 7.72 (m, 3H), 7.37 (m, 3H), 7.10 (t, 1H), 4.48 (d, 1H), 4.36 (d, 1H), 3.58 (m, 1H), 3.47 (m, 1H), 3.23 (m, 1H), 3.10 (m, 1H), 2.88 (m, 1H), 2.40 (s, 3H), 0.86 (d, 3H). MS (ESI) for C₂₄H₂₄BrN₇O: 506 (MH⁺).

[0857] 3-[(2S)-4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-N-(phenylmethyl)benzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 9.01 (t, 1H), 8.37 (s, 1H), 7.76 (s, 1H), 7.63 (d, 1H), 7.31 (m, 5H), 7.23 (m, 1H), 4.47 (m, 3H), 4.34 (m, 1H), 3.56 (m, 1H), 3.41 (m, 1H), 3.20 (m, 1H), 3.05 (m, 1H), 2.82 (t, 1H), 2.37 (s, 3H), 0.83 (d, 3H). MS (ESI) for C₂₅H₂₆BrN₇O: 520 (MH⁺).

[0858] 3-[(2R)-4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-(hydroxymethyl)piperazin-1-yl]-4-methyl-N-phenylbenzamide: ¹H NMR (400 MHz, d₆-DMSO) δ 10.1 (s, 1H), 8.34 (s, 1H), 7.81 (m, 1H), 7.70 (m, 4H), 7.33 (m, 4H), 7.08 (m, 1H), 4.60 (m, 1H), 4.48 (m, 1H), 4.17 (m, 1H), 3.73 (m, 2H), 3.52 (m, 2H), 3.20 (m, 3H), 2.95 (m, 1H), 2.68 (m, 1H). MS (ESI) for C₂₄H₂₄BrN₇O₂: 522 (MH⁺).

[0859] Methyl-3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate: ¹H NMR (400 MHz, CDCl₃) δ 11.97 (1H, Br s), 8.45 (1H, s), 7.73 (1H, s), 7.72-7.70 (1H, d), 7.29-7.26 (1H, d), 4.10 (4H, m), 3.90 (3H, s), 3.15-3.02 (4H, m), 2.43 (3H, s). MS (ESI) for C₁₈H₁₉BrN₆O₂: 433 (MH⁺).

- [0860] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoic acid: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.07 (1H, Br s), 12.84 (1H, Br s), 8.38 (1H, s), 7.60-7.57 (2H, m), 7.34-7.32 (1H, d), 3.95 (4H, m), 3.07-3.05 (4H, m), 2.38 (3H, s). MS (ESI) for $\text{C}_{17}\text{H}_{17}\text{BrN}_6\text{O}_2$: 417 (MH^+).
- [0861] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.11 (1H, Br s), 10.13 (1H, s), 8.38 (1H, s), 7.73-7.71 (2H, d), 7.61-7.59 (2H, m), 7.34-7.30 (3H, m), 7.09-7.05 (1H, t), 3.98 (4H, m), 3.11-3.09 (4H, m), 2.39 (3H, s). MS (ESI) for $\text{C}_{23}\text{H}_{22}\text{BrN}_7\text{O}$: 492 (MH^+).
- [0862] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethylbenzamide: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.07 (1H, Br s), 8.38 (1H, s), 8.37-8.35 (1H, m), 7.53 (1H, s), 7.48-7.46 (1H, d), 7.28-7.26 (1H, d), 3.97 (4H, m), 3.06-3.04 (4H, m), 2.76-2.75 (3H, d), 2.08 (3H, s). MS (ESI) for $\text{C}_{18}\text{H}_{20}\text{BrN}_7\text{O}$: 430 (MH^+).
- [0863] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N,4-trimethylbenzamide: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.07 (1H, Br s), 8.37 (1H, s), 7.26-7.24 (1H, d), 7.06 (1H, s), 7.03-7.01 (1H, d), 3.95 (4H, m), 3.06-3.04 (4H, m), 2.95 (3H, s), 2.91 (3H, s), 2.34 (3H, s). MS (ESI) for $\text{C}_{19}\text{H}_{22}\text{BrN}_7\text{O}$: 444 (MH^+).
- [0864] 3-[4-(3-Chloro-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(2-methylpropyl)benzamide: ^1H NMR (400 MHz, d_6 -DMSO) δ 13.96 (1H, Br s), 8.41-8.38 (1H, t), 8.37 (1H, s), 7.54 (1H, s), 7.51-7.49 (1H, d), 7.28-7.26 (1H, d), 4.01 (4H, m), 3.07-3.04 (6H, m), 1.84-1.80 (1H, m), 0.88-0.86 (6H, d). MS (ESI) for $\text{C}_{21}\text{H}_{26}\text{ClN}_7\text{O}$: 428 (MH^+).
- [0865] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-[2-(dimethylamino)ethyl]-4-methylbenzamide: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.75 (1H, Br s), 8.38 (1H, s), 8.37-8.29 (1H, t), 7.54 (1H, s), 7.50-7.47 (1H, d), 7.28-7.26 (1H, d), 3.97 (4H, m), 3.36 (2H, t), 3.05-3.04 (4H, m), 2.40 (2H, t), 2.36 (3H, s), 2.19 (6H, s). MS (ESI) for $\text{C}_{21}\text{H}_{27}\text{BrN}_8\text{O}$: 487 (MH^+).
- [0866] EXAMPLE 46: 3-Bromo-4-{4-[4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine.
- [0867] 4-Bromo-1-methyl-2-nitro-benzene (3.76 g, 17.4 mmol), 2-benzyloxyphenylboronic acid (7.91 g, 34.7 mmol), and K_3PO_4 (13.1 g, 61.7 mmol) were combined in dry THF (20 mls) and the mixture sparged with N_2 for 1 min. Biphenyl-2-yl-

dicyclohexyl-phosphane (574 mg, 1.6 mmol) and palladium(II) acetate (206 mg, 0.92 mmol) were then added and the mixture was stirred under N₂ overnight at room temperature. The reaction was partitioned between H₂O and EtOAc and the biphasic mixture was filtered through Celite with washing with H₂O and EtOAc. The filtrate was transferred to a separatory funnel, the phases were separated and the organic phase was further washed with 1N HCl (3x), H₂O (1x), 1N NaOH (3x), sat'd NaCl (1x), dried (Na₂SO₄), and conc'd in vacuo. The crude product was purified by flash chromatography (100% hexanes, followed by 5% EtOAc in hexanes) to give 2'-benzyloxy-4-methyl-3-nitro-biphenyl (5.51g, 99%). ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, 1H), 7.70 (dd, 1H), 7.35 (complex multiplet, 8H), 7.05 (m, 2H), 5.11 (s, 2H), 2.63 (s, 3H).

[0868] 2'-Benzyl-4-methyl-3-nitro-biphenyl (5.51g, 17.2 mmol), toluene (50 mls), H₂O (50 mls), iron powder (5.0 g, 89.5 mmol), and ammonium formate (10.0 g, 158 mmol) were combined and heated to reflux overnight. The cooled reaction mixture was filtered through Celite with washing with H₂O and EtOAc. The filtrate was transferred to a separatory funnel and the phases were separated. The aqueous phase was further extracted with EtOAc (1x). The combined EtOAc extractions were washed with H₂O (1x), sat'd NaCl (1x), dried (Na₂SO₄), and concentrated in vacuo. The crude product was purified by flash chromatography (9:1 hexane:EtOAc, followed by 4:1 hexane:EtOAc) to give 2'-benzyloxy-4-methyl-biphenyl-3-ylamine (3.99 g, 80%). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (m, 4H), 7.26 (m, 3H), 7.10 (d, 1H), 6.98 (complex multiplet, 4H), 5.08 (s, 2H), 3.57 (br. s, 2H), 2.20 (s, 3H). MS (ESI) for C₂₀H₁₉NO: 290 (MH⁺).

[0869] 2'-Benzyl-4-methyl-biphenyl-3-ylamine (3.99 g, 13.8 mmol), bis-(2-chloroethyl)-amine hydrochloride (2.50 g, 14.0 mmol), K₂CO₃ (1.93 g, 13.9 mmol), and diglyme (25 mls) were combined and the mixture stirred at 145°C overnight. The cooled reaction mixture was diluted with 1N HCl and EtOAc and stirred vigorously for several minutes. The resulting solid was washed with H₂O and EtOAc and dried under vacuum to give crude 1-(2'-benzyloxy-4-methyl-biphenyl-3-yl)-piperazine hydrochloride (5.60 g, 103%) which was used in the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃) δ 10.22 (br. s, 1H), 7.76 (s, 1H), 7.47 (d, 1H), 7.27 (complex multiplet, 8H), 7.03 (m, 2H), 5.04 (s, 2H), 3.96 (br. m, 4H), 3.75 (br. m, 4H), 2.64 (s, 3H). MS (ESI) for C₂₄H₂₆N₂O: 359 (MH⁺).

[0870] 1-(2'-Benzyl-4-methyl-biphenyl-3-yl)-piperazine hydrochloride (5.60 g, 14.2 mmol) was dissolved in dioxane (40 mls) and 5N NaOH (8 mls), to which was added

Boc anhydride (3.72 g, 17.0 mmol) and the mixture stirred at room temperature overnight. The reaction mixture was diluted with EtOAc and washed with H₂O (1x), sat'd NaCl (1x), dried (Na₂SO₄), and conc'd in vacuo. The crude product was purified by flash chromatography (5%EtOAc in hexanes) followed by a second purification by flash chromatography (5% ether in hexanes) to give 4-(2'-benzyloxy-4-methyl-biphenyl-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (2.84 g, 45%). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (m, 8H), 7.20 (m, 2H), 7.04 (m, 2H), 5.06 (s, 2H), 3.51 (m, 4H), 2.73 (m, 4H), 2.32 (s, 2H), 1.50 (s, 9H). MS (ESI) for C₂₉H₃₄N₂O₃: 459 (MH⁺).

[0871] 4-(2'-Benzyl-oxo-4-methyl-biphenyl-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (2.84 g, 6.2 mmol), methanol (10 ml), ethyl acetate (10 ml), acetic acid (few drops) and 10% Pd/C (0.200 g) were agitated under hydrogen gas (40 psi) for 2 days. The mixture was diluted with methanol (200 ml) and ethyl acetate (100 ml), and heated to reflux, filtered through Celite and concentrated to give 4-(2'-hydroxy-4-methyl-biphenyl-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (1.98 g, 88%). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (d, 1H), 7.22 (m, 2H), 7.11 (d, 1H), 7.07 (s, 1H), 6.98 (m, 2H), 5.27 (br. s, 1H), 3.61 (m 4H), 2.91 (m, 4H), 2.38 (s, 3H), 1.48 (s, 9H). MS (ESI) for C₂₂H₂₈N₂O₃: 369 (MH⁺).

[0872] 4-(2'-Hydroxy-4-methyl-biphenyl-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (552 mgs, 1.5 mmol), K₂CO₃ (622 mgs, 4.5 mmol), and 1-(2-chloro-ethyl)-pyrrolidine hydrochloride (273 mgs, 1.6 mmol) were combined in DMA (10 mls) and stirred at room temperature overnight. The reaction had proceeded only slightly at room temperature, so it was heated at 60C overnight to drive it to completion. The cooled reaction was partitioned between 1N HCl and EtOAc. The phases were separated and the organic phase was further extracted with 1N HCl (2x). The combined aqueous extractions were washed with EtOAc (1x), then basified with ice-cold 10N NaOH and the resulting basic aqueous mixture extracted with EtOAc (3x). The combined EtOAc extractions were washed with sat'd NaCl (1x), dried (Na₂SO₄), and conc'd in vacuo. The crude product was purified by flash chromatography (2% Et₃N in EtOAc) to give 4-[4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazine-1-carboxylic acid tert-butyl ester (511 mg, 73%). ¹H NMR (400 MHz, CDCl₃) δ 7.31 (m, 2H), 7.18 (m, 3H), 7.00 (m, 2H), 4.10 (t, 2H), 3.58 (m, 4H), 2.88 (m, 4H), 2.83 (t, 2H), 2.52 (m, 4H), 2.34 (s, 3H), 1.75 (m, 4H), 1.49 (s, 9H). MS (ESI) for C₂₈H₃₉N₃O₃: 466 (MH⁺).

[0873] 4-[4-Methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazine-1-carboxylic acid tert-butyl ester (261 mgs, 0.56 mmol) was dissolved in DCM (5 mls) to which was added TFA (5 mls) and the mixture stirred at room temperature for 2 hrs. The reaction mixture was concentrated in vacuo and dried under high vacuum for several hrs to give 1-[4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazine trifluoroacetate (100%). MS (ESI) for C₂₃H₃₁N₃O: 366 (MH⁺).

[0874] 3-Bromo-4-{4-[4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine. 1-[4-Methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazine, di-TFA salt (0.56 mmol), Et₃N (600 µl, 4.3 mmol), dry THF (10 mls), and 3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (146 mgs, 0.62 mmol) were combined and stirred at 40C overnight. The cooled reaction was diluted with EtOAc and washed with H₂O (1x), sat'd NaHCO₃ (2x), sat'd NaCl (1x), dried (Na₂SO₄), and conc'd in vacuo. The crude material was purified by flash chromatography (2.5% MeOH, 0.5% Et₃N in DCM), followed by purification by preparative HPLC (solvent A = 0.05% ammonium acetate in H₂O, Solvent B = 100% AcCN). Lyophilization of the pure HPLC fractions gave 3-bromo-4-{4-[4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine as the 0.5 AcOH salt (118 mg, 37%). ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 7.30 (complex multiplet, 4H), 7.12 (m, 2H), 7.02 (t, 1H), 4.12 (t, 2H), 3.98 (m, 4H), 3.06 (m, 4H), 2.92 (m, 2H), 2.58 (m, 4H), 2.35 (s, 3H), 1.91 (s, 1.5H, 0.5 AcOH), 1.62 (m, 4H). MS (ESI) for C₂₈H₃₂BrN₇O: 562 (MH⁺).

[0875] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0876] 1-(3-{5-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbiphenyl-3-yl}propyl)pyridinium. ¹H NMR (400 MHz, d₆-DMSO) δ 9.14 (d, 2H), 8.59 (t, 1H), 8.22 (s, 1H), 8.14 (t, 2H), 7.64 (d, 2H), 7.45 (t, 2H), 7.34 (t, 1H), 7.20 (s, 2H), 4.73 (t, 2H), 3.86 (m, 2H), 3.07 (m, 4H), 2.73 (t, 2H), 2.30 (m, 4H), 1.80 (s, 3H). MS (ESI) for C₃₀H₃₁BrN₇: 568 (MH⁺).

[0877] EXAMPLE 47: 3-Bromo-4-(4-{3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine.

[0878] To a 150 mL pressure vessel was added 4-bromo-2-nitrotoluene (4.85 g, 22.4 mmol, 1.0 eq.), 3-fluoro-2-methoxy-phenylboronic acid (4.20 g, 24.7 mmol, 1.1 eq.),

Pd(dppf)₂Cl₂ (CH₂Cl₂ complex, 917 mg, 2.24 mmol, 0.1 eq.), sodium carbonate (7.14 g, 67.4 mmol, 3.0 eq.), H₂O (40 mL), and toluene (40 mL). The vessel was sealed and heated at 88°C overnight. GC/MS analysis indicated product is present as the major component. The reaction mixture was cooled and filtered through Celite, followed by a rinse of EtOAc. The organic phase was washed with H₂O (100 mL) and saturated aq. NaCl (100 mL). The combined aqueous phases were extracted with EtOAc (2 x 100 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give black oil. The crude material was purified via column chromatography to afford 3-fluoro-2-methoxy-4'-methyl-3'-nitro-biphenyl as orange oil which later solidified upon standing (5.18 g, 88%).

[0879] To a 500 mL recovery flask was added 3-fluoro-2-methoxy-4'-methyl-3'-nitro-biphenyl (5.14 g, 19.6 mmol, 1.0 eq.) and CH₂Cl₂ (150 mL). Upon stirring, BBr₃ (1.0 M in CH₂Cl₂, 58.6 mL, 58.6 mmol, 3.0 eq.) was added. Upon addition, the reaction mixture color turns light orange to dark red. After stirring for 1h, the reaction color becomes lighter red. The reaction was stirred for 4h at room temperature whereupon CH₃OH was added to quench any excess BBr₃. The reaction was concentrated and then taken up in CH₂Cl₂. The organic phase was washed with H₂O (100 mL) and saturated aq. NaCl (100 mL). The combined aqueous phases were extracted with CH₂Cl₂ (2 x 100 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give a brown solid. The solid was suspended in 10% EtOAc/Hex. The insoluble material was filtered to give 3-fluoro-4'-methyl-3'-nitro-biphenyl-2-ol as a tan solid. (4.08 g, 84%).

[0880] To a 150 mL pressure vessel was added 3-fluoro-4'-methyl-3'-nitro-biphenyl-2-ol (1.00 g, 4.04 mmol, 1.0 eq.), Cs₂CO₃ (3.69 g, 11.3 mmol, 2.8 eq.), 1-(2-chloroethyl)-pyrrolidine hydrochloride (894 mg, 5.26 mmol, 1.3 eq.), and DMF (40 mL). The vessel was sealed and heated at 70°C overnight. The reaction mixture was cooled and was diluted with EtOAc (150 mL) and 10% aq. LiCl (50 mL). The organic phase was washed with 10% aq. LiCl (2 x 75 mL) and saturated aq. NaCl (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 75 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated to give brown oil. The crude material was purified via column chromatography (3% CH₃OH/CH₂Cl₂) to afford pure product 1-[2-(3-fluoro-4'-methyl-3'-nitro-biphenyl-2-yloxy)-ethyl]-pyrrolidine as light-brown oil (1.39 g, 100%).

[0881] To a 50 mL recovery flask was added 1-[2-(3-fluoro-4'-methyl-3'-nitro-biphenyl-2-yloxy)-ethyl]-pyrrolidine (1.39 g, 4.04 mmol, 1.0 eq.), AcOH (8 mL), and tin (II) chloride dihydrate (3.64 g, 16.1 mmol, 4.0 eq.). The reaction was stirred vigorously at room temperature. After 3h, LC/MS shows approximately 1:1 ratio of starting material to product. The reaction mixture was heated at 75°C overnight, which drove the reaction to completion. The reaction mixture was cooled and poured into a 250 mL Erlenmeyer flask containing H₂O (100 mL). 4N NaOH was added until the solution became alkaline. The thick mixture was extracted with Et₂O (5 x 75 mL). The organic phase was dried over Na₂SO₄, filtered, and concentrated to afford 3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-ylamine as a brown oil which was used in the next reaction without further purification (1.25 g, 98%).

[0882] To a 48 mL pressure vessel was added 3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-ylamine (333 mg, 1.06 mmol, 1.0 eq.), bis-(2-chloroethyl)amine hydrochloride (189 mg, 1.06 mmol, 1.0 eq.), K₂CO₃ (146 mg, 1.06 mmol, 1.0 eq.), and diglyme (10 mL). The vessel was sealed and heated at 145°C overnight. The reaction was cooled and diluted with H₂O (30 mL) and EtOAc (50 mL). The organic phase was washed with H₂O (30 mL), saturated aq. NaHCO₃ (30 mL), and brine (30 mL). The combined aqueous phases were extracted with EtOAc (4 x 30 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated to give black oil which still contained a large amount of diglyme. The crude mixture was purified by column chromatography (20% CH₃OH/CH₂Cl₂ to 20% CH₃OH/CH₂Cl₂ with 1% Et₃N) to afford 1-[3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazine as black oil (257 mg, 62%).

[0883] 3-Bromo-4-(4-{3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: To a 50 mL recovery flask was added 1-[3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-yl-ethoxy)-biphenyl-3-yl]-piperazine (255 mg, 0.665 mmol, 1.0 eq.), isopropanol (8 mL), *t*-Pr₂NEt (348 μL, 1.99 mmol, 3.0 eq.). Upon stirring, chloropyrimidine 7 (155 mg, 0.665 mmol, 1.0 eq.) was added and the reaction was heated at 65°C for 1h and overnight while cooling to room temperature. The reaction mixture was concentrated and then redissolved in EtOAc (100 mL). The organic phase was washed with H₂O (2 x 50 mL) and brine (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give a brown solid. Column

chromatography (3% to 10% CH₃OH/CH₂Cl₂) afforded 3-bromo-4-(4-{3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine as an off-white solid (160 mg, 41%). ¹H NMR (400 MHz, d₆-DMSO) δ 10.29 (br s, 1H), 8.38 (s, 1H), 7.36-7.17 (m, 6H), 4.11 (t, 2H), 3.98 (m, 4H), 3.36-3.33 (m, 4H), 3.11-3.09 (m, 4H), 2.97-2.92 (m, 2H), 2.38 (s, 3H), 1.92 (m, 2H), 1.80 (m, 2H). MS(ESI) for C₂₈H₃₁FBrN₇O: 582 (MH⁺).

[0884] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0885] 5-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(2-pyrrolidin-1-ylethyl)biphenyl-3-amine. ¹H NMR (400 MHz, d₆-DMSO) δ 8.69 (s, 1H), 8.36 (s, 1H), 7.61 (m, 2H), 7.41 (m, 1H), 7.31 (m, 1H), 6.68 (s, 1H), 6.61 (s, 1H), 4.97 (m, 1H), 3.98 (m, 3H), 3.25 (m, 2H), 3.03 (m, 3H), 2.91 (br, s, 1), 2.76 (m, 3H), 2.57 (m, 4H), 2.13 (s, 2H), 1.19 (s, 2H), 1.78 (m, 3H). MS (ESI) for C₂₈H₃₃BrN₈: 560 (MH⁺).

[0886] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-(1,3-thiazol-2-yl)aniline. ¹H NMR (400 MHz, d₆-DMSO) δ 8.38 (s, 1H), 7.76 (d, 2H), 7.71 (d, 1H), 6.99 (s, 1H), 6.92 (s, 1H), 6.61 (s, 1H), 5.07 (t, 1H), 4.01 (m, 3H), 2.73 (m, 4H), 2.67 (m, 2H), 2.55 (m, 4H), 2.45 (m, 2H), 2.13 (d, 3H), 2.07 (s, 2H), 1.75 (m, 3H). MS (ESI) for C₂₅H₃₀BrN₉S: 568 (MH⁺).

[0887] 1-[3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-[2-methyl-4-[(3-(2-pyrrolidin-1-ylethoxy)]phenyl]phenyl]piperazine: ¹H-NMR, (400 MHz CDCl₃) δ 8.45 (s, 1H), 7.22-7.33 (m, 4H), 7.13 (d, J= 8 Hz, 1H), 7.08 (m, 1H), 6.86 (dd, J= 1.5, J= 8 Hz), 4.20 (t, J= 6 Hz, 2H), 4.10 (m, 4H), 3.15 (m, 4H), 2.98 (t, J= 6 Hz, 2H), 2.70 (m, 4H), 2.40 (s, 3H), 1.84 (m, 4H). MS (ESI) for C₂₈H₃₂BrN₇O: 564 (MH⁺).

[0888] 3-Bromo-4-(4-{4-methyl-2'-(3-morpholin-4-ylpropyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 7.26 (m, 4H), 7.09 (m, 2H), 7.00 (t, 1H), 4.00 (m, 6H), 3.44 (m, 4H), 3.07 (m, 4H), 2.35 (m, 5H), 2.25 (br s, 4H), 1.81 (m, 2H). MS (ESI) for C₂₉H₃₄BrN₇O₂: 592 (MH⁺).

[0889] 3-Bromo-4-(4-{4-methyl-2'-(2-morpholin-4-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.37 (s, 1H), 7.26 (m, 4H), 7.13 (dd, 2H), 7.01 (t, 1H), 4.09 (m, 2H), 3.98 (m, 4H), 3.49

(m, 4H), 3.07 (m, 4H), 2.62 (m, 2H), 2.35 (br s, 7H). MS (ESI) for C₂₈H₃₂BrN₇O₂: 578 (MH⁺).

[0890] 3-({3'-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)-N,N-dimethylpropan-1-amine: ¹H NMR (400 MHz, d₆-DMSO) δ 10.7 (s, 1H), 8.40 (s, 1H), 7.28 (m, 3H), 7.23 (s, 1H), 7.18 (d, 1H), 7.11 (d, 1H), 7.03 (t, 1H), 5.40 (m, 4H), 4.06 (m, 4H), 3.15 (s, 3H), 3.07 (m, 2H), 2.68 (m, 5H), 2.39 (s, 3H), 2.09 (m, 2H). MS (ESI) for C₂₇H₃₂BrN₇O: 551 (MH⁺).

[0891] 1-[2-({3'-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)ethyl]pyrrolidine-2,5-dione: ¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (s, 1H), 7.30 (m, 2H), 7.20 (d, 1H), 7.12 (s, 1H), 7.04 (m, 3H), 4.10 (t, 2H), 3.97 (m, 4H), 3.69 (t, 2H), 3.35 (m, 4H), 3.09 (m, 4H), 2.35 (s, 3H). MS (ESI) for C₂₈H₂₈BrN₇O₃: 591 (MH⁺).

[0892] 3-Bromo-4-(4-{4-chloro-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 9.6 (br s, 1H), 8.38 (s, 1H), 7.49 (d, 1H), 7.42 (m, 2H), 7.28 (d, 1H), 7.20 (m, 1H), 7.10 (t, 1H), 4.70 (t, 2H), 3.98 (br q, 4H), 3.55 (br q, 2H), 3.45 (m, 2H), 3.22 (br q, 2H), 1.89 (br m, 2H), 1.75 (br m, 2H). MS (ESI) for C₂₇H₂₉BrClN₇O: 582 (MH⁺).

[0893] 3-Bromo-4-(4-{4-chloro-4'-fluoro-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 10.0 (br s, 1H), 8.37 (s, 1H), 7.49 (d, 1H), 7.40 (t, 1H), 7.25 (s, 1H), 7.18 (dt, 2H), 6.94 (dt, 1H), 4.35 (t, 2H), 3.98 (br s, 4H), 3.41 (m, 4H), 3.21 (br s, 4H), 2.93 (br q, 2H), 1.90 (br m, 2H), 1.75 (br m, 2H). MS (ESI) for C₂₇H₂₈BrClFN₇O: 600 (MH⁺).

[0894] EXAMPLE 48: 6-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-3,5-difluoro-N4-(3-methyl-butyl)-N2-(2-pyrrolidin-1-yl-ethyl)-pyridine-2,4-diamine.

[0895] To 2,3,4,5,6-pentafluoro-pyridine (770mg, 4.55 mmol) in dichloromethane (3mL) was added 3-methyl-butylamine (530 uL, 4.55 mmol) slowly. After the reaction mixture was stirred at r.t. for 1 hr, it was concentrated to yield (3-methyl-butyl)-(2,3,5,6-tetrafluoro-pyridin-4-yl)-amine and used for next reaction. MS (ESI) for C₁₀H₁₂F₄N₂: 237 (MH⁺).

[0896] The mixture of (3-methyl-butyl)-(2,3,5,6-tetrafluoro-pyridin-4-yl)-amine and Boc-piperazine (4.35 mmol) was heated at 110°C for overnight. The product 4-[3,5,6-trifluoro-4-(3-methyl-butylamino)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl

ester was purified by column chromatography (624 mg). MS (ESI) for C₁₉H₂₉F₃N₄O₂: 401 (MH⁺).

[0897] The mixture of 4-[3,5,6-trifluoro-4-(3-methyl-butylamino)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester (122 mg) and 2-amino-ethyl pyrrolidine (700 uL, 40eq.) in sealed tube was heated at 130°C for 3 days. The product 4-[3,5-difluoro-4-(3-methyl-butylamino)-6-(2-pyrrolidin-1-yl-ethylamino)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester was purified by column chromatography (91mg). MS (ESI) for C₂₅H₄₂F₂N₆O₂: 497 (MH⁺).

[0898] 4-[3,5-Difluoro-4-(3-methyl-butylamino)-6-(2-pyrrolidin-1-yl-ethylamino)-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester (4, 91 mg, 0.18 mmol) was treated with 4N-HCl-dioxane (2mL) in methanol (2mL) at r.t. for 1 hr. and gave 3,5-difluoro-N4-(3-methyl-butyl)-6-piperazin-1-yl-N2-(2-pyrrolidin-1-yl-ethyl)-pyridine-2,4-diamine hydrochloride. MS (ESI) for C₂₀H₃₄F₂N₆: 397 (MH⁺).

[0899] To the crude 3,5-difluoro-N4-(3-methyl-butyl)-6-piperazin-1-yl-N2-(2-pyrrolidin-1-yl-ethyl)-pyridine-2,4-diamine hydrochloride in THF (3mL), 3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (43 mg, 0.18 mmol), and triethylamine (150uL, 1.1 mmol) were added. The mixture was heated at 60°C for 2 hrs. After concentrated, the product was purified by HPLC and gave to 6-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-3,5-difluoro-N4-(3-methyl-butyl)-N2-(2-pyrrolidin-1-yl-ethyl)-pyridine-2,4-diamine. ¹H-NMR (400 MHz, CDCl₃) δ 8.4 (s, 1H), 4.98(br s, 1H), 4.04 (m, 4H), 3.58 (m, 2H), 3.48(m, 4H), 3.42(m, 2H), 2.84 (m, 2H), 2.73(br s, 4H), 1.85 (s, 4H), 1.68 (m, 1H), 1.49 (m, 2H), 0.94(d, 6H). MS (ESI) for C₂₅H₃₅BrF₂N₁₀: 595 (MH⁺).

[0900] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0901] 2-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5,6-trifluoro-N-(3-methylbutyl)pyridin-4-amine: ¹H-NMR (400 MHz, CDCl₃) δ 12.69 (br s, 1H), 8.44 (s, 1H), 4.18 (s, 1H), 4.03 (m, 4H), 3.53 (m, 4H), 3.48 (m, 2H), 1.72 (m, 1H), 1.53 (m, 2H), 0.94(m, 6H). MS (ESI) for C₁₉H₂₂BrF₃N₈: 501 (MH⁺).

[0902] EXAMPLE 49: [3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-5-(1,1-difluoro-butyl)-2-methyl-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine.

[0903] To a round bottom flask was added 1-(3,5-dibromo-4-methyl-phenyl)-butane-1-one (1.0 g, 3.1 mmol), 1,2-ethanedithiol (0.52 mL, 6.2 mmol), and boron trifluoride

acetic acid complex (0.43 mL, 3.1 mmol). The reaction was stirred vigorously at r.t. for 30 min before diluting with hexanes (20 mL). The organic solution was washed (3 X 20mL) with saturated NaHCO₃, 15% NaOH, and finally with brine. The organic layer was dried with Na₂SO₄, and concentrated. Column chromatography with 10:90 EtOAc:Hexanes gave 2-(3,5-dibromo-4-methyl-phenyl)-2-propyl-[1,3]dithiolane as a clear oil that solidified upon standing (1.14 g, 90% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.82 (s, 2H), 3.40 (m, 2H), 3.20 (m, 2H), 2.58 (s, 3H), 2.25 (m, 2H), 1.30 (m, 2H), 0.90 (t, 3H).

[0904] To an oven dried round bottom flask was added dry 1,3-dibromo-5,5-dimethylhydantoin (360 mg, 1.26 mmol), CH₂Cl₂ (2.5mL), and hydrogen fluoride pyridine (0.62 mL, 2.73 mmol). The mixture was cooled to -78°C before adding dropwise a solution of 2-(3,5-Dibromo-4-methyl-phenyl)-2-propyl-[1,3]dithiolane (500 mg, 1.26 mmol) in 0.5 mL dry CH₂Cl₂. The reaction changed from yellow to orange to red in color. After 30 min at -78°C, the reaction was filtered through a 50mL polypropylene/polyethylene column packed with basic alumina. The column was rinsed with hexanes and then CH₂Cl₂. The combined organics were concentrated and columned with EtOAc: hexane (5:95) to give 1,3-dibromo-5-(1,1-difluoro-butyl)-2-methyl-benzene as an oil (240 mg, 70% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (m, 2H), 2.60 (m, 3H), 2.05 (m, 2H), 1.42 (m, 2H), 0.95 (t, 3H).

[0905] To a sealed tube was added 1,3-dibromo-5-(1,1-difluoro-butyl)-2-methyl-benzene (235 mg, 0.68 mmol), toluene (3.0 mL), Boc-piperazine (115 mg, 0.62 mmol), NaOtBu (91.0 mg, 0.95 mmol), and BINAP (42.0 mg, 0.068 mmol). The reaction was purged with nitrogen before adding Pd₂(dba)₃ (15.0 mg, 0.017 mmol). The tube was sealed and heated to 110°C overnight. The reaction was then cooled to r.t., filtered through celite, rinsed with EtOAc, and concentrated. Column purification with 10:90 EtOAc: hexane gave 4-[3-bromo-5-(1,1-difluoro-butyl)-2-methyl-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (200 mg, 66% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.40 (s, 1H), 7.00 (s, 1H), 3.60 (br s, 4H), 2.82 (br t, 4H), 2.40 (s, 3H), 2.05 (m, 2H), 1.50 (s, 9H), 1.45 (m, 2H), 0.95 (t, 3H).

[0906] To a sealed tube was added 4-[3-bromo-5-(1,1-difluoro-butyl)-2-methyl-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (200 mg, 0.44 mmol), dioxane (5.0 mL), NaOtBu (68.0 mg, 0.72 mmol), and xantphos (25.0 mg, 0.044 mmol). The reaction was purged with nitrogen before adding Pd₂(dba)₃ (20.0 mg, 0.022 mmol). The tube was sealed and stirred at RT for 10 min before adding 1-(2-aminoethyl)-pyrrolidine (75 mg,

0.66 mmol), sealed and heated to 100°C overnight. The reaction was then cooled to r.t., filtered through celite, rinsed with MeOH, and concentrated. Column purification with MeOH: CH₂Cl₂ (7:93) gave 4-5-(1,1-difluoro-butyl)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (130 mg, 62% yield). ¹H NMR (400 MHz, d₆-DMSO) δ 6.42 (d, 2H), 4.95 (br s, 1H), 3.60 (s, 2H), 3.20 (m, 4H), 2.70 (m, 4H), 2.15 (m, 2H), 2.01 (s, 3H), 1.70 (br s, 4H), 1.42 (s, 9H), 1.40 (m, 2H), 0.93 (t, 3H). MS (ESI) for C₂₆H₄₂F₂N₄O₂: 481 (MH⁺).

[0907] [3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-5-(1,1-difluoro-butyl)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine: To a round bottom flask was added 4-5-(1,1-difluoro-butyl)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid *tert*-butyl ester (130 mg, 0.27 mmol), dry methanol (3.0 mL) and 4N HCl in dioxane (3.0 mL). The reaction was stirred at RT for 1 hr, then concentrated to remove trace HCl. The residue was then dissolved in THF (5.0 mL), and triethyl amine (0.156 mL, 1.08 mmol), before adding 3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (63.0 mg, 0.27 mmol). The reaction was stirred at 65°C for 30 min, concentrated and prep purified to give the TFA salt of [3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-5-(1,1-difluoro-butyl)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine. The salt was converted to the HCl salt by adding excess 4N HCl and lyophilizing in H₂O/CH₃CN to give [3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-piperazin-1-yl]-5-(1,1-difluoro-butyl)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine as a white solid (101 mg, 64% yield): ¹H NMR (400MHz, d₆-DMSO) δ 9.60 (br s, 1H), 8.40 (s, 1H), 6.60 (d, 2H), 3.45 (m, 4H), 3.40 (m, 4H), 3.00 (m, 6H), 2.20 (s, 3H), 2.10 (m, 4H), 1.95 (m, 2H), 1.40 (m, 2H), 0.95 (t, 3H). MS (ESI) for C₂₆H₃₅BrF₂N₈: 577 (MH⁺).

[0908] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0909] 1-{3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-ol: ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 6.47 (s, 1H), 6.38 (s, 1H), 4.39 (m, 1H), 3.95 (br, 3H), 3.62 (br, 2H), 3.43 (m, 2H), 3.36 (m, 2H), 3.08 (br, 2H), 2.94 (s, 4H), 2.10 (s, 3H), 1.95 (br, 5H), 1.52 (m, 2H), 1.45 (m, 1H), 1.25 (m, 1H), 0.86 (t, 3H). MS (ESI) for C₂₆H₃₇BrN₈O: 557 (MH⁺).

[0910] EXAMPLE 50: 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethyoxy)methyl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline.

[0911] To a 500 mL recovery flask was added methyl 3,5-dibromo-4-methylbenzoate (26 g, 84.4 mmol, 1.0 eq.), anhydrous ethanol (300 mL), and NaBH₄ (9.58 g, 253 mmol, 3.0 eq.). The reaction was stirred at reflux overnight. TLC analysis indicated that the reaction was complete. The reaction was concentrated and chromatographed (10% EtOAc/Hex) to give (3,5-dibromo-4-methyl-phenyl)-methanol as a white solid (17.2 g, 73%).

[0912] To a 50 mL recovery flask was added (3,5-dibromo-4-methyl-phenyl)-methanol (0.50 g, 1.78 mmol, 1.0 eq.) and DMF (15 mL). NaH (60% dispersion in mineral oil, 143 mg, 3.57 mmol, 2.0 eq.) was added and the mixture was stirred at 70°C for 5 min. Bromoethane (400 μL, 5.36 mmol, 3.0 eq.) was added and the reaction was stirred overnight at 70°C. The reaction mixture was diluted with EtOAc (100 mL) and the organic phase was washed with 10% aq. LiCl (2 x 50 mL) and saturated aq. sodium chloride (50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated. The crude oil was purified via column chromatography (5% EtOAc/Hex) to give 1,3-dibromo-5-ethoxymethyl-2-methyl-benzene as yellow oil (410 mg, 75%).

[0913] To a 48 mL pressure vessel was added 1,3-dibromo-5-ethoxymethyl-2-methyl-benzene (1.24 g, 4.02 mmol, 1.0 eq.), Boc-piperazine (675 mg, 3.62 mmol, 0.9 eq.), BINAP (250 mg, 0.402 mmol, 0.1 eq.), and toluene (15 mL). The suspension was bubbled with N₂ upon which Pd₂(dba)₃ (92 mg, 0.0100 mmol, 0.025 eq.) and sodium *tert*-butoxide (542 mg, 5.64 mmol, 1.4 eq.) was added. The vessel was sealed and heated at 110°C overnight. The crude mixture was filtered through Celite and the Celite cake was rinsed with EtOAc. The filtrate was concentrated and chromatographed (5% to 15% EtOAc/Hex) to afford 4-(3-bromo-5-ethoxymethyl-2-methyl-phenyl)-piperazine-1-carboxylic acid *tert*-butyl ester as yellow oil (1.01 g, 61%).

[0914] To a 75 mL pressure vessel was added 4-(3-bromo-5-ethoxymethyl-2-methyl-phenyl)-piperazine-1-carboxylic acid *tert*-butyl ester (1.00 g, 2.42 mmol, 1.0 eq.), XantPHOS (84 mg, 0.145 mmol, 0.06 eq.), 2-pyrrolidinoethylamine (457 μL, 3.63 mmol, 1.5 eq.), and dioxane (25 mL). The suspension was bubbled with N₂ upon which Pd₂(dba)₃ (66 mg, 0.0725 mmol, 0.03 eq.) and sodium *tert*-butoxide (349 mg, 3.63 mmol, 1.5 eq.) was added. The vessel was sealed and heated at 100°C overnight. The crude mixture was filtered through Celite and the Celite cake was rinsed with EtOAc. The filtrate was concentrated and chromatographed (5%-15% CH₃OH/CH₂Cl₂) to afford 4-[5-

ethoxymethyl-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester as bronze oil (535 mg, 49%).

[0915] To a 50 mL recovery flask was added 4-[5-ethoxymethyl-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (535 mg, 1.20 mol, 1.0 eq.) and methanol (8 mL). 4N HCl/dioxane (8 mL) was added and the reaction was stirred for 2h at room temperature. LC/MS analysis indicated that the deprotection was complete, whereupon the reaction was concentrated and placed on high vacuum. The crude material of (5-ethoxymethyl-2-methyl-3-piperazin-1-yl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine was used in the next reaction without further purification.

[0916] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethyloxy)methyl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: To a 50 mL recovery flask was added (5-ethoxymethyl-2-methyl-3-piperazin-1-yl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine (502 mg, 1.20 mmol, 1.0 eq.), isopropanol (15 mL), *i*-Pr₂NEt (1.04 mL, 5.98 mmol, 5.0 eq.). Upon stirring, 3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (279 mg, 1.20 mmol, 1.0 eq.) was added and the reaction was heated at 65°C for 1h. The reaction mixture was concentrated and then redissolved in EtOAc (100 mL). The organic phase was washed with H₂O (2 x 50 mL) and brine (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give light-brown oil. Column chromatography (5% to 15% CH₃OH/CH₂Cl₂) afforded pure product 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethyloxy)methyl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline as a light yellow oil (277 mg, 43%). ¹H NMR (400 MHz, d₆-DMSO) δ 11.18 (br s, 1H), 8.42 (s, 1H), 6.62 (s, 1H), 6.59 (s, 1H), 4.37 (s, 2H), 4.09 (br s, 3H), 3.60 (m, 2H), 3.54 (t, 2H), 3.47 (q, 2H), 3.38 (m, 2H), 3.12 (m, 3H), 3.04 (m, 2H), 2.24 (s, 3H), 2.00 (m, 2H), 1.91 (m, 2H), 1.14 (t, 3H). MS(ESI) for C₂₅H₃₅BrN₈O: 545 (MH⁺).

[0917] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compound of the invention was prepared:

[0918] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-{{(2,2,2-trifluoroethyl)oxy}methyl}aniline:

[0919] The key intermediate of 1,3-dibromo-2-methyl-5-(2,2,2-trifluoroethoxymethyl)-benzene was synthesized by following method and further reactions were the same as the previous section.

[0920] To a 200 mL recovery flask was added (3,5-dibromo-4-methyl-phenyl)-methanol (1.50 g, 5.36 mmol, 1.0 eq.) and azodicarbonyldipiperidine (2.70 g, 10.7 mmol, 2.0 eq.). Benzene (60 mL) was added and the mixture was stirred at room temperature. Tri-*n*-butylphosphine (2.64 mL, 10.7 mmol, 2.0 eq.) was added at the reaction mixture was stirred for 10 minutes whereupon 2,2,2-trifluoroethanol (3.85 mL, 53.6 mmol, 10.0 eq.) was added. The reaction was stirred for 6 hours at room temperature. TLC analysis at 2 h and 6 h indicated the reaction progression had slowed and therefore the reaction was concentrated and chromatographed (100% CH₂Cl₂) to afford the product 1,3-dibromo-2-methyl-5-(2,2,2-trifluoro-ethoxymethyl)-benzene as a white solid (1.11 g, 57%, 79% based on recovered starting material).

[0921] To a 50 mL recovery flask was added [2-methyl-3-piperazin-1-yl-5-(2,2,2-trifluoro-ethoxymethyl)-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine dihydrochloride (570 mg, 1.20 mmol, 1.0 eq.), isopropanol (15 mL), *i*-Pr₂NEt (1.05 mL, 6.02 mmol, 5.0 eq.). Upon stirring, 3-Bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (281 mg, 1.20 mmol, 1.0 eq.) was added and the reaction was heated at 65°C for 1h. The reaction mixture was concentrated and then redissolved in EtOAc (100 mL). The organic phase was washed with water (2 x 50 mL) and brine (1 x 50 mL). The combined aqueous phases were extracted with EtOAc (2 x 50 mL). The organic phases were combined and dried over anhydrous Na₂SO₄, filtered, and concentrated to give light-brown oil. Column chromatography (3% to 15% CH₃OH/CH₂Cl₂) afforded 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-{[(2,2,2-trifluoroethyl)oxy]methyl}aniline as a light yellow oil (258 mg, 36%). ¹H NMR (400 MHz, d₆-DMSO) δ 11.00 (br s, 1H), 8.40 (s, 1H), 6.55 (s, 1H), 6.52 (s, 1H), 4.56 (s, 2H), 4.09-4.02 (m, 5H), 3.59 (m, 2H), 3.51 (t, 2H), 3.34 (m, 2H), 3.04 (m, 6H), 2.19 (s, 3H), 2.00 (m, 2H), 1.90 (m, 2H). MS (ESI) for C₂₅H₃₂BrF₃N₈O: 599 (MH⁺).

[0922] EXAMPLE 51: [3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine.

[0923] To a pressure vessel was added 3,5-dibromo-4-methyl phenol (12.0g, 45 mmol), dry DMF (80 mL), cesium carbonate (35.4 g, 108.6mmol), and 2-(Bromomethyl)-

1,2,3-trifluoropropane (11.2g, 58 mmol). The reaction was sealed and heated to 80°C overnight. The reaction was then cooled to r.t. then partitioned between EtOAc and water. The organic layer was washed with brine, dried with Na₂SO₄, and concentrated. Column chromatography on silica gel with 5:95 EtOAc: hexanes gave 15 g of 1,3-dibromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-benzene as a white solid (89% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.10 (s, 2H), 4.70 (dd, 4H), 4.2 (d, 2H), 2.44 (s, 3H). MS (ESI) for C₁₁H₁₁Br₂F₃O: 375 (MH⁺).

[0924] To a pressure vessel was added pure trifluoro ether 1,3-dibromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-benzene (15.0 g, 40 mmol), toluene (100 mL), Boc piperazine (6.7g, 36.0 mmol), sodium t-butoxide (5.35g, 56.0 mmol), and BINAP (2.49 g, 4.0mmol). The vessel was then purged with N₂ before adding Pd₂(dba)₃ (915 mg, 1.0 mmol), sealed and heated to 110°C overnight. The reaction was then cooled to r.t., filtered through celite, rinsed with EtOAc and concentrated. Column chromatography on silica gel with 10:90 EtOAc: hexane gave 12.7g of 4-[3-bromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-piperazine-1-carboxylic acid t-butyl ester as a pale yellow solid (67% yield). ¹H NMR (400 MHz, CDCl₃) δ 6.90 (s, 1H), 6.60 (s, 1H), 4.75 (dd, 4H), 4.2 (d, 2H), 3.60 (br s, 4H), 2.81 (br s, 4H), 2.34 (s, 3H), 1.45 (s, 9H). MS (ESI) for C₂₀H₂₈BrF₃N₂O₃: 481 (MH⁺).

[0925] To a pressure vessel was added 4-[3-bromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-piperazine-1-carboxylic acid t-butyl ester (6.8g, 14.2 mmol), dry dioxane (100 mL), sodium t-butoxide (2.2g, 22.7 mmol), and Xantphos (821 mg, 1.4mmol). The reaction was purged with N₂ before adding Pd₂(dba)₃ (649 mg, 0.71 mmol). The reaction was stirred at rt for 5 min before adding 1-(2-aminoethyl pyrrolidine) (2.7 mL, 21.3mmol). The reaction was then sealed and stirred at 90°C overnight. The reaction was cooled to rt, filtered through celite, rinsed with methanol, concentrated and column purified with silica gel and 10:90 MeOH: CH₂Cl₂ to give 4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid t-butyl ester as a brown solid (6.2g, 85% yield). ¹H NMR (400 MHz, d₆-DMSO) δ 6.00 (d, 2H), 4.80 (m, 4H), 4.2 (d, 2H), 3.50 (br s, 4H), 3.19 (q, 2H), 2.72 (br s, 4H), 2.70 (t, 2H), 2.44 (m, 4H), 2.00 (s, 3H), 1.70 (br s, 4H), 1.45 (s, 9H). MS (ESI) for C₂₆H₄₁F₃N₄O₃: 515 (MH⁺).

[0926] [3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]-piperazin-1-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine: To a

round bottom flask was added 4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid t-butyl ester (6.2 g, 12.0 mmol), dry MeOH (35 mL) and 4N HCl in dioxane (35 mL). The reaction was stirred at rt for 1 hr or until complete as monitored by LC/MS. The reaction was then concentrated, and placed on high vacuum for 1 hr before carrying onto the next step without further purification.

[0927] To the round bottom flask containing [5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-piperazin-1-yl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine was added in order: THF (60mL), triethyl amine (6.9mL, 48.0 mmol), and 3-bromo-4-chloro-1H-pyrazolo[3,4-d]pyrimidine (2.8g, 12.0 mmol). The reaction was stirred at 65°C for 1 hr or until complete as monitored by LC/MS. The reaction was then concentrated before adding EtOAc (200 mL). The organic layer was washed with saturated NaHCO₃ (2X), water, brine, and then dried with Na₂SO₄ before concentrating. Column purification with silica gel and a gradient of 5:95 to 15:85 MeOH: CH₂Cl₂ gave [3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine (5.41 g, 73% yield). Conversion to the HCl salt was achieved by dissolving [3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]- (2-pyrrolidin-1-yl-ethyl)-amine in 1:1 water: acetonitrile and adding 1.0 eq. of 4N HCl, and lyophilizing. The HCl salt was then lyophilized again with water-acetonitrile. ¹H NMR (400MHz, d₆-DMSO) δ 10.90 (br s, 1H), 8.20 (s, 1H), 6.19 (d, 2H), 4.85 (d sextet, 4H), 4.25 (d, 2H), 4.00 (br s, 4H), 3.80 (br s, 2H), 3.75 (br t, 2H), 3.25 (br s, 2H), 3.00 (br s, 4H), 2.10 (s, 3H), 1.95 (br m, 4H). MS (ESI) for C₂₆H₃₄BrF₃N₈O: 609 (MH⁺).

[0928] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0929] {3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl]-5-isobutoxy-2-methyl-phenyl}-2-pyrrolidin-1-yl-ethyl)-amine: ¹H NMR (400MHz, d₆-DMSO) δ 10.85 (br s, 1H), 8.40 (s, 1H), 6.12 (d, 2H), 3.7 (d, 2H), 3.62 (br s, 2H), 3.45 (br t, 2H), 3.22 (br s, 4H), 3.00 (br s, 8H), 2.18 (s, 3H), 1.80 (m, 4H), 1.00 (d, 6H). MS (ESI) for C₂₆H₃₇BrN₈O: 557 (MH⁺).

[0930] N'-{3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-piperazin-1-yl]-5-isobutoxy-2-methyl-phenyl}-N,N-diethyl-ethane-1,2-diamine: ¹H NMR (400MHz, d₆-DMSO) δ 12.2 (br s, 1H), 10.20 (br s, 1H), 8.20 (s, 1H), 6.12 (d, 2H), 3.80 (d, 2H), 3.22

(m, 5H), 3.00 (br s, 2H), 2.18 (s, 3H), 1.90 (m, 1H), 1.25 (t, 6H), 1.00 (d, 6H). MS (ESI) for C₂₆H₃₉BrN₈O: 558 (MH⁺).

[0931] N'-{3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]-piperazin-1-yl]-5-isobutoxy-2-methyl-phenyl}-N,N-methyl-ethane-1,2-diamine: ¹H NMR (400MHz, d₆-DMSO) δ 12.2 (br s, 1H), 10.20 (br s, 1H), 8.40 (s, 1H), 6.02 (d, 2H), 3.70 (d, 2H), 3.60 (t, 2H), 3.30 (t, 2H), 3.00 (br s, 4H), 2.80 (s, 6H), 2.18 (s, 3H), 1.90 (m, 1H), 1.00 (d, 6H). MS (ESI) for C₂₄H₃₅BrN₈O: 531 (MH⁺).

[0932] [3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]-piperazin-1-yl]-5-(2-fluoro-2-methyl-propoxy)-2-methyl-phenyl]-2-pyrrolidin-1-yl-ethyl)-amine: ¹H NMR (400MHz, d₆-DMSO) δ 10.60 (br s, 1H), 8.40 (s, 1H), 6.12 (d, 2H), 4.0 (d, 4H), 3.60 (m, 4H), 3.00 (m, 8H), 2.18 (s, 3H), 1.80 (m, 4H), 1.40 (d, 6H). MS (ESI) for C₂₆H₃₆BrFN₈O: 555 (MH⁺).

[0933] N'-[3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]-piperazin-1-yl]-5-(2-fluoro-2-methyl-propoxy)-2-methyl-phenyl]-N,N-dimethyl-ethane-diamine: ¹H NMR (400MHz, d₆-DMSO) δ 10.80 (br s, 1H), 8.40 (s, 1H), 6.12 (d, 2H), 4.0 (d, 4H), 3.30 (t, 2H), 3.00 (s, 2H), 2.80 (s, 6H), 2.18 (s, 3H), 1.40 (d, 6H). MS (ESI) for C₂₄H₃₄BrFN₈O: 549 (MH⁺).

[0934] N'-[3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]-piperazin-1-yl]-5-(2,3-difluoro-2-fluoromethylpropoxy)-2-methyl-phenyl]-N,N-dimethyl-ethane-1,2diamine: ¹H NMR (400MHz, d₆-DMSO) δ 10.80 (br s, 1H), 8.40 (s, 1H), 6.19 (d, 2H), 4.90 (dq, 2H), 4.80 (dq, 2H), 4.25 (d, 2H), 4.00 (br s, 4H), 3.50 (t, 2H), 3.23 (t, 2H), 3.00 (br s, 4H), 2.80 (s, 6H), 2.12 (s, 3H). MS (ESI) for C₂₄H₃₂BrF₃N₈O: 585 (MH⁺).

[0935] 3-Bromo-4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1*H*-pyrazolo[3,4-*d*]pyrimidine: ¹H NMR (400MHz, d₆-DMSO) δ 10.60 (br s, 1H), 8.40 (s, 1H), 6.60 (s, 2H), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.25 (d, 2H), 3.80 (m, 6H), 3.19 (m, 2H), 3.00 (br m, 6H), 2.80 (m, 2H), 2.20 (s, 3H), 1.95 (m, 6H). MS (ESI) for C₂₇H₃₅BrF₃N₇O: 610 (MH⁺).

[0936] 3-Bromo-4-{4-[5-isobutoxy-2-methyl-3-(3-pyrrolidin-1-yl-propyl)-phenyl]-piperazin-1-yl}-1*H*-pyrazolo[3,4-*d*]pyrimidine: ¹H NMR (400MHz, d₆-DMSO) δ 10.23 (br s, 1H), 8.40 (s, 1H), 6.60 (d, 2H), 4.00 (br s, 4H), 3.70 (d, 2H), 3.20 (m, 2H), 3.00 (br s, 6H), 2.60 (m, 2H), 2.20 (s, 3H), 1.95 (m, 6H). MS (ESI) for C₂₇H₃₈BrN₇O: 556 (MH⁺).

- [0937] 3-Bromo-4-{4-[3-Bromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-piperazin-1-yl}-1*H*-pyrazolo[3,4-*d*]pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 8.40 (s, 1H), 7.05 (s, 1H), 6.80 (s, 1H), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.32 (d, 2H), 4.00 (br s, 4H), 3.00 (br s, 4H), 2.20 (s, 3H). MS (ESI) for $\text{C}_{20}\text{H}_{21}\text{Br}_2\text{F}_3\text{N}_6\text{O}$: 579 (MH^+).
- [0938] 4-{4-[3-Bromo-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-piperazin-1-yl}-3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 8.40 (br s, 1H), 7.05 (s, 1H), 6.79 (s, 1H), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.32 (d, 2H), 4.00 (br s, 4H), 3.00 (br s, 6H), 2.20 (s, 3H), 1.4 (t, 3H). MS (ESI) for $\text{C}_{22}\text{H}_{26}\text{BrN}_6\text{O}$: 526 (MH^+).
- [0939] {3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-piperazin-1-yl]-5-difluoromethoxy-2-methyl-phenyl}- (2-pyrrolidin-1-yl-ethyl)- amine: ^1H NMR (400MHz, d_6 -DMSO) δ 8.40 (s, 1H), 7.25 (t, 1H), 6.25 (d, 2H), 4.00 (br s, 4H), 3.60 (m, 2H), 3.45 (t, 2H), 3.31 ((br t, 2H), 3.00 (br s, 6H), 2.18 (s, 3H), 1.95 (m, 4H). MS (ESI) for $\text{C}_{23}\text{H}_{29}\text{BrF}_2\text{N}_8\text{O}$: 551 (MH^+).
- [0940] {3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-piperazin-1-yl]-5-difluoromethoxymethyl-2-methyl-phenyl}- (2-pyrrolidin-1-yl-ethyl)- amine: ^1H NMR (400MHz, d_6 -DMSO) δ 10.95 (br s, 1H), 8.40 (s, 1H), 6.80 (t, 1H), 6.60 (d, 2H), 4.00 (br s, 4H), 3.60 (m, 2H), 3.55 (m, 2H), 3.39 (m, 2H), 3.00 (br s, 6H), 2.18 (s, 3H), 1.95 (m, 4H). MS (ESI) for $\text{C}_{24}\text{H}_{31}\text{BrF}_2\text{N}_8\text{O}$: 565 (MH^+).
- [0941] 3-Bromo-4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-piperazin-1-yl}-1*H*-pyrazolo[3,4-*d*]pyrimidine: ^1H NMR (400MHz, d_6 -DMSO) δ 8.40 (s, 1H), 7.15 (d, 1H), 6.70 (s, 1H), 6.65 (dd, 2H), 4.90 (dq, 2H), 4.85 (dq, 2H), 4.32 (d, 2H), 4.00 (br s, 4H), 3.00 (br s, 4H), 2.20 (s, 3H). MS (ESI) for $\text{C}_{20}\text{H}_{22}\text{F}_3\text{BrN}_6\text{O}$: 579 (MH^+).
- [0942] [3-[4-(3-Bromo-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-piperazin-1-yl]-4-methyl-5-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-methanol: ^1H NMR (400MHz, d_6 -DMSO) δ 10.95 (br s, 1H), 8.20 (s, 1H), 6.60 (d, 2H), 4.50 (s, 2H), 3.80 (m, 8H), 3.10 (br s, 6H), 2.18 (s, 3H), 1.99 (m, 4H). MS (ESI) for $\text{C}_{23}\text{H}_{31}\text{BrN}_8\text{O}$: 515 (MH^+).
- [0943] 5-{{[2,3-Difluoro-2-(fluoromethyl)propyl]oxy }-3-[4-(3-ethyl-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 9.58 (br s, 1H), 8.37 (br s, 1H), 6.08 (dd, 2H), 4.78 (m, 4H), 4.23 (d, 4H), 3.90 (br s, 4H), 3.65 (br s, 2H), 3.44 (t, 2H), 3.35 (br s, 2H), 3.01 (br m, 4H), 2.91

(br s, 4H), 2.06 (s, 3H), 1.89 (m, 4H), 1.29 (t, 3H). MS (ESI) for C₂₈H₃₉F₃N₈O: 561 (MH⁺).

[0944] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline: ¹H NMR (400 MHz, d₆-DMSO) δ 8.38 (s, 1H), 6.10 (s, 1H), 6.03 (s, 1H), 4.88 (t, 2H), 4.66 (q, 2H), 3.93 (m, 4H), 3.34 (m, 2H), 3.19 (q, 2H), 2.95 (q, 2H), 2.95 (m, 4H), 2.68 (t, 3H), 2.01 (s, 3H), 1.7 (m, 4H). MS (ESI) for C₂₄H₃₀BrF₃N₈O: 585 (MH⁺).

[0945] EXAMPLE 52: 4-[4-(3-Bromo-5-chloro-2-methyl-phenyl)-piperazin-1-yl]-1*H*-pyrazolo[3,4-d]-pyrimidin-6-ylamine.

[0946] To a round bottom flask cooled to -78°C was added 2-amino-4,6-dichloro-5-formyl-pyrimidine (576 mg, 3.0 mmol), dry THF (30.0 mL), DIEA (0.96mL, 6.0 mmol), and 1-(5-chloro-2-methyl-phenyl)piperazine (630 mg, 3.0 mmol). The reaction was then warmed to rt, and stirred for 3 hr. The yellow precipitate was then filtered out, and the supernatant containing crude product was then concentrated to give crude 2-amino-4-chloro-6-[4-(5-chloro-2-methyl-phenyl)-piperazin-1-yl]-pyrimidine-5-carbaldehyde (1.0 g, 90% yield). ¹H NMR, (400 MHz, d₆-DMSO) δ 9.88 (s, 1H), 7.65 (d, 2H), 7.20 (d, 1H), 7.00 (d, 1H), 3.62 (m, 4H), 2.98 (m, 4H), 2.42 (s, 3H), 2.20 (s, 3H). MS (ESI) for C₁₆H₁₇Cl₂N₅O: 366 (MH⁺).

[0947] To a round bottom flask was added 2-amino-4-chloro-6-[4-(5-chloro-2-methyl-phenyl)-piperazin-1-yl]-pyrimidine-5-carbaldehyde (364 mg, 1.0 mmol), isopropanol (6.0 mL), and hydrazine (0.080 mL, 1.4 mmol). The reaction was heated to 80°C overnight in a sealed tube before cooling to RT. Product precipitated out of the reaction mixture as a white solid, was filtered, rinsed with iPrOH and dried to give 4-[4-(5-chloro-2-methyl-phenyl)-piperazin-1-yl]-1*H*-pyrazolo[3,4-d]-pyrimidin-6-ylamine (220 mg, 64% yield): ¹H NMR (400MHz, d₆-DMSO) δ 12.80 (br s, 1H), 8.82 (s, 1H), 7.25 (d, 1H), 7.10 (m, 2H), 4.19 (m, 4H), 3.00 (br s, 4H), 2.30 (s, 3H). MS (ESI) for C₁₆H₁₈ClN₇: 344 (MH⁺).

[0948] EXAMPLE 53: 4-[4-(3-bromo-5-chloro-2-methyl-phenyl)-piperazin-1-yl]-1*H*-pyrazolo[3,4-d]-pyrimidin-6-ylamine.

[0949] 4-[4-(3-Bromo-5-chloro-2-methyl-phenyl)-piperazin-1-yl]-1*H*-pyrazolo[3,4-d]-pyrimidin-6-ylamine: To a sealed tube was added 4-[4-(5-Chloro-2-methyl-phenyl)-piperazin-1-yl]-1*H*-pyrazolo[3,4-d]-pyrimidin-6-ylamine (85 mg, 0.25 mmol), water (1.5 mL), and bromine (0.014 mL, 0.27 mmol). The reaction was heated to 110°C overnight in

a sealed tube. Three compounds were detected by LC/MS: major portion was starting material, second one was unidentified, and third one was the desired product. The reaction was cooled to r.t.. The brown precipitate was filtered and rinsed with water and purified by prep-HPLC to give 4-[4-(3-bromo-5-chloro-2-methyl-phenyl)-piperazin-1-yl]-1*H*-pyrazolo[3,4-*d*]-pyrimidin-6-ylamine (6.0 mg, 1.4%): ¹H NMR (400MHz, d₆-DMSO) δ 12.70 (br s, 1H), 8.82 (s, 1H), 7.61 (s, 1H), 7.23 (s, 1H), 4.19 (m, 4H), 3.00 (br s, 4H), 2.30 (s, 3H). MS (ESI) for C₁₆H₁₇BrClN₇: 422 (MH⁺).

[0950] EXAMPLE 54: (2E)-3-[4-{5-{{[2,3-Difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl}-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoic acid.

[0951] To a round bottom flask was added 4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester (539 mg, 1.04 mmol), dry MeOH (2.0 mL) and 4N HCl in dioxane (2.0 mL). The reaction was stirred at RT for 1 hr, then concentrated to remove trace HCl. The residue was then dissolved in THF (20.0 mL), and triethyl amine (0.69 mL, 4.8 mmol), before adding 3-bromo-1-(tetrahydro-pyran-2-yl)-4-[1,2,4]triazol-1-yl-1*H*-pyrazolo[3,4-*d*]pyrimidine (420.0 mg, 1.2 mmol). The reaction was then stirred at 65°C overnight, concentrated, extract with EtOAc and water, washed with saturated NaHCO₃, brine, and dried with Na₂SO₄, concentrated and columned with 20:80 CH₂Cl₂ to give [3-{4-[3-bromo-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]-pyrimidin-4-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl}-(2-pyrrolidin-1-yl-ethyl)-amine as a pale yellow solid (509 mg, 61% yield). ¹H NMR, (400 MHz, d₆-DMSO) δ 8.40 (s, 1H), 6.08 (d, 2H), 5.90 (dd, 1H), 4.80 (m, 5H), 4.22 (d, 2H), 3.98 (m, 4H), 3.68 (m, 1H), 3.19 (q, 2H), 2.98 (br s, 4H), 2.40 (dq, 2H), 2.0 (m, 5H), 1.80-1.60 (m, 8H). MS (ESI) for C₃₁H₄₂BrF₃N₈O₂: 695 (MH⁺).

[0952] To a sealed tube was added [3-{4-[3-bromo-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]-pyrimidin-4-yl]-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl}-(2-pyrrolidin-1-yl-ethyl)-amine (130 mg, 0.19 mmol), DMF (3.0 mL), triethylamine (0.23 mL, 1.9 mmol), CuI (12 mg, 0.06 mmol), and tert-butyldimethyl-(2-propynyl)-silane (0.11 mL, 0.56 mmol). The reaction mixture was purged with nitrogen before adding Pd(PPh₃)₄ (23 mg, 0.02 mmol). The tube was sealed and heated to 105°C overnight and cooled to RT, filtered through celite, rinsed with MeOH and columned with 5:95 MeOH: CH₂Cl₂ to give [3-{4-[3-[3-(*tert*-butyl-dimethyl-silyloxy)-

prop-1-ynyl]-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-piperazin-1-yl}-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine (113 mg, 65 % yield). MS (ESI) for C₄₀H₅₉F₃N₈O₃Si: 785 (MH⁺).

[0953] To a round bottom flask was added [3-{4-[3-[3-(*tert*-butyl-dimethyl-silyloxy)-prop-1-ynyl]-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-piperazin-1-yl}-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine (113 mg, 0.14 mmol), MeOH (2.0 mL), and 4N HCl in dioxane (2.0 mL). The reaction was stirred at RT for 15 min, concentrated, prep purified and converted to the HCl salt to give 3-(4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazin-1-yl}-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl)-prop-2-yn-1-ol as a white solid (48.0 mg, 65% yield): ¹H NMR (400MHz, d₆-DMSO) δ 10.60 (br s, 1H), 8.40 (br s, 1H), 6.10 (d, 2H), 4.83 (dq, 4H), 4.79 (dq, 4H), 4.40 (s, 1H), 4.30 (d, 2H), 3.60 (m, 6H), 3.35 (br s, 4H), 3.00 (br s, 6H), 2.05 (s, 3H), 1.95 (m, 4H). MS (ESI) for C₂₉H₃₇F₃N₈O₂: 587 (MH⁺).

[0954] EXAMPLE 55: (2E)-3-[4-(4-{5-[(2,3-Difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]prop-2-enoic acid.

[0955] To a sealed tube was added [3-{4-[3-bromo-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl]-piperazin-1-yl}-5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine (250 mg, 0.36 mmol), DMF (3.0 mL), potassium phosphate tribasic (382 mg, 1.8 mmol), and t-butyl acrylate (0.29 mL, 1.44 mmol). The reaction mixture was purged with nitrogen before adding Pd(dppf)Cl₂CH₂Cl₂ (59 mg, 0.072 mmol). The tube was sealed and heated to 120°C overnight and cooled to RT, filtered through celite, rinsed with MeOH and concentrated to give crude 3-[4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazin-1-yl}-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]-acrylic acid tert-butyl ester which was carried to the next step without further purification. MS (ESI) for C₃₈H₅₃F₃N₈O₄: 743 (MH⁺).

[0956] To a round bottom flask was added 3-[4-{4-[5-(2,3-difluoro-2-fluoromethyl-propoxy)-2-methyl-3-(2-pyrrolidin-1-yl-ethylamino)-phenyl]-piperazin-1-yl}-1-(tetrahydro-pyran-2-yl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-3-yl]-acrylic acid tert-butyl ester (250 mg, 0.33 mmol), CH₂Cl₂ (2.0 mL), and TFA (2.0 mL). The reaction was stirred at r.t. for 2 hr, concentrated, prep purified and converted to the HCl salt to give (2E)-3-[4-(4-

{5-[{[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl}piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid as a yellow solid (102.0 mg, 51% yield over two steps): ^1H NMR (400MHz, d_6 -DMSO) δ 9.42 (br s, 1H), 7.75 (d, 2H), 6.60 (d, 2H), 4.80 (m, 4H), 4.22 (d, 2H), 3.00 (m, 8H), 2.05 (s, 3H), 1.95 (m, 4H). MS (ESI) for $\text{C}_{29}\text{H}_{37}\text{F}_3\text{N}_8\text{O}_3$: 603 (MH^+).

[0957] Using the same or analogous synthetic techniques and/or substituting with alternative reagents, the following compounds of the invention were prepared:

[0958] 4-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylquinoline. ^1H NMR (400 MHz, d_6 -DMSO) δ 8.40 (s, 1H), 8.08 (d, 1H), 7.88 (d, 1H), 7.68 (t, 1H), 7.52 (t, 1H), 6.98 (s, 1H), 4.10 (m, 4H), 3.35 (m, 4H), 2.58 (s, 3H). MS (ESI) for $\text{C}_{19}\text{H}_{18}\text{BrN}_7$: 424 (MH^+).

[0959] 3-Bromo-4-[4-(3,5-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrCl}_2\text{N}_6$: 429 (MH^+).

[0960] 3-[4-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-1-methyl-6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol: ^1H NMR (400 MHz, CDCl_3) δ 8.42 (s, 1H), 7.24 (s, 1H), 6.89 (s, 1H), 4.19 (m, 4H), 3.86 ((q, 2H), 3.79 (s, 3H), 3.70 (m, 4H), 3.12 (t, 2H), 2.20 (m, 2H). MS (ESI) for $\text{C}_{21}\text{H}_{22}\text{BrF}_3\text{N}_8\text{O}$: 541 (MH^+).

[0961] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[4,4,4-trifluoro-1,1-bis(methyloxy)butyl]aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.33 (s, 1H), 6.45 (s, 1H), 6.38 (s, 1H), 4.8 (br. 1H), 3.9 (br. 4H), 3.15 (q, 2H), 3.05 (s, 6H), 2.91 (br. 4H), 2.61 (t, 2H), 2.45 (m, 4H), 2.04 (s, 3H), 2.00 (m, 2H), 1.8 (m, 2H), 1.67 (br. 4H). MS (ESI) for $\text{C}_{28}\text{H}_{38}\text{BrF}_3\text{N}_8\text{O}_2$: 657 (MH^+).

[0962] 3-Bromo-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.12 (br. s, 1H), 8.38 (m, 2 H), 7.19 (br s, 1H), 6.95 (br d, $J = 5.2$ Hz, 1H), 3.95 (m, 4H), 3.84 (m, 4H). MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrF}_3\text{N}_7$: 430 (MH^+).

[0963] 3-Bromo-4-{4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.10 (br. s, 1H), 8.75 (d, $J = 4.8$ Hz, 1 H), 8.38 (s, 1H), 7.10 (d, $J = 4.8$ Hz, 1H), 3.99 (m, 4H), 3.92 (m, 4H). MS (ESI) for $\text{C}_{14}\text{H}_{12}\text{BrF}_3\text{N}_8$: 431 (MH^+).

- [0964] 2-(3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazin-2-yl)oxy)-N,N-dimethylethanamine: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.10 (br s, 1H), 8.38 (s, 1H), 7.87 (d, J = 2.9 Hz, 1H), 7.68 (d, J = 2.9 Hz, 1H), 4.66 (m, 2H), 3.92 (4H), 3.67 (m, 4H), 3.61 (m, 2H), 2.91 (m, 6H). MS (ESI) for $C_{17}\text{H}_{22}\text{BrN}_9\text{O}$: 430 (MH^+).
- [0965] 3-Bromo-4-{4-[3-(methyloxy)pyrazin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 - DMSO) δ 14.20 (s, 1H), 8.37 (s, 1H), 7.80 (d, J = 2.7 Hz, 1H), 7.67 (d, J = 2.9 Hz, 1H), 3.94 (s, 3H), 3.92 (m, 4H), 3.65 (m, 4H). MS (ESI) for $C_{14}\text{H}_{15}\text{BrN}_8\text{O}$: 391 (MH^+).
- [0966] 4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)piperazin-2-one: ^1H NMR (400 MHz, d_6 -DMSO) δ 14.12 (br s, 1H), 8.42 (s, 1H), 7.43 (br s, 1H), 7.34 (m, 2H), 4.56 (m, 2H), 4.38 (m, 1H), 4.21 (m, 1H), 3.87 (m, 1H), 3.63 (m, 1H), 2.12 (s, 3H). MS (ESI) for $C_{16}\text{H}_{14}\text{BrClN}_6\text{O}$: 421(MH^+).
- [0967] 3-({6-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-methylpyrimidin-4-yl}oxy)-N,N-diethylpropan-1-amine: ^1H NMR (400 MHz, CDCl_3) δ 8.37 (s, 1H), 4.40 (t, 2H), 4.10 (m, 4H), 3.64 (m, 4H), 3.17 (m, 6H), 2.33 (m, 2H), 2.25 (s, 3H), 1.38 (t, 6H). MS (ESI) for $C_{21}\text{H}_{29}\text{BrClN}_9\text{O}$: 538 (MH^+).
- [0968] 3-({4-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6-chloro-5-methylpyrimidin-2-yl}oxy)-N,N-diethylpropan-1-amine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.37 (s, 1H), 4.35 (t, 2H), 3.91 (m, 4H), 3.56 (m, 4H), 3.08 (m, 6H), 2.07 (m, 5H), 1.15 (m, 6H). MS (ESI) for $C_{21}\text{H}_{29}\text{BrClN}_9\text{O}$: 538 (MH^+).
- [0969] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.38 (s, 1H), 7.05 (s, 1H), 6.99 (s, 1H), 5.09 (t, 1H), 3.97 (br s, 8H), 3.24 (m, 2H), 3.02 (br s, 4H), 2.69 (t, 2H), 2.64 (s, 3H), 2.14 (s, 3H), 1.71 (m, 4H). MS (ESI) for $C_{25}\text{H}_{31}\text{BrN}_{10}\text{O}$: 567 (MH^+).
- [0970] 3-Bromo-4-[(3S)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.36 (s, 1H), 7.25 (m, 2H), 7.11 (dd, 1H), 4.38 (d, 1H), 4.28 (d, 1H), 3.56 (m, 1H), 3.38 (m, 1H), 3.23 (m, 1H), 3.07 (m, 1H), 2.80 (m, 1H), 2.29 (s, 3H), 0.84 (d, 3H). MS (ESI) for $C_{17}\text{H}_{18}\text{BrClN}_6$: 421 (MH^+).

- [0971] 3-Bromo-4-[(3R)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 12.2 (s, 1H), 8.41 (s, 1H), 7.09 (m, 3H), 4.57 (m, 1H), 4.48 (m, 1H), 3.60 (m, 1H), 3.33 (m, 1H), 3.28 (m, 1H), 3.06 (m, 1H), 2.88 (m, 1H), 2.32 (s, 3H), 0.94 (d, 3H). MS (ESI) for $\text{C}_{17}\text{H}_{18}\text{BrClN}_6$: 421 (MH^+).
- [0972] 2-((3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl)oxy)-N-ethylacetamide: ^1H NMR (400 MHz, CDCl_3) δ 11.92 (br s, 1H), 8.42 (s, 1H), 7.21-7.19 (m, 1H), 6.65-6.63 (m, 1H), 6.56 (m, 1H), 6.52 (s, 1H), 6.45-6.43 (m, 1H), 4.48 (s, 2H), 4.09-4.06 (m, 4H), 3.41-3.40 (m, 6H), 1.21-1.18 (t, 3H). MS (ESI) for $\text{C}_{19}\text{H}_{22}\text{BrN}_7\text{O}_2$: 460 (MH^+).
- [0973] 2-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N-diethylpyrimidin-4-amine: ^1H NMR (400 MHz, CDCl_3) δ 12.10 (br s, 1H), 8.40 (s, 1H), 7.91-7.89 (d, 1H), 5.82-5.80 (d, 1H), 3.99-3.96 (m, 8H), 3.47 (m, 4H), 1.20-1.17 (t, 6H). MS (ESI) for $\text{C}_{17}\text{H}_{22}\text{BrN}_9$: 432 (MH^+).
- [0974] 3-Bromo-4-[4-(3-[(3-methylphenyl)methyl]oxy)phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 11.35 (br s, 1H), 8.39 (s, 1H), 7.39-7.37 (m, 1H), 7.25-7.23 (m, 1H), 7.22-7.19 (m, 2H), 6.94 (s, 4H), 4.99 (s, 2H), 4.09-4.06 (m, 4H), 3.28-3.25 (m, 4H), 2.37 (s, 3H). MS (ESI) for $\text{C}_{23}\text{H}_{23}\text{BrN}_6\text{O}$: 479 (MH^+).
- [0975] 3-Bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]phenyl)piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 8.43 (s, 1H), 6.94-6.92 (d, 2H), 6.87-6.84 (d, 2H), 4.09-4.07 (m, 6H), 3.27-3.25 (m, 4H), 2.78-2.75 (t, 2H), 2.52 (m, 4H), 1.64-1.59 (m, 4H), 1.45 (m, 2H). MS (ESI) for $\text{C}_{22}\text{H}_{28}\text{BrN}_7\text{O}$: 486 (MH^+).
- [0976] 3-Bromo-4-[4-(4-furan-2-ylpyrimidin-2-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 11.56 (br s, 1H), 8.44 (s, 1H), 8.40-8.39 (d, 1H), 7.58-7.58 (m, 1H), 7.22-7.21 (m, 1H), 6.94-6.93 (d, 1H), 6.57-6.56 (m, 1H), 4.11-4.09 (m, 4H), 4.05-4.03 (m, 4H). MS (ESI) for $\text{C}_{17}\text{H}_{15}\text{BrN}_8\text{O}$: 427 (MH^+).
- [0977] 6-{2-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrimidin-4-yl}-2H-1,4-benzoxazin-3(4H)-one: ^1H NMR (400 MHz, $d_6\text{-DMSO}$) δ 14.10 (br s, 1H), 10.85 (s, 1H), 8.46-8.44 (d, 1H), 8.38 (s, 1H), 7.79 (s, 1H), 7.74-7.71 (d, 1H), 7.14-7.13 (d, 1H), 7.07-7.05 (d, 1H), 4.66 (s, 2H), 4.05 (m, 4H), 3.94-3.92 (m, 4H). MS (ESI) for $\text{C}_{21}\text{H}_{18}\text{BrN}_9\text{O}_2$: 508 (MH^+).

- [0978] 2-(*{*3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl*}*oxy)-N-cyclopropylacetamide: ^1H NMR (400 MHz, CDCl_3) δ 8.32 (s, 1H), 7.25-7.21 (m, 1H), 6.68 (br s, 1H), 6.65-6.63 (m, 1H), 6.51-6.47 (m, 2H), 4.50 (s, 2H), 4.36-4.33 (m, 4H), 3.45-3.42 (m, 4H), 2.81-2.78 (m, 1H), 0.88-0.83 (m, 2H), 0.61-0.57 (m, 2H). MS (ESI) for $\text{C}_{20}\text{H}_{22}\text{BrN}_7\text{O}_2$: 472 (MH^+).
- [0979] 3-Bromo-4-(4-{3-[*(*2-piperidin-1-ylethyl*)*oxy]pyrazin-2-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, CDCl_3) δ 12.48 (br s, 1H), 8.28 (s, 1H), 7.82-7.81 (d, 1H), 7.60-7.59 (d, 1H), 4.86-4.84 (t, 2H), 4.26-4.23 (m, 4H), 3.79-3.72 (m, 6H), 3.51-3.48 (t, 2H), 2.77-2.71 (m, 4H), 2.06-1.98 (m, 2H), 1.91-1.89 (m, 2H). MS (ESI) for $\text{C}_{20}\text{H}_{26}\text{BrN}_9\text{O}$: 488 (MH^+).
- [0980] 3-Bromo-4-[4-(2,4-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 7.57 (d, 1H), 7.37 (dd, 1H), 7.21 (d, 1H), 3.94 (t, 4H), 3.14 (t, 4H). MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrCl}_2\text{N}_6$: 427 (MH^+).
- [0981] 4-{4-[3,5-Bis-(methyloxy)phenyl]piperazin-1-yl}-3-bromo-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 6.19 (d, 2H), 6.02 (t, 1H), 3.94 (t, 4H), 3.70 (s, 6H), 3.36 (t, 4H). MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{BrN}_6\text{O}_2$: 419 (MH^+).
- [0982] 3-Bromo-4-[4-(3,4-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 6.98 (d, 1H), 6.84 (s, 1H), 6.74 (d, 1H), 3.91 (br s, 4H), 3.28 (br s, 4H), 2.18 (s, 3H), 2.12 (s, 3H). MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{BrN}_6$: 387 (MH^+).
- [0983] 3-Bromo-4-[4-(4-nitrophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 8.07 (d, 2H), 7.05 (d, 2H), 3.96 (t, 4H), 3.71 (t, 4H). MS (ESI) for $\text{C}_{15}\text{H}_{14}\text{BrN}_7\text{O}_2$: 404 (MH^+).
- [0984] 3-Bromo-4-[4-(2,6-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.33 (s, 1H), 6.97 (m, 3H), 3.91 (t, 4H), 3.18 (t, 4H), 2.39 (s, 6H). MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{BrN}_6$: 387 (MH^+).
- [0985] 3-Bromo-4-{4-[4-(ethyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 6.97 (d, 2H), 6.84 (d, 2H), 3.95 (m, 4H), 3.25 (br t, 4H), 1.29 (t, 3H). MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{BrN}_6\text{O}$: 403 (MH^+).
- [0986] 3-Bromo-4-[4-(2-ethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.35 (s, 1H), 7.23 (dd, 1H), 7.14 (m, 2H), 7.04 (dt, 1H),

3.95 (br s, 4H), 2.99 (t, 4H), 2.73 (q, 2H), 1.22 (t, 3H). MS (ESI) for C₁₇H₁₉BrN₆: 387 (MH⁺).

[0987] 3-Bromo-4-[4-(2-nitrophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (s, 1H), 7.84 (dd, 1H), 7.60 (dt, 1H), 7.38 (dd, 1H), 7.15 (dt, 1H), 3.92 (t, 4H), 3.22 (t, 4H). MS (ESI) for C₁₅H₁₄BrN₇O₂: 404 (MH⁺).

[0988] 2-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile: ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 7.73 (d, 1H), 7.61 (t, 1H), 7.22 (d, 1H), 7.12 (t, 1H), 3.98 (br s, 4H), 3.33 (br s, 4H). MS (ESI) for C₁₆H₁₄BrN₇: 384 (MH⁺).

[0989] 4-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile: ¹H NMR (400 MHz, d₆-DMSO) δ 8.35 (s, 1H), 7.60 (d, 2H), 7.05 (d, 2H), 3.93 (t, 4H), 3.58 (t, 4H). MS (ESI) for C₁₆H₁₄BrN₇: 384 (MH⁺).

[0990] 3-Bromo-4-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 7.25 (d, 2H), 7.11 (d, 2H), 3.94 (t, 4H), 3.50 (t, 4H). MS (ESI) for C₁₆H₁₄BrF₃N₆: 427 (MH⁺).

[0991] 3-Bromo-4-(4-{4-[(phenylmethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.36 (s, 1H), 7.40 (m, 5H), 6.95 (q, 4H), 5.04 (s, 2H), 3.93 (t, 4H), 3.46 (t, 4H). MS (ESI) for C₂₂H₂₁BrN₆O: 465 (MH⁺).

[1000] 2-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carbonitrile: ¹H NMR (400 MHz, d₆-DMSO) δ 8.42 (dd, 1H), 8.35 (s, 1H), 8.09 (dd, 1H), 6.96 (q, 1H), 3.93 (m, 4H), 3.46 (m, 4H). MS (ESI) for C₁₅H₁₃BrN₈: 385 (MH⁺).

[1001] 3-Bromo-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.37 (s, 1H), 7.34 (m, 2H), 7.22 (m, 1H), 3.97 (t, 4H), 3.17 (t, 4H). MS (ESI) for C₁₅H₁₃BrCl₂N₆: 427 (MH⁺).

[1002] 3-Bromo-4-{4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.37 (s, 1H), 7.68 (m, 3H), 7.37 (m, 1H), 3.94 (br m, 4H), 3.05 (t, 4H). MS (ESI) for C₁₆H₁₄BrF₃N₆: 427 (MH⁺).

[1003] 2-({3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N,N-diethylethanamine: ¹H NMR (400 MHz, d₆-DMSO) δ 9.40 (br s, 1H), 8.35 (s, 1H), 7.16 (t, 1H), 6.64 (d, 1H), 6.58 (s, 1H), 6.45 (d, 1H), 4.28 (t, 2H), 3.92 (br s, 2H), 3.49 (d, 4H), 3.35 (br s, 4H), 3.21 (q, 4H), 1.23 (t, 6H). MS (ESI) for C₂₁H₂₈BrN₇O: 474 (MH⁺).

[1004] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methoxy)-N-(2-pyrrolidin-1-ylethyl)aniline: ^1H NMR (400 MHz, d_6 -DMSO) δ 9.40 (br s, 1H), 8.36 (s, 1H), 6.06 (d, 1H), 5.99 (d, 1H), 3.85 (br m, 4H), 3.69 (s, 3H), 3.62 (br m, 4H), 3.43 (t, 2H), 3.35 (m, 2H), 3.05 (br s, 4H), 2.94 (br s, 4H), 2.05 (s, 3H), 1.85 (br m, 4H). MS (ESI) for $\text{C}_{23}\text{H}_{31}\text{BrN}_8\text{O}$: 515 (MH^+).

[1005] 3-Bromo-4-[4-(3',4',6-trifluoro-4-methylbiphenyl-3-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.37 (s, 1H), 7.63 (m, 1H), 7.52 (m, 1H), 7.42 (br m, 1H), 7.20 (d, 1H), 7.18 (s, 1H), 3.96 (br s, 4H), 3.07 (t, 4H), 2.36 (s, 3H). MS (ESI) for $\text{C}_{22}\text{H}_{18}\text{BrF}_3\text{N}_6$: 503 (MH^+).

[1006] 3-Bromo-4-[4-(3,4-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrCl}_2\text{N}_6$: 428 (MH^+).

[1007] 3-Bromo-4-[4-(3,4-difluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrF}_2\text{N}_6$: 394 (MH^+).

[1008] 3-Bromo-4-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.39 (s, 1H), 7.29 (t, 1H), 7.19 (m, 1H), 7.02 (m, 1H), 3.92 (t, 4H), 3.33 (t, 4H). MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrClFN}_6$: 412 (MH^+).

[1009] 1-{4-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}ethanone: MS (ESI) for $\text{C}_{17}\text{H}_{17}\text{BrN}_6\text{O}$: 403 (MH^+).

[1010] 3-Bromo-4-[4-(2,5-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.39 (s, 1H), 7.49 (d, 1H), 7.26 (d, 1H), 7.16 (dd, 1H), 3.95 (m, 4H), 3.20 (m, 4H). MS (ESI) for $\text{C}_{15}\text{H}_{13}\text{BrCl}_2\text{N}_6$: 428 (MH^+).

[1011] 4-{4-[2,4-Bis(methoxy)phenyl]piperazin-1-yl}-3-bromo-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $\text{C}_{17}\text{H}_{19}\text{BrN}_6\text{O}_2$: 421 (MH^+).

[1012] 3-Bromo-4-(4-pyrazin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $\text{C}_{13}\text{H}_{13}\text{BrN}_8$: 361 (MH^+).

[1013] 3-Bromo-4-(4-pyrimidin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for $\text{C}_{13}\text{H}_{13}\text{BrN}_8$: 361 (MH^+).

[1014] 4-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)quinoline: ^1H NMR (400 MHz, d_6 -DMSO) δ 8.39 (s, 1H) 8.21 (d, 1H), 8.09 (d, 1H), 7.84 (t, 3H), 7.73 (t, 3H), 7.34 (s, 1H), 4.11 (m, 4H), 3.54 (m, 4H). MS (ESI) for $\text{C}_{19}\text{H}_{15}\text{BrF}_3\text{N}_7$: 480 (MH^+).

[1015] 3-[4-(3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazine-2-carbonitrile: MS (ESI) for C₁₄H₁₂BrN₉: 386 (MH⁺).

[1016] 3-Bromo-4-[4-(3-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.38 (s, 1H), 7.22 (t, 1H), 7.01 (s, 1H), 6.97 (d, 1H), 6.81 (d, 1H), 3.91 (t, 4H), 3.40 (t, 4H). MS (ESI) for C₁₅H₁₄BrClN₆: 395 (MH⁺).

[1017] 3-Bromo-4-{4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₁₅H₁₃BrF₃N₇: 429 (MH⁺).

[1018] 3-Bromo-4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₁₅H₁₂BrClF₃N₇: 464 (MH⁺).

[1019] 3-Bromo-4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.38 (s, 1H), 7.24 (t, 2H), 7.02 (d, 2H), 6.83 (t, 1H), 3.94 (t, 4H), 3.37 (t, 4H). MS (ESI) for C₁₅H₁₅BrN₆: 360 (MH⁺).

[1020] 3-Bromo-4-[4-(4-fluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₁₅H₁₄BrFN₆: 378 (MH⁺).

[1021] 3-Bromo-4-[4-(4-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₁₅H₁₄BrClN₆: 395 (MH⁺).

[1022] 3-Bromo-4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.38 (s, 1H), 7.42 (t, 1H), 7.29 (d, 1H), 7.25 (s, 1H), 7.11 (d, 1H), 3.94 (m, 4H), 3.43 (m, 4H). MS (ESI) for C₁₆H₁₄BrF₃N₆: 430 (MH⁺).

[1023] 3-Bromo-4-[4-(4-bromophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: MS (ESI) for C₁₅H₁₄Br₂N₆: 439 (MH⁺).

[1024] 3-Bromo-4-[3-methyl-4-(3-méthylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine: ¹H NMR (400 MHz, d₆-DMSO) δ 8.39 (s, 1H), 7.20 (m, 1H), 6.92 (m, 2H), 6.76 (m, 1H), 4.30 (m, 2H), 4.11 (m, 2H), 3.52 (m, 2H), 3.40 (m, 1H), 2.38 (s, 3H), 0.94 (d, 3H). MS (ESI) for C₁₇H₁₉BrN₆: 388 (MH⁺).

[1025] Additional examples of compounds that were made according to the methods and procedures described above are set forth in Table 1. Each of these compounds are further aspects of this invention.

Assays

[1026] For assay of activity, generally p70S6K and/or AktK, or a compound according to the invention is non-diffusably bound to an insoluble support having isolated sample-receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble support may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, Teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusible. Exemplary methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.

[1027] One measure of inhibition is K_i . For compounds with IC_{50} 's less than 1 μM , the K_i or K_d is defined as the dissociation rate constant for the interaction of the agent with a p70S6K and/or AktK. Exemplary compositions have K_i 's of, for example, less than about 100 μM , less than about 10 μM , less than about 1 μM , and further for example having K_i 's of less than about 100 nM, and still further, for example, less than about 10 nM. The K_i for a compound is determined from the IC_{50} based on three assumptions. First, only one compound molecule binds to the enzyme and there is no cooperativity. Second, the concentrations of active enzyme and the compound tested are known (i.e., there are no significant amounts of impurities or inactive forms in the preparations). Third, the enzymatic rate of the enzyme-inhibitor complex is zero. The rate data (i.e. compound concentration) are fitted to the equation:

[1028] where V is the observed rate, V_{max} , is the rate of the free enzyme, I_0 is the inhibitor concentration, E_0 is the enzyme concentration, and K_d is the dissociation constant of the enzyme-inhibitor complex.

[1029] Another measure of inhibition is GI_{50} , defined as the concentration of the compound that results in a decrease in the rate of cell growth by fifty percent. Exemplary compounds have GI_{50} 's of, for example, less than about 1 mM, less than about 10 μ M, less than about 1 μ M, and further, for example, having GI_{50} 's of less than about 100 nM, still further having GI_{50} 's of less than about 10 nM. Measurement of GI_{50} is done using a cell proliferation assay.

[1030] Tyrosine kinase activity is determined by 1) measurement of kinase-dependent ATP consumption by in the presence of a generic substrate such as polyglutamine, tyrosine (pEY), by luciferase/luciferin-mediated chemiluminescence or; 2) incorporation of radioactive phosphate derived from ^{33}P -ATP into a generic substrate which has been adsorbed onto the well surface of polystyrene microtiter plates. Phosphorylated substrate products are quantified by scintillation spectrometry.

Luciferase-Coupled Chemiluminescence Assay Protocol

[1031] Kinase activity is measured as the percent of ATP consumed following the kinase reaction using luciferase-luciferin-coupled chemiluminescence. Reactions were conducted in 384-well white, medium binding microtiter plates (Greiner). Kinase reactions were initiated by combining test compounds, ATP and kinase in a 20 μ L volume. The reaction mixture was incubated at ambient temperature for 3 hrs. For p70S6K and/or AktK, 2.5-5 nM of the enzyme was pre-incubated with compound in 20 mM Tris pH 7.5, 10 mM MgCl₂, 0.03% TX-100, and 1mM DTT for 30 minutes at room temperature. Following the kinase reaction, a 20 μ L aliquot of luciferase-luciferin mix was added and the chemiluminescence signal measured using a Victor² plate reader (Perkin Elmer). The luciferase-luciferin mix contained 50 mM HEPES, pH 7.8, 67 mM oxalic acid (pH 7.8), 5 (or 50) mM DTT, 0.4% Triton X-100, 0.25 mg/mL coenzyme A, 63 μ M AMP, 28 μ g/mL luciferin and 40,000 units/mL luciferase. Total ATP consumption was limited to 25-60% and the IC₅₀ values correlate well with those determined by radiometric assays.

^{33}P -Phosphoryl Transfer Kinase Assay Protocol II

[1032] Direct p70S6K and/or AktK activity was measured as incorporated ^{33}P in the method described below. Reactions were performed in a 96-well polypropylene V-bottom

plate. Samples were incubated for 30 minutes and then transferred to a 96-well P81 Unifilter plate (Whatman). Each reaction contained 50 nM p70S6 and/or Akt kinase with 5 uM ATP and ^{33}P - γ -ATP (3.3 $\mu\text{Ci}/\text{nmol}$) in 20 mM Tris pH 7.5, 10 mM MgCl₂, 0.03% TX-100, and 1mM DTT. Plates were washed 10 times with 0.075% phosphoric acid. 100 μl of scintillation fluid was added and incorporated ^{33}P was measured by liquid scintillation spectrometry using a MicroBeta scintillation counter (Perkin Elmer).

Structure Activity Relationships

[1033] Table 1 shows structure activity relationship data for selected compounds of the invention. Inhibition is indicated as IC₅₀ with following key: A = IC₅₀ less than 100 nM, B = IC₅₀ greater than 100 nM, but less than or equal to 1000 nM, C = IC₅₀ greater than 1000 nM, but less than 10,000 nM, D = IC₅₀ 10,000 nM or greater. An empty cell indicates lack of data only.

Table 1

Entry	Name	P70S6K IC50	AKT-1 IC50
1	3-(azetidin-3-ylidenemethyl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	C	C
2	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-fluoropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	D
3	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-chloropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	D
4	2-((5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl)oxy)-N,N-dimethylethanamine	A	C
5	2-((5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl)oxy)-N,N-diethylethanamine	A	C
6	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl)piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
7	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-piperazin-1-yl-1H-pyrazolo[3,4-d]pyrimidine	B	C
8	N-(3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-yl)acetamide	A	C
9	N,N-diethyl-2-((3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl)oxy)ethanamine	C	C
10	3-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-diethylpropan-1-amine	A	A
11	3-bromo-4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	A
12	3-bromo-4-{4-(5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl)piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	B
13	2-((3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl)oxy)-N,N-diethylethanamine	A	B
14	4-[4-(5-chloro-2-methyl-3-[(2-(1-methylpiperidin-4-yl)ethyl)oxy]phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
15	5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	B

Entry	Name	P70S6K IC50	AKT-1 IC50
16	4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
17	4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
18	3-bromo-4-(4-{5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
19	3-bromo-4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
20	3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
21	3-bromo-4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
22	4-{4-[5-chloro-2-methyl-3-(3-morpholin-4-ylpropyl)phenyl}piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
23	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-diethylethane-1,2-diamine	A	B
24	4-{4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl}piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
25	4-[4-(5-chloro-3-[[2-(4-ethylpiperazin-1-yl)ethyl]oxy]-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
26	4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
27	3-bromo-4-(4-[5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl]piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
28	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-diethylethane-1,2-diamine	A	A
29	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
30	4-[4-(5-chloro-2-methyl-3-[[2-(4-methylpiperazin-1-yl)ethyl]oxy]phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
31	4-[4-(5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methyl]oxy)phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
32	N,N-diethyl-2-({3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}oxy)ethanamine	B	C
33	2-[(5-chloro-3-{4-[1-(1,1-dimethylethyl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-2-methylphenyl)oxy]-N,N-diethylethanamine	C	C
34	2-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-N,N-diethylethanamine	A	B
35	4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
36	4-[4-(5-chloro-2-methyl-3-[(3-(4-methylpiperazin-1-yl)propyl)oxy]phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
37	3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
38	3-bromo-4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
39	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
40	4-(4-{5-chloro-2-methyl-3-[(3-morpholin-4-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C

Entry	Name	P70S6K IC50	AKT-1 IC50
41	4-(4-{5-chloro-2-methyl-3-[(2-morpholin-4-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
42	4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
43	4-[4-(5-chloro-3-[(3-(4-ethylpiperazin-1-yl)propyl)oxy]-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
44	5-chloro-2-methyl-3-[4-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline	A	C
45	5-chloro-2-methyl-3-[4-(3-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
46	N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-dimethylethane-1,2-diamine	A	A
47	3-({5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl)oxy)-N,N-diethylpropan-1-amine	A	B
48	N'-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-diethylethane-1,2-diamine	A	B
49	5-chloro-2-methyl-N-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline	A	B
50	3-bromo-4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
51	4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	C	C
52	3-methyl-4-(4-{4-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	C
53	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
54	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-methyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
55	4-(4-{5-chloro-2-methyl-3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
56	3-[(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)oxy]-N,N-diethylpropan-1-amine	A	B
57	5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	B	C
58	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
59	4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	C
60	3-bromo-4-{4-[5-fluoro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	B
61	4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine.	A	A
62	4-(4-{5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
63	3-bromo-4-(4-pyridin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	C
64	3-bromo-4-[4-(2,4-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	C
65	3-bromo-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	C
66	3-bromo-4-{4-[2-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	D

Entry	Name	P70S6K IC50	AKT-1 IC50
67	3-bromo-4-{4-[4-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	C
68	4-(4-{5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
69	4-(4-{5-chloro-2-methyl-3-[(3-piperidin-1-ylpropyl)oxy]phenyl}piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
70	4-[4-(5-chloro-2-methyl-3-[[3-(4-methylpiperazin-1-yl)propyl]oxy]phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
71	4-[4-(5-chloro-3-[[3-(4-ethylpiperazin-1-yl)propyl]oxy]-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
72	3-bromo-4-[4-(5-chloro-2-methyl-3-[[2-(4-methylpiperazin-1-yl)ethyl]oxy]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	B
73	4-[4-(5-chloro-2-methyl-3-[[2-(4-methylpiperazin-1-yl)ethyl]oxy]phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
74	3-bromo-4-[4-(5-chloro-3-[[2-(4-ethylpiperazin-1-yl)ethyl]oxy]-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A
75	3-bromo-4-[4-(3,4-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
76	3-bromo-4-[4-(3,4-difluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
77	3-bromo-4-[4-(2,4-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
78	3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	C
79	5-fluoro-2-methyl-N-(2-pyrrolidin-1-ylethyl)-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}aniline	A	B
80	4-[4-[3,5-bis(methoxy)phenyl]piperazin-1-yl]-3-bromo-1H-pyrazolo[3,4-d]pyrimidine	A	C
81	4-[4-(5-chloro-3-[[2-(4-ethylpiperazin-1-yl)ethyl]oxy]-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
82	N-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N',N'-trimethylethane-1,2-diamine	A	C
83	3-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}oxy)-N,N-diethylpropan-1-amine	A	A
84	3-bromo-4-(4-(5-chloro-2-methyl-3-[(3-pyrrolidin-1-ylpropyl)oxy]phenyl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
85	3-bromo-4-[4-(5-chloro-2-methyl-3-[[3-(4-methylpiperazin-1-yl)propyl]oxy]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A
86	3-bromo-4-[4-(5-chloro-3-[[3-(4-ethylpiperazin-1-yl)propyl]oxy]-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A
87	3-(5-chloro-2-methyl-3-{4-[3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}phenyl)-N,N-diethylpropan-1-amine	A	B
88	3-bromo-4-[4-(5-chloro-2-methyl-3-{{(1-methylpiperidin-4-yl)methyl}oxy}phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A
89	3-bromo-4-[4-(5-chloro-2-methyl-3-[[2-(1-methylpiperidin-4-yl)ethyl]oxy]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A

Entry	Name	P70S6K IC50	AKT-1 IC50
90	4-[4-(5-chloro-2-methyl-3-[(1-methylpiperidin-4-yl)methyl]oxy)phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
91	4-[4-(5-chloro-2-methyl-3-{[2-(1-methylpiperidin-4-yl)ethyl]oxy}phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
92	4-(4-(5-chloro-2-methyl-3-[3-(4-methylpiperazin-1-yl)propyl]phenyl)piperazin-1-yl)-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
93	3-bromo-4-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	C
94	1-{4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}ethanone	B	C
95	3-bromo-4-[4-(2,5-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	D
96	3-bromo-4-[4-(3,4-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
97	3-bromo-4-[4-(4-nitrophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
98	3-ethyl-4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	D
99	3-ethyl-4-{4-[3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
100	4-[4-(5-chloro-2-methyl-3-(3-piperidin-1-ylpropyl)phenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	B
101	4-[4-(3,6-dimethylpyrazin-2-yl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	B	D
102	1-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]isoquinoline	A	D
103	3-bromo-4-[4-(2,6-dimethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
104	3-bromo-4-{4-[4-(ethyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
105	3-bromo-4-[4-(2-ethylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
106	4-[4-[2,4-bis(methyloxy)phenyl]piperazin-1-yl]-3-bromo-1H-pyrazolo[3,4-d]pyrimidine	B	D
107	3-bromo-4-(4-pyrazin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	D
108	3-bromo-4-(4-pyrimidin-2-ylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	D
109	4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)quinoline	A	D
110	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazine-2-carbonitrile	B	D
111	4-[4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	C	D
112	ethyl 4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(trifluoromethyl)pyrimidine-5-carboxylate	C	D
113	4-{4-[3-chloro-5-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	D
114	4-[4-(3-bromo-2-chloro-5-fluorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	B	D
115	2-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carboxamide	B	D

Entry	Name	P70S6K IC50	AKT-1 IC50
116	3-ethyl-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
117	3-bromo-4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
118	3-bromo-4-{4-[4-(trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
119	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrazin-2-yl}oxy)-N,N-dimethylethanamine	B	C
120	4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylquinoline	A	D
121	3-bromo-4-[4-(2-nitrophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
122	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile	B	D
123	4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]benzonitrile	A	D
124	3-bromo-4-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
125	3-bromo-4-(4-{4-[(phenylmethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	D
126	4-{4-[5-chloro-2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	D
127	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyridine-3-carbonitrile	B	D
128	3-bromo-4-[4-(3,5-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
129	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-fluoro-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
130	2-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-fluoro-N-(2-pyrrolidin-1-ylethyl)aniline	A	C
131	3-bromo-4-[4-(2,5-difluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	D
132	4-[4-(2,5-difluorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	B	D
133	3-bromo-4-{4-[3-(methyloxy)pyrazin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
134	3-bromo-4-[4-(3-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	D
135	3-bromo-4-{4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
136	3-bromo-4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	C	D
137	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
138	5-chloro-2-methyl-3-{4-[3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-N-(2-pyrrolidin-1-ylethyl)aniline	A	C
139	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N-ethylacetamide	A	C
140	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N-diethylpyrimidin-4-amine	B	C
141	3-bromo-4-[4-(3-[(3-methylphenyl)methyl]oxy)phenyl]piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
142	3-bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	C

Entry	Name	P70S6K IC50	AKT-1 IC50
143	3-bromo-4-[4-(4-furan-2-ylpyrimidin-2-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine.	B	D
144	6-{2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]pyrimidin-4-yl}-2H-1,4-benzoxazin-3(4H)-one	C	C
145	3-ethyl-4-{4-[2-methyl-3-(methyloxy)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	D
146	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N-methyl-N-(1-methylethyl)ethane-1,2-diamine	A	B
147	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N-ethyl-N-methylethane-1,2-diamine	A	B
148	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N,N-dimethylethane-1,2-diamine	A	A
149	3-({6-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-chloro-5-methylpyrimidin-4-yl}oxy)-N,N-diethylpropan-1-amine	B	C
150	3-bromo-4-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
151	3-bromo-4-{4-[2-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	B	D
152	3-bromo-4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	D
153	3-bromo-4-[4-(4-fluorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
154	3-bromo-4-[4-(4-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
155	3-bromo-4-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	D
156	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-amine	C	D
157	3-bromo-4-[4-(4-bromophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
158	3-bromo-4-[3-methyl-4-(3-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	C
159	4-[4-(3-bromo-5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-amine	C	D
160	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
161	5-chloro-3-[4-(3-cyclopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
162	5-chloro-2-methyl-3-{4-[3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]piperazin-1-yl}-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
163	4-(4-{5-chloro-2-methyl-3-[(2-pyrrolidin-1-ylethyl)oxy]phenyl}piperazin-1-yl)-3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
164	3-bromo-4-[(3S)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	B
165	5-bromo-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylaniline	A	B
166	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N-cyclopropylacetamide	A	C
167	3-bromo-4-(4-{3-[(2-piperidin-1-ylethyl)oxy]pyrazin-2-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	C
168			
169	4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6,7-bis(methyloxy)quinazoline	C	D

Entry	Name	P70S6K IC50	AKT-1 IC50
170	2-({3-chloro-5-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N,N-diethylethanamine	B	D
171	4-{4-[2-chloro-5-(trifluoromethyl)phenyl]piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
172	3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
173	3-({4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-6-chloro-5-methylpyrimidin-2-yl}oxy)-N,N-diethylpropan-1-amine	B	C
174	3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(phenylmethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
175			
176	3-bromo-4-[(3R)-4-(5-chloro-2-methylphenyl)-3-methylpiperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
177	3-[(2S)-4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-N-phenylbenzamide	A	B
178	3-[(2S)-4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-methylpiperazin-1-yl]-4-methyl-N-(phenylmethyl)benzamide	A	C
179	methyl 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate	A	A
180	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoic acid	A	B
181	(2E)-3-(4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-enoic acid	A	A
182	3-(4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)prop-2-yn-1-ol	A	A
183	4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-1-(5-chloro-2-methylphenyl)piperazin-2-one	A	D
184	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
185	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]phenyl}-N,N-diethylethane-1,2-diamine	A	A
186	methyl 3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbenzoate	A	B
187	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide	A	A
188	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethylbenzamide	A	B
189	2-({3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]phenyl}oxy)-N,N-diethylethanamine	B	D
190	methyl 3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoate	A	A
191	3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide	A	B
192	3-bromo-5-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenylbenzamide	A	B
193	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-2-methylphenyl}-N-methyl-N-(1-methylethyl)ethane-1,2-diamine	A	A
194	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-phenyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
195	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methylpropyl)oxy]phenyl}-N,N-dimethylethane-1,2-diamine	A	A

Entry	Name	P70S6K IC50	AKT-1 IC50
196	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N,4-trimethylbenzamide	A	B
197	3-[4-(3-chloro-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(2-methylpropyl)benzamide	A	C
198	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,N,4-trimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	B
199	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-oxopiperazin-1-yl]-4-methyl-N-phenylbenzamide	A	C
200	3-[(2R)-4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-(hydroxymethyl)piperazin-1-yl]-4-methyl-N-phenylbenzamide	A	A
201	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(pyrrolidin-1-ylcarbonyl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
202	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	B
203	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(4-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
204	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-chlorophenyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
205	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopropylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
206	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(3-methylbutyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
207	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-ethylbutyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
208	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(butyloxy)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
209	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
210	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-N-(1-methylethyl)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	B
211	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclobutylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
212	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethyloxy)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
213	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-[2-(dimethylamino)ethyl]-4-methylbenzamide	A	C
214	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(1,1-dimethylethyl)-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
215	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-pyridin-3-yl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
216	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-fluoro-2-methylpropyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
217	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclohexylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
218	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(cyclopentylmethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
219	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-ethyl-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	A
220	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(1-methylethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline	A	A

Entry	Name	P70S6K IC50	AKT-1 IC50
221	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,2-dimethylpropyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
222	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(tetrahydrofuran-2-ylmethyl)oxy]aniline	A	A
223	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-[(2-methoxyethyl)oxy]-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
224	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(propoxy)-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
225	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-(dimethylamino)ethyl)amino]-4-methyl-N-phenylbenzamide	A	A
226	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-fluoro-2-methylpropyl)oxy]-2-methylphenyl}-N,N-dimethylethane-1,2-diamine	A	A
227	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-(dimethylamino)ethyl)amino]-4-methyl-N-(1-methylethyl)benzamide	A	A
228	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one	A	A
229	N'-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,3-difluoro-2-(fluoromethyl)propyl)oxy]-2-methylphenyl}-N,N-dimethylethane-1,2-diamine	A	A
230	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,3-difluoro-2-(fluoromethyl)propyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
231	5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-N-(2-pyrrolidin-1-ylethyl)biphenyl-3-amine	A	A
232	1-(3-{5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methylbiphenyl-3-yl}propyl)pyridinium	A	A
233	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-(1,3-thiazol-2-yl)aniline	A	A
234	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzoic acid	A	C
235	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(phenylethynyl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
236	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(phenyl)methanone	A	A
237	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethynyl-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
238	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbut-1-yn-1-yl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
239	3-bromo-4-{4-[5-([2,3-difluoro-2-(fluoromethyl)propyl)oxy]-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	A
240	3-bromo-4-{4-[2-methyl-5-[(2-methylpropyl)oxy]-3-(3-pyrrolidin-1-ylpropyl)phenyl]piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidine	A	A
241	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-phenyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	C
242	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
243	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}propan-1-one	A	A
244	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(3,3-dimethylbutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A

Entry	Name	P70S6K IC50	AKT-1 IC50
245	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-ethyl-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
246	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[2-(trimethylsilyl)ethyl]aniline	A	A
247	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(2-phenylethyl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
248	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one	A	A
249	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N,4-dimethyl-N-(methyloxy)-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	B
250	3-bromo-4-[4-(3-bromo-5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy]-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	B
251	4-[4-(3-bromo-5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy]-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B
252	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}ethanone	A	A
253	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(difluoromethyl)oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
254	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[[difluoromethyl]oxy]methyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
255	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methyloxy)-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
256	5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy]-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
257	2-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5,6-trifluoro-N-(3-methylbutyl)pyridin-4-amine	B	C
258	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-[(cyclopropylmethyl)oxy]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]benzamide	A	B
259	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
260	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(ethylsulfonyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
261	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-5-(methylsulfonyl)-N-(2-pyrrolidin-1-ylethyl)aniline	A	B
262	1-{3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}pentan-1-one	A	A
263	3-bromo-4-[4-(5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy]-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A
264	6-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-3,5-difluoro-N-4-(3-methylbutyl)-N-2-(2-pyrrolidin-1-ylethyl)pyridine-2,4-diamine	A	B
265	3-bromo-5-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
266	3-bromo-4-[4-(3',4',6-trifluoro-4-methylbiphenyl-3-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	B
267	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-chloro-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
268	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}methanol	A	B
269	3-bromo-4-(4-{4-methyl-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	A

Entry	Name	P70S6K IC50	AKT-1 IC50
270	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2,2-difluorocyclopropyl)methyl]oxy]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
271	5-bromo-3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
272	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethyloxy)methyl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
273	3-[4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-1-methyl-6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol	A	B
274	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}-4,4-trifluorobutan-1-one	A	A
275	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(cyclopropyl)methanone	A	A
276	3-({3'-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)-N,N-dimethylpropan-1-amine	A	A
277	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(1,1-difluorobutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline	A	A
278	3-bromo-4-(4-{4-methyl-2'-(3-morpholin-4-ylpropyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
279	3-bromo-4-(4-{4-methyl-2'-(2-morpholin-4-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
280	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]methyl]aniline	A	A
281	1-[2-({3'-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy)ethyl]pyrrolidine-2,5-dione	A	A
282	3-bromo-4-(4-{3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
283	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one	A	A
284	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline	A	A
285	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline	A	A
286	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one	A	A
287	3-bromo-4-(4-{4-chloro-2'-(2-pyrrolidin-1-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
288	3-[4-(4-{5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol	A	A
289	3-bromo-4-(4-{4-chloro-4'-fluoro-2'-(2-pyrrolidin-1-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
290	3-bromo-4-(4-{4-methyl-3'-(2-pyrrolidin-1-ylethyl)oxy}biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	A
291	(2E)-3-[4-(4-{5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid	A	A
292	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[4,4,4-trifluoro-1,1-bis(methyloxy)butyl]aniline	A	A
293	6-(4-phenylpiperazin-1-yl)-9H-purine	C	D
294	6-[4-(3-chlorophenyl)piperazin-1-yl]-9H-purine	B	D

Entry	Name	P70S6K IC50	AKT-1 IC50
295	4-(4-phenylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine	B	D
296	4-[4-(3-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	C
297	4-(4-phenylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	D
298	4-[4-(3-chlorophenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
299	6-[4-(2-chlorophenyl)piperazin-1-yl]-9H-purine	C	D
300	6-[4-(2-fluorophenyl)piperazin-1-yl]-9H-purine	C	D
301	4-[4-(2-methylphenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
302	4-[4-[2-(methyloxy)phenyl]piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
303	4-[4-[3-(methyloxy)phenyl]piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
304	4-[4-[4-(methyloxy)phenyl]piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	C	D
305	4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
306	6-[4-[4-(methyloxy)phenyl]piperazin-1-yl]-9H-purine	C	D
307	6-[4-[2-(methyloxy)phenyl]piperazin-1-yl]-9H-purine	B	D
308	6-[4-(4-chlorophenyl)piperazin-1-yl]-9H-purine	C	D
309	6-[4-(4-fluorophenyl)piperazin-1-yl]-9H-purine	C	D
310	4-[4-(4-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	C	D
311	4-[4-(2-chlorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
312	4-[4-(4-fluorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
313	4-[4-(2-fluorophenyl)piperazin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine	B	D
314	6-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-9H-purine	B	D
315	6-[4-(2-methylphenyl)piperazin-1-yl]-9H-purine	B	D
316	4-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	D
317	4-[4-(2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	D
318	4-[4-(3-chlorophenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine	A	D
319	3-methyl-4-[4-(2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	
320	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	C
321	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
322	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-methyl-6-phenyl-1H-pyrazolo[3,4-d]pyrimidine	C	C
323	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
324	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-methyl-1H-pyrazolo[3,4-d]pyrimidine	C	C
325	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-ethyl-1H-pyrazolo[3,4-d]pyrimidine	C	C
326	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-6-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine	C	C
327	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
328	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-({[2-(methyloxy)ethyl]oxy}methyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C






Entry	Name	P70S6K IC50	AKT-1 IC50
329	3-bromo-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	A	B
330	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-propyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
331	4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenol	A	C
332	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-N-phenyl-1H-pyrazolo[3,4-d]pyrimidin-3-amine	C	C
333	4-[4-(3-chlorophenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
334	4-[4-[5-chloro-2-(methoxy)phenyl]piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
335	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}phenol	B	C
336	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{3-[(phenylmethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine	C	C
337	3-(1,3-benzodioxol-5-yl)-4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	C
338	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-thienyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
339	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}aniline	B	C
340	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}benzoic acid	C	C
341	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidine	C	C
342	N-(4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl)phenylacetamide	B	C
343	4-[4-(3-chlorophenyl)-1,4-diazepan-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	B	D
344	4-[5-(3-chlorophenyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
345	4-(4-(3-chloro-4-[(2-morpholin-4-ylethyl)oxy]phenyl)piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	C	D
346	methyl 1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate	C	D
347	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-methylbut-2-en-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	
348	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
349	methyl 4-(3-chlorophenyl)-1-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylate	C	D
350	4-(4-(3-chloro-4-[(2-piperidin-1-ylethyl)oxy]phenyl)piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	C	D
351	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1-methylethyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
352	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxylic acid	B	D
353	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-methylpiperazine-2-carboxamide	B	C
354	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidine	B	C


Entry	Name	P70S6K IC50	AKT-1 IC50
355	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
356	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine	B	C
357	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidine	B	C
358	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[4-(phenyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine	B	C
359	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(piperidin-4-yl)methyl]oxy}phenyl]-1H-pyrazolo[3,4-d]pyrimidine	B	
360	1-(3-chlorophenyl)-N-[2-(dimethylamino)ethyl]-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazine-2-carboxamide	C	C
361	4-[4-(5-chloro-2-methyl-3-morpholin-4-ylphenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	B	C
362	4-(3-chlorophenyl)-1-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-methylpiperazine-2-carboxamide	C	
363	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[2-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine	B	C
364	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-pyridin-4-yl-1H-pyrazolo[3,4-d]pyrimidine	A	C
365	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(methyloxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidine	C	C
366	4-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}benzonitrile	C	C
367	[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methanol	A	C
368	methyl 5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate	B	C
369	(2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoic acid	A	B
370	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propanoic acid	A	C
371	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}propan-1-ol	A	C
372	methyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate	A	C
373	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-{4-[(2-morpholin-4-ylethyl)oxy]phenyl}-1H-pyrazolo[3,4-d]pyrimidine	C	C
374	5-chloro-N-[2-(dimethylamino)ethyl]-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzamide	A	C
375	4-(4-{5-chloro-2-(methyloxy)-3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}piperazin-1-yl)-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	B	D
376	2-(dimethylamino)ethyl 5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)benzoate	A	C
377	1-[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]-N,N-dimethylmethanamine	B	D
378	N'-{[5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl]methyl}-N,N-dimethylethane-1,2-diamine	B	C
379	[1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-2-yl]methanol	A	C

Entry	Name	P70S6K IC50	AKT-1 IC50
380	3-[(4-{4-(5-chloro-2-methylphenyl)piperazin-1-yl}-1H-pyrazolo[3,4-d]pyrimidin-3-yl)oxy]-N,N-dimethylpropan-1-amine	C	C
381	2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenol	A	C
382	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(1-methylpiperidin-4-yl)piperazine-2-carboxamide	C	D
383	1-(3-chlorophenyl)-4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-N-(2-morpholin-4-ylethyl)piperazine-2-carboxamide	C	D
384	2-{{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-(methyloxy)phenyl}oxy}-N,N-dimethylethanamine	A	C
385	3-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-dimethylprop-2-yn-1-amine	A	C
386	N'-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-dimethylethane-1,2-diamine	A	B
387	1,1-dimethylethyl (2E)-3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-enoate	B	C
388	3-({2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-N,N-dimethylpropan-1-amine	B	C
389	2-({2-chloro-4-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-methylphenyl}oxy)-N,N-dimethylethanamine	B	C
390	4-{4-[5-chloro-2-methyl-4-(methyloxy)phenyl)piperazin-1-yl]-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	C
391	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(4-methylpiperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	C	C
392	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N,N-diethylprop-2-yn-1-amine	A	C
393	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}prop-2-yn-1-ol	A	B
394	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(piperidin-4-ylmethyl)-1H-pyrazolo[3,4-d]pyrimidine	C	C
395	phenylmethyl (3aR,6aS)-5-({4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl)methylidene)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate	C	C
396	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[(E)-(3aR,6aS)-hexahydrocyclopenta[c]pyrrol-5(1H)-yldenemethyl]-1H-pyrazolo[3,4-d]pyrimidine	C	C
397	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidine	B	C
398	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-[3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl]-1H-pyrazolo[3,4-d]pyrimidine	B	C
399	3-{4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-N,N-diethylpropan-1-amine	C	C
400	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(3-pyrrolidin-1-ylpropyl)-1H-pyrazolo[3,4-d]pyrimidine	C	C
401	4-[4-(5-chloro-2-methylphenyl)piperazin-1-yl]-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidine	A	C
402	3-{5-chloro-3-[4-(3-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methylphenyl}-N,N-diethylpropan-1-amine	A	B
403	4-{4-[5-chloro-2-methyl-3-(3-pyrrolidin-1-ylpropyl)phenyl)piperazin-1-yl}-3-ethyl-1H-pyrazolo[3,4-d]pyrimidine	A	B


[1034] As discussed above, the names of the compounds are generated using the nomenclature engine published by ACD/Labs of Toronto Canada. In order to further describe the compounds of the present invention, a representative number of compounds set forth in Table 1 are provided below in Table 2, wherein the structure of the compound is provided as well as the name generated by the nomenclature engine. These examples are provided to further clarify the compounds of the present invention.

Table 2


	5-bromo-3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(ethoxy)methyl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline
	3-[4-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-1-methyl-6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol
	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}-4,4,4-trifluorobutan-1-one
	{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}(cyclopropyl)methanone




3-[{3'-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4'-methylbiphenyl-2-yl}oxy]-N,N-dimethylpropan-1-amine




3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-(1,1-difluorobutyl)-2-methyl-N-(2-pyrrolidin-1-ylethyl)aniline









3-bromo-4-(4-{4-methyl-2'-(3-morpholin-4-ylpropyl)oxy)biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine




3-bromo-4-(4-{4-methyl-2'-(2-morpholin-4-ylethyl)oxy)biphenyl-3-yl}piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine




3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline


	1-[2-{[3'-(4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl)-4'-methylbiphenyl-2-yl]oxy}ethyl]pyrrolidine-2,5-dione
	3-bromo-4-(4-{3'-fluoro-4-methyl-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine
	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-one
	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(3,3,3-trifluoropropyl)oxy]aniline
	3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-2-methyl-N-(2-pyrrolidin-1-ylethyl)-5-[(2,2,2-trifluoroethyl)oxy]aniline
	1-{3-[4-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperazin-1-yl]-4-methyl-5-[(2-pyrrolidin-1-ylethyl)amino]phenyl}butan-1-ol




3-bromo-4-(4-{4-chloro-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine




3-[4-(4-{5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-yn-1-ol



3-bromo-4-(4-{4-chloro-4'-fluoro-2'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine



3-bromo-4-(4-{4-methyl-3'-(2-pyrrolidin-1-ylethyl)oxy)biphenyl-3-yl)piperazin-1-yl)-1H-pyrazolo[3,4-d]pyrimidine




(2E)-3-[4-(4-{5-[[2,3-difluoro-2-(fluoromethyl)propyl]oxy}-2-methyl-3-[(2-pyrrolidin-1-ylethyl)amino]phenyl)piperazin-1-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]prop-2-enoic acid

[1035] The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the invention and that modifications may be made

therein without departing from the spirit or scope of the invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

What is claimed is:

1. A compound of Formula I,



I

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,
 X_{21} is N or CR_{22} ;
 X_{22} is N or CR_{23} ;
 X_{23} is N or CR_{24} , but when X_{22} is N then X_{23} is CR_{24} ;
each of R_{21} , R_{22} , R_{23} , R_{24} , R_{25} , R_{26} , R_{27} , R_{28} , R_{29} and R_{30} , and each R_{31} , R_{32} and R_{33} is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂, -NR₃₅R_{35a}, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -N(R₃₅)SO₂R₃₅, -N(R₃₅)C(O)R₃₅, -N(R₃₅)CO₂R₃₅, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl;
R is selected from -H, halogen, trihalomethyl, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, and optionally substituted arylalkyl; or
two of R_{25} , R_{26} , R_{27} , R_{28} , R_{29} , R_{30} , R_{31} or R_{32} , together with the atom or respective atoms to which they are attached, combine to form an optionally substituted spirocyclic ring system, optionally substituted fused ring system, and optionally substituted saturated bridged ring system;
each of R_{35} and R_{35a} is independently selected from -H, optionally substituted lower alkyl, optionally substituted lower alkoxy, optionally substituted aryl,

optionally substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally substituted heterocyclyl, and optionally substituted lower heterocyclylalkyl; or

R₃₅ and R_{35a}, together with the atom or respective atoms to which they are attached, combine to form an optionally substituted five- to seven-membered heterocyclyl; and


m is an integer from 0 to 5;

n is an integer from 1 to 2; and

with the provisos that when X₂₂ is CR₂₃ and X₂₃ is N then R is not optionally substituted aryl, aralkyl or heteroaryl, and that when X₂₂ is N and X₂₃ is CR₂₄ then R is not optional substituted aryl or heteroaryl and R₂₁ is not -NR₃₅R_{35a}, and that when X₂₂ is CR₂₃ and X₂₃ is CR₂₄ then R₂₁ is not optionally substituted aryl, and that compounds with CAS Registration Nos. 732271-60-2, 565169-26-8, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-34-2, 47281-43-6, 37425-49-3, 37425-48-2, 24932-89-6 and 24932-78-3 are not included in Formula I.

2. A compound of Claim 1, wherein In one example, the compound is according to Formula I, wherein n is 1.
3. A compound according to Claim 2, wherein X₂₁ is N.
4. A compound according to Claim 3, wherein X₂₃ is N..
5. A compound according to Claim 4, wherein X₂₂ is CR₂₃.
6. A compound according to Claim 5, wherein R is -H.
7. A compound according to Claim 5, wherein R is optionally substituted alkyl.
8. A compound according to Claim 6, wherein R₂₁ is -H.
9. A compound according to Claim 6, wherein R₂₁ is optionally substituted alkyl.
10. A compound according to Claim 8, wherein R₂₅ and R₂₆ are -H.
11. A compound according to Claim 10, wherein R₂₇ and R₂₈ are -H.
12. A compound according to Claim 11, wherein R₂₉ is -H.
13. A compound according to Claim 12, wherein R₃₀ is -H.
14. A compound according to Claim 12, wherein R₃₀ is optionally substituted alkyl.

15. A compound according to Claim 12, wherein R₃₀ is -C(O)R₃₅.
16. A compound according to Claim 12, wherein R₃₀ is -C(O)NR₃₅R_{35a}.
17. A compound according to Claim 13, wherein R₃₁ is -H.
18. A compound according to Claim 17, wherein R₃₂ is -H.
19. A compound according to Claim 17, wherein R₃₂ is -C(O)R₃₅.
20. A compound according to Claim 17, wherein R₂₉, R₃₀, R₃₁, and R₃₂ are -H.
21. A compound according to Claim 18, wherein R₂₃ is optionally substituted alkyl.
22. A compound according to Claim 18, wherein R₂₃ is halogen.
23. A compound according to Claim 22, wherein R₂₃ is Br.
24. A compound according to Claim 18, wherein R₂₃ is -H.
25. A compound according to Claim 18, wherein m is 2.
26. A compound according to Claim 18, wherein m is 3.
27. A compound according to Claim 18, wherein R₃₃ is -H.
28. A compound according to Claim 18, wherein R₃₃ is halogen.
29. A compound according to Claim 18, wherein R₃₃ is optionally substituted alkyl.
30. A compound according to Claim 18, wherein R₃₃ is -NR₃₅R_{35a}.
31. A compound according to Claim 18, wherein R₃₃ is -C(O)R₃₅.
32. A compound according to Claim 18, wherein R₃₃ is trihalomethyl.
33. A compound of Formula II,



II

or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, wherein,
 X_{21} is N or CR₂₂;
 X_{22} is N or CR₂₃;
 X_{23} is N or CR₂₄, but when X_{22} is N then X_{23} is CR₂₄;
each of R₂₁, R₂₂, R₂₃, R₂₄, R₂₅, R₂₆, R₂₇, R₂₈, R₂₉ and R₃₀ and each of R₃₁, R₃₂ and
R₃₃ is independently selected from -H, halogen, trihalomethyl, -CN, -NO₂,
-NR₃₅R_{35a}, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅, -C(O)NR₃₅R_{35a}, -N(R₃₅)SO₂R₃₅,
-N(R₃₅)C(O)R₃₅, -N(R₃₅)CO₂R₃₅, -OR₃₅, -C(O)R₃₅, optionally substituted lower
alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally
substituted heterocyclalkyl, and optionally substituted arylalkyl;
R is selected from -H, halogen, trihalomethyl, -S(O)₀₋₂R₃₅, -SO₂NR₃₅R_{35a}, -CO₂R₃₅,
-C(O)NR₃₅R_{35a}, -OR₃₅, -C(O)R₃₅, optionally substituted lower alkyl, optionally
substituted aryl, optionally substituted heterocyclyl, optionally substituted
heterocyclalkyl, and optionally substituted arylalkyl; or
two of R₂₅, R₂₆, R₂₇, R₂₈, R₂₉, R₃₀, R₃₁ or R₃₂, together with the atom or respective
atoms to which they are attached, combine to form an optionally substituted
spirocyclic ring system, optionally substituted fused ring system, and optionally
substituted saturated bridged ring system;
each R₃₅ and R_{35a} is independently selected from -H, optionally substituted lower
alkyl, optionally substituted lower alkoxy, optionally substituted aryl, optionally
substituted lower arylalkyl, optionally substituted lower aryl alkoxy, optionally
substituted heterocyclyl, and optionally substituted lower heterocyclalkyl; or
R₃₅ and R_{35a}, together with the atom or respective atoms to which they are
attached, combine to form an optionally substituted five- to seven-membered
heterocyclyl;
Q₁ optionally substituted heterocyclyl;
n is an integer from 1 to 2; and

with the provisos that when X_{22} is CR₂₃ and X_{23} is N then R is not optionally substituted
aryl, aralkyl or heteroaryl, and that when X_{22} is N and X_{23} is CR₂₄ then R is not optional
substituted aryl or heteroaryl and R₂₁ is not -NR₃₅R_{35a}, and that when X_{22} is CR₂₃ and X_{23}
is CR₂₄ then R₂₁ is not optionally substituted aryl and X₂₁ is N, and that compounds with
CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-

34-7, 537667-22-4, 252722-35-3, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 24932-90-9, and 24932-77-2 are not included in Formula II.

34. A compound of Claim 33, wherein n is 1.
35. A compound of Claim 34, wherein X_{21} is N.
36. A compound of Claim 35, wherein X_{23} is N.
37. A compound of Claim 36, wherein X_{22} is CR_{23} .
38. A compound of Claim 37, wherein R is -H.
39. A compound of Claim 37, wherein R is optionally substituted alkyl.
40. A compound of Claim 38, wherein R_{21} is -H.
41. A compound of Claim 38, wherein R_{21} is optionally substituted alkyl.
42. A compound of Claim 40, wherein R_{25} and R_{26} are -H.
43. A compound of Claim 42, wherein R_{27} and R_{28} are -H.
44. A compound of Claim 43, wherein R_{29} is -H.
45. A compound of Claim 44, wherein R_{30} is -H.
46. A compound of Claim 44, wherein R_{30} is optionally substituted alkyl.
47. A compound of Claim 44, wherein R_{30} is $-C(O)R_{35}$.
48. A compound of Claim 44, wherein R_{30} is $-C(O)NR_{35}R_{35a}$.
49. A compound of Claim 45, wherein R_{31} is -H.
50. A compound of Claim 49, wherein R_{32} is -H.
51. A compound of Claim 50, wherein R_{32} is $-C(O)R_{35}$.
52. A compound of Claim 50, wherein R_{29} , R_{30} , R_{31} , and R_{32} are -H.
53. A compound of Claim 50, wherein R_{23} is optionally substituted alkyl.
54. A compound of Claim 50, wherein R_{23} is halogen.
55. A compound of Claim 50, wherein R_{23} is -H.
56. A compound of Claim 50, wherein Q_1 is a substituted heterocyclyl wherein the heterocyclyl has at least one nitrogen.

57. A compound of Claim 55, wherein Q₁ is a substituted heterocyclyl wherein the heterocyclyl has at least one oxygen.
58. A composition comprising the compound of Claim 1 or 33, and at least one pharmaceutically acceptable carrier or excipient.
59. A metabolite of the compound of Claim 1 or 33.
60. A method of modulating the *in vivo* activity of a kinase, the method comprising administering to a subject an effective amount of a composition comprising at least one compound of Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X₂₂ is CR₂₃ and X₂₃ is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X₂₂ is N and X₂₃ is CR₂₄ then R₂₁ is -NR₃₅R₃₅, and when X₂₂ is CR₂₃ and X₂₃ is CR₂₄ then R₂₁ is optionally substituted aryl and X₂₁ is N.
61. A method of Claim 60, wherein the kinase is p70S6 and/or Akt.
62. A method of Claim 61, wherein modulating the *in vivo* activity of p70S6K and/or AktK comprises inhibition of p70S6K and/or AktK.
63. A method of treating and/or inhibiting diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of a composition comprising at least one of the compound according to Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X₂₂ is CR₂₃ and X₂₃ is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X₂₂ is N

and X_{23} is CR_{24} then R_{21} is $-NR_{35}R_{35}$, and when X_{22} is CR_{23} and X_{23} is CR_{24} then R_{21} is optionally substituted aryl and X_{21} is N.

64. A method of screening for modulator of a p70S6K and/or AktK, the method comprising combining at least one of the compound according to Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X_{22} is CR_{23} and X_{23} is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X_{22} is N and X_{23} is CR_{24} then R_{21} is $-NR_{35}R_{35}$, and when X_{22} is CR_{23} and X_{23} is CR_{24} then R_{21} is optionally substituted aryl and X_{21} is N, and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.

65. A method of inhibiting proliferative activity in a cell or a plurality of cells, the method comprising administering an effective amount of at least one of the compound according to Claim 1 or 33, and the CAS Registration Nos. 749908-53-0, 749908-52-9, 749908-36-9, 749908-35-8, 749908-34-7, 732271-60-2, 565169-26-8, 537667-22-4, 537667-19-9, 537667-18-8, 537667-17-7, 537667-16-6, 537667-15-5, 537667-14-4, 537667-13-3, 537667-12-2, 537667-11-1, 252722-59-1, 252722-35-3, 252722-34-2, 215524-11-1, 215524-10-0, 215524-09-7, 95950-61-1, 92495-50-6, 47281-43-6, 37425-49-3, 37425-48-2, 24932-90-9, 24932-89-6, 24932-78-3 and 24932-77-2 and also compounds of Formulas I and II when X_{22} is CR_{23} and X_{23} is N then R is optionally substituted aryl, aralkyl or heteroaryl, and when X_{22} is N and X_{23} is CR_{24} then R_{21} is $-NR_{35}R_{35}$, and when X_{22} is CR_{23} and X_{23} is CR_{24} then R_{21} is optionally substituted aryl and X_{21} is N, to said cell or plurality of cells.